WO2004065380A1 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia - Google Patents

1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia Download PDF

Info

Publication number
WO2004065380A1
WO2004065380A1 PCT/US2004/001267 US2004001267W WO2004065380A1 WO 2004065380 A1 WO2004065380 A1 WO 2004065380A1 US 2004001267 W US2004001267 W US 2004001267W WO 2004065380 A1 WO2004065380 A1 WO 2004065380A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidin
nitro
carboxylic acid
piperidine
ethyl ester
Prior art date
Application number
PCT/US2004/001267
Other languages
French (fr)
Other versions
WO2004065380A8 (en
Inventor
Robert M. Jones
Graeme Semple
Beatriz Fioravanti
Guilherme Pereira
Imelda Calderon
Jane Uy
Kameshwari Duvvuri
Jin Sun Karoline Choi
Yifeng Xiong
Vibha Dave
Original Assignee
Arena Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2004800022039A priority Critical patent/CN1835943B/en
Priority to DK04702248T priority patent/DK1599468T3/en
Application filed by Arena Pharmaceuticals Inc. filed Critical Arena Pharmaceuticals Inc.
Priority to BR0406761-4A priority patent/BRPI0406761A/en
Priority to JP2006501019A priority patent/JP2006516572A/en
Priority to EA200501132A priority patent/EA011009B1/en
Priority to DE602004009295T priority patent/DE602004009295T2/en
Priority to AU2004205642A priority patent/AU2004205642C1/en
Priority to NZ540612A priority patent/NZ540612A/en
Priority to US10/541,657 priority patent/US8293751B2/en
Priority to MXPA05007485A priority patent/MXPA05007485A/en
Priority to YUP-2005/0532A priority patent/RS20050532A/en
Priority to SI200430529T priority patent/SI1599468T1/en
Priority to EP04702248A priority patent/EP1599468B1/en
Priority to CA002512899A priority patent/CA2512899A1/en
Publication of WO2004065380A1 publication Critical patent/WO2004065380A1/en
Publication of WO2004065380A8 publication Critical patent/WO2004065380A8/en
Priority to IL169081A priority patent/IL169081A/en
Priority to HR20050696A priority patent/HRP20050696B1/en
Priority to NO20053803A priority patent/NO20053803L/en
Priority to IS7979A priority patent/IS2713B/en
Priority to HK05111332A priority patent/HK1076815A1/en
Priority to US12/945,712 priority patent/US20110082134A1/en
Priority to AU2010257356A priority patent/AU2010257356A1/en
Priority to US13/618,592 priority patent/US8933083B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
  • Diabetes mellitus is a serious disease afflicting over 100 million people worldwide. In the United States, there are more than 12 million diabetics, with 600,000 new cases diagnosed each year.
  • Diabetes mellitus is a diagnostic term for a group of disorders characterized by abnormal glucose homeostasis resulting in elevated blood sugar.
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • the etiology of the different types of diabetes is not the same; however, everyone with diabetes has two things in common: overproduction of glucose by the liver and little or no ability to move glucose out of the blood into the cells where it becomes the body's primary fuel.
  • Diabetes is a syndrome with interrelated metabolic, vascular, and neuropathic components.
  • the metabolic syndrome generally characterized by hyperglycemia, comprises alterations in carbohydrate, fat and protein metabolism caused by absent or markedly reduced insulin secretion and/or ineffective insulin action.
  • the vascular syndrome consists of abnormalities in the blood vessels leading to cardiovascular, retinal and renal complications. Abnormalities in the peripheral and autonomic nervous systems are also part of the diabetic syndrome.
  • IDDM People with IDDM, which accounts for about 5% to 10% of those who have diabetes, don't produce insulin and therefore must inject insulin to keep their blood glucose levels normal. IDDM is characterized by low or undetectable levels' of endogenous insulin production caused by destruction of the insulin-producing ⁇ cells of the pancreas, the characteristic that most readily distinguishes IDDM from NIDDM. IDDM, once termed juvenile-onset diabetes, strikes young and older adults alike.
  • NIDDM Type II diabetes Approximately 90 to 95% of people with diabetes have Type II (or NIDDM). NIDDM subjects produce insulin, but the cells in their bodies are insulin resistant: the cells don't respond properly to the hormone, so glucose accumulates in their blood. NIDDM is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to elevated blood glucose levels. In contrast to IDDM, there is always some endogenous insulin production in NIDDM; many NTDDM patients have normal or even elevated blood insulin levels, while other NIDDM patients have inadequate insulin production (Rotwein, R. et al. N. Engl. J. Med. 308, 65-71 (1983)). Most people diagnosed with ⁇ TDDM are age 30 or older, and half of all new cases are age 55 and older. Compared with whites and Asians, ⁇ TJDDM is more common among Native Americans, African-Americans, Latinos, and Hispanics. In addition, the onset can be insidious or even clinically inapparent, making diagnosis difficult
  • NIDDM neurodegenerative disease
  • Obesity and diabetes are among the most common human health problems in industrialized societies. In industrialized countries a third of the population is at least 20% overweight. In the United States, the percentage of obese people has increased from 25% at the end of the 1970s, to 33% at the beginning the 1990s. Obesity is one of the most important risk factors for NIDDM. Definitions of obesity differ, but in general, a subject weighing at least 20% more than the recommended weight for his/her height and build is considered obese. The risk of developing NIDDM is tripled in subjects 30% overweight, and three-quarters with NIDDM are overweight.
  • Obesity which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals and human.
  • the molecular mechanisms that are involved in obesity-diabetes syndromes are not clear.
  • increase insulin secretion balances insulin resistance and protects patients from hyperglycemia (Le Stunf ⁇ et al. Diabetes 43, 696-702 (1989)).
  • ⁇ cell function deteriorates and non-insulin-dependent diabetes develops in about 20% of the obese population (Pederson, P. Diab. Metab. Rev. 5, 505- 509 (1989)) and (Brancati, F. L., et al., Arch. Intern. Med.
  • BMI body mass index
  • m 2 body weight index
  • Overweight is defined as a BMI in the range 25-30 kg/m 2
  • obesity is a BMI greater than 30 kg/m 2 (see TABLE below).
  • Orlistat a lipase inhibitor
  • Sibutramine a mixed 5-HT/noradrenaline reuptake inhibitor
  • fenfluramine Pieris-associated fenfluramine
  • ReduxTM dexfenfluramine
  • Kidney disease also called nephropathy
  • Diabetes occurs when the kidney's "filter mechanism” is damaged and protein leaks into urine in excessive amounts and eventually the kidney fails. Diabetes is also a leading cause of damage to the retina at the back of the eye and increases risk of cataracts and glaucoma.
  • diabetes is associated with nerve damage, especially in the legs and feet, which interferes with the ability to sense pain and contributes to serious infections. Taken together, diabetes complications are one of the nation's leading causes of death.
  • the present invention is drawn to compounds, which bind to and modulate the activity of a GPCR referred to herein as RUP3, and uses thereof.
  • RUP3, as used herein includes the human sequences found in GeneBank accession number XM_066873, naturally-occurring allelic variants, mammalian orthologs, and recombinant mutants thereof.
  • a preferred human RUP3 for use in screening and testing of the compounds of the invention is provided in the nucleotide sequence of Seq. ID .No: 1 and the corresponding amino acid sequence in Seq. ID.No:2.
  • One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la):
  • a and B are independently C ⁇ - 3 alkylene optionally substituted with 1 to 4 methyl groups
  • D is O, S, S(O), S(0) 2 , CR 2 R 3 or N-R 2 ;
  • V is selected from the group consisting of C1. 3 alkylene, ethynylene and C1- 2 heteroalkylene wherein each are optionally substituted with 1 to 4 substituents selected from the group consisting of C1- 3 alkyl, C ⁇ ialkoxy, carboxy, cyano, - 3 haloalkyl and halogen; or V is absent;
  • W is NR,, O, S, S(O) or S(0) 2 ; or W is absent;
  • X is N or CR 5 ;
  • Y is or CRe
  • Z is selected from the group consisting of C 1 - 5 acyl, C1- 5 acyloxy, C ⁇ alkoxy, C ⁇ - 8 alkyl, C 1 - 4 alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C alkylureyl, amino, C ⁇ - 2 alkylamino, C 2 - 4 dialkylamino, carbo-Ci- ⁇ -alkoxy, carboxamide, carboxy, cyano, -s diacylamino, C 2 - 6 dialkylcarboxamide, C ⁇ dialkylthiocarboxamide, C 2 _ 6 dialkylsulfonamide, C ⁇ dialkylsulfonylamino, formyl, C ⁇ haloalkoxy, C ⁇ haloalkyl,
  • Z is a group of Formula (A):
  • R 7 is H, Ci-s alkyl or C3-6 cycloalkyl
  • R 8 is H, nitro or nitrile
  • a ⁇ is aryl or heteroaryl wherein each are optionally substituted with R9-R1 3 ;
  • Ri is selected from the group consisting of H, C1- 5 acyloxy, C 2 . 6 alkenyl, C ⁇ alkoxy, -g alkyl, C ⁇ alkylcarboxamide, C 2 .
  • R 2 is selected from the group consisting of H, C,- 5 acyl, C1- 5 acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, amino, carbo-C -alkoxy, carboxamide, carboxy, cyano, C 3 - 6 -cycloalkyl, C 2 .
  • R 2 is -Ar 2 -Ar 3 wherein Ar 2 and Ar 3 are independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of H, C ⁇ acyl, C 1 - 5 acyloxy, C ⁇ alkoxy, C ⁇ - 8 alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, amino, carbo-C -alkoxy, carboxamide, carboxy, cyano, C 3 . 6 -cycloa.kyl, C 2 . 6 dialkylcarboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, halogen, hydroxyl and nitro; or
  • R 2 is a group of Formula (B):
  • R ⁇ is C ⁇ . 8 alkyl or C 3 . 6 cycloalkyl; and R 15 is F, Cl, Br or CN; or R 2 is a group of Formula (C):
  • Ar 4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 .
  • R 3 is H, C ⁇ alkyl, C ⁇ alkoxy, halogen or hydroxyl
  • R t is H or C ⁇ alkyl
  • R 5 and Re are independently H, C alkyl or halogen
  • R 9 is selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C 2 . 6 alkenyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylamino, C ⁇ alkylcarboxamide, C 2 .g alkynyl, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylureyl, amino, arylsulfonyl, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 . 6 cycloalkyl, C 2 . 6 dialkylamino, C 2 .
  • R 9 is a group of Formula (D): ⁇ p ⁇ R. 18
  • R 18 is H, C ⁇ acyl, C 2 . 6 alkenyl, C ⁇ alkyl, C ⁇ alkylcarboxamide, C 2 - 6 alkynyl, C ⁇ alkylsulfonamide, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 . s cycloalkyl, C 2 .
  • Some embodiments of the present invention include pharmaceutical compositions comprising at least one compound of the present invention and a pharmaceutically acceptable carrier.
  • Some embodiments of the present invention include methods for prophylaxis or treatment of a metabolic disorder in an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
  • Some embodiments of the present invention include methods of controlling or decreasing weight gain of an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or pharmaceutical composition thereof.
  • Some embodiments of the present invention include methods of modulating a RUP3 receptor comprising contacting the receptor with a compound of the present invention.
  • Some embodiments of the present invention include methods of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention.
  • the compound is an agonist.
  • the compound is an inverse agonist.
  • Some embodiments of the present invention include methods of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor is prophylaxis or treatment of a metabolic disorder.
  • Some embodiments of the present invention include methods of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor controls or reduces weight gain of the individual.
  • Some embodiments of the present invention include the use of compounds of the present invention for production of a medicament for use in prophylaxis or treatment of a metabolic disorder.
  • Some embodiments of the present invention include the use of compounds of the present invention for production of a medicament for use in controlling or decreasing weight gain in an individual.
  • One aspect of the present invention pertains to compounds of the present invention, as described herein, for use in methods of treatment of the human or animal body by therapy.
  • One aspect of the present invention pertains to compounds of the present invention, as described herein, for use in methods of prophylaxis or treatment of a metabolic disorder of the human or animal body by therapy.
  • the metabolic disorder is type I, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X or metabolic syndrome.
  • One aspect of the present invention pertains to methods of producing a pharmaceutical compositions comprising admixing at least one compound of the present invention and a pharmaceutically acceptable carrier.
  • Figure 1A shows RT-PCR analysis of RUP3 expression in human tissues. A total of twenty-two (22) human tissues were analyzed.
  • Figure IB shows the cDNA Dot-Blot analysis of RUP 3 expression in human tissues.
  • Figure 1C shows analysis of RUP3 by RT-PCR with isolated huyman pancreatic islets of Langerhans.
  • Figure ID shows analysis of RUP3 expression with cDNAs of rat origin by RT-PCR.
  • Figure 2 A shows a polyclonal anti-RUP3 antibody prepared in Rabbits.
  • Figure 2B shows the expression of RUP3 in insulin-producing ⁇ cells of pancreatic islets.
  • Figure 3 shows functional activities of RUP3 In vitro.
  • Figure 4A shows a RUP3 RNA blot.
  • Figure 4B shows RUP3 agonist, Compound B84, stimulates cAMP production in HIT cells, at a level comparable to that seen with the adenyl cyclase activator forskolin.
  • Figure 4C shows RUP3 agonist, Compound B84, stimulates insulin secretion in HIT cells exposed to 15 mM glucose, at a level comparable to that seen with the adenylcyclase activator forskolin.
  • Figure 4D shows two RUP3 compounds, Compounds A48 and A51 (at 10 ⁇ M concentration), and the enhanced glucose-dependent insulin release compared to control.
  • Figure 5A shows the In vivo effects of a RUP3 agonist (Compound B70) on glucose homeostasis in mice and specifically the effect by a RUP3 agonist in a dose-dependent manner on the lowering of blood glucose after glucose challenge.
  • a RUP3 agonist Compound B70
  • Figure 5B shows the acute response of db mice to a RUP 3 agonist and Ex-4.
  • Figure 5B shows Compound B70 and Ex-4 significantly reduces glucose levels compared to vehicle control.
  • Figure 6 shows a representative scheme for the syntheses of compounds of the present invention.
  • AGONISTS shall mean moieties that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes.
  • AMTNO ACID ABBREVIATIONS used herein are set out in Table 1 :
  • C ⁇ acyl denotes an alkyl radical attached to a carbonyl wherein the definition of alkyl has the same definition as described herein; some examples include formyl, acetyl, propionyl, butanoyl, iso-butanoyl. pentanoyl, hexanoyl, heptanoyl, and the like.
  • C ⁇ acyloxy denotes an acyl radical attached to an oxygen atom wherein acyl has the same definition has described herein; some examples include acetyloxy, propionyloxy, butanoyloxy, zw-butanoyloxy and the like.
  • C 2 -6 alkenyl denotes a radical containing 2 to 6 carbons wherein at least one carbon-carbon double bond is present, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons. Both E and Z isomers are embraced by the term “alkenyl.” Furthermore, the term “alkenyl” includes di- and tri-alkenyls. Accordingly, if more than one double bond is present then the bonds may be all E or Z or a mixtures of E and Z.
  • alkenyl examples include vinyl, allyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3- pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexanyl, 2,4-hexadienyl and the like.
  • C ⁇ alkoxy denotes a radical alkyl, as defined herein, attached directly to an oxygen atom.
  • Example include methoxy, ethoxy, n- propoxy, z ' s ⁇ -propoxy, n-butoxy, t-butoxy, iso-butoxy and the like.
  • C ⁇ alkyl denotes a straight or branched carbon radical containing 1 to 8 carbons, some embodiments are 1 to 6 carbons, some embodiments are 1 to 3 carbons, and some embodiments are 1 or 2 carbons.
  • Examples of an alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, t-butyl, amyl, t-amyl, n-pentyl and the like.
  • C ⁇ alkylcarboxamido denotes a single alkyl group attached to an amide, wherein alkyl has the same definition as found herein.
  • the C ⁇ alkylcarboxamido may be represented by the following:
  • Examples include N-methylcarboxamide, N-ethylcarboxamide, N-(iso- pro ⁇ yl)carboxamide and the like.
  • C 1 -C 3 alkylene refers to a divalent straight carbon group, such as, -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -.
  • C ⁇ alkylsulfinyl denotes an alkyl radical attached to a sulfoxide radical of the formula: -S(O)- wherein the alkyl radical has the same definition as described herein. Examples include methylsulfinyl, ethylsulfinyl and the like.
  • C ⁇ alkylsulfonamide refers to the groups
  • C ⁇ alkylsulfonyl denotes an alkyl radical attached to a sulfone radical of the formula: -S(O) 2 - wherein the alkyl radical has the same definition as described herein. Examples include methylsulfonyl, ethylsulfonyl and the like.
  • C ⁇ alkylthio denotes an alkyl radical attached to a sulfide of the formula: -S- wherein the alkyl radical has the same definition as described herein. Examples include methylsulfanyl (i.e., CH 3 S-), ethylsulfanyl, isopropylsulfanyl and the like.
  • C ⁇ alkylthiocarboxamide denotes a thioamide of the following formulae:
  • C ⁇ alkylthioureyl denotes the group of the formula: - ⁇ C(S) ⁇ - wherein one are both of the nitrogens are substituted with the same or different alkyl group and alkyl has the same definition as described herein.
  • alkylthioureyl examples include, CH 3 NHC(0)NH-, NH 2 C(0)NCH 3 -, (CH 3 ) 2 N(0)NH-, (CH 3 ) 2 N(0)NH-, (CH 3 ) 2 N(0)NCH 3 -, CH 3 CH 2 NHC(0)NH-, CH 3 CH 2 NHC(0)NCH 3 -, and the like.
  • C ⁇ alkylureyl denotes the group of the formula: -NC(0)N- wherein one are both of the nitrogens are substituted with the same or different alkyl group wherein alkyl has the same definition as described herein.
  • alkylureyl examples include, CH 3 NHC(0)NH-, NH 2 C(0)NCH 3 -, (CH 3 ) 2 N(0)NH-, (CH 3 ) 2 N(0)NH-, (CH 3 ) 2 N(0)NCH 3 -, CH 3 CH 2 NHC(0)NH-, CH 3 CH 2 NHC(0)NCH 3 -, and the like.
  • C 2 _ 6 alkynyl denotes a radical containing 2 to 6 carbons and at least one carbon-carbon triple bond, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons.
  • alkynyl examples include ethynyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3- hexynyl, 4-hexynyl, 5-hexynyl and the like.
  • alkynyl includes di- and tri- ynes.
  • amino denotes the group -NH 2 .
  • C ⁇ alkylamino denotes one alkyl radical attached to an amino radical wherein the alkyl radical has the same meaning as described herein. Some examples include methylamino, ethylamino, propylamino and the like.
  • aryl denotes an aromatic ring radical containing 6 to 10 ring carbons. Examples include phenyl and naphthyl.
  • arylalkyl defines a C 1 -C 4 alkylene, such as -CH 2 -, -CH 2 CH 2 - and the like, which is further substituted with an aryl group.
  • Examples of an “arylalkyl” include benzyl, phenethylene and the like.
  • ary ⁇ carboxamido denotes a single aryl group attached to the amine of an amide, wherein aryl has the same definition as found herein.
  • the example is N-phenylcarboxamide.
  • arylureyl denotes the group - ⁇ C(O) ⁇ - where one of the nitrogens are substituted with an aryl.
  • benzyl denotes the group -CH 2 C-6H 5 .
  • carbo-C ⁇ -alkoxy refers to an alkyl ester of a carboxylic acid, wherein the alkyl group is C ⁇ . Examples include carbomethoxy, carboethoxy, carboisopropoxy and the like.
  • carboxylate refers to the group -CONH 2 .
  • carboxy or “carboxyl” denotes the group -CO 2 H; also referred to as a carboxylic acid.
  • cyano denotes the group -CN.
  • C 3 . 7 cycloalkenyl denotes a non-aromatic ring radical containing 3 to 6 ring carbons and at least one double bond; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentenyl, cyclohexenyl, and the like.
  • C 3 . 7 cycloalkyl denotes a saturated ring radical containing 3 to 6 carbons; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
  • C 3 - 6 cycloalkyl-C ⁇ -alkylene denotes a saturated ring radical containing 3 to 6 carbons bonded to a C ⁇ -alkylene as described herein; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl-CH 2 -, cyclopropyl-CH 2 CH 2 -, cyclobutyl-CH 2 -, cyclopentyl-CH 2 -, cyclohexyl-CH 2 -, and the like.
  • G t -s diacylamino denotes an amino group bonded with two acyl groups defined herein wherein the acyl groups may be the same or different, such as:
  • Represented dialkylamino groups include diacetylamino, dipropionylamino, acetylpropionylamino and the like.
  • C 2 - 6 dialkylamino denotes an amino substituted with two of the same or different alkyl radicals wherein alkyl radical has the same definition as described herein. Some embodiments are C ⁇ dialkylamino groups. Some examples include dimethylamino, methylethylamino, diethylamino and the like.
  • C ⁇ dialkylcarboxamido or "C ⁇ dialkylcarboxamide”denotes two alkyl radicals, that are the same or different, attached to an amide group, wherein alkyl has the same definition as described herein.
  • a C ⁇ dialkylcarboxamido may be represented by the following groups:
  • dialkylcarboxamide examples include N,N-dimethylcarboxamide, N-methyl-N- ethylcarboxamide and the like.
  • C 2 . 6 dialkylsulfonamide refers to one of the following groups shown below:
  • C ⁇ dialkylthiocarboxamido or "C ⁇ dialkylthiocarboxamide” denotes two alkyl radicals, that are the same or different, attached to a thioamide group, wherein alkyl has the same definition as described herein.
  • a C ⁇ dialkylthiocarboxamido may be represented by the following groups: S S if N N C ⁇ alkyl
  • dialkylthiocarboxamide examples include NN-dimethylthiocarboxamide, N- methyl-N-ethylthiocarboxamide and the like.
  • C ⁇ dialkylsulfonylamino refers to an amino group bonded with two C ⁇ alkylsulfonyl groups as defined herein.
  • ethynylene refers to the carbon-carbon triple bond group as represented below:
  • C ⁇ haloalkoxy denotes a haloalkyl, as defined herein, that is directly attached to an oxygen to form a difluoromethoxy, trifluoromethoxy, 2,2,2- trifluoroethoxy, pentafluoroethoxy and the like.
  • C ⁇ haloalkyl denotes an alkyl group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted represented by the formula C n F 2n+I ; when more than one halogen is present they may be the same or different and selected from F, Cl, Br or I. Some embodiments are 1 to 3 carbons. Examples include fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2- trifluoroethyl, pentafluoroethyl and the like.
  • C ⁇ haloalkylcarboxamide denotes an alkylcarboxamide group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted represented by the formula C n F 2n+ ⁇ and "n" is 1, 2, 3 or 4.
  • n is 1, 2, 3 or 4.
  • halogen When more than one halogen is present they may be the same or different and selected from F, Cl, Br or I. Examples include 2-fluoroacetyl, 2,2-difluoroacetyl, 2,2,2-trifluoroacetyl, 2-chloro-2,2- difluoroacetyl, 3,3,3-trifluoropropionyl, 2,2,3,3,3-pentafluoropropionyl and the like.
  • C ⁇ haloalkylsulfinyl denotes a haloalkyl radical attached to a sulfoxide of the formula: -S(O)- wherein the alkyl radical has the same definition as described herein. Examples include trifluoromethylsulfinyl, 2,2,2-trifluoroethylsulfinyl, 2,2-difluoroethylsulfinyl and the like.
  • C ⁇ haloalkylsulfonyl denotes a haloalkyl attached to a sulfone of the formula: -S(O) 2 - wherein haloalkyl has the same definition as described herein. Examples include trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2,2- difiuoroethylsulfonyl and the like.
  • C ⁇ haloalkylthio denotes an alkylthio radical substituted with one or more halogens. Examples include trifluoromethylthio, 1,1-difluoroethylthio, 2,2,2-trifluoroethylthio and the like.
  • halogen or halo denotes to a fluoro, chloro, bromo or iodo group.
  • C ⁇ heteroalkylene refers to a C ⁇ alkylene bonded to a heteroatom selected from O, S, S(O), S(0) 2 and NH.
  • heteroaryl denotes an aromatic ring system that may be a single ring, two fused rings or three fused rings containing carbons and at least one ring heteroatom selected from O, S and N.
  • heteroaryl groups include, but not limited to, pyridyl, benzofuranyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, quinoline, benzoxazole, benzothiazole, lH-benzimidazole, isoquinoline, quinazoline, quinoxaline, l ⁇ -imidazolyl, [l,2,4]triazolyl, [l,2,3]triazolyl, [l,2,4jtriazolyl, pyrrolyl, pyrazolyl, l ⁇ -pyrazolyl, imidazolyl, oxazolyl, oxazolyl, [l,3,4]oxadiazolyl, [l,3,4]thi
  • heterocyclic denotes a non-aromatic carbon ring (i.e., cycloalkyl or cycloalkenyl as defined herein) wherein one, two or three ring carbons are replaced a heteroatom, such as, O, S, N, wherein the N can be optionally substituted with ⁇ , C ⁇ acyl or C ⁇ alkyl, and ring carbon atoms optionally substituted with oxo or a thiooxo thus forming a carbonyl or thiocarbonyl group.
  • the heterocyclic group is a 3-, 4-, 5-, 6- or 7-membered containing ring.
  • heterocyclic group examples include but not limited to aziridin-1-yl, aziridin-2-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, piperidin-1-yl, piperidin-4-yl, morpholin-4-yl, piperzin-1-yl, piperzin-4- yl, pyrrolidin-1-yl, pyrrolidin-3-yl, [l,3]-dioxolan-2-yl and the like. Additional examples of heterocyclic groups are shown in Tables 2B, 2C, 2D, 2E, 2F and 2G, infra.
  • heterocycliccarboxamido denotes a heterocyclic group with a ring nitrogen where the ring nitrogen is bonded directly to the carbonyl forming an amide. Examples include:
  • heterocyclicsulfonyl denotes a heterocyclic group with a ring nitrogen where the ring nitrogen is bonded directly to an S0 2 group forming an sulfonamide. Examples include:
  • hydroxyl refers to the group -OH.
  • hydroxylamino refers to the group -NHOH.
  • nitro refers to the group -N0 2 .
  • Q- 7 oxo-cycloalkyl refers to a C 4 - 7 cycloalkyl, as defined herein, wherein one of the ring carbons is replaced with a carbonyl.
  • G ⁇ ? oxo- cycloalkyl include but are not limited to: 2-oxo-cyclobutyl, 3-oxo-cyclobutyl, 3-oxo- cyclopentyl, 4-oxo-cyclohexyl, and the like and represented the following structures respectively:
  • perfluoroalkyl denotes the group of the formula -C n F 2n+ ⁇ ; stated differently, a perfluoroalkyl is an alkyl as defined herein herein wherein the alkyl is fully substituted with fluorine atoms and is therefore considered a subset of haloalkyl.
  • perfluoroalkyls include CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 , CF(CF 3 ) 2 , CF 2 CF 2 CF 2 CF 3 , CF 2 CF(CF 3 ) 2 , CF(CF 3 )CF 2 CF 3 and the like.
  • phenoxy refers to the group C ⁇ HsO-.
  • phenyl refers to the group CgHs-.
  • sulfonic acid refers to the group -S0 3 H.
  • tetrazolyl refers to the five membered heteroaryl of the following formulae:
  • the tetrazolyl group is further substituted at either the 1 or 5 position resepectively.
  • thiol denotes the group -SH.
  • CODON shall mean a grouping of three nucleotides (or equivalents to nucleotides) which generally comprise a nucleoside (adenosine (A), guanosine (G), cytidine (C), uridine (U) and thymidine (T)) coupled to a phosphate group and which, when translated, encodes an amino acid.
  • A adenosine
  • G guanosine
  • C cytidine
  • U uridine
  • T thymidine
  • COMPOSITION shall mean a material comprising at least two compounds or two components; for example, and not limitation, a Pharmaceutical Composition is a Composition.
  • COMPOUND EFFICACY shall mean a. measurement of the ability of a compound to inhibit or stimulate receptor functionality, as opposed to receptor binding affinity.
  • CONSTITUTIVELY ACTIVATED RECEPTOR shall mean a receptor subject to constitutive receptor activation.
  • CONSTITUTIVE RECEPTOR ACTIVATION shall mean stabilization of a receptor in the active state by means other than binding of the receptor with its endogenous ligand or a chemical equivalent thereof.
  • CONTACT or CONTACTING shall mean bringing at least two moieties together, whether in an in vitro system or an in vivo system.
  • ENDOGENOUS shall mean a material that a mammal naturally produces.
  • ENDOGENOUS in reference to, for example and not limitation, the term "receptor" shall mean that which is naturally produced by a mammal (for example, and not limitation, a human) or a virus.
  • the term NON-ENDOGENOUS in this context shall mean that which is not naturally produced by a mammal (for example, and not limitation, a human) or a virus.
  • a receptor which is not constitutively active in its endogenous form, but when manipulated becomes constitutively active is most preferably referred to herein as a "non-endogenous, constitutively activated receptor.”
  • Both terms can be utilized to describe both "in vivo" and “in vitro" systems.
  • the endogenous or non-endogenous receptor may be in reference to an in vitro screening system.
  • screening of a candidate compound by means of an in vivo system is viable.
  • INDIVIDUAL refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • INHIBIT or INHIBITING in relationship to the term "response” shall mean that a response is decreased or prevented in the presence of a compound as opposed to in the absence of the compound.
  • INVERSE AGONISTS shall mean moieties that bind the endogenous form of the receptor or to the constitutively activated form of the receptor, and which inhibit the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of agonists or partial agonists, or decrease GTP binding to membranes.
  • the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50%, and most preferably by at least 75%), as compared with the baseline response in the absence of the inverse agonist.
  • LIGAND shall mean an endogenous, naturally occurring molecule specific for an endogenous, naturally occurring receptor.
  • MODULATE or MODULATING shall mean to refer to an increase or decrease in the amount, quality, response or effect of a particular activity, function or molecule.
  • PHARMACEUTICAL COMPOSITION shall mean a composition comprising at least one active ingredient, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, and not limitation, a human).
  • a mammal for example, and not limitation, a human.
  • One aspect of the present invention pertains to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la):
  • One aspect of the present invention encompasses N-oxides of 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (la).
  • One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is NR 4 and compounds may be represented by Formula (lb) as shown below:
  • P ⁇ is H. In some embodiments, is CH 3 or CH 2 CH 3 .
  • One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is O, (i.e., an oxygen atom) and compounds may be represented by Formula (Ic) as shown below:
  • One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is S, S(O) or S(0) 2 and compounds may be represented by Formulae (Id), (le) and (If) respectively as shown below:
  • One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is absent and compounds may be represented by Formula (Ig) as shown below: dg) wherein each variable in Formula (Ig) has the same meaning as described herein.
  • compounds of the present invention are of Formula (Ig) wherein V is absent and accordingly these compounds may be represented by Formula (Ih) as shown below:
  • One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is absent and V is ethynylene.
  • Compounds may be represented by Formula (Ii) as shown below:
  • V is C ⁇ alkylene optionally substituted with 1 to 4 substituents selected from the group consisting of C ⁇ alkyl, C ⁇ alkoxy and halogen.
  • V is a methylene group (i.e., -CH 2 -).
  • V is an ethylene group (i.e., -CH 2 CH 2 -).
  • V is a methylene and W is an oxygen atom.
  • V is methylene and W is a N j group.
  • V is methylene and W is a NH group.
  • V is ethylene and W is an oxygen atom.
  • V is ethylene and W is a R group.
  • V is ethylene and W is a NH group.
  • V is C ⁇ heteroalkyle ⁇ e optionally substituted with 1 to 4 substituents selected from the group consisting of C ⁇ alkyl, C ⁇ alkoxy and halogen.
  • V is -OCH 2 CH 2 -.
  • V is -OCH 2 CH 2 - and W is an oxygen atom and may be represented by the formula: -OCH 2 CH 2 0-.
  • N is -OCH 2 CH 2 - and W is a ⁇ H group and may be represented by the formula: - OCH 2 CH 2 ⁇ H-.
  • V is absent and may be represented by Formula (Ij) as shown below:
  • a and B are both methylene wherein A and B are optionally substituted with 1 to 2 methyl groups and therefore form a four-membered nitrogen containing ring.
  • compounds of the invention may be represented by Formula (Ik) as shown below:
  • A is ethylene and B is methylene wherein A is optionally substituted with 1 to 4 methyl groups and B is optionally substituted with 1 to 2 methyl groups.
  • compounds of the invention may be represented by Formula (Im) as shown below:
  • D is -CHR 2 -.
  • R 2 is C ⁇ alkylsulfonyl.
  • A is propylene and B is methylene wherein A is optionally substituted with 1 to 4 methyl groups and B is optionally substituted with 1 to 2 methyl groups.
  • compounds of the invention may be represented by Formula (In) as shown below:
  • a and B are both ethylene wherein A and B are optionally substituted with 1 to 4 methyl groups.
  • compounds of the invention may be represented by Formula (Io) as shown below:
  • A is propylene and B is ethylene wherein A and B are optionally substituted with 1 to 4 methyl groups.
  • compounds of the invention may be represented by Formula (Ip) as shown below:
  • a and B are both propylene wherein A and B are optionally substituted with 1 to 4 methyl groups.
  • compounds of the invention may be represented by Formula (Iq) as shown below:
  • D is O, S, S(O) or S(0) 2 . In some embodiments, D is S, S(O) or S(0) 2 ; and A and B are independently optionally substituted with 1 or 2 methyl groups. In some embodiments, A and B are ethylene groups. In some embodiments, A and B are ethylene groups substituted with 2 methyl groups and D is an oxygen atom (i.e., forming a 2,6-dimethyl-morpholin-4-yl group).
  • D is CR 2 R3.
  • R 2 is selected from the group consisting of H, C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ allcylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxyl, C 3 . ⁇ cycloalkyl, C ⁇ haloalkoxy, C ⁇ haloalkyl, halogen and hydroxyl.
  • R 2 is selected from the group consisting of C(0)CH 3 , C(0)CH 2 CH 3 , C(0)CH 2 CH 2 CH 3 , C(0)CH(CH 3 ) 2 , C(0)CH 2 CH 2 CH 2 CH 3; OC(0)CH 3 , 0C(0)CH 2 CH 3j OC(0)CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 (CH 2 ) 2 CH 3 , CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 3 )(CH 2 CH 3 ), CH 2 (CH 2 ) 2 CH 3 , CH 2 (CH 2 ) 3 CH 3 , C(0)NHCH 3 , C(0)NHCH 2 CH 3 , C(0)NHCH 2 CH 2 CH 3 , C(0)NHCH(CH 3 ) 2 , C(0)NHCH 2 (CH 2 ) 2 CH 3 , C0 2 CH 3
  • R 2 is selected from the group consisting of C(0)CH 3 , C(0)CH 2 CH 3 , C(0)CH 2 CH 2 CH 3 , C(0)CH(CH 3 ) 2 , C(0)CH 2 CH 2 CH 2 CH 3 , OC(0)CH 3 , OC(0)CH 2 CH 3 , OC(0)CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 (CH 2 ) 2 CH 3 , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 3 )(CH 2 CH 3 ), CH 2 (CH 2 ) 2 CH 3 , CH 2 (CH 2 ) 3 CH 3 , C(0)NH 2 , C0 2 CH 3 , C0 2 CH 2 CH 3 , C0 2 CH 2 CH 2 CH 3 , C0 2 CH(CH 3 ) 2 , C0 2 CH 2 (CH 2 ) 2 CH 3 , C(0)NH 2 , C0 2 CH
  • R 2 is selected from the group consisting of SCH 3 , SCH 2 CH 3 , SCH 2 CH 2 CH 3 , SCH(CH 3 ) 2 , SCH 2 (CH 2 ) 2 CH 3 , S(0)CH 3 , S(0)CH 2 CH 3 , S(0)CH 2 CH 2 CH 3 , S(0)CH(CH 3 ) 2 , S(0)CH 2 (CH 2 ) 2 CH 3 , S(0) 2 CH 3 , S(0) 2 CH 2 CH 3 , S(0) 2 CH 2 CH 2 CH 3 , S(0) 2 CH(CH 3 ) 2 , S(0) 2 CH 2 (CH 2 ) 2 CH 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, OCF3, OCHF 2 , CF 3 , CHF 2 and F.
  • R 2 is selected from the group consisting of S(0) 2 CH 3 , S(0) 2 CH 2 CH 3 , S(0) 2 CH 2 CH 2 CH 3 , S(0) 2 CH(CH 3 ) 2 , S(0) 2 CH 2 (CH 2 ) 2 CH 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, hydroxyl, and F.
  • R 2 is C ⁇ alkyl, or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfonyl, carbo-C ⁇ -alkoxy, carboxamide, carboxy, C 3 - 6 -cycloalkyl, Q ⁇ -cycloalkyl- C ⁇ -alkylene, C 3 . 6 -cycloalkyl-C ⁇ - 3 -heteroalkylene, and hydroxyl.
  • R 2 is selected from the group consisting of CH 2 OCH 3 , CH 2 CH 2 OCH 3 , CH 2 OCH 2 CH 3 , CH 2 OCH 2 CH 2 CH 3 , CH 2 CH 2 OCH 2 CH 3 , CH 2 CH 2 OCH 2 CH 2 CH 3) CH 2 OCH(CH 3 ) 2 , CH 2 OCH 2 CH(CH 3 ) 2 , CH 2 C0 2 H, CH 2 CH 2 C0 2 H, CH 2 OH, CH 2 CH 2 OH and CH 2 CH 2 CH 2 0H.
  • R 2 is C ⁇ - 8 alkyl, heteroaryl or phenyl each optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylamino, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 _ 6 -cycloalkyl-C ⁇ -heteroalkylene, C 2 - 8 dialkylamino, C 2 .
  • R 2 is selected from the group consisting of CH 2 OCH 3 , CH 2 CH 2 OCH 3 , CH 2 OCH 2 CH 3 , CH 2 OCH 2 CH 2 CH 3 , CH 2 CH 2 OCH 2 CH 3 , CH 2 CH 2 OCH 2 CH 2 CH 3 , CH 2 OCH(CH 3 ) 2 , CH 2 OCH 2 CH(CH 3 ) 2 , CH 2 C0 2 H, CH 2 CH 2 C0 2 H, CH 2 OH, CH 2 CH 2 OH and CH 2 CH 2 CH 2 OH.
  • R 2 is selected from the group consisting of CH 2 SCH , CH 2 SCH 2 CH 3 , CH 2 SCH 2 CH 2 CH 3 , CH 2 SCH(CH 3 ) 2 , CH 2 SCH 2 (CH 2 ) 2 CH 3 , CH 2 CH 2 SCH 3 , CH 2 CH 2 SCH 2 CH 3 , CH 2 CH 2 SCH(CH 3 ) 2 , CH 2 CH 2 SCH 2 (CH 2 ) 2 CH 3 , CH 2 S(0)CH 3 , CH 2 S(0)CH 2 CH 3 , CH 2 S(0)CH 2 CH 2 CH 3 , CH 2 S(0)CH(CH 3 ) 2 , CH 2 S(0)CH 2 (CH 2 ) 2 CH 3 , CH 2 CH 2 S(0)CH 3 , CH 2 CH 2 S(0)CH 2 CH 3 , CH 2 CH 2 S(0)CH 3 , CH 2 CH 2 S(0)CH 2 CH 3 , CH 2 CH 2 S(0)CH 3 , CH 2 CH 2 S(0)CH 2 CH 3 , CH 2 CH 2 S(0)CH 3 , CH 2 CH 2 S
  • R 2 is selected from the group consisting of CH 2 0CH 2 ⁇ cyclopropyl, CH 2 OCH 2 -cyclobutyl, CH 2 OCH 2 -cyclopentyl, CH 2 OCH 2 -cyclohexyl, CH 2 OCH 2 CH 2 -cyclopropyl, CH 2 OCH 2 CH 2 -cyclobutyl, CH 2 OCH 2 CH 2 -cyclopentyl, CH 2 OCH 2 CH 2 -cyclohexyl, CH 2 CH 2 OCH 2 -cyclopropyl, CH 2 CH 2 ⁇ CH 2 -cyclobutyl, CH 2 CH 2 ⁇ CH 2 -cyclopentyl, CH 2 CH 2 OCH 2 -cyclohexyl, CH 2 CH 2 OCH 2 CH 2 -cyclopropyl, CH 2 CH 2 OCH 2 CH 2 -cyclobutyl, CH 2 CH 2 OCH 2 CH 2 -cyclopropyl, CH 2 CH 2 OCH 2 CH 2 -cyclobut
  • R 2 is selected from the group consisting of l,2,4-oxadiazol-3- yl, l,2,4-oxadiazol-5-yl, l,3,4-oxadiazol-2-yl, l,2,4-triazol-5-yl and 1,2,4-triazol-l-yl, 3- methyl-l,2,4-oxadiazol-5-yl, 3-methyl-l,2,4-oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 5- ethyl-l,2,4-oxadiazol-3-yl, 5-methyl-l,3,4-oxadiazol-2-yl, 5-ethyl-l,3,4-oxadiazol-2-yl, 3- methyl-l,2,4-triazol-5-yl, 3-ethyl-l,2,4-triazol-5-yl, 3-ethyl-l,2,4-triazol-5-yl, 3-methyl-
  • R 2 is selected from the group consisting of l,2,4-oxadiazol-3- yl, l,2,4-oxadiazol-5-yl, l,3,4-oxadiazol-2-yl, 3-methyl-l,2,4-oxadiazol-5-yl, 3 -ethyl- 1,2,4- oxadiazol-5-yl, 3-isopropyl-l,2,4-oxadiazol-5-yl, 3-propyl-l,2,4-oxadiazol-5-yl, 3-t-butyl- l,2,4-oxadiazol-5-yl, and 3-cyclopropyl-l,2,4-oxadiazol-5-yl.
  • R 2 is selected from the group consisting of 3-methyl-l,2,4- oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 3-propyl-l,2,4-oxadiazol-5-yl, 3-isopropyl- l,2,4-oxadiazol-5-yl, 3-butyl-l,2,4-oxadiazol-5-yl, and 3-(t-butyl)-l,2,4-oxadiazol-5-yl.
  • R 2 is a heteroaryl comprising 5 -atoms in the aromatic ring and are represented by the following formulae:
  • a imidazolyl ring can be bonded at one of the ring nitrogens (i.e., imidazol-1-yl group) or at one of the ring carbons (i.e., imidazol-2-yl, imidazol-4-yl or imiadazol-5-yl group).
  • R 2 is a 5-membered heteroaryl optionally substituted with 1 to 4 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylamino, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 _ 6 -cycloalkyl-C ⁇ - heteroalkylene, C 2 .
  • R 2 is a 5 -membered heteroaryl optionally substituted with 1 to 4 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylamino, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ - alkoxy, carboxamide, carboxy, cyano, C 3 - 6 -cycloalkyl-C ⁇ -heteroalkylene, C 2 .
  • R 2 is a 5-membered heteroaryl optionally substituted with 1 or 2 substituents selected from the group consisting of C ⁇ alkyl, C ⁇ haloalkyl and halogen; and R 3 is hydrogen.
  • R 2 is a 5-membered heteroaryl optionally substituted with lor 2 C ⁇ alkyl substituents; and R 3 is hydrogen.
  • R 2 is a 5-membered heteroaryl optionally substituted with CH 3 , CH 2 CH 3 . CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , C(CH 3 ) 3 ; and R 3 is hydrogen.
  • R 2 is a fused heteroaryl group containing to aromatic rings wherein at least one is a heteroaryl ring, such as, benzofuranyl, benzimidazole, benzoxazole, benzothiazole, indole, benzothiophenyl.
  • R 2 is a benzofuran-2-yl group.
  • R 2 is a heterocyclic represented, for example, by the formulae in TABLE 2B.
  • any one of the heterocyclic groups shown in TABLES 2B to 2E may be bonded at any available ring carbon or ring nitrogen as allowed by the respective formula.
  • a 2,5-dioxo-imidazolidinyl group may be bonded at the ring carbon or at either of the two ring nitrogens to give the following formulae respectively:
  • R 2 is a heterocyclic represented, for example, by the formulae in TABLE 2C.
  • R 2 is a heterocyclic represented, for example, by the formulae in TABLE 2D.
  • R 2 is a heterocyclic represented, for example, by the formulae in TABLE 2E.
  • R 2 is a heterocyclic represented, for example, by the formulae in TABLE 2F wherein the C ⁇ alkyl group on the respective ring nitrogen atoms may be the same or different.
  • R 2 is a heterocyclic represented, for example, by the formulae in TABLE 2G wherein the C ⁇ alkyl group on the respective ring nitrogen atoms may be the same or different.
  • D is CR 2 R 3 and R 2 is -Ar 2 -Ar 3 wherein Ar 2 and Ar 3 are independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, amino, carbo- C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 .
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, amino, carbo- C
  • Ar 2 is a heteroaryl comprising 5-atoms in the aromatic ring and are represented by the following formulae:
  • a imidazolyl ring can be bonded at one of the ring nitrogens (i.e., imidazol-1-yl group) or at one of the ring carbons (i.e., imidazol-2-yl, imidazol-4-yl or imiadazol-5-yl group) and Ar 3 is bonded to any remaining available ring atom.
  • Ar 2 is a heteroaryl and Ar 3 is phenyl.
  • the heteroaryl and phenyl are optionally substituted with 1 to 5 substituents selected from the .. group consisting of H, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, halogen, hydroxyl and nitro.
  • D is CR 2 R 3 and R 2 is Formula (B):
  • R ⁇ 4 is C ⁇ ' alkyl or C 3 - 6 cycloalkyl; and R1 5 is F, Cl, Br or CN. Li some embodiments, R M is C ⁇ alkyl and R 15 is F, Cl or CN.
  • D is CR 2 R 3 and R 2 is Formula (C):
  • Ar 4 is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. Li some embodiments, Ar is 2-pyridyl.
  • compounds of the present invention are represented by Formula (Is) as shown below:
  • D is CR 2 R 3
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 - 6 -cycloalkyl-C 1 - 3 -heteroalkylene, C 2 _ 6 dialkylcarboxamide, C ⁇ dialkylthiocarboxamide, C 2 .
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C ⁇ -cycloalkyl-C ⁇ -heteroalkylene, C 2 -6 dialkylcarboxamide, C ⁇ dialkylthiocarboxamide, C 2 - 6 dialkylsulfonamide, C ⁇ alkylthioureyl, C ⁇ haloalkoxy, - 4 haloalkyl, C ⁇ haloalkylsul
  • Ar is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is a 5-membered heteroaryl, for example, as shown in TABLE 2A supra.
  • Ar is a 6-membered heteroaryl, for example, the 6-membered heteroaryls as shown in TABLE 4:
  • Ar is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
  • Ar is 2-pyridyl.
  • D is CR 2 R 3
  • R 2 is Formula (C)
  • G is CR ⁇ 6 R ⁇ 7 and R 16 and R !7 are independently H or C ⁇ alkyl.
  • D is CR 2 R 3
  • R 2 is Formula (C)
  • G is S, S(0) or S(0) .
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 - 6 -cycloalkyl-C ⁇ -heteroalkylene, C 2 - 6 dialkylcarboxamide, C ⁇ dialkylthiocarboxamide, C 2 .
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C ⁇ -cycloalkyl-C ⁇ -heteroalkylene, C 2 .
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulf
  • dialkylcarboxamide C ⁇ dialkylthiocarboxamide, C 2 - 6 dialkylsulfonamide, C ⁇ alkylthioureyl, C ⁇ haloalkoxy, Ci- 4 haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, C ⁇ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro.
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ halo
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is a 5-membered heteroaryl, for example, as shown in TABLE 2A, supra.
  • Ar 4 is a 6-membered heteroaryl, for example, as shown in TABLE 4, supra.
  • Ar 4 is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. Li some embodiments, Ar is 2-pyridyl.
  • R 3 is H.
  • D is N-R 2 .
  • R 2 is selected from the group consisting of H, C ⁇ acyl, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonyl, carbo- C ⁇ -alkoxy, carboxamide, C 3 . 6 -cycloalkyl and C ⁇ haloalkyl.
  • R 2 is selected from the group consisting of C(0)CH 3 , C(0)CH 2 CH 3 , C(0)CH 2 CH 2 CH 3 , C(0)CH(CH 3 ) 2 , C(0)CH 2 CH 2 CH 2 CH 3 , CH 3 , CH 2 CH 3) CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 3 )(CH 2 CH 3 ), CH 2 (CH 2 ) 2 CH 3; CH 2 (CH 2 ) 3 CH 3 , C(0)NHCH 3 , C(0)NHCH 2 CH 3 , C(0)NHCH 2 CH 2 CH 3 , C(0)NHCH(CH 3 ) 2 , C(0)NHCH 2 (CH 2 ) 2 CH 3 , C0 2 CH 3 , C0 2 CH 2 CH 3 , C0 2 CH 2 CH 2 CH 3 , C0 2 CH(CH 3 ) 2 and C0 2 CH 2 (CH 2 ) 2 CH 3 .
  • R 2 is selected from the group consisting of S(0) 2 CH 3 , S(0) 2 CH 2 CH 3 , S(0) 2 CH 2 CH 2 CH 3 , S(0) 2 CH(CH 3 ) 2 , S(0) 2 CH 2 (CH 2 ) 2 CH 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH 2 CF 3 , CF 3 and CHF 2 .
  • D is N-R 2 and R 2 is H, or carbo-C ⁇ -alkoxy.
  • R 2 is selected from the group consisting of C0 2 CH 3 , C0 2 CH 2 CH 3 , C0 2 CH 2 CH 2 CH 3 , C0 2 CH(CH 3 ) 2 and C0 2 CH 2 (CH 2 ) 2 CH 3 .
  • R 2 is C ⁇ alkyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ alkylsulfonyl, carbo-C ⁇ -alkoxy, and carboxy.
  • R 2 is CH 2 C0 2 Et,.or , CH 2 CH 2 C0 2 H.
  • R 2 is selected from the group consisting of CH 2 CH 2 S(0) 2 CH 3 , CH 2 CH 2 S(0) 2 CH 2 CH 3 , CH 2 CH 2 S(0) 2 CH 2 CH 2 CH 3 , CH 2 CH 2 S(0) 2 CH(CH 3 ) 2 and CH 2 CH 2 S(0) 2 CH 2 (CH 2 ) 2 CH 3 .
  • D is N-R 2 wherein R 2 is C ⁇ alkyl, heteroaryl or phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylamino, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C ⁇ -cycloalkyl-C ⁇ -heteroalkylene, C 2 .
  • R 2 is C ⁇ alkyl, heteroaryl or phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy
  • dialkylamino C 2 . 6 dialkylcarboxamide, C ⁇ dialkylthiocarboxamide, C 2 - 6 dialkylsulfonamide, C ⁇ allcylthioureyl, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, C ⁇ haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro.
  • R 2 is selected from the group consisting of CH 2 CH 2 OCH 3 , CH 2 CH 2 OCH 2 CH 3 , CH 2 CH 2 OCH 2 CH 2 CH 3 , CH 2 C0 2 H, CH 2 CH 2 C0 2 H, CH 2 CH 2 OH and CH 2 CH 2 CH 2 OH.
  • R 2 is selected from the group consisting of CH 2 CH 2 SCH 3 , CH 2 CH 2 SCH 2 CH 3 , CH 2 CH 2 SCH 2 CH 2 CH 3 , CH 2 CH 2 SCH(CH 3 ) 2 , CH 2 CH 2 SCH 2 (CH 2 ) 2 CH 3 , CH 2 CH 2 S(0)CH 3 , CH 2 CH 2 S(0)CH 2 CH3, CH 2 CH 2 S(0)CH 2 CH 2 CH 3J CH 2 CH 2 S(0)CH(CH 3 ) 2 , CH 2 CH 2 S(0)CH 2 (CH 2 ) 2 CH 3 , CH 2 CH 2 S(0) 2 CH 3 , CH 2 CH 2 S(0) 2 CH 3 , CH 2 CH 2 S(0) 2 CH 2 CH 3 , CH 2 CH 2 S(0) 2 CH 2 CH 3 , CH 2 CH 2 S(0) 2 CH 2 CH 3 , CH 2 CH 2 S(0) 2 CH(CH 3 ) 2 and CH 2 CH 2 S(0) 2 CH 2 (CH 2 ) 2 CH 3 .
  • R 2 is selected from the group consisting of l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl, 1,3,4- oxadiazol-2-yl, l,2,4-triazol-5-yl and 1,2,4-triazol-l-yl, 3-methyl-l,2,4-oxadiazol-5-yl, 3- methyl-l,2,4-oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 5- methyl-l,3,4-oxadiazol-2-yl, 5-ethyl-l,3,4-oxadiazol-2-yl, 3 -methyl- l,2,4-xriazol-5-yl, 3- ethyl-l,2,4-triazol-5-yl, 3 -methyl- 1,2,4-triazol-l-
  • D is N-R 2 and R 2 is -Ar 2 -Ar 3 wherein Ar 2 and Ar 3 are independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of H, C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 . 6 -cycloalkyl, C 2 . 6 dialkylcarboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, halogen, hydroxyl and nitro.
  • Formula (It) as shown below:
  • Ar 2 is a heteroaryl and Ar 3 is phenyl.
  • the heteroaryl and phenyl are optionally substituted with 1 to 5 substituents selected from the group consisting of H, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, halogen, hydroxyl and nitro.
  • D is N-R 2 wherein R 2 is Formula (C):
  • D is N-R 2
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo ⁇ C ⁇ -alkoxy, carboxamide, carboxy, cyano, C ⁇ -cycloalkyl-C ⁇ -heteroalkylene, C 2 .
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ aikylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 .6-cycloalkyl-C ⁇ -heteroalkylene, C 2 .
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alky
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ halo
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar is a 5-membered heteroaryl, for example, as shown in TABLE 2A, supra.
  • Ar 4 is a 6-membered heteroaryl, for example, as shown in TABLE 4, supra.
  • Ar is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
  • Ar is 2-pyridyl.
  • D is N-R 2 wherein R 2 is Formula (C) and G is CR 16 R ⁇ -
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 .
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ allcylthioureyl, C ⁇ alkylureyl, amino, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C ⁇ -cycloalkyl-C ⁇ -heteroalkylene, C 2 .
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsul
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfinyl, C ⁇ haloalkylsulfonyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, C ⁇ halo
  • Ar 4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkyl, halogen and hydroxyl.
  • Ar 4 is a 5-membered heteroaryl, for example, as shown in TABLE 2A, supra.
  • Ar 4 is a 6-membered heteroaryl, for example, as shown in TABLE 4, supra.
  • Ar 4 is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
  • Ar is 2-pyridyl.
  • D is N-R 2 wherein R 2 is Formula (C), G is CR ⁇ 6 R ⁇ 7 and R ⁇ 6 and R i7 are independently H or C ⁇ alkyl.
  • Z is selected from the group consisting of C ⁇ acyl, C ⁇ alkyl, C ⁇ alkylcarboxamide, amino, cyano, Q-s diacylamino, C ⁇ dialkylsulfonamide, formyl, halogen, heterocyclic, and nitro wherein C ⁇ alkyl and C ⁇ acyl are each optionally substituted with 1, or 2 groups selected from the group consisting of C 2 . 4 dialkylmino, hydroxy, and halogen.
  • Z is selected from the group consisting of nitro, amino, formyl, NHC(0)CF 3 , Br, NHC(0)CH 3 , N(C(0)CH 3 ) 2 , N(S(0) 2 CH 3 ) 2 , CH 3 , [l,3]dioxolan-2- yl, CH 2 OH, CH 2 N(CH 3 ) 2 , and C(0)CH 3 .
  • Z is selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, C ⁇ alkylthioureyl, C ⁇ alkylureyl, carboxamide, carboxy, cyano, aryl, C ⁇ haloalkyl, C ⁇ haloalkylcarboxamide, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl, wherein C ⁇ alkyl is optionally substituted with 1, 2, 3 or 4 groups selected from the group consisting of C ⁇ acyl, C ⁇ acyloxy, C ⁇ alkoxy, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsul
  • Z is selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C ⁇ alkylthiocarboxamide, C ⁇ alkylthioureyl, C ⁇ alkylureyl, carboxamide, carboxy, cyano, aryl, C ⁇ haloalkyl, C ⁇ haloalkylcarboxamide, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl.
  • Z is a heterocyclic group.
  • Z is a 5- membered heterocyclic group containing two oxygen atoms.
  • Z is an alkyl group optionally substituted C 2 . 4 -dialkylamino or hydroxy.
  • Z is selected from the group consisting of formyl, NHC(0)CH 3 , NHC(0)CH 2 CH 3 , NHC(0)CH(CH 3 ) 2 , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 2 CH 3 , NHC(0)CF 3 , carboxy, CF 3 , CF 2 CF 3 , nitro and lH-tetrazol-5-yl.
  • Z is selected from the group consisting of carboxy, CF 3 , nitro and lH-tetrazol-5-yl.
  • Z is [l,3]-dioxolan-2-yl.
  • Z is a formyl group.
  • Z is a carboxy group.
  • Z is a -C ⁇ 2 O ⁇ group.
  • Z is a -CH 2 N(CH 3 ) 2 group.
  • Z is Formula (A):
  • R 7 is H, C ⁇ - 8 alkyl or C 3 - 6 cycloalkyl; and R 8 is H, nitro or nitrile. Li some embodiments, R 7 is H or C ⁇ alkyl.
  • Ri is selected from the group consisting of H, C ⁇ alkoxy, C ⁇ alkyl, C 2 - 6 alkynyl, amino, C 3 . 6 cycloalkyl and C ⁇ haloalkyl. Li some embodiments, Ri is H or amino.
  • Ri is selected from the group consisting of H, C ⁇ alkyl, and amino.
  • Ari is aryl optionally substituted with R 9 -R ]3 .
  • Ari is phenyl.
  • ⁇ is heteroaryl.
  • Ari is heteroaryl optionally substituted with R 9 -R ⁇ 3 .
  • Ari is a heteroaryl selected from TABLE 2A.
  • Ari is a heteroaryl selected from TABLE 4 or an N-oxide thereof.
  • compounds of the invention are of Formula (Iv):
  • Ari is heteroaryl and R 9 is selected from the group consisting of H, C ⁇ acyl, C alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C 2 . 6 alkynyl, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide and sulfonamide.
  • R 9 is selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C 2 - 6 alkynyl, C ⁇ alkylsulfonamide, C 2 . 6 dialkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, amino, arylsulfonyl, C 2 . 6 dialkylamino, C ⁇ dialkylsulfonamide, and carboxamide.
  • R 9 is selected from the group consisting of C(0)CH 3 , C(0)CH 2 CH 3 , C(0)CH 2 CH 2 CH 3 , C(0)CH(CH 3 ) 2 , C(0)CH 2 CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 2 CH 3 , CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 3 )(CH 2 CH 3 ), CH 2 (CH 2 ) 2 CH 3 , CH 2 (CH 2 ) 3 CH 3 , CH 2 (CH 2 ) 4 CH 3 , CH 2 (CH 2 ) 5 CH 3 , C(0)NHCH 3 , C(0)NHCH 2 CH 3 , C(0)NHCH 2 CH 2 CH 3 , C(0)NHCH(CH 3 ) 2 , C ⁇ CH, S(0) 2 NHCH 3 , S(0) 2 NHCH 2 CH 3 ,
  • R 9 is selected from the group consisting of cyano, C 3 . 6 cycloalkyl, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylsulfonyl, and C ⁇ haloalkylthio.
  • R 9 is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cl, F, Br, OCF 3 , OCHF 2 , OCH 2 CF 3 , CF 3 , CHF 2 , CH 2 CF 3 , SCF 3 , SCHF 2 and SCH 2 CF 3 .
  • R 9 is selected from the group consisting of CN, C0 2 Me, C0 2 Et, S(0) 2 CH 3 , S(0) 2 CF 3 , N(CH 3 ) 2 , N(Et) 2 , C(0)NHCH 3 , C(0)NHEt, C(0)N(CH 3 ) 2 , OH, OCH 3 , and OEt.
  • R 9 is selected from the group consisting of heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxy, C 4 - 7 oxo-cycloalkyl, phenoxy and phenyl.
  • R 9 is selected from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C 2 . 6 alkynyl, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, halogen "and sulfonamide.
  • R 9 is selected from the group consisting of C(0)CH 3 , C(0)CH 2 CH 3 , C(0)CH 2 CH 2 CH 3 , C(0)CH(CH 3 ) 2 , C(0)CH 2 CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 2 CH 3 , CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 3 )(CH 2 CH 3 ), CH 2 (CH 2 ) 2 CH 3 , CH 2 (CH 2 ) 3 CH 3 , CH 2 (CH 2 ) 4 CH 3 , CH 2 (CH 2 ) 5 CH 3; C(0)NHCH 3 , C(0)NHCH 2 CH 3 , C(0)NHCH 2 CH 2 CH 3 , C(0)NHCH(CH 3 ) 2 , C(0)NHCH 2 (CH 2 ) 2 CH 3 , CCH, S(0) 2 NHCH 3
  • R 9 is selected from the group consisting of amino, arylsulfonyl, carboxy, cyano, C 3 . 6 cycloalkyl, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl and C ⁇ haloalkylthio.
  • R 9 is selected from the group consisting of phenylsulfonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cl, F, Br, OCF 3 , OCHF 2 , OCH 2 CF 3 , CF 3 , CHF 2 , CH 2 CF 3 , SCF 3 , SCHF 2 and SCH 2 CF 3 .
  • R 9 is selected from the group consisting of heterocyclic, heteroaryl, C 4 - 7 oxo-cycloalkyl, phenoxy and phenyl.
  • R 9 is selected from the group consisting of morpholin-4-yl, thiomorpholin-4-yl, l-oxo-l ⁇ 4 -thiomorpholin-4- yl, l,l-Dioxo-l ⁇ 6 -thiomorpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-l-yl, 4-ethyl- piperazin-1-yl, 4-propyl-piperazin-l-yl, piperidin-1-yl, pyrrolidin-1-yl, 2,5-dioxo- imidazolidin-4-yl, 2,4-dioxo-thiazolidin-5-yl, 4-oxo-2-thioxo-thiazolidin-5-yl, 3-methyl-2,
  • R 9 is selected from the group consisting of lH-imidazol-4-yl, [l,2,4]triazol-l-yl, [l,2,3]triazol-l-yl, [l,2,4]triazol-4-yl, pyrrol- 1-yl, pyrazol-1-yl, 1H- pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2-yl, [l,3,4]oxadiazol-2-yl, [l,3,4]thiadiazol- 2-yl, [l,2,4]oxadiazol-3-yl, [l,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5-yl, pyrimidin-2- yl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl, pyr
  • R 9 is C ⁇ - 8 alkyl or C ⁇ alkoxy optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ alkoxy, C ⁇ alkylcarboxamide, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, heterocyclic, hydroxyl and phenyl.
  • R 9 is C ⁇ alkylsulfonyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ alkoxy, carboxamide, heteroaryl, heterocyclic and phenyl.
  • R 9 is C ⁇ alkylsulfonyl substituted with the heteroaryl group.
  • the heteroaryl is selected from the group consisting of lH-imidazol-4- yl, [l,2,4jtriazol-l-yl, [l,2,3]triazol-l-yl, [l,2,4]triazol-4-yl, pyrrol-1-yl, pyrazol-1-yl, 1H- pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2-yl, [l,3,4]oxadiazol-2-yl, * [l,3,4]thiadiazol- 2-yl, [l,2,4]oxadiazol-3-yl, [l,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5-yl, pyrimidin-2- yl, pyrimidin-4-
  • R 9 is arylsulfonyl, heteroaryl, phenoxy or phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, C ⁇ alkylthio, carboxamide, carboxy, cyano, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl, C ⁇ haloalkylthio and hydroxyl.
  • R 9 is arylsulfonyl, heteroaryl, phenoxy or phenyl each optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ alkoxy, C ⁇ alkyl, cyano, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl and hydroxyl.
  • R 9 is a heterocyclic group as described herein.
  • R 9 is a heterocyclic group represented by the formulae shown in Table 2B, supra. Li some embodiments, R 9 is a heterocyclic group represented by the formulae shown in Table 2C, supra. Li some embodiments, R 9 is a heterocyclic group represented by the formulae shown in Table 2D, supra. i some embodiments, R 9 is a heterocyclic group represented by the formulae shown in Table 2E, supra. Li some embodiments, R 9 is a heterocyclic group represented by the formulae shown in Table 2F, supra. Li some embodiments, R 9 is a heterocyclic group represented by the formulae shown in Table 2G, supra.
  • R 9 is of Formula (D):
  • R 18 is H, C ⁇ acyl, C 2 - 6 alkenyl, C ⁇ alkyl, C ⁇ alkylcarboxamide, C 2 - 6 alkynyl, C ⁇ alkylsulfonamide, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 . 6 cycloalkyl, C 2 . 6 dialkylcarboxamide, halogen, heteroaryl or phenyl, and wherein the heteroaryl or phenyl may be optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ alkoxy, amino, C ⁇ alkylamino, C 2 . 6 alkynyl, C 2 . 8 dialkylamino, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl and hydroxyl.
  • R 9 is of Formula (D) wherein "p" and “r” are independently 0, or 1; and R ⁇ 8 is H, carbo-C ⁇ -alkoxy, heteroaryl or phenyl, and wherein the heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ alkoxy, amino, C ⁇ alkylamino, C 2 - 6 alkynyl, C 2 . 8 dialkylamino, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl and hydroxyl.
  • R 18 is phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ alkoxy, amino, C ⁇ alkylamino, C 2 - ⁇ alkynyl, C 2 - 8 dialkylamino, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl and hydroxyl.
  • R 18 is carbo-C ⁇ -alkoxy or carboxy.
  • R 18 is heteroaryl or phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of C ⁇ alkoxy, amino, C ⁇ alkylamino, C 2 . 6 alkynyl, C 2 . 8 dialkylamino, halogen, C ⁇ haloalkoxy, C ⁇ haloalkyl and hydroxyl.
  • the heteroaryl is selected from the group consisting of 1H- imidazol-4-yl, [l,2,4]triazol-l-yl, [l,2,3]triazol-l-yl, [l,2,4]triazol-4-yl, pyrrol-1-yl, pyrazol- 1-yl, lH-pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2-yl, [l,3,4]oxadiazol-2-yl, [l,3,4]thiadiazol-2-yl, [l,2,4]oxadiazol-3-yl, [l,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5- yl, pyrimidin-2-yl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-
  • R 18 is H, C ⁇ acyl or C ⁇ alkyl.
  • R 10 -R 13 are independently C ⁇ acyl, C ⁇ alkoxy, C ⁇ alkyl, Ci- 4 alkylcarboxamide, C ⁇ alkylureyl, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 . 6 cycloalkyl, halogen, C ⁇ haloalkoxy and C ⁇ haloalkyl.
  • one or two R 10 -R1 3 groups are independently halogen. In some embodiments, one R10-R 1 3 group is a halogen.
  • Ari is phenyl and R 9 is substituted at the para position on the phenyl.
  • Ari is phenyl optionally substituted with R 9 , Rio and R u .
  • the compounds of the invention are of Formula (Iw):
  • R 9 is cyano, carbo-C ⁇ -alkoxy, carboxy, C 2 . 6 dialkylamino, C ⁇ alkylcarboxamide, C ⁇ dialkylsulfonamide, C ⁇ alkylsulfonyl, hydroxyl, C ⁇ alkoxy, 5-membered heteroaryl, 6- membered heteroaryl, or heterocyclic, wherein the 6-membered heteoaryl is optionally an N- oxide; and Rio and R ⁇ are independently H or halogen.
  • R 9 is cyano, carbomethoxy, carboethoxy, carboisopropoxy, carboxy, dimethylamino, diethylamino, methylethylamino, C(0)NHCH 3 , C(0)NHCH 2 CH 3 , C(0)NH(CH 3 ) 2 , S(0) 2 CH 3 , S(0) 2 CH 2 CH 3 , hydroxyl, OCH 3 , [l,2,4]triazol-4-yl, thiazol-2-yl, 3H-imidazol-4-yl, 1H- imidazol-2-yl, lH-imidazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, l-oxy-pyridin-2-yl, l-oxy-pyridin-3-yl, l-oxy-pyridin-4-yl, or 2-oxo-oxazolidin-4-yl.
  • Ari is phenyl and two adjacent R ⁇ 0 -R ⁇ groups form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group with the phenyl group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
  • Ari is phenyl and two adjacent R1 0 -R 11 groups form a 5, 6 or 7 membered cycloalkyl group with the phenyl group and is of the formulae shown below:
  • a is 1, 2 or 3 to give a 5, 6 or 7 membered cycloalkyl fused together with the phenyl group where two of the ring carbons are shared between the cycloalkyl and phenyl group.
  • the cycloalkyl is optionally substituted with halogen.
  • the halogen is fluorine.
  • Ari is phenyl and two adjacent R1 0 -R 11 groups form a 5, 6 or 7 membered cycloalkenyl group with the phenyl group and is of the formulae shown in TABLE 5 and has at least one carbon-carbon ring double bond present that is not part of the phenyl group (i.e., cycloalkenyl), for example, lH-Lidenyl and dihydro-naphthyl.
  • the cycloalkenyl is optionally substituted with halogen.
  • the halogen is fluorine.
  • Ari is phenyl and two adjacent R 10 -R ⁇ 1 groups form a 5, 6 or 7 heterocyclic group with the phenyl group and is of the formulae in TABLE 5 wherein one or more ring cycloalkyl carbons are replaced by a O, S, S(O), S(0) 2 , N ⁇ or N-C ⁇ -alkyl group.
  • the heterocyclic group is optionally substituted with halogen.
  • the halogen is fluorine.
  • Ari is phenyl and two adjacent R1 0 -R. 1 groups form a 5 membered heterocyclic group with the phenyl group.
  • the 5 membered heterocyclic group with the phenyl group together form a 2,3-dihydro-benzofuran-5-yl or benzo[l,3]dioxol-5-yl group.
  • the two adjacent groups form a 6 membered heterocyclic group with the phenyl group.
  • the 6 membered heterocyclic group with the phenyl group together form a 2,3-dihydro-benzo[l,4]dioxin-6-yl or 2,3-dihydro-benzo[l,4]dioxin-2-yl group.
  • the two adjacent groups form a 7 membered heterocyclic group with the phenyl group.
  • the 7 membered heterocyclic group with the phenyl group together form a 3,4-dihydro-2H- benzo[b][l,4]dioxepin-7-yl group.
  • Ari is heteroaryl and two adjacent R10-R.1 groups form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group with the heteroaryl group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
  • Ari is a heteroaryl selected from TABLE 2A.
  • Arj is a heteroaryl selected from TABLE 4.
  • the two adjacent groups form a 5 membered heterocyclic group with the heteroaryl group.
  • the two adjacent groups form a 6 membered heterocyclic group with the heteroaryl group.
  • the two adjacent groups form a 7 membered heterocyclic group with the heteroaryl group.
  • R 5 is H, C ⁇ acyl, C ⁇ acyloxy, C 2 - 6 alkenyl, C ⁇ alkoxy, C ⁇ alkyl, C ⁇ alkylcarboxamide, C 2 . 6 alkynyl, C ⁇ alkylsulfonamide, C ⁇ alkylsulfinyl, C ⁇ alkylsulfonyl, Ci- 4 alkylthio, C ⁇ alkylureyl, amino, arylsulfonyl, carbo-C ⁇ -alkoxy, carboxamide, carboxy, cyano, C 3 . 6 cycloalkyl, C 2 .
  • R 5 and e are independently H or F.
  • X is N and Y is CH.
  • X is N and Y is CF.
  • X is CH and Y is N.
  • Li some embodiments, X and Y are N.
  • X and Y are CH.
  • X is CH and Y is CF.
  • Some embodiments of the present invention include compounds illustrated in TABLES A, B, C, D and E; these TABLES are shown below. TABLE A
  • A128 4-[4-(2-Methoxy-ethyl)- piperidin-1 -yl]-6-(2-methyl-5- trifluoromethyl-2H- ⁇ yrazol-3 - yloxy)-5-nitro-pyrimidine
  • Some embodiments of the present invention include a pharmaceutical composition comprising at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.
  • compounds of Formula (la) encompass all pharmaceutically acceptable solvates, particularly hydrates, thereof.
  • the present invention also encompasses diastereomers as well as optical isomers, e.g. mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds of Formula (la). Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art.
  • compounds of the invention are useful in the prophylaxis or treatment of additional diseases. Without limitation, these include the following.
  • Type II diabetes The most significant pathologies in Type II diabetes are impaired insulin signaling at its target tissues ("insulin resistance") and failure of the insulin-producing cells of the pancreas to secrete an appropriate degree of insulin in response to a hyperglycemic signal.
  • Current therapies to treat the latter include inhibitors of the ⁇ -cell ATP-sensitive potassium channel to trigger the release of endogenous insulin stores, or administration of exogenous insulin. Neither of these achieves accurate normalization of blood glucose levels and both carry the risk of inducing hypoglycemia. For these reasons, there has been intense interest in the development of pharmaceuticals that function in a glucose-dependent action, i.e. potentiators of glucose signaling.
  • Physiological signaling systems which function in this manner are well-characterized and include the gut peptides GLP1, GIP and PACAP. These hormones act via their cognate G-protein coupled receptor to stimulate the production of cAMP in pancreatic ⁇ -cells. The increased cAMP does not appear to result in stimulation of insulin release during the fasting or preprandial state.
  • a series of biochemical targets of cAMP signaling including the ATP-sensitive potassium channel, voltage-sensitive potassium channels and the exocytotic machinery, are modified in such a way that the insulin secretory response to a postprandial glucose stimulus is markedly enhanced.
  • agonists of novel, similarly functioning, ⁇ -cell GPCRs, including RUP3 would also stimulate the release of endogenous insulin and consequently promote normoglycemia in Type II diabetes.
  • cAMP for example as a result of GLP1 stimulation, promotes ⁇ -cell proliferation, inhibits ⁇ -cell death and thus improves islet mass.
  • This positive effect on ⁇ -cell mass is expected to be beneficial in both Type II diabetes, where insufficient insulin is produced, and Type I diabetes, where ⁇ -cells are destroyed by an inappropriate autoimmune response.
  • metabolic diseases exert a negative influence on other physiological systems. Thus, there is often the codevelopment of multiple disease states (e.g.
  • Some embodiments of the present invention include a method for prophylaxis or treatment of a metabolic disorder or complications thereof in an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
  • the metabolic disorder or complications thereof is type I, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia syndrome X, or metabolic syndrome.
  • the metabolic disorder is type II diabetes.
  • the metabolic disorder is hyperglycemia.
  • the metabolic disorder is hyperlipidemia.
  • the metabolic disorder is hypertriglyceridemia.
  • ' the metabolic disorder is type I diabetes.
  • the metabolic disorder is dyslipidemia.
  • the metabolic disorder is syndrome X.
  • the individual is a mammal. In some embodiments, the mammal is a human.
  • Some embodiments of the present invention include a method of controlling or decreasing weight gain of an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or pharmaceutical composition thereof.
  • the individual is a mammal.
  • the mammal is a human.
  • the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.
  • One aspect of the present invention pertains to a compound of Formula (la), as described herein, for use in a method of treatment of the human or animal body by therapy.
  • Some embodiments of the present invention include a method of modulating a RUP3 receptor comprising contacting the receptor with a compound of the present invention.
  • Some embodiments of the present invention include a method of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present , invention.
  • the compound is an agonist.
  • the compound is an inverse agonist.
  • Some embodiments of the present invention include a method of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor is prophylaxis or treatment of a metabolic disorder and complications thereof.
  • the metabolic disorder is type I, type ⁇ diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia syndrome X, or metabolic syndrome.
  • the metabolic disorder is type II diabetes. In some embodiments, the metabolic disorder is hyperglycemia. In some embodiments, the metabolic disorder is hyperlipidemia. In some embodiments, the metabolic disorder is hypertriglyceridemia. In some embodiments, the metabolic disorder is type I diabetes. In some embodiments, the metabolic disorder is dyslipidemia. ⁇ n some embodiments, the metabolic disorder is syndrome X. In some embodiments, the individual is a mammal. In some embodiments, the mammal is a human.
  • Some embodiments of the present invention include a method of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor controls or reduces weight gain o the , individual.
  • the individual is a mammal.
  • the mammal is a human.
  • the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.
  • Some embodiments of the present invention include the use of a compound of the present invention for production of a medicament for use in prophylaxis or treatment of a metabolic disorder.
  • the metabolic disorder is type ⁇ diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia syndrome X, or metabolic syndrome.
  • Some embodiments of the present invention include the use of a compound of the present invention for production of a medicament for use in controlling or decreasing weight gain in an individual.
  • the individual is a mammal.
  • the mammal is a human.
  • the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.
  • Compounds of the present invention are identified as an agonist or an inverse agonist using methods known to those skilled in art, such as an assay as described in Example 1. Accordingly, representative examples of compounds of the present invention that are agonists include the following:
  • Representative examples of compounds of the present invention that are inverse agonists include the following:
  • Some embodiments of the present invention include a method of producing a pharmaceutical composition comprising admixing at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.
  • a compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically- acceptable carriers, outside those mentioned herein, are available to those in the art; for example, see Remington's Pharmaceutical Sciences, 16 th Edition, 1980, Mack Publishing Co., (Oslo et al., eds.) and the most current version.
  • a compound of the invention may in an alternative use be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.
  • the invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and/or prophylactic ingredients.
  • the carrier(s) must be acceptable" in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
  • compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • the compounds of the invention may thus be placed into the form of pharmaceutical formulations and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such ⁇ 4
  • unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
  • dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl- cellulose; and with lubricants such as talc or magnesium stearate.
  • the active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.
  • the dose when using the compounds of Formula (la) can vary within wide limits, and as is customary and is known to the physician, it is to be tailored to the individual conditions in each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the Formula (la).
  • Representative doses of the present invention include, about 0.01 mg to about 1000 mg, about 0.01 to about 750 mg, about 0.01 to about 500 mg, 0.01 to about 250 mg, 0.01 mg to about 200 mg, about 0.01 mg to 150 mg, about 0.01 mg to about 100 mg, and about 0.01 mg to about 75 mg.
  • Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or 4, doses. If appropriate, depending on individual behavior and as appropriate from the patients physician or care-giver it may be necessary to deviate upward or downward from the daily dose.
  • the amount of active ingredient, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician.
  • animal models include, but are not limited to, the rodents diabetes models as described in Example 6, infra (other animal models have been reported by Reed and Scribner in Diabetes, Obesity and Metabolism, 1, 1999, 75-86).
  • these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors. Representative factors include the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, on whether an acute or chronic disease state is being treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the Formula (la) and as part of a drug combination.
  • factors include the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, on
  • the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety factors as cited above.
  • the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
  • the daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4, part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
  • the compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
  • a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desire shape and size.
  • the powders and tablets may contain varying percentage amounts of the active compound.
  • a representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active compound; however, an artisan would know when amounts outside of réelle-_ -, ⁇ . ft
  • Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as an admixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and or gelling agents.
  • Lotions may be formulated . with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant.
  • the compounds of the Formula (la) or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler.
  • Pharmaceutical forms for administration of the compounds of the Formula (la) as an aerosol can be prepared by processes well-known to the person skilled in the art.
  • solutions or dispersions of the compounds of the Formula (la) in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others, and, if appropriate, customary propellants, for example include carbon dioxide, CFC's, such as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like.
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
  • the active ingredients may be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PNP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PNP).
  • PNP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number ofany of these in packaged form.
  • Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood.
  • a thorough discussion is provided in T. Higuchi and N. Stella, "Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference.
  • the compounds of the invention can be administered as the sole active pharmaceutical agent as described herein above, they can also be used in combination with one or more agents belonging to the class of drugs known as ⁇ -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrate compounds, LDL catabolism enhancers and angiotensin converting enzyme (ACE) inhibitors.
  • ⁇ -Glucosidase inhibitors belong to the class of drugs which competitively inhibit digestive enzymes such as ⁇ -amylase, maltase, ⁇ -dextrinase, sucrase, etc. in the pancreas and or small infesting.
  • ⁇ -glucosidase inhibitors include acarbose, N-(l,3-dihydroxy-2- propyl)valiolamine (generic name; voglibose), miglitol, and ⁇ -glucosidase inhibitors known in the art.
  • the class of aldose reductase inhibitors are drugs which inhibit the first-stage rate- limiting enzyme in the polyol pathway that prevent or arrest diabetic complications.
  • the utilization of glucose in the polyol pathway is increased and the excess csorbitol accumulated intracellularly as a consequence acts as a tissue toxin and hence evokes the onset of complications such as diabetic neuropathy, retinopathy, and nephropathy.
  • aldose reductase inhibitors examples include tolurestat; epalrestat; 3,4- dihydro-2,8-diisopropyl-3-thioxo-2H-l ,4-benzoxazine-4-acetic acid; 2,7-difluorospiro(9H- fluorene-9,4'-imidazolidine)-2',5'-dione (generic name: imirestat); 3-[(4-bromo-2- flurophenyl)methy]-7-chloro-3,4-dihydro-2,4-dioxo-l(2H)-qumazoline acetic acid (generic name: zenarestat); 6-fluoro-2,3-dihydro-2',5'-dioxo-spiro[4H-l-benzopyran-4,4'- imidazolidine]-2-carboxamide (SNK-860); zopolrestat; sorbinil; and
  • the biguanides are a class of drugs that stimulate anaerobic glycolysis, increase the sensitivity to insulin in the peripheral tissues, inhibit glucose absorption from the intestine, suppress of hepatic gluconeogenesis, and inhibit fatty acid oxidation.
  • Examples of biguanides include phenformin, metformin, buformin, and biguanides l ⁇ iown in the art.
  • Statin compounds belong to a class of drugs that lower blood cholesterol levels by inhibiting hydroxymethylglutalyl CoA ( ⁇ MG-CoA) reductase.
  • ⁇ MG-CoA reductase is the rate-limiting enzyme in cholesterol biosynthesis.
  • a statin that inhibits this reductase lowers serum LDL concentrations by upregulating the activity of LDL receptors and responsible for clearing LDL from the blood.
  • the statin compounds include rosuvastatin, pravastatin and its sodium salt, simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, and ⁇ MG-CoA reductase inhibitors known in the art.
  • Squalene synthesis inhibitors belong to a class of drugs that lower blood cholesterol levels by inhibiting synthesis of squalene.
  • examples of the squalene synthesis inhibitors include (S)- ⁇ -[Bis[2,2-dimethyl-l -oxopropoxy)methoxy] phosphinyl]-3- phenoxybenzenebutanesulfonic acid, mono potassium salt (BMS- 188494) and squalene synthesis inhibitors known in the art.
  • Fibrate compounds belong to a class of drugs that lower blood cholesterol levels by inhibiting synthesis and secretion of triglycerides in the liver and activating a lipoprotein lipase. Fibrates have been known to activate peroxisome proliferators-activated receptors and induce lipoprotein lipase expression.
  • fibrate compounds include bezafibrate, beclobrate, binifibrate, ciplof ⁇ brate, clinofibrate, clofibrate, clofibric acid, etofibrate, fenofibrate, gemfibrozil, nicof ⁇ brate, pirifibrate, ronifibrate, simfibrate, theof ⁇ brate, and fibrates known in the art.
  • LDL (low-density lipoprotein) catabolism enhancers belong to a class of drugs that lower blood cholesterol levels by increasing the number of LDL (low-density lipoprotein) receptors, examples include LDL catabolism enhancers known in the art.
  • Angiotensin converting enzyme (ACE) inhibitors belong to the class of drugs that partially lower blood glucose levels as well as lowering blood pressure by inhibiting angiotensin converting enzymes.
  • the angiotensin converting enzyme inhibitors include captopril, enalapril, alacepril, delapril; ramipril, lisinopril, imidapril, benazepril, ceronapril, cilazapril, enalaprilat, fosinopril, moveltopril, perindopril, quinapril, spirapril, temocapril, trandolapril, and angiotensin converting enzyme inhibitors known in the art.
  • Insulin secretion enhancers belong to the class of drugs having the property to promote secretion of insulin from pancreatic ⁇ cells.
  • Examples of the insulin secretion enhancers include sulfonylureas (SU).
  • the sulfonylureas (SU) are drugs which promote secretion of insulin from pancreatic ⁇ cells by transmitting signals of insulin secretion via SU receptors in the cell membranes.
  • sulfonylureas examples include tolbutamide; chlorpropamide; tolazamide; acetohexamide; 4-chloro-N-[(l-pyrolidinylamino) carbonyl]- benzenesulfonamide (generic name: glycopyramide) or its ammonium salt; glibenclamide (glyburide); gliclazide; l-butyl-3-metanilylurea; carbutamide; glibonuride; glipizide; gliquidone; glisoxepid; glybuthiazole; glibuzole; glyhexamide; glymidine; glypinamide; phenbutamide; tolcyclamide, glimepiride, and other insulin secretion enhancers known in the art.
  • insulin secretion enhancers include N-[[4-(l-methylethyl)cyclohexyl)carbonyl]-D- phenylalanine (Nateglinide); calcium (2S)-2-benzyl-3-(cis-hexahydro-2- isoindolinylcarbonyl)propionate dihydrate (Mitiglinide, KAD-1229); and other insulin secretion enhancers known in the art.
  • Thiazolidinediones belong to the class of drugs more commoningly known as TZDs.
  • Examples of thiazolidinediones include rosiglitazone, pioglitazone, and thiazolidinediones known in the art.
  • Some embodiments of the invention include, a pharmaceutical composition comprising a compound of Formula (la) or a pharmaceutically acceptable salt thereof in combination with at least one member selected from the group consisting of an ⁇ -glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a HMG-CoA reductase inhibitor, a squalene synthesis inhibitor, a fibrate compound, a LDL catabolism enhancer and an angiotensin converting enzyme inhibitor.
  • a pharmaceutical composition comprising a compound of Formula (la) or a pharmaceutically acceptable salt thereof in combination with at least one member selected from the group consisting of an ⁇ -glucosidase inhibitor, an aldose reductase
  • the pharmaceutical composition is a compound of Formula (la) or a pharmaceutically acceptable salt thereof in combination with a HMG-CoA reductase inhibitor.
  • the HMG- CoA reductase inhibitor is selected from the group consisting of prevastatin, simvastatin, lovastatin, atorvastatin, fluvastatin and lipitor.
  • the combination can be used by mixing the respective active components either all together or independently with a physiologically acceptable carrier, excipient, binder, diluent, etc., as described herein above, and administering the mixture or mixtures either orally or non-orally as a pharmaceutical composition.
  • a compound or a mixture of compounds of Formula (la) are administered as a combination therapy or prophylaxis with another active compound the therapeutic agents can be formulated as a separate pharmaceutical compositions given at the same time or at different times, or the therapeutic agents can be given as a single composition.
  • Another object of the present invention relates to radiolabelled compounds of Formula (la) that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating RUP3 in tissue samples, including human, and for identifying RUP3 ligands by inhibition binding of a radiolabelled compound. It is a further object of this invention to develop novel RUP3 assays of which comprise such radiolabelled compounds.
  • Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3 H (also written as T), n C, 14 C, 18 F, 125 1, 82 Br, 123 1, 124 I, 125 1, 131 1, 75 Br, 76 Br, 15 0, 13 N, 35 S and 77 Br.
  • the radionuclide that is incorporated in the instant radiolabelled compounds will depend on the specific application of that radiolabelled compound. Thus, for in vitro RUP3 labeling and competition assays, compounds that incorporate 3 H, 14 C, 125 1 , 131 1, 35 S or 82 Br will generally be most useful.
  • n C, 18 F, ,25 1, 123 1, 124 1, 131 1, 75 Br, 76 Br or 77 Br will generally be most useful.
  • a “radio-labelled " or “labelled compound” is a compound of Formula (la) that has incorporated at least one radionuclide;
  • the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1 , 35 S and 82 Br; In some embodiments, the radionuclide 3 H or 14 C.
  • all of the atoms represented in the compounds of the invention can be either the most commonly occurring isotope of such atoms or the more scarce radio-isotope or nonradio-active isotope.
  • Synthetic methods for incorporating radio-isotopes into organic compounds including those applicable to those compounds of the invention are well known in the art and include incorporating activity levels of tritium into target molecules include: A. Catalytic Reduction with Tritium Gas - This procedure normally yields high specific activity products and requires halogenated or unsaturated precursors. B. Reduction with Sodium Borohydride [ 3 H] - This procedure is rather inexpensive and requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like. C. Reduction with Lithium Aluminum Hydride [ 3 H ] - This procedure offers products at almost theoretical specific activities.
  • D. Tritium Gas Exposure Labeling This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst.
  • Synthetic methods for incorporating activity levels of 125 I into target molecules include: A. Sandmeyer and like reactions - This procedure transforms an aryl or heteroaryl amine into a diazonium salt, such as a tetrafluoroborate salt, and subsequently to 125 I labelled compound using Na 125 I. A represented procedure was reported by Zhu, D.-G. and co-workers in J. Org. Chem. 2002, 67, 943-948. B. Ortho 125 Iodination of phenols - This procedure . allows for the incorporation of 125 I at the ortho position of a phenol as reported by Collier, T. L. and co-workers in J. Labelled Compd Radiopharm.
  • This method is generally a two step process.
  • the first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, a Pd catalyzed reaction [i.e. Pd(Ph 3 P) 4 ] or through an aryl or heteroaryl lithium, in the presence of a xri-alkyltinhalide or hexaalkylditin [e.g., (CH 3 ) 3 SnSn(CH 3 ) 3 ].
  • a xri-alkyltinhalide or hexaalkylditin e.g., (CH 3 ) 3 SnSn(CH 3 ) 3 ].
  • a radiolabelled RUP3 compound as described herein can be used in a screening assay to identify/evaluate compounds.
  • a newly synthesized or identified compound i.e., test compound
  • the ability of a test compound to compete with the "radio-labelled compound of Formula (la)" for the binding to the RUP3 receptor directly correlates to its binding affinity.
  • the labelled compounds of the present invention bind to the RUP3 receptor.
  • the labelled compound has an IC5 0 less than about 500 ⁇ M, in another embodiment the labelled compound has an IC50 less than about 100 ⁇ M, in yet another embodiment the labelled compound has an IC50 less than about 10 ⁇ M, in yet another embodiment the labelled compound has an IC5 0 less than about 1 ⁇ M, and in still yet another embodiment the labelled inhibitor has an IC 50 less than about 0.1 ⁇ M.
  • Adenlyl cyclase Activation Flashplate Assay kit from Perkin Elmer — 96 wells (SMP004B) and 125 I tracer (NEX130) which comes with the kit. Keep in refrigerator, in a box, and do not expose the Flashplates to light.
  • Regeneration buffer can be aliquotted into 40-45 ml portions (in 50 ml sterile tubes) and kept frozen for up to 2 months. Simply put the tube in a beaker with room temperature water to thaw out the regeneration buffer on the day of the assay.
  • Flashplate can therefore be set up to handle 3 compounds, (i.e., columns 2, 3, and 4 are for compound #1, columns 5, 6, and 7 are for compound #2, and columns 8, 9, and 10 are for compound #3.)
  • An acceptable signal-to-noise ratio for RUP3 can vary from 4 to 6.
  • the raw cpms are approximately 1800 to 2500 for RUP3 and 3500-4500 for CMN.
  • the cpm (or ultimately pmoles of cAMP/well) cannot be outside the standard curve, and should not approach well A of the standard curve (50 pmole/well) and well H (no cAMP).
  • the pmoles of cAMP produced by RUP3 receptor are around 11 to 13 pmole/well (for 15 ug/well protein), and for CMN are between 2 to 3 pmole/well (for 15 ug protein /well).
  • the slope should be linear and the error bars for duplicates should be very small.
  • the receptor and CMN controls cannot be off scale of the standard curve, as described above. If the receptor controls are off the high end of the standard curve,i.e. 50 pmole/well or higher, one must repeat the experiment using less protein. However, such a case has not been observed with transiently transfected RUP3 membranes (10 ug D ⁇ A/ 15 cm plate, using 60 ul Lipofectamine, and preparing membranes after 24 hour of transfection.)
  • the IC 50 or EC 50 curve should be at 100% (+ or - 20%) of control RUP3 membranes at the top, and should go down to 0 (or up to 20%) at the bottom.
  • the standard error of the triplicate determinations should be + or - 10%.
  • H1T-T15 (ATCC CRL#1777) is an immortalized hamster insulin-producing cell line. These cells express RUP3 and therefore can be used to assess the ability of RUP3 ligands to stimulate or inhibit cAMP accumulation via its endogenously expressed receptor.
  • cells are grown to 80% confluence and then distributed into a 96-well Flashplate (50,000 cells/ well) for detection of cAMP via a "cAMP Flashplate Assay" (NEN, Cat # SMP004). Briefly, cells are placed into anti-cAMP antibody-coated wells that contain either vehicle, the test ligand(s) at a concentration of interest, or 1 uM forskolin.
  • the latter is a direct activator of adenylyl cyclase and serves as a positive control for stimulation of cAMP in HIT-T15 cells. All conditions are tested in triplicate. After a 1 hour incubation to allow for stimulation of cAMP, a Detection Mix containing 125 I-cAMP is added to each well and the plate is allowed to incubate for another 1 hour. The wells are then aspirated to remove unbound 125 I-cAMP. Bound 125 I-cAMP is detected using a Wallac Microbeta Counter. The amount of cAMP in each sample is determined by comparison to a standard curve, obtained by placing known concentrations of cAMP in some wells on the plate.
  • RUP3 ligands can also be tested for their ability to stimulate glucose-dependent insulin secretion (GSIS) in HIT-T15 cells.
  • GSIS glucose-dependent insulin secretion
  • 30,000 cells/well in a 12-well plate are incubated in culture media containing 3 mM glucose and no serum for 2 hours. The media is then changed; wells receive media containing either 3 mM or 15 mM glucose, and in both cases the media contains either vehicle (DMSO) or RUP3 ligand at a concentration of interest. Some wells receive media containing 1 uM forskolin as a positive control.
  • RUP3 is an endogenously expressed GPCR in the till-_ -, ⁇ . ft
  • RUP3 ligands can also be tested for their ability to stimulate GSIS in rat islet cultures. This assay is performed as follows:
  • IEQ islet equivalents
  • RT-PCR was applied to determine the tissue distribution of RUP3.
  • Ohgonucleotides used for PCR had the following sequences:
  • ZC47 5'-CATTGCCGGGCTGTGGTTAGTGTC-3' (forward primer), (SEQ ID NO:3);
  • ZC48 5'-GGCATAGATGAGTGGGTTGAGCAG-3' (reverse primer), (SEQ ID NO:4); and the human multiple tissue cDNA panels (MTC, Clontech) were used as templates (1 ng cDNA per PCR amplification). Twenty-two (22) human tissues were analyzed. PCR was performed using Platinum PCR SuperMix (Life Technologies, Inc.; manufacture instructions were followed) in a 50 ⁇ l reaction by the following sequences: step 1, 95°C for 4 min; step 2, 95°C for 1 min; step 3, 60°C for 30 sec; step 4, 72°C for 1 min; and step 5, 72°C for 7 min. Steps 2 through 4 were repeated 35 times.
  • the resulting PCR reactions (15 ⁇ l) were loaded on a 1.5% agarose gel to analyze the RT-PCR products, and a specific 466 base-pair DNA fragment representing RUP3 was specifically amplified from cDNA of pancreas origin. Low expression was also evident in subregions of brain.
  • results from RT-PCR analysis were further confirmed in cDNA dot-blot analysis.
  • a dot-blot membrane containing cDNA from 50 human tissues (Clontech) was hybridized with a 32 P-radiolabelled DNA probe having sequences derived from human RUP3. Hybridyzation signals were seen in pancreas and fetal liver, suggesting these tissues express RTJP3. No significant expression was detected in other tissues analyzed.
  • RUP3 expression was further analyzed with cDNAs of rat origin by RT-PCR technique.
  • Tissue cDNAs used for this assay were obtained from Clontech except those for hypothalamus and islets, which were prepared in house. Concentrations of each cDNA sample were normalized via a control RT-PCR analysis of the house-keeping gene GAPDH before assaying for RUP3 expression.
  • Ohgonucleotides used for PCR had the following sequences: rat RUP3 ("rRUP3") forward: 5'-CATGGGCCCTGCACCTTCTTTG-3' (SEQ ID NO:5); rRUP3 reverse: 5'-GCTCCGGATGGCTGATGATAGTGA-3' (SEQ ID NO:6).
  • PCR was performed using Platinum PCR SuperMix (Life Technologies, Inc.; manufacture instructions were followed) in a 50 ⁇ l reaction by the following sequences: step 1, 95°C for 4 min; step 2, 95°C for 1 min; step 3, 60°C for 30 sec; step 4, 72°C for 1 min; and step 5, 72°C for 7 min. Steps 2 through 4 were repeated 35 times.
  • PCR reactions (15 ⁇ l) were loaded on a 1.5% agarose gel to analyze the RT-PCR products, and a specific 547 base-pair DNA fragment representing rat RUP3 was specifically amplified from cDNA of pancreas origin, revealing a similar expression profile with human. Of particular note, robust expression was seen in isolated islets and hypothalamus.
  • RUP3 protein expression is restricted to ⁇ cell lineage of pancreatic islets ( Figure 2).
  • a polyclonal anti-RUP3 antibody was prepared in rabbits ( Figure 2A). Rabbits were immunized with an antigenic peptide with sequence derived from rat
  • RUP3 (“rRUP3").
  • the peptide sequence was RGPERTRESAYHINTISHPELDG and shared 100% identity with mouse RUP3 in the corresponding region.
  • a cysteine residue was incorporated at the ⁇ -terminal end of this antigenic peptide to facilitate KLH crosslinking before injecting into rabbits.
  • the resulting antisera (“anti-rRUP3”) and the corresponding preimmune sera (“pre-rRUP3”) were tested for immune reactivity to mouse RUP3 in immunobloting assays (lanes 1 thought 4).
  • the GST-RUP3 fusion protein was readily recognized by the anti-rRUP3 antisera (lane 4), but not by the preimmurie sera (lane 2).
  • the immunoreactive signal could be efficiently eliminated when the immunobloting assay was performed in the presence of excess antigenic peptide (lane 6).
  • Rat pancreas was perfused with 4% paraformaldehyde (PFA) in PBS and embedded in OCT embedding medium.
  • PFA paraformaldehyde
  • Ten micron sections were prepared, fixed on glass slides, and immunostained with either pre-rRUP3 (Figure 2B, panel a) or with anti-rRUP3 antisera ( Figure 2B, panels c and e) followed by secondary staining with donkey anti-rabbit IgG conjugated to the fluorochrome Cy-3.
  • Each section was also co-immunostained with a dire-_ fame, ftyl /ft «
  • RUP3 stimulates the production of cAMP by cotransfection of 293 cells with: (1) a CRE-Luciferase reporter, wherein the ability to stimulate the production of firefly luciferase depends on increased cAMP in cells, and (2) an expression plasmid encoding the human form of RUP3 (Figure 3A).
  • a CRE-Luciferase reporter wherein the ability to stimulate the production of firefly luciferase depends on increased cAMP in cells
  • an expression plasmid encoding the human form of RUP3 Figure 3A. Note that cells co-transfected with an expression plasmid containing no RUP3 sequences (“CMN" in Figure 3A) produce very little luciferase activity, whereas cells transfected with an expression plasmid encoding RUP3 (“RUP3" in Figure 3A) have at least a 10-fold increase in luciferase activity.
  • RUP3 stimulates the production of cAMP when introduced into 293 cells. This property of RUP3 is conserved across species, because hamster RUP3 stimulates luciferase activity when introduced into 293 cells in a manner analogous to that described for human RUP3 ( Figure 3B).
  • Tu6 cells that express high levels of RUP3. Tu6 cells produce insulin, but do not express appreciable levels of RUP3 and do not normally exhibit an increase in insulin release when increased glucose is present in the culture media. As shown in Figure 3C, Tu6 cells transduced with a control virus that contains no receptor are still able to produce insulin, but do not show an increase in insulin secretion when the concentration of glucose in the culture media is shifted from 1 mM to 16 mM. By contrast, Tu6 cells transduced with RUP3-containing retrovirus display significant glucose-dependent insulin secretion (Figure 3C).
  • RUP3 agonists stimulate endogenously expressed RUP3 in insulin-producing cells
  • two in vitro models can be used.
  • RUP3 agonists are used to stimulate HIT-T15 cells, which express RUP3 at significant levels, as indicated in the Northern blot shown in Figure 4A.
  • these cells are known to exhibit enhanced glucose-dependent insulin release when intracellular cAMP concentrations are elevated.
  • the RUP3 agonist Compound B84 stimulates cAMP production in HIT cells, at a level comparable to that seen with the adenyl cyclase activator forskolin. This indicates that Compound B84 is a very robust stimulator of cAMP in HIT- T15 cells.
  • Compound B84 also stimulates insulin secretion in HIT cells exposed to 15 mM glucose, once again at a level comparable to that seen with the adenyl cyclase activator forskolin. This indicates that Compound B 84 is a very robust potentiator of insulin secretion in HIT-T15 cells.
  • Isolated rat islets are the other in vitro model used to demonstrate the efficacy of RUP3 agonists.
  • agents that induce cAMP are not expected to stimulate insulin secretion when glucose concentrations are low (e.g. 60 mg/dl). However, when glucose concentrations are increased (e.g. to 300 mg/dl), these agents are expected to enhance insulin secretion to levels above those seen with glucose alone.
  • both RUP3 agonists Compounds 48 and 51 at 10 uM concentration
  • the level of enhancement was comparable to that seen with 25 nM GLP-1, a gut hormone known to act on islets in this manner.
  • Compound B70 was delivered orally via a gavage needle (p.o. volume at 100 ⁇ l).
  • Control Ex-4 was delivered intraperitoneally. Thirty minutes after administration of test compound and control ex-4, mice were administered orally with dextrose at 5 g/kg dose. Levels of blood glucose were determined at the indicated time points using Glucometer Elite XL (Bayer).
  • Figure 5A shows the mean glucose concentration averaged from eleven animals in each treatment group.
  • 293 cells were plated in 96-well tissue culture plates at a concentration of 20,000 cells per well. The following day, the cells are transfected with a mixture of pCRE-Luc (Stratagene, Cat. # 219076), the indicated expression plasmid, and pEGFP-Nl (Clontech, Cat. # 6085-1) at a ratio of 5:1:0.25 using Lipofectamine Reagent (Invitrogen, Cat. #18324-020) according to the manufacturer's directions.
  • pEGFP-Nl encodes a "green fluorescent protein" and was used as a control to determine that most cells were successfully transfected.
  • the cells were lysed in situ with 100 ul/ well reconstituted Luclite buffer (Luclite- Reporter Gene Assay Kit, Packard, Cat. # 6016911), according to the manufacturer's directions. After a 10 minute incubation in the dark, luminescence was measured using a TRJLUX 1450 Microbeta Counter (Wallac).
  • Retrovirus bearing an expression cassette for RUP3 was generated. Briefly, RUP3 coding sequence was cloned into the retroviral vector pLNCX2 (Clontech, Cat # 6102-1). The amphotropic packaging cell line PT-67 (Clontech, K1060-D) was then transfected with either the parental vector pLNCX2 or pLNCX2/RTJP3 using Lipofectamine and stable lines were established using guidelines provided by the PT-67 vendor. Retrovirus-containing supernatant was obtained by collecting media from the resultant stables according to the manufacturer's directions.
  • Tu6 cells in a 10 cm dish, were then infected with retroviras by incubating in a solution of 1 ml viral supernatant/ 9 ml culture media containing 40 ug/ml polybrene for 24 hours. The medium was then changed to culture media containing 300 ug/ml G418. G418-resistant clones were ultimately created by virtue of the neomycin-resistance gene cassette present in the pLNCX2 vector, thus indicating the successful integration of retroviras into the Tu6 genome. The expression of RUP3 in the Tu6/RUP3 G418-resistant colonies was confirmed by Northern blot.
  • EIA Rat Insulin Enzyme-Immunoassay
  • the denatured probe, 10 ml ExpressHyb solution (Clontech, Cat # 8015-2) and the RNA blot were incubated in a hybridization oven, washed and exposed to film using standard molecular biology practices.
  • another means for evaluating a test compound is by determining binding affinities to the RUP3 receptor.
  • This type of assay generally requires a radiolabelled ligand to the RUP3 receptor. Absent the use of known ligands for the RUP3 receptor and radiolabels thereof, compounds of Formula (la) can be labelled with a radioisotope and used in an assay for evaluating the affinity of a test compound to the RUP3 receptor.
  • a radiolabelled RUP3 compound as described herein can be used in a screening assay to identify/evaluate compounds.
  • a newly synthesized or identified compound i.e., test compound
  • the ability to compete with the "radio-labelled compound of Formula (la)" or Radiolabelled RUP3 Ligand for the binding to the RUP3 receptor directly correlates to its binding affinity of the test compound to the RUP3 receptor.
  • 293 cells human kidney, ATCC
  • transiently transfected with 10 ug human RUP3 receptor and 60 ul Lipofectamine per 15-cm dish
  • 10 ml/dish of Hepes-EDTA buffer 20mM Hepes + 10 mM EDTA, pH 7.4
  • the cells were then centrifuged in a Beckman Coulter centrifuge for 20 minutes, 17,000 rpm (JA-25.50 rotor).
  • the pellet was resuspended in 20 mM Hepes + 1 mM EDTA, pH 7.4 and homogenized with a 50- ml Dounce homogenizer and again centrifuged. After removing the supernatant, the pellets were stored at -80°C, until used in binding assay.
  • membranes were thawed on ice for 20 minutes and then 10 mL of incubation buffer (20 mM Hepes, 1 mM MgCl 2 ,100 mM NaCl, pH 7.4) added. The membranes were then vortexed to resuspend the crude membrane pellet and homogenized with a Brinkmann PT-3100 Polytron homogenizer for 15 seconds at setting 6. The concentration of membrane protein was determined using the BRL Bradford protein assay.
  • a total volume of 50ul of appropriately diluted membranes (diluted in assay buffer containing 50mM Tris HCl (pH 7.4), lOmM MgCl 2 , and ImM EDTA; 5-50ug protein) is added to 96-well polyproylene microtiter plates followed by addition of lOOul of assay buffer and 50ul of Radiolabelled RUP3 Ligand.
  • 50 ul of assay buffer is added instead of lOOul and an additional 50ul of lOuM cold RUP3 is added before 50ul of Radiolabelled RUP3 Ligand is added. Plates are then incubated at room temperature for 60-120 minutes.
  • the binding reaction is terminated by filtering assay plates through a Microplate Devices GF/C Unifilter filtration plate with a Brandell 96-well plate harvester followed by washing with cold 50 mM Tris HCl, pH 7.4 containing 0.9% NaCl. Then, the bottom of the filtration plate are sealed, 50ul of Optiphase Supermix is added to each well, the top of the plates are sealed, and plates are counted in a Trilux MicroBeta scintillation counter. For compound competition studies, instead of adding lOOul of assay buffer, lOOul of appropriately diluted test compound is added to appropriate wells followed by addition of 50ul of Radiolabelled RTJP3 Ligand.
  • test compounds are initially assayed at 1 and 0.1 ⁇ M and then at a range of concentrations chosen such that the middle dose would cause about 50% inhibition of a Radio-RUP3 Ligand binding (i.e., IC 50 ).
  • IC 50 Specific binding in the absence of test compound (Bo) is the difference of total binding (B ⁇ ) minus non-specific binding (NSB) and similarly specific binding (in the presence of test compound) (B) is the difference of displacement binding (Bp) minus non-specific binding (NSB).
  • IC 50 is determined from an inhibition response curve, logit-log plot of % B/B 0 vs concentration of test compound.
  • Ki ⁇ C 5 o / (i + [Lj ⁇ D )
  • [L] is the concentration of a Radio-RUP3 Ligand used in the assay and K D is the dissociation constant of a Radio-RUP3 Ligand determined independently under the same binding conditions.
  • N-oxides can be prepared at normal or elevated pressure, in the presence of an oxidizing agent, such as, hydrogen peroxide, peracetic acid, perbenzoic, m- chloroperbenzoic acid (mCPBA), ozone, oxygen and the like, in the presence or absence of solvent, such as chloroform, dichlormethane, acetic acid, trifluoroacetic acid, and the like or mixtures thereof.
  • an oxidizing agent such as, hydrogen peroxide, peracetic acid, perbenzoic, m- chloroperbenzoic acid (mCPBA), ozone, oxygen and the like
  • solvent such as chloroform, dichlormethane, acetic acid, trifluoroacetic acid, and the like or mixtures thereof.
  • TLC Thin-layer chromatography
  • PK6F silica gel 60 A 1 mm plates (Whatman)
  • column chromatography was carried out on a silica gel column using Kieselgel 60, 0.063-0.200 mm (Merck). Evaporation was done in vacuo on a Buchi rotary evaporator. Celite 545 ® was used during palladium filtrations. '
  • LCMS specs 1) PC: HPLC-pumps: LC-IOAD VP, Shimadzu Inc.; HPLC system controller: SCL-10A VP, Shimadzu Inc; UN-Detector: SPD-10A VP, Shimadzu Pnc; Autosampler: CTC HTS, PAL, Leap Scientific; Mass spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex; Software: Analyst 1.2. 2) Mac: HPLC-pumps: LC-8A VP, Shimadzu Inc; HPLC system controller: SCL-10A VP, Shimadzu Inc.
  • UN-Detector SPD-10A VP, Shimadzu Inc; Autosampler: 215 Liquid Handler, Gilson Inc; Mass, spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex Software: Masschrom 1.5.2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.

Description

,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM
AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA
FIELD OF THE INVENTION
The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a serious disease afflicting over 100 million people worldwide. In the United States, there are more than 12 million diabetics, with 600,000 new cases diagnosed each year.
Diabetes mellitus is a diagnostic term for a group of disorders characterized by abnormal glucose homeostasis resulting in elevated blood sugar. There are many types of diabetes, but the two most common are Type I (also referred to as insulin-dependent diabetes mellitus or IDDM) and Type II (also referred to as non-insulin-dependent diabetes mellitus or NIDDM).
The etiology of the different types of diabetes is not the same; however, everyone with diabetes has two things in common: overproduction of glucose by the liver and little or no ability to move glucose out of the blood into the cells where it becomes the body's primary fuel.
People who do not have diabetes rely on insulin, a hormone made in the pancreas, to move glucose from the blood into the cells of the body. However, people who have diabetes either don't produce insulin or can't efficiently use the insulin they produce; therefore, they can't move glucose into their cells. Glucose accumulates in the blood creating a condition called hyperglycemia, and over time, can cause serious health problems.
Diabetes is a syndrome with interrelated metabolic, vascular, and neuropathic components. The metabolic syndrome, generally characterized by hyperglycemia, comprises alterations in carbohydrate, fat and protein metabolism caused by absent or markedly reduced insulin secretion and/or ineffective insulin action. The vascular syndrome consists of abnormalities in the blood vessels leading to cardiovascular, retinal and renal complications. Abnormalities in the peripheral and autonomic nervous systems are also part of the diabetic syndrome.
People with IDDM, which accounts for about 5% to 10% of those who have diabetes, don't produce insulin and therefore must inject insulin to keep their blood glucose levels normal. IDDM is characterized by low or undetectable levels' of endogenous insulin production caused by destruction of the insulin-producing β cells of the pancreas, the characteristic that most readily distinguishes IDDM from NIDDM. IDDM, once termed juvenile-onset diabetes, strikes young and older adults alike.
Approximately 90 to 95% of people with diabetes have Type II (or NIDDM). NIDDM subjects produce insulin, but the cells in their bodies are insulin resistant: the cells don't respond properly to the hormone, so glucose accumulates in their blood. NIDDM is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to elevated blood glucose levels. In contrast to IDDM, there is always some endogenous insulin production in NIDDM; many NTDDM patients have normal or even elevated blood insulin levels, while other NIDDM patients have inadequate insulin production (Rotwein, R. et al. N. Engl. J. Med. 308, 65-71 (1983)). Most people diagnosed with ΝTDDM are age 30 or older, and half of all new cases are age 55 and older. Compared with whites and Asians, ΝTJDDM is more common among Native Americans, African-Americans, Latinos, and Hispanics. In addition, the onset can be insidious or even clinically inapparent, making diagnosis difficult
The primary pathogenic lesion on NIDDM has remained elusive. Many have suggested that primary insulin resistance of the peripheral tissues is the initial event. Genetic epidemiological studies have supported this view. Similarly, insulin secretion abnormalities have been argued as the primary defect in NIDDM. It is likely that both phenomena are important contributors to the disease process (Ri oin, D. L., et. al. Emery and Rimoin's Principles and Practice of Medical Genetics 3rd Ed. 1:1401-1402 (1996)).
Many people with NIDDM have sedentery lifestyles and are obese; they weigh approximately 20% more than the recommended weight for their height and build. Furthermore, obesity is characterized by hyperinsulinemia and insulin resistance, a feature shared with NIDDM, hypertension and atherosclerosis.
Obesity and diabetes are among the most common human health problems in industrialized societies. In industrialized countries a third of the population is at least 20% overweight. In the United States, the percentage of obese people has increased from 25% at the end of the 1970s, to 33% at the beginning the 1990s. Obesity is one of the most important risk factors for NIDDM. Definitions of obesity differ, but in general, a subject weighing at least 20% more than the recommended weight for his/her height and build is considered obese. The risk of developing NIDDM is tripled in subjects 30% overweight, and three-quarters with NIDDM are overweight.
Obesity, which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals and human. However, the molecular mechanisms that are involved in obesity-diabetes syndromes are not clear. During early development of obesity, increase insulin secretion balances insulin resistance and protects patients from hyperglycemia (Le Stunfζ et al. Diabetes 43, 696-702 (1989)). However, after several decades, β cell function deteriorates and non-insulin-dependent diabetes develops in about 20% of the obese population (Pederson, P. Diab. Metab. Rev. 5, 505- 509 (1989)) and (Brancati, F. L., et al., Arch. Intern. Med. 159, 957-963 (1999)). Given its high prevalence in modern societies, obesity has thus become the leading risk factor for NIDDM (Hill, J. O., et al., Science 280, 1371-1374 (1998)). However, the factors which predispose a fraction of patients to alteration of insulin secretion in response to fat accumulation remain unknown.
Whether someone is classified as overweight or obese is generally determined on the basis of their body mass index (BMI) which is calculated by dividing body weight (kg) by height squared (m2). Thus, the units of BMI are kg/m2 and it is possible to calculate the BMI range associated with minimum mortality in each decade of life. Overweight is defined as a BMI in the range 25-30 kg/m2, and obesity as a BMI greater than 30 kg/m2 (see TABLE below). There are problems with this definition in that it does not take into account the proportion of body mass that is muscle in relation to fat (adipose tissue). To account for this, obesity can also be defined on the basis of body fat content: greater than 25% and 30% in males and females, respectively.
CLASSIFICATION OF WEIGHT BY BODY MASS INDEX (BMI)
Figure imgf000004_0001
As the BMI increases there is an increased risk of death from a variety of causes that is independent of other risk factors. The most common diseases with obesity are cardiovascular disease (particularly hypertension), diabetes (obesity aggravates the development of diabetes), gall bladder disease (particularly cancer) and diseases of reproduction. Research has shown that even a modest reduction in body weight can correspond to a significant reduction in the risk of developing coronary heart disease.
Compounds marketed as anti-obesity agents include Orlistat (XENICAL™) and Sibutramine. Orlistat (a lipase inhibitor) inhibits fat absorption directly and tends to produce a high incidence of unpleasant (though relatively harmless) side-effects such as diarrhea. Sibutramine (a mixed 5-HT/noradrenaline reuptake inhibitor) can increase blood pressure and heart rate in some patients. The serotonin releaser/reuptake inhibitors fenfluramine (Pondimin™) and dexfenfluramine (Redux™) have been reported to decrease food intake and body weight over a prolonged period (greater than 6 months). However, both products were withdrawn after reports of preliminary evidence of heart valve abnormalities associated with their use. Accordingly, there is a need for the development of a safer anti-obesity agent.
Obesity considerably increases the risk of developing cardiovascular diseases as well. Coronary insufficiency, atheromatous disease, and cardiac insufficiency are at the forefront of the cardiovascular complication induced by obesity. It is estimated that if the entire population had an ideal weight, the risk of coronary insufficiency would decrease by 25%> and the risk of cardiac insufficiency and of cerebral vascular accidents by 35%. The incidence of coronary diseases is doubled in subjects less than 50 years of age who are 30% overweight. The diabetes patient faces a 30% reduced lifespan. After age 45, people with diabetes are about three times more likely than people without diabetes to have significant heart disease and up to five times more likely to have a stroke. These findings emphasize the inter-relations between risks factors for NIDDM and coronary heart disease and the potential value of an integrated approach to the prevention of these conditions based on the prevention of these conditions based on the prevention of obesity (Perry, I. J., et al., BMJ310, 560-564 (1995)).
Diabetes has also been implicated in the development of kidney disease, eye diseases and nervous-system problems. Kidney disease, also called nephropathy, occurs when the kidney's "filter mechanism" is damaged and protein leaks into urine in excessive amounts and eventually the kidney fails. Diabetes is also a leading cause of damage to the retina at the back of the eye and increases risk of cataracts and glaucoma. Finally, diabetes is associated with nerve damage, especially in the legs and feet, which interferes with the ability to sense pain and contributes to serious infections. Taken together, diabetes complications are one of the nation's leading causes of death.
SUMMARY OF THE INVENTION
The present invention is drawn to compounds, which bind to and modulate the activity of a GPCR referred to herein as RUP3, and uses thereof. The term RUP3, as used herein, includes the human sequences found in GeneBank accession number XM_066873, naturally-occurring allelic variants, mammalian orthologs, and recombinant mutants thereof. A preferred human RUP3 for use in screening and testing of the compounds of the invention is provided in the nucleotide sequence of Seq. ID .No: 1 and the corresponding amino acid sequence in Seq. ID.No:2.
One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la):
Figure imgf000006_0001
(la) or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
A and B are independently Cι-3 alkylene optionally substituted with 1 to 4 methyl groups;
D is O, S, S(O), S(0)2, CR2R3 or N-R2; V is selected from the group consisting of C1.3 alkylene, ethynylene and C1-2 heteroalkylene wherein each are optionally substituted with 1 to 4 substituents selected from the group consisting of C1-3 alkyl, Cμ ialkoxy, carboxy, cyano, -3 haloalkyl and halogen; or V is absent; W is NR,, O, S, S(O) or S(0)2; or W is absent;
X is N or CR5;
Y is or CRe;
Z is selected from the group consisting of C1-5 acyl, C1-5 acyloxy, Cμ alkoxy, Cι-8 alkyl, C1-4 alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, C alkylureyl, amino, Cι-2 alkylamino, C2-4 dialkylamino, carbo-Ci-β-alkoxy, carboxamide, carboxy, cyano, -s diacylamino, C2-6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2_6 dialkylsulfonamide, Cμ dialkylsulfonylamino, formyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylcarboxamide, Cμ haloalkylsulfmyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio, halogen, aryl, heterocyclic, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl, wherein Cι-8 alkyl and C1-5 acyl are each optionally substituted with 1, 2, 3 or 4 groups selected from the group consisting of C1-5 acyl, C1-5 acyloxy, Cμ alkoxy, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylureyl, amino, Cι-2 alkylamino, C2. dialkylamino, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, formyl, Cμ haloalkoxy, Cμ haloalkylsulfmyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio, halogen, hydroxyl, hydroxylamino and nitro; or
Z is a group of Formula (A):
Figure imgf000006_0002
(A) wherein: R7 is H, Ci-s alkyl or C3-6 cycloalkyl; and R8 is H, nitro or nitrile;
Aτι is aryl or heteroaryl wherein each are optionally substituted with R9-R13; Ri is selected from the group consisting of H, C1-5 acyloxy, C2.6 alkenyl, Cμ alkoxy, -g alkyl, Cμ alkylcarboxamide, C2.6 alkynyl, Cι-4 alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylureyl, amino, Cμ alkylamino, C2-8 dialkylamino, carboxamide, cyano, C3.6 cycloalkyl, C2-6 dialkylcarboxamide, C2.6 dialkylsulfonamide, halogen, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfmyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio and hydroxyl;
R2 is selected from the group consisting of H, C,-5 acyl, C1-5 acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, amino, carbo-C -alkoxy, carboxamide, carboxy, cyano, C3-6-cycloalkyl, C2.6 dialkylcarboxamide, Cμ haloalkoxy, Cμ haloalkyl, halogen, heteroaryl, hydroxyl and phenyl; and wherein C alkyl, heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected from the group consisting of C1-5 acyl, C1-5 acyloxy, Cμ alkoxy, Cι-8 alkyl, Cμ alkylamino, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-C -alkoxy, carboxamide, carboxy, cyano, C3-6-cycloalkyl, C3_6- cycloalkyl-Cι-3-alkylene, C3-6-cycloalkyl-Cι-3-heteroalkylene, C2.8 dialkylamino, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfmyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro; or
R2 is -Ar2-Ar3 wherein Ar2 and Ar3 are independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of H, Cμ acyl, C1-5 acyloxy, Cμ alkoxy, Cι-8 alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, amino, carbo-C -alkoxy, carboxamide, carboxy, cyano, C3.6-cycloa.kyl, C2.6 dialkylcarboxamide, Cμ haloalkoxy, Cμ haloalkyl, halogen, hydroxyl and nitro; or
R2 is a group of Formula (B):
,OR 14
N
(B) wherein:
Rμ is Cι.8 alkyl or C3.6 cycloalkyl; and R15 is F, Cl, Br or CN; or R2 is a group of Formula (C):
Figure imgf000008_0001
(C) wherein: G is C=0, CR16Ri7, O, S, S(O), S(0)2; where R16 and R17 are independently
H or Cμ alkyl; and Ar4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6-cycloalkyl, C2-6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2-6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro;
R3 is H, Cμ alkyl, Cμ alkoxy, halogen or hydroxyl;
Rt is H or Cμ alkyl;
R5 and Re are independently H, C alkyl or halogen;
R9 is selected from the group consisting of Cμ acyl, Cμ acyloxy, C2.6 alkenyl, Cμ alkoxy, Cμ alkyl, Cμ alkylamino, Cμ alkylcarboxamide, C2.g alkynyl, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylureyl, amino, arylsulfonyl, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, C2.6 dialkylamino, C2.6 dialkylcarboxamide, C2.6 dialkylsulfonamide, halogen, Cμ haloalkoxy, - 4 haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio, heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxyl, nitro, C -7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide and sulfonic acid, and wherein Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfonamide, alkylsulfonyl, arylsulfonyl, heteroaryl, phenoxy and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ acyl, Cμ acyloxy, C2-6 alkenyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, C2-6 alkynyl, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylureyl, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3-6 cycloalkyl, C2-6 dialkylcarboxamide, halogen, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio, heteroaryl, heterocyclic, hydroxyl, nitro and phenyl; or
R9 is a group of Formula (D): θpγ R. 18
O (D) wherein:
"p" and "r" are independently 0, 1, 2 or 3; and
R18 is H, Cμ acyl, C2.6 alkenyl, Cμ alkyl, Cμ alkylcarboxamide, C2- 6 alkynyl, Cμ alkylsulfonamide, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.s cycloalkyl, C2.6 dialkylcarboxamide, halogen, heteroaryl or phenyl, and wherein the heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, amino, Cμ alkylamino, C2-6 alkynyl, C2-8 dialkylamino, halogen, Cμ haloalkoxy, Cμ haloalkyl and hydroxyl; and R10-Ri3 are independently selected form the group consisting of Cμ acyl, Cμ acyloxy, C2.6 alkenyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, C2.6 alkynyl, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylureyl, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, C2.6 dialkylcarboxamide, halogen, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio, hydroxyl and nitro; or two adjacent Rio-R.i groups together with Aτι form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
Some embodiments of the present invention include pharmaceutical compositions comprising at least one compound of the present invention and a pharmaceutically acceptable carrier.
Some embodiments of the present invention include methods for prophylaxis or treatment of a metabolic disorder in an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
Some embodiments of the present invention include methods of controlling or decreasing weight gain of an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or pharmaceutical composition thereof.
Some embodiments of the present invention include methods of modulating a RUP3 receptor comprising contacting the receptor with a compound of the present invention.
Some embodiments of the present invention include methods of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention. In some embodiments, the compound is an agonist. In some embodiments, the compound is an inverse agonist.
Some embodiments of the present invention include methods of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor is prophylaxis or treatment of a metabolic disorder.
Some embodiments of the present invention include methods of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor controls or reduces weight gain of the individual.
Some embodiments of the present invention include the use of compounds of the present invention for production of a medicament for use in prophylaxis or treatment of a metabolic disorder.
Some embodiments of the present invention include the use of compounds of the present invention for production of a medicament for use in controlling or decreasing weight gain in an individual.
One aspect of the present invention pertains to compounds of the present invention, as described herein, for use in methods of treatment of the human or animal body by therapy.
One aspect of the present invention pertains to compounds of the present invention, as described herein, for use in methods of prophylaxis or treatment of a metabolic disorder of the human or animal body by therapy.
In some embodiments, the metabolic disorder is type I, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X or metabolic syndrome.
One aspect of the present invention pertains to methods of producing a pharmaceutical compositions comprising admixing at least one compound of the present invention and a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1A shows RT-PCR analysis of RUP3 expression in human tissues. A total of twenty-two (22) human tissues were analyzed.
Figure IB shows the cDNA Dot-Blot analysis of RUP 3 expression in human tissues.
Figure 1C shows analysis of RUP3 by RT-PCR with isolated huyman pancreatic islets of Langerhans.
Figure ID shows analysis of RUP3 expression with cDNAs of rat origin by RT-PCR.
Figure 2 A shows a polyclonal anti-RUP3 antibody prepared in Rabbits.
Figure 2B shows the expression of RUP3 in insulin-producing β cells of pancreatic islets.
Figure 3 shows functional activities of RUP3 In vitro.
Figure 4A shows a RUP3 RNA blot. Figure 4B shows RUP3 agonist, Compound B84, stimulates cAMP production in HIT cells, at a level comparable to that seen with the adenyl cyclase activator forskolin.
Figure 4C shows RUP3 agonist, Compound B84, stimulates insulin secretion in HIT cells exposed to 15 mM glucose, at a level comparable to that seen with the adenylcyclase activator forskolin.
Figure 4D shows two RUP3 compounds, Compounds A48 and A51 (at 10 μM concentration), and the enhanced glucose-dependent insulin release compared to control.
Figure 5A shows the In vivo effects of a RUP3 agonist (Compound B70) on glucose homeostasis in mice and specifically the effect by a RUP3 agonist in a dose-dependent manner on the lowering of blood glucose after glucose challenge.
Figure 5B shows the acute response of db mice to a RUP 3 agonist and Ex-4. Figure 5B shows Compound B70 and Ex-4 significantly reduces glucose levels compared to vehicle control.
Figure 6 shows a representative scheme for the syntheses of compounds of the present invention.
DEFINITIONS
The scientific literature that has evolved around receptors has adopted a number of terms to refer to ligands having various effects on receptors. For clarity and consistency, the following definitions will be used throughout this patent document.
AGONISTS shall mean moieties that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes.
AMTNO ACID ABBREVIATIONS used herein are set out in Table 1 :
Figure imgf000011_0001
Figure imgf000012_0001
CHEMICAL GROUP, MOIETY OR RADICAL:
The term "Cμ acyl" denotes an alkyl radical attached to a carbonyl wherein the definition of alkyl has the same definition as described herein; some examples include formyl, acetyl, propionyl, butanoyl, iso-butanoyl. pentanoyl, hexanoyl, heptanoyl, and the like.
The term "Cμ acyloxy" denotes an acyl radical attached to an oxygen atom wherein acyl has the same definition has described herein; some examples include acetyloxy, propionyloxy, butanoyloxy, zw-butanoyloxy and the like.
The term "C2-6 alkenyl" denotes a radical containing 2 to 6 carbons wherein at least one carbon-carbon double bond is present, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons. Both E and Z isomers are embraced by the term "alkenyl." Furthermore, the term "alkenyl" includes di- and tri-alkenyls. Accordingly, if more than one double bond is present then the bonds may be all E or Z or a mixtures of E and Z. Examples of an alkenyl include vinyl, allyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3- pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexanyl, 2,4-hexadienyl and the like.
The term "Cμ alkoxy" as used herein denotes a radical alkyl, as defined herein, attached directly to an oxygen atom. Example include methoxy, ethoxy, n- propoxy, z'sø-propoxy, n-butoxy, t-butoxy, iso-butoxy and the like.
The term "Cμ alkyl" denotes a straight or branched carbon radical containing 1 to 8 carbons, some embodiments are 1 to 6 carbons, some embodiments are 1 to 3 carbons, and some embodiments are 1 or 2 carbons. Examples of an alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, t-butyl, amyl, t-amyl, n-pentyl and the like. The term "Cμ alkylcarboxamido" denotes a single alkyl group attached to an amide, wherein alkyl has the same definition as found herein. The Cμ alkylcarboxamido may be represented by the following:
Figure imgf000013_0001
Examples include N-methylcarboxamide, N-ethylcarboxamide, N-(iso- proρyl)carboxamide and the like.
The term "C1-C3 alkylene" refers to a divalent straight carbon group, such as, -CH2-, -CH2CH2-, -CH2CH2CH2-.
The term "Cμ alkylsulfinyl" denotes an alkyl radical attached to a sulfoxide radical of the formula: -S(O)- wherein the alkyl radical has the same definition as described herein. Examples include methylsulfinyl, ethylsulfinyl and the like.
The term "Cμ alkylsulfonamide" refers to the groups
alkyl
Figure imgf000013_0002
Figure imgf000013_0003
The term "Cμ alkylsulfonyl" denotes an alkyl radical attached to a sulfone radical of the formula: -S(O)2- wherein the alkyl radical has the same definition as described herein. Examples include methylsulfonyl, ethylsulfonyl and the like.
The term "Cμ alkylthio" denotes an alkyl radical attached to a sulfide of the formula: -S- wherein the alkyl radical has the same definition as described herein. Examples include methylsulfanyl (i.e., CH3S-), ethylsulfanyl, isopropylsulfanyl and the like.
The term "Cμ alkylthiocarboxamide" denotes a thioamide of the following formulae:
Figure imgf000013_0004
The term "Cμ alkylthioureyl" denotes the group of the formula: -ΝC(S)Ν- wherein one are both of the nitrogens are substituted with the same or different alkyl group and alkyl has the same definition as described herein. Examples of an alkylthioureyl include, CH3NHC(0)NH-, NH2C(0)NCH3-, (CH3)2N(0)NH-, (CH3)2N(0)NH-, (CH3)2N(0)NCH3-, CH3CH2NHC(0)NH-, CH3CH2NHC(0)NCH3-, and the like.
The term "Cμ alkylureyl" denotes the group of the formula: -NC(0)N- wherein one are both of the nitrogens are substituted with the same or different alkyl group wherein alkyl has the same definition as described herein. Examples of an alkylureyl include, CH3NHC(0)NH-, NH2C(0)NCH3-, (CH3)2N(0)NH-, (CH3)2N(0)NH-, (CH3)2N(0)NCH3-, CH3CH2NHC(0)NH-, CH3CH2NHC(0)NCH3-, and the like.
The term "C2_6 alkynyl" denotes a radical containing 2 to 6 carbons and at least one carbon-carbon triple bond, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons. Examples of an alkynyl include ethynyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3- hexynyl, 4-hexynyl, 5-hexynyl and the like. The term "alkynyl" includes di- and tri- ynes.
The term "amino" denotes the group -NH2.
The term "Cμ alkylamino" denotes one alkyl radical attached to an amino radical wherein the alkyl radical has the same meaning as described herein. Some examples include methylamino, ethylamino, propylamino and the like.
The term "aryl" denotes an aromatic ring radical containing 6 to 10 ring carbons. Examples include phenyl and naphthyl.
The term "arylalkyl" defines a C1-C4 alkylene, such as -CH2-, -CH2CH2- and the like, which is further substituted with an aryl group. Examples of an "arylalkyl" include benzyl, phenethylene and the like.
The term "aryϊcarboxamido" denotes a single aryl group attached to the amine of an amide, wherein aryl has the same definition as found herein. The example is N-phenylcarboxamide.
The term "arylureyl" denotes the group -ΝC(O)Ν- where one of the nitrogens are substituted with an aryl.
The term "benzyl" denotes the group -CH2C-6H5.
The term "carbo-Cμ-alkoxy" refers to an alkyl ester of a carboxylic acid, wherein the alkyl group is Cμ. Examples include carbomethoxy, carboethoxy, carboisopropoxy and the like.
The term "carboxamide" refers to the group -CONH2.
The term "carboxy" or "carboxyl" denotes the group -CO2H; also referred to as a carboxylic acid.
The term "cyano" denotes the group -CN.
The term "C3.7 cycloalkenyl" denotes a non-aromatic ring radical containing 3 to 6 ring carbons and at least one double bond; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentenyl, cyclohexenyl, and the like.
The term "C3.7 cycloalkyl" denotes a saturated ring radical containing 3 to 6 carbons; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
The term "C3-6 cycloalkyl-Cμ-alkylene" denotes a saturated ring radical containing 3 to 6 carbons bonded to a Cμ-alkylene as described herein; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl-CH2-, cyclopropyl-CH2CH2-, cyclobutyl-CH2-, cyclopentyl-CH2-, cyclohexyl-CH2-, and the like.
The term "Gt-s diacylamino" denotes an amino group bonded with two acyl groups defined herein wherein the acyl groups may be the same or different, such as:
0
)~CM alkyl -N
^— C|-3 alkyl O
Represented dialkylamino groups include diacetylamino, dipropionylamino, acetylpropionylamino and the like.
The term "C2-6 dialkylamino" denotes an amino substituted with two of the same or different alkyl radicals wherein alkyl radical has the same definition as described herein. Some embodiments are Cμ dialkylamino groups. Some examples include dimethylamino, methylethylamino, diethylamino and the like.
The term "Cμ dialkylcarboxamido" or "Cμ dialkylcarboxamide"denotes two alkyl radicals, that are the same or different, attached to an amide group, wherein alkyl has the same definition as described herein. A Cμ dialkylcarboxamido may be represented by the following groups:
O O
(X N N C alkyl
Cμ alkyl Cμ alkyl
Examples of a dialkylcarboxamide include N,N-dimethylcarboxamide, N-methyl-N- ethylcarboxamide and the like.
The term "C2.6 dialkylsulfonamide" refers to one of the following groups shown below:
Figure imgf000015_0001
The term "Cμ dialkylthiocarboxamido" or "Cμ dialkylthiocarboxamide" denotes two alkyl radicals, that are the same or different, attached to a thioamide group, wherein alkyl has the same definition as described herein. A Cμ dialkylthiocarboxamido may be represented by the following groups: S S if N N Cμ alkyl
Cμ alkyl Cμ alkyl
Examples of a dialkylthiocarboxamide include NN-dimethylthiocarboxamide, N- methyl-N-ethylthiocarboxamide and the like.
The term "Cμ dialkylsulfonylamino" refers to an amino group bonded with two Cμ alkylsulfonyl groups as defined herein.
The term "ethynylene" refers to the carbon-carbon triple bond group as represented below:
Figure imgf000016_0001
The term "formyl" refers to the group -CHO.
The term "Cμ haloalkoxy" denotes a haloalkyl, as defined herein, that is directly attached to an oxygen to form a difluoromethoxy, trifluoromethoxy, 2,2,2- trifluoroethoxy, pentafluoroethoxy and the like.
The term "Cμ haloalkyl" denotes an alkyl group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted represented by the formula CnF2n+I; when more than one halogen is present they may be the same or different and selected from F, Cl, Br or I. Some embodiments are 1 to 3 carbons. Examples include fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2- trifluoroethyl, pentafluoroethyl and the like.
The term "Cμ haloalkylcarboxamide" denotes an alkylcarboxamide group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted represented by the formula CnF2n+ι and "n" is 1, 2, 3 or 4. When more than one halogen is present they may be the same or different and selected from F, Cl, Br or I. Examples include 2-fluoroacetyl, 2,2-difluoroacetyl, 2,2,2-trifluoroacetyl, 2-chloro-2,2- difluoroacetyl, 3,3,3-trifluoropropionyl, 2,2,3,3,3-pentafluoropropionyl and the like.
The term "Cμ haloalkylsulfinyl" denotes a haloalkyl radical attached to a sulfoxide of the formula: -S(O)- wherein the alkyl radical has the same definition as described herein. Examples include trifluoromethylsulfinyl, 2,2,2-trifluoroethylsulfinyl, 2,2-difluoroethylsulfinyl and the like.
The term "Cμ haloalkylsulfonyl" denotes a haloalkyl attached to a sulfone of the formula: -S(O)2- wherein haloalkyl has the same definition as described herein. Examples include trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2,2- difiuoroethylsulfonyl and the like.
The term "Cμ haloalkylthio" denotes an alkylthio radical substituted with one or more halogens. Examples include trifluoromethylthio, 1,1-difluoroethylthio, 2,2,2-trifluoroethylthio and the like.
The term "halogen" or "halo" denotes to a fluoro, chloro, bromo or iodo group.
The term "Cμ heteroalkylene" refers to a Cμ alkylene bonded to a heteroatom selected from O, S, S(O), S(0)2 and NH. Some represented examples include the groups of the following formulae:
Figure imgf000017_0001
and the like
The term "heteroaryl" denotes an aromatic ring system that may be a single ring, two fused rings or three fused rings containing carbons and at least one ring heteroatom selected from O, S and N. Examples of heteroaryl groups include, but not limited to, pyridyl, benzofuranyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, quinoline, benzoxazole, benzothiazole, lH-benzimidazole, isoquinoline, quinazoline, quinoxaline, lΗ-imidazolyl, [l,2,4]triazolyl, [l,2,3]triazolyl, [l,2,4jtriazolyl, pyrrolyl, pyrazolyl, lΗ-pyrazolyl, imidazolyl, oxazolyl, oxazolyl, [l,3,4]oxadiazolyl, [l,3,4]thiadiazolyl, [l,2,4]oxadiazolyl, [l,2,4]thiadiazolyl, tetrazolyl, l,3-dioxo-l,3- dihydro-isoindolyl, [l,2,3]thiadiazol-4-yl and the like.
The term "heterocyclic" denotes a non-aromatic carbon ring (i.e., cycloalkyl or cycloalkenyl as defined herein) wherein one, two or three ring carbons are replaced a heteroatom, such as, O, S, N, wherein the N can be optionally substituted with Η, Cμ acyl or Cμ alkyl, and ring carbon atoms optionally substituted with oxo or a thiooxo thus forming a carbonyl or thiocarbonyl group. The heterocyclic group is a 3-, 4-, 5-, 6- or 7-membered containing ring. Examples of a heterocyclic group include but not limited to aziridin-1-yl, aziridin-2-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, piperidin-1-yl, piperidin-4-yl, morpholin-4-yl, piperzin-1-yl, piperzin-4- yl, pyrrolidin-1-yl, pyrrolidin-3-yl, [l,3]-dioxolan-2-yl and the like. Additional examples of heterocyclic groups are shown in Tables 2B, 2C, 2D, 2E, 2F and 2G, infra. The term "heterocycliccarboxamido" denotes a heterocyclic group with a ring nitrogen where the ring nitrogen is bonded directly to the carbonyl forming an amide. Examples include:
Figure imgf000018_0001
and the like.
The term "heterocyclicsulfonyl" denotes a heterocyclic group with a ring nitrogen where the ring nitrogen is bonded directly to an S02 group forming an sulfonamide. Examples include:
Figure imgf000018_0002
The term "hydroxyl" refers to the group -OH.
The term "hydroxylamino" refers to the group -NHOH.
The term "nitro" refers to the group -N02.
The term "Q-7 oxo-cycloalkyl" refers to a C4-7 cycloalkyl, as defined herein, wherein one of the ring carbons is replaced with a carbonyl. Examples of Gμ? oxo- cycloalkyl include but are not limited to: 2-oxo-cyclobutyl, 3-oxo-cyclobutyl, 3-oxo- cyclopentyl, 4-oxo-cyclohexyl, and the like and represented the following structures respectively:
Figure imgf000018_0003
The term "perfluoroalkyl" denotes the group of the formula -CnF2n+ι; stated differently, a perfluoroalkyl is an alkyl as defined herein herein wherein the alkyl is fully substituted with fluorine atoms and is therefore considered a subset of haloalkyl. Examples of perfluoroalkyls include CF3, CF2CF3, CF2CF2CF3, CF(CF3)2, CF2CF2CF2CF3, CF2CF(CF3)2, CF(CF3)CF2CF3 and the like.
The term "phenoxy" refers to the group CβHsO-.
The term "phenyl" refers to the group CgHs-.
The term"sulfonic acid" refers to the group -S03H.
The term "tetrazolyl" refers to the five membered heteroaryl of the following formulae:
Figure imgf000018_0004
In some embodiments, the tetrazolyl group is further substituted at either the 1 or 5 position resepectively.
The term "thiol" denotes the group -SH.
CODON shall mean a grouping of three nucleotides (or equivalents to nucleotides) which generally comprise a nucleoside (adenosine (A), guanosine (G), cytidine (C), uridine (U) and thymidine (T)) coupled to a phosphate group and which, when translated, encodes an amino acid.
COMPOSITION shall mean a material comprising at least two compounds or two components; for example, and not limitation, a Pharmaceutical Composition is a Composition.
COMPOUND EFFICACY shall mean a. measurement of the ability of a compound to inhibit or stimulate receptor functionality, as opposed to receptor binding affinity.
CONSTITUTIVELY ACTIVATED RECEPTOR shall mean a receptor subject to constitutive receptor activation.
CONSTITUTIVE RECEPTOR ACTIVATION shall mean stabilization of a receptor in the active state by means other than binding of the receptor with its endogenous ligand or a chemical equivalent thereof.
CONTACT or CONTACTING shall mean bringing at least two moieties together, whether in an in vitro system or an in vivo system.
ENDOGENOUS shall mean a material that a mammal naturally produces. ENDOGENOUS in reference to, for example and not limitation, the term "receptor" shall mean that which is naturally produced by a mammal (for example, and not limitation, a human) or a virus.
Li contrast, the term NON-ENDOGENOUS in this context shall mean that which is not naturally produced by a mammal (for example, and not limitation, a human) or a virus. For example, and not limitation, a receptor which is not constitutively active in its endogenous form, but when manipulated becomes constitutively active, is most preferably referred to herein as a "non-endogenous, constitutively activated receptor." Both terms can be utilized to describe both "in vivo" and "in vitro" systems. For example, and not a limitation, in a screening approach, the endogenous or non-endogenous receptor may be in reference to an in vitro screening system. As a further example and not limitation, where the genome of a mammal has been manipulated to include a non-endogenous constitutively activated receptor, screening of a candidate compound by means of an in vivo system is viable.
INDIVIDUAL as used herein refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. INHIBIT or INHIBITING, in relationship to the term "response" shall mean that a response is decreased or prevented in the presence of a compound as opposed to in the absence of the compound.
INVERSE AGONISTS shall mean moieties that bind the endogenous form of the receptor or to the constitutively activated form of the receptor, and which inhibit the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of agonists or partial agonists, or decrease GTP binding to membranes. Preferably, the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50%, and most preferably by at least 75%), as compared with the baseline response in the absence of the inverse agonist.
LIGAND shall mean an endogenous, naturally occurring molecule specific for an endogenous, naturally occurring receptor.
As used herein, the terms MODULATE or MODULATING shall mean to refer to an increase or decrease in the amount, quality, response or effect of a particular activity, function or molecule.
PHARMACEUTICAL COMPOSITION shall mean a composition comprising at least one active ingredient, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, and not limitation, a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.
DETAILED DESCRIPTION Compound Of The Present Invention
One aspect of the present invention pertains to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la):
Figure imgf000020_0001
(la) or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein A, B, D, V, W, X, Y, Z Aτι, and Ri are as described herein, supra and infra.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
One aspect of the present invention encompasses N-oxides of 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (la).
One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is NR4 and compounds may be represented by Formula (lb) as shown below:
Figure imgf000021_0001
(lb) wherein each variable in Formula (lb) has the same meaning as described herein. In some embodiments, P^ is H. In some embodiments, is CH3 or CH2CH3.
One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is O, (i.e., an oxygen atom) and compounds may be represented by Formula (Ic) as shown below:
Figure imgf000021_0002
(Ic) wherein each variable in Formula (Ic) has the same meaning as described herein.
One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is S, S(O) or S(0)2 and compounds may be represented by Formulae (Id), (le) and (If) respectively as shown below:
Figure imgf000021_0003
(Id) (le) (If) wherein each variable in Formulae (Id), (le) and (If) has the same meaning as described herein.
One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is absent and compounds may be represented by Formula (Ig) as shown below:
Figure imgf000022_0001
dg) wherein each variable in Formula (Ig) has the same meaning as described herein. In some embodiments, compounds of the present invention are of Formula (Ig) wherein V is absent and accordingly these compounds may be represented by Formula (Ih) as shown below:
Figure imgf000022_0002
(Ih) wherein each variable in Formula (Ih) has the same meaning as described herein.
One aspect of the present invention encompasses 1,2,3-trisubstituted aryl and heteroaryl derivatives as shown in Formula (la) wherein W is absent and V is ethynylene. Compounds may be represented by Formula (Ii) as shown below:
Figure imgf000022_0003
(Ii) wherein each variable in Formula (Ii) has the same meaning as described herein.
In some embodiments, V is Cμ alkylene optionally substituted with 1 to 4 substituents selected from the group consisting of Cμ alkyl, Cμ alkoxy and halogen. In some embodiments, V is a methylene group (i.e., -CH2-). In some embodiments, V is an ethylene group (i.e., -CH2CH2-). In some embodiments, V is a methylene and W is an oxygen atom. In some embodiments, V is methylene and W is a N j group. In some embodiments, V is methylene and W is a NH group. In some embodiments, V is ethylene and W is an oxygen atom. In some embodiments, V is ethylene and W is a R group. In some embodiments, V is ethylene and W is a NH group.
In some embodiments, V is Cμ heteroalkyleήe optionally substituted with 1 to 4 substituents selected from the group consisting of Cμ alkyl, Cμ alkoxy and halogen. In some embodiments, V is -OCH2CH2-. In some embodiments, V is -OCH2CH2- and W is an oxygen atom and may be represented by the formula: -OCH2CH20-. In some embodiments, N is -OCH2CH2- and W is a ΝH group and may be represented by the formula: - OCH2CH2ΝH-.
Ih some embodiments, V is absent and may be represented by Formula (Ij) as shown below:
Figure imgf000023_0001
(Ij) wherein each variable in Formula (Ij) has the same meaning as described herein.
In some embodiments, A and B are both methylene wherein A and B are optionally substituted with 1 to 2 methyl groups and therefore form a four-membered nitrogen containing ring. In some embodiments, compounds of the invention may be represented by Formula (Ik) as shown below:
Figure imgf000023_0002
(Ik) wherein each variable in Formula (Ik) has the same meaning as described herein. In some embodiments, D is -CHR2-.
In some embodiments, A is ethylene and B is methylene wherein A is optionally substituted with 1 to 4 methyl groups and B is optionally substituted with 1 to 2 methyl groups. In some embodiments, compounds of the invention may be represented by Formula (Im) as shown below:
Figure imgf000023_0003
(Im) wherein each variable in Formula (Im) has the same meaning as described herein. In some embodiments, D is -CHR2-. In some embodiments, R2 is Cμ alkylsulfonyl.
In some embodiments, A is propylene and B is methylene wherein A is optionally substituted with 1 to 4 methyl groups and B is optionally substituted with 1 to 2 methyl groups. In some embodiments, compounds of the invention may be represented by Formula (In) as shown below:
Figure imgf000024_0001
(In) wherein each variable in Formula (In) has the same meaning as described herein. In some embodiments, D is -CHR2-.
In some embodiments, A and B are both ethylene wherein A and B are optionally substituted with 1 to 4 methyl groups. In some embodiments, compounds of the invention may be represented by Formula (Io) as shown below:
Figure imgf000024_0002
(Io) wherein each variable in Formula (Io) has the same meaning as described herein. In some embodiments, D is -CHR2-.
In some embodiments, A is propylene and B is ethylene wherein A and B are optionally substituted with 1 to 4 methyl groups. In some embodiments, compounds of the invention may be represented by Formula (Ip) as shown below:
Figure imgf000024_0003
(Ip) wherein each variable in Formula (Ip) has the same meaning as described herein. In some embodiments, D is -CHR2-.
In some embodiments, A and B are both propylene wherein A and B are optionally substituted with 1 to 4 methyl groups. In some embodiments, compounds of the invention may be represented by Formula (Iq) as shown below:
Figure imgf000024_0004
(Iq) wherein each variable in Formula (Iq) has the same meaning as described herein. In some embodiments, D is -CHR2-.
In some embodiments, D is O, S, S(O) or S(0)2. In some embodiments, D is S, S(O) or S(0)2; and A and B are independently optionally substituted with 1 or 2 methyl groups. In some embodiments, A and B are ethylene groups. In some embodiments, A and B are ethylene groups substituted with 2 methyl groups and D is an oxygen atom (i.e., forming a 2,6-dimethyl-morpholin-4-yl group).
In some embodiments, D is CR2R3.
In some embodiments, R2 is selected from the group consisting of H, Cμ acyl, Cμ acyloxy, Cμ alkoxy, C alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ allcylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, amino, carbo-Cμ-alkoxy, carboxamide, carboxyl, C3.β cycloalkyl, Cμ haloalkoxy, Cμ haloalkyl, halogen and hydroxyl.
In some embodiments, R2 is selected from the group consisting of C(0)CH3, C(0)CH2CH3, C(0)CH2CH2CH3, C(0)CH(CH3)2, C(0)CH2CH2CH2CH3; OC(0)CH3, 0C(0)CH2CH3j OC(0)CH2CH2CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, OCH2(CH2)2CH3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3, CH2(CH2)3CH3, C(0)NHCH3, C(0)NHCH2CH3, C(0)NHCH2CH2CH3, C(0)NHCH(CH3)2, C(0)NHCH2(CH2)2CH3, C02CH3, C02CH2CH3, C02CH2CH2CH3, C02CH(CH3)2 and C02CH2(CH2)2CH3.
In some embodiments, R2 is selected from the group consisting of C(0)CH3, C(0)CH2CH3, C(0)CH2CH2CH3, C(0)CH(CH3)2, C(0)CH2CH2CH2CH3, OC(0)CH3, OC(0)CH2CH3, OC(0)CH2CH2CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, OCH2(CH2)2CH3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3, CH2(CH2)3CH3, C(0)NH2, C02CH3, C02CH2CH3, C02CH2CH2CH3, C02CH(CH3)2, C02CH2(CH2)2CH3, and C02H.
In some embodiments, R2 is selected from the group consisting of SCH3, SCH2CH3, SCH2CH2CH3, SCH(CH3)2, SCH2(CH2)2CH3, S(0)CH3, S(0)CH2CH3, S(0)CH2CH2CH3, S(0)CH(CH3)2, S(0)CH2(CH2)2CH3, S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, S(0)2CH2(CH2)2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, OCF3, OCHF2, CF3, CHF2 and F. fn some embodiments, R2 is selected from the group consisting of S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, S(0)2CH2(CH2)2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, hydroxyl, and F.
In some embodiments, R2 is Cμ alkyl, or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfonyl, carbo-Cμ-alkoxy, carboxamide, carboxy, C3-6-cycloalkyl, Qμ-cycloalkyl- Cμ-alkylene, C3.6-cycloalkyl-Cι-3-heteroalkylene, and hydroxyl. In some embodiments, R2 is selected from the group consisting of CH2OCH3, CH2CH2OCH3, CH2OCH2CH3, CH2OCH2CH2CH3, CH2CH2OCH2CH3, CH2CH2OCH2CH2CH3) CH2OCH(CH3)2, CH2OCH2CH(CH3)2, CH2C02H, CH2CH2C02H, CH2OH, CH2CH2OH and CH2CH2CH20H.
In some embodiments, R2 is Cι-8 alkyl, heteroaryl or phenyl each optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylamino, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, C alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3_6-cycloalkyl-Cμ-heteroalkylene, C2-8 dialkylamino, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro.
In some embodiments, R2 is selected from the group consisting of CH2OCH3, CH2CH2OCH3, CH2OCH2CH3, CH2OCH2CH2CH3, CH2CH2OCH2CH3, CH2CH2OCH2CH2CH3, CH2OCH(CH3)2, CH2OCH2CH(CH3)2, CH2C02H, CH2CH2C02H, CH2OH, CH2CH2OH and CH2CH2CH2OH.
In some embodiments, R2 is selected from the group consisting of CH2SCH , CH2SCH2CH3, CH2SCH2CH2CH3, CH2SCH(CH3)2, CH2SCH2(CH2)2CH3, CH2CH2SCH3, CH2CH2SCH2CH3, CH2CH2SCH2CH2CH3, CH2CH2SCH(CH3)2, CH2CH2SCH2(CH2)2CH3, CH2S(0)CH3, CH2S(0)CH2CH3, CH2S(0)CH2CH2CH3, CH2S(0)CH(CH3)2, CH2S(0)CH2(CH2)2CH3, CH2CH2S(0)CH3, CH2CH2S(0)CH2CH3, CH2CH2S(0)CH2CH2CH3, CH2CH2S(0)CH(CH3)2, CH2CH2S(0)CH2(CH2)2CH3, CH2S(0)2CH3, CH2S(0)2CH2CH3, CH2S(0)2CH2CH2CH3, CH2S(0)2CH(CH3)2, CH2S(0)2CH2(CH2)2CH3, CH2CH2S(0)2CH3, CH2CH2S(0)2CH2CH3, CH2CH2S(0)2CH2CH2CH3, CH2CH2S(0)2CH(CH3)2 and CH2CH2S(0)2CH2(CH2)2CH3.
In some embodiments, R2 is selected from the group consisting of CH20CH2~ cyclopropyl, CH2OCH2-cyclobutyl, CH2OCH2-cyclopentyl, CH2OCH2-cyclohexyl, CH2OCH2CH2-cyclopropyl, CH2OCH2CH2-cyclobutyl, CH2OCH2CH2-cyclopentyl, CH2OCH2CH2-cyclohexyl, CH2CH2OCH2-cyclopropyl, CH2CH2θCH2-cyclobutyl, CH2CH2θCH2-cyclopentyl, CH2CH2OCH2-cyclohexyl, CH2CH2OCH2CH2-cyclopropyl, CH2CH2OCH2CH2-cyclobutyl, CH2CH2OCH2CH2-cyclopentyl and CH2CH2OCH2CH2- cyclohexyl.
In some embodiments, R2 is selected from the group consisting of l,2,4-oxadiazol-3- yl, l,2,4-oxadiazol-5-yl, l,3,4-oxadiazol-2-yl, l,2,4-triazol-5-yl and 1,2,4-triazol-l-yl, 3- methyl-l,2,4-oxadiazol-5-yl, 3-methyl-l,2,4-oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 5- ethyl-l,2,4-oxadiazol-3-yl, 5-methyl-l,3,4-oxadiazol-2-yl, 5-ethyl-l,3,4-oxadiazol-2-yl, 3- methyl-l,2,4-triazol-5-yl, 3-ethyl-l,2,4-triazol-5-yl, 3-methyl-l,2,4-triazol-l-yl, 3 -ethyl- 1,2,4- triazol-1-yl, 5 -methyl- 1,2,4-triazol-l-yl and 5-ethyl-l,2,4-triazol-l-yl.
In some embodiments, R2 is selected from the group consisting of l,2,4-oxadiazol-3- yl, l,2,4-oxadiazol-5-yl, l,3,4-oxadiazol-2-yl, 3-methyl-l,2,4-oxadiazol-5-yl, 3 -ethyl- 1,2,4- oxadiazol-5-yl, 3-isopropyl-l,2,4-oxadiazol-5-yl, 3-propyl-l,2,4-oxadiazol-5-yl, 3-t-butyl- l,2,4-oxadiazol-5-yl, and 3-cyclopropyl-l,2,4-oxadiazol-5-yl.
La some embodiments, R2 is selected from the group consisting of 3-methyl-l,2,4- oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 3-propyl-l,2,4-oxadiazol-5-yl, 3-isopropyl- l,2,4-oxadiazol-5-yl, 3-butyl-l,2,4-oxadiazol-5-yl, and 3-(t-butyl)-l,2,4-oxadiazol-5-yl.
In some embodiments, R2 is a heteroaryl comprising 5 -atoms in the aromatic ring and are represented by the following formulae:
TABLE 2A
Figure imgf000027_0001
r=\ ? N=Λ ? N=Λ N=ι Λ =^ -s '0 s VNH Nv°
Figure imgf000027_0002
wherein the 5 -membered heteroaryl is bonded at any available position of the ring, for example, a imidazolyl ring can be bonded at one of the ring nitrogens (i.e., imidazol-1-yl group) or at one of the ring carbons (i.e., imidazol-2-yl, imidazol-4-yl or imiadazol-5-yl group).
Li some embodiments, R2 is a 5-membered heteroaryl optionally substituted with 1 to 4 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylamino, Cμ alkylcarboxamide, CΪ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3_6-cycloalkyl-Cμ- heteroalkylene, C2.8 dialkylamino, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro. In some embodiments, compounds of the present invention are of the following formula:
Figure imgf000028_0001
wherein R2 is a 5 -membered heteroaryl optionally substituted with 1 to 4 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylamino, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ- alkoxy, carboxamide, carboxy, cyano, C3-6-cycloalkyl-Cμ-heteroalkylene, C2.8 dialkylamino, C2_6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro; and R3 is hydrogen or Cμ alkyl.
Li some embodiments, R2 is a 5-membered heteroaryl optionally substituted with 1 or 2 substituents selected from the group consisting of Cμ alkyl, Cμ haloalkyl and halogen; and R3 is hydrogen.
Li some embodiments, R2 is a 5-membered heteroaryl optionally substituted with lor 2 Cμ alkyl substituents; and R3 is hydrogen.
Li some embodiments, R2 is a 5-membered heteroaryl optionally substituted with CH3, CH2CH3. CH(CH3)2, CH2CH2CH3, C(CH3)3; and R3 is hydrogen.
Li some embodiments, R2 is a fused heteroaryl group containing to aromatic rings wherein at least one is a heteroaryl ring, such as, benzofuranyl, benzimidazole, benzoxazole, benzothiazole, indole, benzothiophenyl. Li some embodiments, R2 is a benzofuran-2-yl group.
Li some embodiments, R2 is a heterocyclic represented, for example, by the formulae in TABLE 2B.
TABLE 2B
Figure imgf000028_0002
Cμ
Figure imgf000029_0001
lt is understood that any one of the heterocyclic groups shown in TABLES 2B to 2E may be bonded at any available ring carbon or ring nitrogen as allowed by the respective formula. For example, a 2,5-dioxo-imidazolidinyl group may be bonded at the ring carbon or at either of the two ring nitrogens to give the following formulae respectively:
Figure imgf000029_0002
Li some embodiments, R2 is a heterocyclic represented, for example, by the formulae in TABLE 2C.
TABLE 2C
Cι-
Figure imgf000029_0003
Li some embodiments, R2 is a heterocyclic represented, for example, by the formulae in TABLE 2D.
TABLE 2D
Figure imgf000029_0004
Li some embodiments, R2 is a heterocyclic represented, for example, by the formulae in TABLE 2E.
TABLE 2E
Figure imgf000029_0005
Li some embodiments, R2 is a heterocyclic represented, for example, by the formulae in TABLE 2F wherein the Cμ alkyl group on the respective ring nitrogen atoms may be the same or different.
TABLE 2F
Figure imgf000030_0001
Li some embodiments, R2 is a heterocyclic represented, for example, by the formulae in TABLE 2G wherein the Cμ alkyl group on the respective ring nitrogen atoms may be the same or different.
TABLE 2G
Cι-6
Figure imgf000030_0002
Li some embodiments, D is CR2R3 and R2 is -Ar2-Ar3 wherein Ar2 and Ar3 are independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, amino, carbo- Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6-cycloalkyl, C2-6 dialkylcarboxamide, Cμ haloalkoxy, Cμ haloalkyl, halogen, hydroxyl and nitro. Li some embodiments, Ar2 is a heteroaryl and Ar3 is phenyl. Li some embodiments, compounds of the present invention are represented by Formula (Ir) as shown below:
Figure imgf000030_0003
(Ir) wherein each variable in Formula (Ir) has the same meaning as described herein. Li some embodiments, compounds of the present invention are of Formula (Ir) wherein R3 is H.
Li some embodiments, Ar2 is a heteroaryl comprising 5-atoms in the aromatic ring and are represented by the following formulae:
TABLE 3
Figure imgf000030_0004
>
Figure imgf000031_0001
wherein the 5-membered heteroaryl is bonded at any available position of the ring, for example, a imidazolyl ring can be bonded at one of the ring nitrogens (i.e., imidazol-1-yl group) or at one of the ring carbons (i.e., imidazol-2-yl, imidazol-4-yl or imiadazol-5-yl group) and Ar3 is bonded to any remaining available ring atom.
Li some embodiments, Ar2 is a heteroaryl and Ar3 is phenyl. Li some embodiments, the heteroaryl and phenyl are optionally substituted with 1 to 5 substituents selected from the .. group consisting of H, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, halogen, hydroxyl and nitro.
Li some embodiments, D is CR2R3 and R2 is Formula (B):
,OR
,.T>C 14
N
(B) wherein:
Rι4 is Cμ' alkyl or C3-6 cycloalkyl; and R15 is F, Cl, Br or CN. Li some embodiments, RM is Cμ alkyl and R15 is F, Cl or CN.
Li some embodiments, D is CR2R3 and R2 is Formula (C):
Figure imgf000031_0002
(C) wherein: G is C=0, CR16R , O, S, S(O), S(0)2; where R16 and R17 are independently H or Cμ alkyl; and Ar is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C -cycloalkyl-Cμ-heteroalkylene, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro.
Li some embodiments, R2 is Formula (C) wherein G is C=0, CRι6Rπ, O, S, S(O), S(0)2; wherein Rt6 and R17 are independently H or Cμ alkyl; and Ar4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ alkoxy, Cμ alkyl, Cμ haloalkoxy, Cμ haloalkyl, and halogen.
In some embodiments, G is C=0, CH2 or O. Li some embodiments, G is S, S(0) or S(0)2.
Li some embodiments, Ar4 is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. Li some embodiments, Ar is 2-pyridyl.
In some embodiments, compounds of the present invention are represented by Formula (Is) as shown below:
Figure imgf000032_0001
(Is) wherein each variable in Formula (Is) has the same meaning as described herein.
Li some embodiments, D is CR2R3, R2 is Formula (C) and G is C=0, CRι6Rπ or O. In some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3-6-cycloalkyl-C1-3-heteroalkylene, C2_6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, d- 4 haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro.
Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl.
Li some embodiments, Ar is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl.
Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, Cμ-cycloalkyl-Cμ-heteroalkylene, C2-6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2-6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, - 4 haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro.
Li some embodiments, Ar is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl.
Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl.
L some embodiments, Ar4 is a 5-membered heteroaryl, for example, as shown in TABLE 2A supra. Li some embodiments, Ar is a 6-membered heteroaryl, for example, the 6-membered heteroaryls as shown in TABLE 4:
TABLE 4
Figure imgf000033_0001
wherein the heteroaryl group is bonded at any ring carbon. L some embodiments, Ar is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. Li some embodiments, Ar is 2-pyridyl. Li some embodiments, D is CR2R3, R2 is Formula (C), G is CRι6Rι7 and R16 and R!7 are independently H or Cμ alkyl.
Li some embodiments, D is CR2R3, R2 is Formula (C) and G is S, S(0) or S(0) .
Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3-6-cycloalkyl-Cμ-heteroalkylene, C2-6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Ci- 4 haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro.
Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl.
Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl.
Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, Cμ-cycloalkyl-Cμ-heteroalkylene, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2-6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Ci- 4 haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro.
Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl.
Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl. L some embodiments, Ar4 is a 5-membered heteroaryl, for example, as shown in TABLE 2A, supra.
Li some embodiments, Ar4 is a 6-membered heteroaryl, for example, as shown in TABLE 4, supra.
Li some embodiments, Ar4 is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. Li some embodiments, Ar is 2-pyridyl.
Li some embodiments, R3 is H. Li some embodiments, D is N-R2. Li some embodiments, R2 is selected from the group consisting of H, Cμ acyl, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonyl, carbo- Cμ-alkoxy, carboxamide, C3.6-cycloalkyl and Cμ haloalkyl. Li some embodiments, R2 is selected from the group consisting of C(0)CH3, C(0)CH2CH3, C(0)CH2CH2CH3, C(0)CH(CH3)2, C(0)CH2CH2CH2CH3, CH3, CH2CH3) CH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3; CH2(CH2)3CH3, C(0)NHCH3, C(0)NHCH2CH3, C(0)NHCH2CH2CH3, C(0)NHCH(CH3)2, C(0)NHCH2(CH2)2CH3, C02CH3, C02CH2CH3, C02CH2CH2CH3, C02CH(CH3)2 and C02CH2(CH2)2CH3. Li some embodiments, R2 is selected from the group consisting of S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, S(0)2CH2(CH2)2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH2CF3, CF3 and CHF2.
Li some embodiments, D is N-R2 and R2 is H, or carbo-Cμ-alkoxy. Li some embodiments, R2 is selected from the group consisting of C02CH3, C02CH2CH3, C02CH2CH2CH3, C02CH(CH3)2 and C02CH2(CH2)2CH3. Li some embodiments, R2 is Cμ alkyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ alkylsulfonyl, carbo-Cμ-alkoxy, and carboxy. Li some embodiments, R2 is CH2C02Et,.or , CH2CH2C02H. Li some embodiments, R2 is selected from the group consisting of CH2CH2S(0)2CH3, CH2CH2S(0)2CH2CH3, CH2CH2S(0)2CH2CH2CH3, CH2CH2S(0)2CH(CH3)2 and CH2CH2S(0)2CH2(CH2)2CH3.
Li some embodiments, D is N-R2 wherein R2 is Cμ alkyl, heteroaryl or phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylamino, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, Cμ-cycloalkyl-Cμ-heteroalkylene, C2.8 dialkylamino, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2-6 dialkylsulfonamide, Cμ allcylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro. Li some embodiments, R2 is selected from the group consisting of CH2CH2OCH3, CH2CH2OCH2CH3, CH2CH2OCH2CH2CH3, CH2C02H, CH2CH2C02H, CH2CH2OH and CH2CH2CH2OH. Li some embodiments, R2 is selected from the group consisting of CH2CH2SCH3, CH2CH2SCH2CH3, CH2CH2SCH2CH2CH3, CH2CH2SCH(CH3)2, CH2CH2SCH2(CH2)2CH3, CH2CH2S(0)CH3, CH2CH2S(0)CH2CH3, CH2CH2S(0)CH2CH2CH3J CH2CH2S(0)CH(CH3)2, CH2CH2S(0)CH2(CH2)2CH3, CH2CH2S(0)2CH3, CH2CH2S(0)2CH2CH3, CH2CH2S(0)2CH2CH2CH3, CH2CH2S(0)2CH(CH3)2 and CH2CH2S(0)2CH2(CH2)2CH3. Li some embodiments, R2 is selected from the group consisting of l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl, 1,3,4- oxadiazol-2-yl, l,2,4-triazol-5-yl and 1,2,4-triazol-l-yl, 3-methyl-l,2,4-oxadiazol-5-yl, 3- methyl-l,2,4-oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 5- methyl-l,3,4-oxadiazol-2-yl, 5-ethyl-l,3,4-oxadiazol-2-yl, 3 -methyl- l,2,4-xriazol-5-yl, 3- ethyl-l,2,4-triazol-5-yl, 3 -methyl- 1,2,4-triazol-l-yl, 3-ethyl-l,2,4-triazol-l-yl, 5-methyl-l,2,4- triazol-1-yl and 5-ethyl-l,2,4-triazol-l-yl.
Li some embodiments, D is N-R2 and R2 is -Ar2-Ar3 wherein Ar2 and Ar3 are independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of H, Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6-cycloalkyl, C2.6 dialkylcarboxamide, Cμ haloalkoxy, Cμ haloalkyl, halogen, hydroxyl and nitro. . Li some embodiments, compounds of the present invention are represented by Formula (It) as shown below:
Figure imgf000036_0001
(It) wherein each variable in Formula (It) has the same meaning as described herein. Li some embodiments, Ar2 is a heteroaryl and Ar3 is phenyl. Li some embodiments, the heteroaryl and phenyl are optionally substituted with 1 to 5 substituents selected from the group consisting of H, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, halogen, hydroxyl and nitro. Li some embodiments, D is N-R2 wherein R2 is Formula (C):
Figure imgf000036_0002
(C) wherein:
G is C=0 or CRι6Rι7; where R16 and R are independently H or Cμ alkyl; and Ar4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, Cμ-cycloallcyl-Cμ-heteroalkylene, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2-6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Ci-4 haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro. Li some embodiments, compounds of the present invention are represented by Formula (lu) as shown below:
Figure imgf000037_0001
(lu) wherein each variable in Formula (lu) has the same meaning as described herein.
Li some embodiments, D is N-R2, R2 is Formula (C) and G is C=0. Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo~Cμ-alkoxy, carboxamide, carboxy, cyano, Cμ-cycloalkyl-Cμ-heteroalkylene, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2.6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro. Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl. Li some embodiments, Ar is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl. Li some embodiments, Ar is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ aikylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6-cycloalkyl-Cμ-heteroalkylene, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2_6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro. Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl. Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl. Li some embodiments, Ar is a 5-membered heteroaryl, for example, as shown in TABLE 2A, supra. Li some embodiments, Ar4 is a 6-membered heteroaryl, for example, as shown in TABLE 4, supra. L some embodiments, Ar is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. Li some embodiments, Ar is 2-pyridyl.
Li some embodiments, D is N-R2 wherein R2 is Formula (C) and G is CR16Rπ- In some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6-cycloalkyl-Cμ-heteroalkylene, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, Cμ dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro. Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl. Li some embodiments, Ar4 is phenyl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl. Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ allcylthioureyl, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, Cμ-cycloalkyl-Cμ-heteroalkylene, C2.6 dialkylcarboxamide, Cμ dialkylthiocarboxamide, C2-6 dialkylsulfonamide, Cμ alkylthioureyl, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, Cμ haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro. Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkyl, halogen and hydroxyl. Li some embodiments, Ar4 is heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkyl, halogen and hydroxyl. In some embodiments, Ar4 is a 5-membered heteroaryl, for example, as shown in TABLE 2A, supra. Li some embodiments, Ar4 is a 6-membered heteroaryl, for example, as shown in TABLE 4, supra. Li some embodiments, Ar4 is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl. Li some embodiments, Ar is 2-pyridyl. Li some embodiments, D is N-R2 wherein R2 is Formula (C), G is CRι6Rι7 and Rι6 and Ri7 are independently H or Cμ alkyl.
Li some embodiments, Z is selected from the group consisting of Cμ acyl, Cμ alkyl, Cμ alkylcarboxamide, amino, cyano, Q-s diacylamino, Cμ dialkylsulfonamide, formyl, halogen, heterocyclic, and nitro wherein Cμ alkyl and Cμ acyl are each optionally substituted with 1, or 2 groups selected from the group consisting of C2.4 dialkylmino, hydroxy, and halogen.
Li some embodiments, Z is selected from the group consisting of nitro, amino, formyl, NHC(0)CF3, Br, NHC(0)CH3, N(C(0)CH3)2, N(S(0)2CH3)2, CH3, [l,3]dioxolan-2- yl, CH2OH, CH2N(CH3)2, and C(0)CH3.
Li some embodiments, Z is selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylthioureyl, Cμ alkylureyl, carboxamide, carboxy, cyano, aryl, Cμ haloalkyl, Cμ haloalkylcarboxamide, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl, wherein Cμ alkyl is optionally substituted with 1, 2, 3 or 4 groups selected from the group consisting of Cμ acyl, Cμ acyloxy, Cμ alkoxy, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, Cμ alkylureyl, amino, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, formyl, Cμ haloalkoxy, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio, halogen, hydroxyl, hydroxylamino and nitro.
Li some embodiments, Z is selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, Cμ alkylthiocarboxamide, Cμ alkylthioureyl, Cμ alkylureyl, carboxamide, carboxy, cyano, aryl, Cμ haloalkyl, Cμ haloalkylcarboxamide, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl.
Li some embodiments, Z is a heterocyclic group. Li some embodiments, Z is a 5- membered heterocyclic group containing two oxygen atoms.
Li some embodiments, Z is an alkyl group optionally substituted C2.4-dialkylamino or hydroxy.
Li some embodiments, Z is selected from the group consisting of formyl, NHC(0)CH3, NHC(0)CH2CH3, NHC(0)CH(CH3)2, CH3, CH2CH3, CH(CH3)2, CH2CH2CH2CH3, NHC(0)CF3, carboxy, CF3, CF2CF3, nitro and lH-tetrazol-5-yl. In some embodiments, Z is selected from the group consisting of carboxy, CF3, nitro and lH-tetrazol-5-yl.
Li some embodiments, Z is [l,3]-dioxolan-2-yl. Li some embodiments, Z is a formyl group. Li some embodiments, Z is a carboxy group. Li some embodiments, Z is a -CΗ2OΗ group. i some embodiments, Z is a -CH2N(CH3)2 group. Li some embodiments, Z is Formula (A):
Figure imgf000040_0001
(A) wherein:
R7 is H, Cι-8 alkyl or C3-6 cycloalkyl; and R8 is H, nitro or nitrile. Li some embodiments, R7 is H or Cμ alkyl.
Li some embodiments, Ri is selected from the group consisting of H, Cμ alkoxy, Cμ alkyl, C2-6 alkynyl, amino, C3.6 cycloalkyl and Cμ haloalkyl. Li some embodiments, Ri is H or amino.
Li some embodiments, Ri is selected from the group consisting of H, Cμ alkyl, and amino.
Li some embodiments, Ari is aryl optionally substituted with R9-R]3. Li some embodiments, Ari is phenyl.
Li some embodiments, ^ is heteroaryl. L some embodiments, Ari is heteroaryl optionally substituted with R9-Rι3. Li some embodiments, Ari is a heteroaryl selected from TABLE 2A. Li some embodiments, Ari is a heteroaryl selected from TABLE 4 or an N-oxide thereof. Li some embodiments, compounds of the invention are of Formula (Iv):
Figure imgf000040_0002
(Iv) wherein A, B, D, V, W, X, Y, Z, R]5 R9, R]0, Rπ and Rι2 have the same meaning as described herein, supra and infra.
In some embodiments, Ari is heteroaryl and R9 is selected from the group consisting of H, Cμ acyl, C alkoxy, Cμ alkyl, Cμ alkylcarboxamide, C2.6 alkynyl, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide and sulfonamide.
In some embodiments, R9 is selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, C2-6 alkynyl, Cμ alkylsulfonamide, C2.6 dialkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, amino, arylsulfonyl, C2.6 dialkylamino, Cμ dialkylsulfonamide, and carboxamide.
In some embodiments, R9 is selected from the group consisting of C(0)CH3, C(0)CH2CH3, C(0)CH2CH2CH3, C(0)CH(CH3)2, C(0)CH2CH2CH2CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, OCH2CH2CH2CH3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3, CH2(CH2)3CH3, CH2(CH2)4CH3, CH2(CH2)5CH3, C(0)NHCH3, C(0)NHCH2CH3, C(0)NHCH2CH2CH3, C(0)NHCH(CH3)2, C≡CH, S(0)2NHCH3, S(0)2NHCH2CH3, S(0)2NHCH2CH2CH3, S(0)2NHCH(CH3)2, S(0)2NHCH2(CH2)2CH3, S(0)2NHCH(CH3)CH2CH3, S(0)2N(CH3)2, S(0)2N(Et)(CH3), S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, S(0)2CH2(CH2)2CH3, S(0)2CH(CH3)CH2CH3, SCH3, SCH2CH3, SCH2CH2CH3, SCH(CH3)2, SCH2(CH2)2CH3, amino, S(0)2Ph, N(CH3)2, N(CH3)(Et), N(Et)2 and C(0)NH2.
Li some embodiments, R9 is selected from the group consisting of cyano, C3.6 cycloalkyl, halogen, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfonyl, and Cμ haloalkylthio.
Li some embodiments, R9 is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cl, F, Br, OCF3, OCHF2, OCH2CF3, CF3, CHF2, CH2CF3, SCF3, SCHF2 and SCH2CF3.
Li some embodiments, R9 is selected from the group consisting of CN, C02Me, C02Et, S(0)2CH3, S(0)2CF3, N(CH3)2, N(Et)2, C(0)NHCH3, C(0)NHEt, C(0)N(CH3)2, OH, OCH3, and OEt.
Li some embodiments, R9 is selected from the group consisting of heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxy, C4-7 oxo-cycloalkyl, phenoxy and phenyl.
Li some embodiments, R9 is selected from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, C2.6 alkynyl, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, halogen "and sulfonamide.
L some embodiments, R9 is selected from the group consisting of C(0)CH3, C(0)CH2CH3, C(0)CH2CH2CH3, C(0)CH(CH3)2, C(0)CH2CH2CH2CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, OCH2CH2CH2CH3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3, CH2(CH2)3CH3, CH2(CH2)4CH3, CH2(CH2)5CH3; C(0)NHCH3, C(0)NHCH2CH3, C(0)NHCH2CH2CH3, C(0)NHCH(CH3)2, C(0)NHCH2(CH2)2CH3, CCH, S(0)2NHCH3, S(0)2NHCH2CH3, S(0)2NHCH2CH2CH3, S(0)2NHCH(CH3)2, S(0)2NHCH2(CH2)2CH3, S(0)2NHCH(CH3)CH2CH3, S(0)CH3, S(0)CH2CH3, S(0)CH2CH2CH3, S(0)CH(CH3)2, S(0)CH2(CH2)2CH3, S(0)CH(CH3)CH2CH3, S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, S(0)2CH2(CH2)2CH3, S(0)2CH(CH3)CH2CH3, SCH3, SCH2CH3, SCH2CH2CH3, SCH(CH3)2 and SCH2(CH2)2CH3.
Li some embodiments, R9 is selected from the group consisting of amino, arylsulfonyl, carboxy, cyano, C3.6 cycloalkyl, halogen, Cμ haloalkoxy, Cμ haloalkyl and Cμ haloalkylthio.
Li some embodiments, R9 is selected from the group consisting of phenylsulfonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cl, F, Br, OCF3, OCHF2, OCH2CF3, CF3, CHF2, CH2CF3, SCF3, SCHF2 and SCH2CF3.
Li some embodiments, R9 is selected from the group consisting of heterocyclic, heteroaryl, C4-7 oxo-cycloalkyl, phenoxy and phenyl. Li some embodiments, R9 is selected from the group consisting of morpholin-4-yl, thiomorpholin-4-yl, l-oxo-lλ4-thiomorpholin-4- yl, l,l-Dioxo-lλ6-thiomorpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-l-yl, 4-ethyl- piperazin-1-yl, 4-propyl-piperazin-l-yl, piperidin-1-yl, pyrrolidin-1-yl, 2,5-dioxo- imidazolidin-4-yl, 2,4-dioxo-thiazolidin-5-yl, 4-oxo-2-thioxo-thiazolidin-5-yl, 3-methyl-2,5- • dioxo-imidazolidin-4-yl, 3 -methyl-2,4-dioxo-thiazolidin-5 -yl, 3 -methyl-4-oxo-2-thioxo- thiazolidin-5-yl, 3-ethyl-2,5-dioxo-imidazolidin-4-yl, 3-ethyl-2,4-dioxo-thiazolidin-5-yl, and 3-ethyl-4-oxo-2-thioxo-thiazolidin-5-yl.
Li some embodiments, R9 is selected from the group consisting of lH-imidazol-4-yl, [l,2,4]triazol-l-yl, [l,2,3]triazol-l-yl, [l,2,4]triazol-4-yl, pyrrol- 1-yl, pyrazol-1-yl, 1H- pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2-yl, [l,3,4]oxadiazol-2-yl, [l,3,4]thiadiazol- 2-yl, [l,2,4]oxadiazol-3-yl, [l,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5-yl, pyrimidin-2- yl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl, l,3-dioxo-l,3-dihydro- isoindol-2-yl and [l,2,3]thiadiazol-4-yl.
L some embodiments, R9 is Cι-8 alkyl or Cμ alkoxy optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, Cμ alkylcarboxamide, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, heterocyclic, hydroxyl and phenyl.
Li some embodiments, R9 is Cμ alkylsulfonyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, carboxamide, heteroaryl, heterocyclic and phenyl.
Li some embodiments, R9 is Cμ alkylsulfonyl substituted with the heteroaryl group. Li some embodiments, the heteroaryl is selected from the group consisting of lH-imidazol-4- yl, [l,2,4jtriazol-l-yl, [l,2,3]triazol-l-yl, [l,2,4]triazol-4-yl, pyrrol-1-yl, pyrazol-1-yl, 1H- pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2-yl, [l,3,4]oxadiazol-2-yl,*[l,3,4]thiadiazol- 2-yl, [l,2,4]oxadiazol-3-yl, [l,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5-yl, pyrimidin-2- yl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl, l,3-dioxo-l,3-dihydro- isoindol-2-yl and [l,2,3]thiadiazol-4-yl.
Li some embodiments, R9 is arylsulfonyl, heteroaryl, phenoxy or phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ acyl, Cμ alkoxy, Cμ alkyl, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Cμ alkylthio, carboxamide, carboxy, cyano, halogen, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylthio and hydroxyl.
Li some embodiments, R9 is arylsulfonyl, heteroaryl, phenoxy or phenyl each optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, Cμ alkyl, cyano, halogen, Cμ haloalkoxy, Cμ haloalkyl and hydroxyl.
Li some embodiments, R9 is a heterocyclic group as described herein.
Li some embodiments, R9 is a heterocyclic group represented by the formulae shown in Table 2B, supra. Li some embodiments, R9 is a heterocyclic group represented by the formulae shown in Table 2C, supra. Li some embodiments, R9 is a heterocyclic group represented by the formulae shown in Table 2D, supra. i some embodiments, R9 is a heterocyclic group represented by the formulae shown in Table 2E, supra. Li some embodiments, R9 is a heterocyclic group represented by the formulae shown in Table 2F, supra. Li some embodiments, R9 is a heterocyclic group represented by the formulae shown in Table 2G, supra.
Li some embodiments, R9 is of Formula (D):
Figure imgf000043_0001
(D) wherein:
"p" and "r" are independently 0, 1, 2 or 3; and R18 is H, Cμ acyl, C2-6 alkenyl, Cμ alkyl, Cμ alkylcarboxamide, C2-6 alkynyl, Cμ alkylsulfonamide, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, C2.6 dialkylcarboxamide, halogen, heteroaryl or phenyl, and wherein the heteroaryl or phenyl may be optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, amino, Cμ alkylamino, C2.6 alkynyl, C2.8 dialkylamino, halogen, Cμ haloalkoxy, Cμ haloalkyl and hydroxyl.
In some embodiments, R9 is of Formula (D) wherein "p" and "r" are independently 0, or 1; and Rι8 is H, carbo-Cμ-alkoxy, heteroaryl or phenyl, and wherein the heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, amino, Cμ alkylamino, C2-6 alkynyl, C2.8 dialkylamino, halogen, Cμ haloalkoxy, Cμ haloalkyl and hydroxyl.
In some embodiments, p = 0 and r = 0.
Li some embodiments, R18 is phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, amino, Cμ alkylamino, C2-β alkynyl, C2-8 dialkylamino, halogen, Cμ haloalkoxy, Cμ haloalkyl and hydroxyl.
Li some embodiments, p = 0 and r = 1.
Li some embodiments, R18 is carbo-Cμ-alkoxy or carboxy.
In some embodiments, p = 0 and r = 0.
Li some embodiments, R18 is heteroaryl or phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cμ alkoxy, amino, Cμ alkylamino, C2.6 alkynyl, C2.8 dialkylamino, halogen, Cμ haloalkoxy, Cμ haloalkyl and hydroxyl. Li some embodiments, the heteroaryl is selected from the group consisting of 1H- imidazol-4-yl, [l,2,4]triazol-l-yl, [l,2,3]triazol-l-yl, [l,2,4]triazol-4-yl, pyrrol-1-yl, pyrazol- 1-yl, lH-pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2-yl, [l,3,4]oxadiazol-2-yl, [l,3,4]thiadiazol-2-yl, [l,2,4]oxadiazol-3-yl, [l,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5- yl, pyrimidin-2-yl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl, l,3-dioxo-l,3- dihydro-isoindol-2-yl and [l,2,3jthiadiazol-4-yl.
In some embodiments, p = 2 and r = 1. In some embodiments, R18 is H, Cμ acyl or Cμ alkyl.
Li some embodiments, R10-R13 are independently Cμ acyl, Cμ alkoxy, Cμ alkyl, Ci- 4 alkylcarboxamide, Cμ alkylureyl, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, halogen, Cμ haloalkoxy and Cμ haloalkyl.
In some embodiments, one or two R10-R13 groups are independently halogen. In some embodiments, one R10-R13 group is a halogen.
Li some embodiments, Ari is phenyl and R9 is substituted at the para position on the phenyl.
Li some embodiments, Ari is phenyl optionally substituted with R9, Rio and Ru. Li some embodiments, the compounds of the invention are of Formula (Iw):
Figure imgf000044_0001
(Iw) wherein A, B, D, N, W, X, Y, Z, Ri have the same meaning as described herein, supra and infra, and R9 is cyano, carbo-Cμ-alkoxy, carboxy, C2.6 dialkylamino, Cμ alkylcarboxamide, Cμ dialkylsulfonamide, Cμ alkylsulfonyl, hydroxyl, Cμ alkoxy, 5-membered heteroaryl, 6- membered heteroaryl, or heterocyclic, wherein the 6-membered heteoaryl is optionally an N- oxide; and Rio and Rπ are independently H or halogen. Li some embodiments, R9 is cyano, carbomethoxy, carboethoxy, carboisopropoxy, carboxy, dimethylamino, diethylamino, methylethylamino, C(0)NHCH3, C(0)NHCH2CH3, C(0)NH(CH3)2, S(0)2CH3, S(0)2CH2CH3, hydroxyl, OCH3, [l,2,4]triazol-4-yl, thiazol-2-yl, 3H-imidazol-4-yl, 1H- imidazol-2-yl, lH-imidazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, l-oxy-pyridin-2-yl, l-oxy-pyridin-3-yl, l-oxy-pyridin-4-yl, or 2-oxo-oxazolidin-4-yl. Li some embodiments, R10 is H and Rπ is F.
Li some embodiments, Ari is phenyl and two adjacent Rι0-Rιι groups form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group with the phenyl group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
Li some embodiments, Ari is phenyl and two adjacent R10-R11 groups form a 5, 6 or 7 membered cycloalkyl group with the phenyl group and is of the formulae shown below:
TABLE 5
Figure imgf000045_0001
wherein "a" is 1, 2 or 3 to give a 5, 6 or 7 membered cycloalkyl fused together with the phenyl group where two of the ring carbons are shared between the cycloalkyl and phenyl group. Li some embodiments, the cycloalkyl is optionally substituted with halogen. L some embodiments, the halogen is fluorine.
Li some embodiments, Ari is phenyl and two adjacent R10-R11 groups form a 5, 6 or 7 membered cycloalkenyl group with the phenyl group and is of the formulae shown in TABLE 5 and has at least one carbon-carbon ring double bond present that is not part of the phenyl group (i.e., cycloalkenyl), for example, lH-Lidenyl and dihydro-naphthyl. Li some embodiments, the cycloalkenyl is optionally substituted with halogen. Li some embodiments, the halogen is fluorine.
Li some embodiments, Ari is phenyl and two adjacent R10-Rι 1 groups form a 5, 6 or 7 heterocyclic group with the phenyl group and is of the formulae in TABLE 5 wherein one or more ring cycloalkyl carbons are replaced by a O, S, S(O), S(0)2, NΗ or N-Cμ-alkyl group. Li some embodiments, the heterocyclic group is optionally substituted with halogen. Li some embodiments, the halogen is fluorine.
Li some embodiments, Ari is phenyl and two adjacent R10-R.1 groups form a 5 membered heterocyclic group with the phenyl group. In some embodiments, the 5 membered heterocyclic group with the phenyl group together form a 2,3-dihydro-benzofuran-5-yl or benzo[l,3]dioxol-5-yl group. Li some embodiments, the two adjacent groups form a 6 membered heterocyclic group with the phenyl group. Li some embodiments, the 6 membered heterocyclic group with the phenyl group together form a 2,3-dihydro-benzo[l,4]dioxin-6-yl or 2,3-dihydro-benzo[l,4]dioxin-2-yl group. Li some embodiments, the two adjacent groups form a 7 membered heterocyclic group with the phenyl group. Li some embodiments, the 7 membered heterocyclic group with the phenyl group together form a 3,4-dihydro-2H- benzo[b][l,4]dioxepin-7-yl group.
L some embodiments, Ari is heteroaryl and two adjacent R10-R.1 groups form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group with the heteroaryl group wherein the 5, 6 or 7 membered group is optionally substituted with halogen. Li some embodiments, Ari is a heteroaryl selected from TABLE 2A. Li some embodiments, Arj is a heteroaryl selected from TABLE 4. In some embodiments, the two adjacent groups form a 5 membered heterocyclic group with the heteroaryl group. Li some embodiments, the two adjacent groups form a 6 membered heterocyclic group with the heteroaryl group. Li some embodiments, the two adjacent groups form a 7 membered heterocyclic group with the heteroaryl group.
Li some embodiments, R5 is H, Cμ acyl, Cμ acyloxy, C2-6 alkenyl, Cμ alkoxy, Cμ alkyl, Cμ alkylcarboxamide, C2.6 alkynyl, Cμ alkylsulfonamide, Cμ alkylsulfinyl, Cμ alkylsulfonyl, Ci-4 alkylthio, Cμ alkylureyl, amino, arylsulfonyl, carbo-Cμ-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, C2.6 dialkylcarboxamide, halogen, Cμ haloalkoxy, Cμ haloalkyl, Cμ haloalkylsulfinyl, Cμ haloalkylsulfonyl, Cμ haloalkylthio, heterocyclic, hydroxyl, nitro, C4-7 oxo-cycloalkyl, sulfonamide and nitro.
Li some embodiments, R5 and e are independently H or F.
Li some embodiments, X is N and Y is CH.
Li some embodiments, X is N and Y is CF.
Li some embodiments, X is CH and Y is N.
Li some embodiments, X and Y are N.
In some embodiments, X and Y are CH.
Li some embodiments, X is CH and Y is CF. Some embodiments of the present invention include compounds illustrated in TABLES A, B, C, D and E; these TABLES are shown below. TABLE A
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Cmpd# Structure Chemical Name
A32 1 -[6-(4-Bromo-phenoxy)-5 -nitro- pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
A33 l-[6-(4-Chloro-phenoxy)-5-nitro- pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
A34 1 -[6-(4-Carbamoyl-phenoxy)-5 - nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester
A35 1 - {6-[4-(2-Methoxy-ethyl)- phenoxy]-5-nitro-pyrimidin-4-yl} - piperidine-4-carboxylic acid ethyl ester
A36 1 -[6-(4-Cyclopentyl-phenoxy)-5 - nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
A37 1 -[5 -Nitro-6-(4-pyrrol- 1 -yl- phenoxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester
A38 l-[6-(4-Benzoyl-phenoxy)-5-nitro- pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Cmpd# Structure Chemical Name
A84 l-[6-(4-Benzoyl-phenoxy)-5-
(2,2,2-trifluoro-acetylamino)- pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
A85 {4-[5-Nitro-6-(4-proρyl- piperidin-l-yl)-pyrimidin-4- yloxy]-phenyl} -phenyl- methanone
A86 {4-Methoxy-2-[5-nitro-6-(4- propyl-piperidin- 1 -yl)-pyrimidin-
4-yloxy]-phenyl}-phenyl- methanone
A87 4- {4-[5-Nitro-6-(4-propyl- piperidin- 1 -yl)-ρyrimidin-4- yloxy]-phenyl} -butan-2-one
A88 5-Nitro-4-(4-propyl-piperidin- 1 - yl)-6-(4-[l,2,3]thiadiazol-4-yl- phenoxy)-pyrimidine
A89 3- {4-[5-Nitro-6-(4-propyl- piperidin- 1 -yl)-pyrimidin-4- yloxy] -phenyl} -3 -oxo-propionic acid methyl ester
A90 5-Ethanesulfonyl-2-[5-nitro-6-(4- propyl-piperidin- 1 -yl)-pyrimidin-
4-yloxy] -phenylamine
Figure imgf000058_0001
Figure imgf000059_0001
Cmpd# Structure Chemical Name
A100 4'-(4-Benzoyl-phenoxy)-3 '-nitro-
3,4,5,6-tetrahydro-2H-
[ 1 ,2']bipyridinyl-4-carboxylic acid ethyl ester
A101 3,-Nitro-4'-[4-(3-oxo-butyl)- phenoxy] -3 ,4, 5 , 6-tetrahydro-2H-
[1 ,2']bipyridinyl-4-carboxylic acid ethyl ester
A102 4'-[4-(2-Methoxycarbonyl- acetyl)-phenoxy]-3'-nitro-3,4,5,6- tetrahydro-2H-[l ,2']bipyridinyl-
4-carboxylic acid ethyl ester
A103 4'-(2-Amino-4-ethanesulfonyl- phenoxy)-3'-nitro-3,4,5,6- tetrahydro-2H-[l ,2']bipyridinyl-
4-carboxylic acid ethyl ester
A104 4'-(4-Imidazol-l-yl-phenoxy)-3'- nitro-3,4,5,6-tetrahydro-2H-
[1 ,2']bipyridinyl-4-carboxylic acid ethyl ester
A105 4-(2-Methyl-5-trifluoromethyl-
2H-pyrazol-3-yloxy)-5-nitro-6-
(4-trifluoromethyl-piperidin- 1 - yl)-pyrimidine
A106 4-(2-Methyl-5-trifluoromethyl-
2H-pyrazol-3-yloxy)-5-nitro-6-
(4-phenylsulfanyl-ρiperidin- 1 -
Figure imgf000060_0001
yl)-pyrimidine
Figure imgf000061_0001
Cmpd# Structure Chemical Name
A116 4-[4-(3'-Nitro-4-propyl-3,4,5,6- tetrahydro-2H-[l,4']bipyridinyl-
2'-yloxy)-phenyl]-butan-2-one
A117 2'-(4-Benzoyl-phenoxy)-3 '-nitro-
3,4,5,6-tetrahydro-2H-
[1 ,4']bipyridinyl-4-carboxylic acid ethyl ester
A118 4-(4-{5-Nitro-6-[4-(pyridin-2- ylsulf anyl) -piperidin- 1 -yl] - pyrimidin-4-yloxy} -phenyl)- butan-2-one
A119 [4-(3 '-Nitro-4-ρroρyl-3 ,4,5,6- tetrahydro-2H-[ 1 ,4']bipyridinyl-
2'-yloxy)-phenyl]-ρhenyl- methanone
A120 4-(4-{5-Nifro-6-[4-(2- trifluoromethyl-phenoxy)- piperidin- 1 -yl] -pyrimidin-4- yloxy} -phenyl)-butan-2-one
A121 4-(4-{6-[4-(3-Methyl-
[1,2,4] oxadiazol-5 -yl)-piperidin-
1 -yl]-5-nitro-pyrimidin-4-yloxy} - phenyl)-butan-2-one
A122 (4-{6-[4-(3-Methyl-
[l,2,4]oxadiazol-5-yl)-piperidin-
1 -yl] -5 -nitro-pyrimidin-4-yloxy} - phenyl)-phenyl-methanone
Figure imgf000062_0001
Cmpd# Structure Chemical Name
A123 1 - {6-[4-(4-Fluoro-benzoyl)- phenoxy] -5 -nitro-pyrimidin-4- yl}-piperidine-4-carboxylic acid ethyl ester
A124 (4-Fluoro-phenyl)-{4-[5-nitro-6-
(4-ρroρyl-piperidin-l -yl)- pyrimidin-4-yloxy] -phenyl} - methanone
A125 4-[4-(3-Methyl-[l,2,4]oxadiazol-
5 -yl)-piperidin- 1 -yl] -6-(2- methyl-5 -trifluoromethyl-2H- pyrazol-3-yloxy)-5-nitro- pyrimidine
A126 4-(4-Methoxymethyl-piperidin-l yl)-6-(2-methyl-5- trifluoromethyl-2H-ρyrazol-3 - yloxy)-5-nitro-pyrimidine
A127 4- {4-[6-(4-Methoxymethyl- piperidin- 1 -yl)-5 -nitro- pyrimidin-4-yloxy]-phenyl}- butan-2-one
A128 4-[4-(2-Methoxy-ethyl)- piperidin-1 -yl]-6-(2-methyl-5- trifluoromethyl-2H-ρyrazol-3 - yloxy)-5-nitro-pyrimidine
A129 4- {4-[6-(4-Ethoxymethyl- piperidin-1 -yl)-5 -nitro- pyrimidin-4-yloxy]-phenyl} - butan-2-one
A130 4-(2,4-Difluoro-phenoxy)-5 - nitro-6-[4-(pyridin-2-ylsulfanyl)- piρeridin-1 -yl]-pyrimidine
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
TABLE B
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
} -
Figure imgf000073_0001
Cmpd# Structure Chemical Name
B44 1 -[6-(4-Methanesulfonyl- phenylamino)-5 -nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester
Figure imgf000074_0001
o o
B45 l-[6-(4-Dimethylsulfamoyl- phenylamino)-5 -nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester
B46 1 -[6-(3 -Methoxy-phenylamino)-5 - nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
B47 1 -[6-(2-Methoxy-phenylamino)-5 - nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester
B48 1 -[6-(3 ,5-Bis-trifluoromethyl- phenylamino)-5 -nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester
B49 1 -[6-(2,5 -Dimethoxy-phenylamino)-
5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
B50 l-[6-(3,5-Dimethoxy-benzylamino)-
5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester
B51 [5-Nitro-6-(4-proρyl-piperidin-l-yl)- pyrimidin-4-yl] -(3 ,4,5 -trimethoxy- benzyl)-amine
Figure imgf000074_0002
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
-
-
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
TABLE C
Figure imgf000086_0002
Figure imgf000087_0001
Cmpd# Structure Chemical Name
C13 1 -[6-(4-Methanesulfonyl-phenyl)-5 - nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
C14 l-[6-(3,5-Bis-trifluoromethyl-phenyl)-
5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester
C15 l-(6-Dibenzothiophen-4-yl-5-nitro- pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester
C16 1 -[6-(3 ,5 -Dimethyl-isoxazol-4-yl)-5- nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
C17 1 -(5 -Nitro-6-thiophen-2-yl-pyrimidin-4- yl)-piperidine-4-carboxylic acid ethyl ester
C18 1 -[6-(3 ,5 -Dichloro-phenyl)-5 -nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester
C19 1 -(6-Dibenzofuran-4-yl-5 -nitro- pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester
C20 1 -[6-(3 ,5 -Dimethyl-phenyl)-5 -nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester
Figure imgf000088_0001
Figure imgf000089_0001
TABLE D
Cmpd# Structure Chemical Name
Dl l-[5-Nitro-6-(2-trifluoromethyl- phenylethynyl)-pyrimidin-4-yl] - piperidine-4-carboxylic acid ethyl ester
D2 1 -(5 -Nitro-6-phenylethynyl- pyrimidin-4-yl)-piperidine-4- carboxylic acid ethyl ester
D3 l-[5-Nitro-6-(4-trifluoromethyl- phenylethynyl)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester
D4 1 -(5-Nitro-6-m-tolylethynyl- pyrimidin-4-yl)-piperidine-4- carboxylic acid ethyl ester
D5 l-[6-(2-Fluoro-phenylethynyl)-5- nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester
D6 1 -[5-Nitro-6-(3-trifluoromethyl- phenylethynyl)-pyrimidin-4-yl] - piperidine-4-carboxylic acid ethyl ester
Figure imgf000090_0001
TABLE E
Cmpd# Structure Chemical Name
El 5 -Nitro-4-(5 -phenyl-
[l,3,4]oxadiazol-2-ylsulfanyl)-6-[4-
(pyridin-2-ylsulfanyl)-piperidin- 1 -
Figure imgf000090_0002
yl]-pyrimidine
Some embodiments of the present invention include a pharmaceutical composition comprising at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier. Additionally, compounds of Formula (la) encompass all pharmaceutically acceptable solvates, particularly hydrates, thereof. The present invention also encompasses diastereomers as well as optical isomers, e.g. mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds of Formula (la). Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art.
INDICATIONS
In addition to the foregoing beneficial uses for compounds of the present invention disclosed herein, compounds of the invention are useful in the prophylaxis or treatment of additional diseases. Without limitation, these include the following.
The most significant pathologies in Type II diabetes are impaired insulin signaling at its target tissues ("insulin resistance") and failure of the insulin-producing cells of the pancreas to secrete an appropriate degree of insulin in response to a hyperglycemic signal. Current therapies to treat the latter include inhibitors of the β-cell ATP-sensitive potassium channel to trigger the release of endogenous insulin stores, or administration of exogenous insulin. Neither of these achieves accurate normalization of blood glucose levels and both carry the risk of inducing hypoglycemia. For these reasons, there has been intense interest in the development of pharmaceuticals that function in a glucose-dependent action, i.e. potentiators of glucose signaling. Physiological signaling systems which function in this manner are well-characterized and include the gut peptides GLP1, GIP and PACAP. These hormones act via their cognate G-protein coupled receptor to stimulate the production of cAMP in pancreatic β-cells. The increased cAMP does not appear to result in stimulation of insulin release during the fasting or preprandial state. However, a series of biochemical targets of cAMP signaling, including the ATP-sensitive potassium channel, voltage-sensitive potassium channels and the exocytotic machinery, are modified in such a way that the insulin secretory response to a postprandial glucose stimulus is markedly enhanced. Accordingly, agonists of novel, similarly functioning, β-cell GPCRs, including RUP3, would also stimulate the release of endogenous insulin and consequently promote normoglycemia in Type II diabetes.
It is also established that increased cAMP, for example as a result of GLP1 stimulation, promotes β-cell proliferation, inhibits β-cell death and thus improves islet mass. This positive effect on β-cell mass is expected to be beneficial in both Type II diabetes, where insufficient insulin is produced, and Type I diabetes, where β-cells are destroyed by an inappropriate autoimmune response. It is also well-established that metabolic diseases exert a negative influence on other physiological systems. Thus, there is often the codevelopment of multiple disease states (e.g. type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity or cardiovascular disease in "Syndrome X") or secondary diseases which clearly occur secondary to diabetes (e.g. kidney disease, peripheral neuropathy). Thus, it is expected that effective treatment of the diabetic condition will in turn be of benefit to such interconnected disease states.
Some embodiments of the present invention include a method for prophylaxis or treatment of a metabolic disorder or complications thereof in an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof. In some embodiments, the metabolic disorder or complications thereof is type I, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia syndrome X, or metabolic syndrome. In some embodiments, the metabolic disorder is type II diabetes. In some embodiments, the metabolic disorder is hyperglycemia. In some embodiments, the metabolic disorder is hyperlipidemia. In some embodiments, the metabolic disorder is hypertriglyceridemia. In some embodiments, ' the metabolic disorder is type I diabetes. In some embodiments, the metabolic disorder is dyslipidemia. In some embodiments, the metabolic disorder is syndrome X. In some embodiments, the individual is a mammal. In some embodiments, the mammal is a human.
Some embodiments of the present invention include a method of controlling or decreasing weight gain of an individual comprising administering to the individual a therapeutically effective amount of a compound of the present invention or pharmaceutical composition thereof. In some embodiments, the individual is a mammal. In some embodiments, the mammal is a human. In some embodiments, the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.
One aspect of the present invention pertains to a compound of Formula (la), as described herein, for use in a method of treatment of the human or animal body by therapy.
Some embodiments of the present invention include a method of modulating a RUP3 receptor comprising contacting the receptor with a compound of the present invention.
Some embodiments of the present invention include a method of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present , invention. In some embodiments, the compound is an agonist. In some embodiments, the compound is an inverse agonist. Some embodiments of the present invention include a method of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor is prophylaxis or treatment of a metabolic disorder and complications thereof. In some embodiments, the metabolic disorder is type I, type π diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia syndrome X, or metabolic syndrome. In some embodiments, the metabolic disorder is type II diabetes. In some embodiments, the metabolic disorder is hyperglycemia. In some embodiments, the metabolic disorder is hyperlipidemia. In some embodiments, the metabolic disorder is hypertriglyceridemia. In some embodiments, the metabolic disorder is type I diabetes. In some embodiments, the metabolic disorder is dyslipidemia. ϊn some embodiments, the metabolic disorder is syndrome X. In some embodiments, the individual is a mammal. In some embodiments, the mammal is a human.
Some embodiments of the present invention include a method of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound of the present invention wherein the modulation of the RUP3 receptor controls or reduces weight gain o the , individual. In some embodiments, the individual is a mammal. In some embodiments, the mammal is a human. In some embodiments, the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.
Some embodiments of the present invention include the use of a compound of the present invention for production of a medicament for use in prophylaxis or treatment of a metabolic disorder. In some embodiments, the metabolic disorder is type π diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia syndrome X, or metabolic syndrome.
Some embodiments of the present invention include the use of a compound of the present invention for production of a medicament for use in controlling or decreasing weight gain in an individual. In some embodiments, the individual is a mammal. In some embodiments, the mammal is a human. In some embodiments, the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.
Compounds of the present invention are identified as an agonist or an inverse agonist using methods known to those skilled in art, such as an assay as described in Example 1. Accordingly, representative examples of compounds of the present invention that are agonists include the following:
[6-(4-Benzenesulfonyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)- amine; {4-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperazin-l-yl}- acetic acid ethyl ester; (2-Fluoro-ρhenyl)-{5-nitro-6-[4- yridin-2-ylsulfanyl)-piρeridin-l-yl]- pyrimidin-4-yl} -amine; 1 -[6-(4-rmidazol-l -yl-phenoxy)-5 -nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nitro-6-(4-[l,2,4]triazol-l-yl-phenoxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; {6-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-5-nitro- pyrimidin-4-yl} -(4-methanesulfonyl-phenyl)-amine; {6-[4-(3 -Isopropyl-[ 1 ,2,4]oxadiazol-5- yl)-piperid -l-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine; {6-[4-(3- Cyclopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4- methanesulfonyl-phenyl)-amine; (4-Methanesulfonyl-phenyl)-(5-nitro-6- {4-[3 -(3 - trifluoromethyl-phenyl)-[l,2,4]oxadiazol-5-yl]-piperidin-l-yl}-pyrirnidin-4-yl)-amine; {6-[4- (3-Ethyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-ni1xo-pyrimidin-4-yl}-(2-fluoro-phenyl)- amine; (2-Fluoro-4-methanesulfonyl-phenyl)-{6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)- piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-amine; {6-[4-(3-Ethyl-[l,2,4]oxadiazol-5-yl)- piperidin-l-yl]-5-nitro-pyrirnidin-4-yl}-(2-fluoro-4-methanesulfonyl-phenyl)-amine; (4- Methanesulfonyl-phenyl)- {5-nitro-6-[4-(3 -propyl-[ 1 ,2,4]oxadiazol-5-yl)-piperidin-l -yl]- pyrimidin-4-yl} -amine; {6- [4-(3 -Cyclopropylmethyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin-l -yl] -5 - nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine; (4-Methanesulfonyl-phenyl)-{5- nitro-6-[4-(ρyridin-4-yloxy)-piperidin-l-yl]-pyrimidin-4-yl}-amine; (4-Methanesulfonyl- phenyl)-{5-nitro-6-[4-(pyrimidin-2-yloxy)-piperidin-l-yl]-pyrimidin-4-yl}-amine; l-[6-(4- Carbamoylmethyl-phenoxy)-5-nitio-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(l,3-Dioxo-l,3-dihydro-isoindol-2-yl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine- 4-carboxylic acid ethyl ester; 4'-[4-(2-Methoxycarbonyl-acetyl)-phenoxy]-3'-nitro-3,4,5,6- tetrahydro^H-fl^^bipyridinyl^-carboxylic acid ethyl ester; {6-[4-(2-Methoxy- phenylsulfanyl)-piperidin-l-yl]-5-nitio-pyrimidin-4-yl}-(4-[l,2,4]triazol-l-yl-phenyl)-amine; 4,-(2-A-raino-4-ethanesulfonyl-phenoxy)-3'-nitro-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-4- carboxylic acid ethyl ester; 4,-(4-Irnidazol-l-yl-phenoxy)-3'-nitro-3,4,5,6-tetrahydro-2H- [l,2']bipyridinyl-4-carboxylic acid ethyl ester; (4-Methoxy-2-{5-nitro-6-[4-(pyridin-2- ylsulfanyl)-piperidin-l-yl]-pyrimidin-4-yloxy}-phenyl)-phenyl-methanone; 4-{4-[6-(4- Cyclopropylmethoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2-one; 4- {4-[5 -Nitro-6-(4-propoxymethyl-piperidin- 1 -yl)-pyrimidin-4-yloxy] -phenyl} -butan-2-one; 4-{4-[6-(4-Butoxymethyl-piperidin-l -yl)-5-nitro-pyrimidin-4-yloxy]-phenyl} -butan-2-one; 4- {4-[6-(4-Isobutoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2-one; {l-[6-(Benzo[l,3]dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-(4-fluoro- phenyl)-methanone; (2,3.-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l- ylJ-pyrimidin-4-yl} -amine; (2,4-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)- piperidin-l-yl]-pyrimidin-4-yl}-amine; l-{2-Nitro-3-[4-(3-oxo-butyl)-phenoxy]-phenyl}- piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Acetyl-phenoxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; 3'-Nitro-2'-[4-(3-oxo-butyi)-phenoxy]-3,4,5,6- terrahydro-2H-[l,4']bipyridinyl-4-carboxylic acid ethyl ester; 4-(4-{5-Nitro-6-[4-(pyridin-2- ylsulfanyl)-piperidin-l-yl]-pyrimidin-4-yloxy}-phenyl)-butan-2-one; 4-(4-{5-Nitro-6-[4-(2- trifluoromethyl-phenoxy)-piperidin-l -yl]-pyrimidin-4-yloxy} -phenyl)-butan-2-one; 4-(4-{6- [4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)- butan-2-one; 4-(2,4-Difluoro-phenoxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piρeridin-l-yl]- pyrimidine; 4-(4-{6-[4-(4-Fluoro-benzoyl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yloxy}- phenyl)-butan-2-one; 4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)- cyclohexyl]-pyrimidine; 4-(4-Methanesulfonyl-phenoxy)-5-nitio-6-[4-i(pyridin-4-ylsulfanyl)- cyclohexyl]-pyrimidine; 4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-(4-phenylsulfanyl- cyclohexyl)-pyrimidine; l-{6-[(Benzo[l,3]dioxol-5-ylmethyl)-amino]-5-nitro-pyrimidin-4- yl}-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(l,l-Dioxo-lλ6-thiomorpholin-4- ylmethyl)-phenylamino]-5-nitio-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; 1- [6-(4-Methanesulfonyl-phenylamino)-5 -nitro-pyrimidin-4-yl] -piρeridine-4-carboxylic acid ethyl ester; l-[6-(4-Dimethylsulfamoyl-phenylamino)-5-nitio-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(3-Methoxy-phenylamino)-5-nitro-ρyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methoxy-phenylamino)-5-nitro-pyrimidin-4- yl]-piρeridine-4-carboxylic acid ethyl ester; l-[6-(4-Methanesulfonyl-phenoxy)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(2 -Methoxycarbonyl-acetyl)- phenoxy]-5-nifaO-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Amino-4- ethanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 1- [6-(2,5-Dimethoxy-phenylamino)-5-nitro-ρyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; (4-{5-Nitro-6-[4-( yridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4-ylamino}-phenyl)- phenyl-methanone; 1 -[6-(4-Cyclohexyl-phenylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[5-Nitro-6-(4-[l,2,4]triazol-l-yl-phenylamino)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-trifluoromethanesulfonyl- phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4- [l,2,3]thiadiazol-4-yl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; [6-(4-Ethoxymethyl-piperidin- 1 -yl)-5 -nitro-pyrimidin-4-yl] -(4-methanesulfonyl-phenyl)- amine; [5 -Nitro-6-(4-propyl-piperidin- 1 -yl)-pyrimidin-4-yl] -(4-[ 1 ,2,4]triazol- 1 -yl-phenyl)- amine; {5-Nitio-6-[4-(pyridin-2-ylsulfanyl)-piperidm-l-yl]-pyrimidin-4-yl}-(4-[l,2,4]triazol- 1 -yl-phenyl)-amine; (2-Fluoro-phenyl)- { 6-[4-(3 -methyl-[ 1 ,2,4] oxadiazol-5 -yl)-ρiperidin- 1 - yl]-5-nitro-pyrimidin-4-yl}-amine; (4-Methanesulfonyl-phenyl)- {6-[4-(3-methyl- [l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitio-pyrimidin-4-yl}-amine; {6-[4-(3-Methyl- [l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-ni1xo-pyrimidin-4-yl}-(4-[l,2,4]triazol-l-yl-phenyl)- amine; (4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine; (3-Methoxy-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l- yl]-pyrimidin-4-yl} -amine; l-[6-(Benzo[l,3]dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Fluoro-phenylamino)-5-nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3-Fluoro-phenylamino)-5-nitro-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6~(3,4-Dihydro-2H-benzo[b][l,4]dioxepin- 7-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4- (Moi holine-4-sulfonyl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; Benzo[l,3]dioxol-5-yl-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]- amine; (4-Fluoro-phenyl)- { 1 -[5 -nitro-6-(4-[ 1 ,2,4]triazol- 1 -yl-phenylamino)-pyrimidin-4-yl] - piperidin-4-yl } -methanone; [5-Nitro-6-(4-phenylsulfanyl-piperidin- 1 -yl)-pyrimidin-4-yl] -(4- [l,2,4]triazol-l-yl-phenyl)-amine; (4-Fluoro-phenyl)- {1 -[6-(2 -fluoro-phenylamino)-5-nitro- pyrimidin-4-yl]-piperidin-4-yl} -methanone; (4-Methanesulfonyl-phenyl)-[5-nitro-6-(4- phenylsulfanyl-piperidin-l-yl)-pyrimidin-4-yl] -amine; (4-Methanesulfonyl-phenyl)-{5-nitro- 6-[4-(pyridin-2-yloxy)-piperidin-l-yl]-pyrimidin-4-yl}-amine; (4-Methanesulfonyl-phenyl)- {5-nitro-6-[4-(pyridin-4-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4-yl}-amine; (4- Methanesulfonyl-phenyl)- { 6-[4-(4-methoxy-phenylsulfanyl)-piperidin- 1 -yl] -5 -nitro- pyrimidin-4-yl} -amine; 2-Methoxy-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l- yl]-pyrimidin-4-yl}-amine; (4-Methanesulfonyl-phenyl)-(5-nitro-6-{4-[3-(3-trifluoromethyl- phenyl)-[l,2,4]oxadiazol-5-yl]-piperidin-l-yl}-pyrimidin-4-yl)-amine; {6-[4-(3-Ethyl- [l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)- amine; (6-{4-[5-(4-Fluoro-phenyl)-[l,3,4]oxadiazol-2-yl]-piperidin-l-yl}-5-nitro-pyrimidin- 4-yl)-(4-methanesulfonyl-phenyl)-amine; (4-Methanesulfonyl-phenyl)-[5-nitro-6-(4-pyridin- 2-ylmethyl-piperidin-l-yl)-pyrimidin-4-yl] -amine; l-{6-[4-(2,5-Dioxo-imidazolidin-4-yl)- phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4- propionyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4- [l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 1- [6-[4-(3-Oxo-butyl)-phenoxy]-5-(2,2,2-1rifluoro-acetylamino)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(2-Benzoyl-5-methoxy-phenoxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; 3'-Nitro-4'-[4-(3-oxo-butyl)-ρhenoxy]-3,4,5,6- tetrahydro-2H-[l,2']bipyridinyl-4-carboxylic acid ethyl ester; l-[6-(4-Dimethyl sulfamoyl- phenylamino)-5-ni1τo-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(4,5- Dichloro-imidazol-1 -yl)-phenylamino]-5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid ethyl ester; Benzo[l,3]dioxol-5-yl-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine; (4-Fluoro-phenyl)- { 1 -[6-(2-fluoro-phenylan- no)-5-nitro-pyrirnidin-4- yl]-piperidin-4-yl}-methanone; (2,5-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)- piperidin- 1 -yl]-pyrimidin-4-yl} -amine; 1 - {5 -Nitro-6-[4-(3 -oxo-butyl)-phenoxy] -pyrimidin-4- yl}-piperidine-4-carboxylic acid ethyl ester; 4-[4-(3-Isopropyl-[ 1,2,4] oxadiazol-5 -yl)- piperidin-l-yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidine-5-carbonitrile; 5-[l,3]Dioxolan-2- yl-4-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piρeridin-l-yl]-6-(4-methanesulfonyl-phenoxy)- pyrimidine; 4-[4-(3-Isopropyl-[l ,2,4]oxadiazol-5-yl)-piρeridin-l -yl]-6-(4-methanesulfonyl- phenoxy)-pyrimidine-5-carbaldehyde; 5-[l,3]Dioxolan-2-yl-4-[4-(3-isopropyl- [l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine; 4-[4- (3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)- pyrimidine-5-carbaldehyde; 4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- [l,2,3]tWadiazol-4-yl-phenoxy)-pyrimidine-5-carboxylic acid; [4-[4-(3-Isopropyl- [l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-5-yl]- methanol; [4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-[l,2,3]thiadiazol-4- yl-phenoxy)-pyrimidin-5 -ylmethyl] -dimethyl-amine; 4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5- yl)-piperidin-l-yl]-6-(4-methylsulfanyl-phenylamino)-pyrimidine-5-carbonitrile; 4-[4-(3- Isopropyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl] -6-(4-methanesulfinyl-phenylamino)- pyrimidine-5 -carbonitrile; (4-Methanesulfonyl-phenyl)- {5-nitro-6-[4-(4-trifluoromethoxy- , phenoxy)-piperidin-l-yl]-pyrimidin-4-yl} -amine; 4-[4-(3-Isopropyl-[ 1,2,4] oxadiazol-5 -yl)- piperidin- 1 -yl] -6-(4-methanesulfonyl-phenylamino)-pyrimidine-5 -carbonitrile; l-{l-[6-(2- Fluoro-4-methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-hexan-l- one; l-{l-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}- hexan-1-one; {6-[4-(3-tert-Butyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4- yl}-(2-fluoro-4-methanesulfonyl-phenyl)-amine; {6-[4-(3-tert-Butyl-[l,2,4]oxadiazol-5-yl)- piρeridin-l-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine; [6-(4- Benzoιuran-2-yl-piperidin-l-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl-ρhenyl)-amine and 5-Nitro-4-(5-phenyl-[l,3,4]oxadiazol-2-ylsulfanyl)-6-[4-(pyridin-2-ylsulfanyl)-piperidin- l-yl]-pyrimidine.
Representative examples of compounds of the present invention that are inverse agonists include the following:
1 - {6-[4-(2-Carboxy-ethyl)-phenyl]-5-nitro-pyrimidin-4-yl} -piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-5-nitro-pyrimidin-4-yl}- piρeridine-4-carboxylic acid methyl ester; l-{6-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-5- nixro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(2- trifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-(5- Nitro-6-phenylethynyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6- (4-trifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 1- (5-Nitro-6-m-tolylethynyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[6-(2- Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- y / carboxylic acid ethyl ester; l-[6-( erιzo[l,2,5]oxadiazol-5-yloxy)-5-nitiro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid methyl ester; 2,6-Dimethyl-4-[6- (2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-morpholine; l-{6- [4-(5-Hydι,oxy-pyrimidin-2-yl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[5-Ni1ro-6-(4-sulfo-phenoxy)-pyrirnidin-4-yl]-piperidine-4-carboxylic. acid ethyl ester; l-[6-(4,-Methoxy-biphenyl-4-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; 4-(4,4-Difluoro-piperidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H- pyrazol-3-yloxy)-5-nitro-pyrimidine; l-{5-Nitro-6-[4-(4-oxo-cyclohexyl)-phenoxy]- pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(2-Hydroxy-ethyl)- phenoxy]-5-nitio-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5- trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-3-carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethylamide; l-[6-(2-Methyl-5-phenyl-2H-pyrazol-3-yloxy)-5- nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 4-(2-Methyl-5-trifluoromethyl- 2H-pyrazol-3 -yloxy)-5 -nitro-6-piperidin- 1 -yl-pyrimidine; 1 -[5 -Acetylamino-6-(2-methyl-5 - trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Diacetylamino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid; l-{5-Nitro-6-[2-(2- trifiuoromethyl-phenyl)-ethoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; 1- {5-Nitio-6-[2-(3-trifluoromethyl-phenyl)-ethoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[5-Di-(methanesulfonyl)amino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol- 3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(3- trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5- Methyl-6-(2-methyl-5-xrifluoromethyl-2H-pyrazol-3-yloxy)-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nitro-6-(2-trifluoromethyl-phenoxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-trifluoromethyl-phenoxy)-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Fluoro-phenoxy)-5-nitro-pyrimidin-4- yl]-ρiperidine-4-carboxylic acid ethyl ester; l-[6-(2,5-Dimethyl-2H-pyrazol-3-yloxy)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(2-oxo- benzo[l,3]oxathiol-6-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6- (9H-Carbazol-2-yloxy)-5-nitro-pyrimidin-4-yl]-ρiperidine-4-carboxylic acid ethyl ester; l-[5- Nitro-6-(9-oxo-9H-fluoren-2-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 1 - {5-Amino-6-[4-(3 -oxo-butyl)-phenoxy]-pyrimidin-4-yl} -piperidine-4-carboxylic acid ethyl ester; l-{5-A-mino-6-[4-(hydroxy-phenyl-methyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; l-[6-(6-Chloro-pyridin-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(Benzo[l,3]dioxol-5-yloxy)-5-nitro-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Benzyloxy-phenoxy)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Bromo-phenoxy)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Chloro-phenoxy)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Carbamoyl-phenoxy)-5- nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(2-Methoxy-ethyl)- phenoxy]-5-ni1xo-pyrirnidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Benzoyl- phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(4- Hydroxy-benzenesulfonyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[5-Amino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-(2,2,2-trifiuoro-acetylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; Propionic acid l-[2-amino-5-formyl-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-pyrimidin-4-yl]-piperidin-4-yl ester; 4-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-nitro-pyrimidin-4-yl]-piperazine-l-carboxylic acid ethyl ester; l-[6-(4'-Cyano- biphenyl-4-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; {4-[6- (4,4-Difluoro-piperidin-l -yl)-5 -nitro-pyrimidin-4-yloxy] -phenyl} -phenyl-methanone; 3 - {4- [6-(4,4-Difluoro-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-3-oxo-propionic acid methyl ester; 2-[6-(4,4-Difluoro-piperidin- 1 -yl)-5 -nitro-pyrimidin-4-yloxy] -5 -ethanesulfonyl- phenylamine; 4-(4-Cyclopen1yl-phenoxy)-6-(4,4-difluoro-ρiperidin-l-yl)-5-nitro-pyrimidine; l-[6-(2,6-Dichloro-4-methanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-{6-[4-(4-Chloro-benzoyl)-phenoxy]-5-nitro-ρyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(4-Hydroxy-benzoyl)-phenoxy]-5-nitro- pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Cyanomethyl-phenoxy)-5- nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; (4-{6-[4-(2-Methanesulfonyl- ethyl)-piperazin-l-yl]-5-nitro-ρyrimidin-4-yloxy}-phenyl)-phenyl-methanone; 4-(4-{6-[4-(2- Methanesulfonyl-ethyl)-piperazin-l-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)-butan-2-one; 3- (4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-l-yl]-5-nitio-pyrimidin-4-yloxy}-phenyl)-3- oxo-propionic acid methyl ester; 4-(4-Methyl-piperidin-l-yl)-6-(2-methyl-5-trifluoromethyl- 2H-pyrazol-3-yloxy)-5-nitro-pyrimidine; 4-(4-Bromo-piperidin-l-yl)-6-(2-methyl-5- 1rifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine; 4-(2-Methyl-5-trifluoromethyl-2H- pyrazol-3-yloxy)-5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidine; l-[5-Nitro-6-(2- tτifluoromethyl-benzyloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5- Nitro-6-(3 -trifluoromethyl-benzyloxy)-ρyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 1 - [5 -Nitro-6-(4-trifluoromethyl-benzyloxy)-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester; l-[5-Bromo-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin- 4-yl]-piρeridine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol- 3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid amide; l-[5-Nitro-6-(2-oxo- 2H-chromen-6-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3- Mθ holin-4-yl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 1- [5-Nitro-6-(4-1rifluoromethylsulfanyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-1rifluoromethoxy-phenoxy)-pyrimidin-4-yl]-piρeridine-4- carboxylic acid ethyl ester; l-[6-(4-Benzoyl-phenoxy)-5-(2,2,2-trifluoro-acetylamino)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; {4-[5-Nitro-6-(4-propyl-piperidin-l- yl)-pyrimidin-4-yloxy]-phenyl}-phenyl-methanone; {4-Methoxy-2-[5-nitro-6-(4-propyl- piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}-phenyl-methanone; 4-{4-[5-Nitro-6-(4-propyl- piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}-butan-2-one; 5-Nitro-4-(4-propyl-piperidin-l-yl)- 6-(4-[l ,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine; 3-{4-[5-Nitro-6-(4-propyl-piperidin-l -yl)- pyrimidin-4-yloxy] -phenyl} -3 -oxo-propionic acid methyl ester; 5-Ethanesulfonyl-2-[5-nitro- 6-(4-propyl-piperidin-l -yl)-pyrimidin-4-yloxy]-phenylamine; Benzo[l ,3]dioxol-5-yl-[5-nitro- 6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-amine; l-[6-(4-Difiuoromethoxy-benzyloxy)-5- nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3-Ethynyl-phenoxy)-5- nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Chloro-2-fluoro- phenoxy)-5-nitro-pyrimidin-4-yl]-piρeridine-4-carboxylic acid ethyl ester; l-[6-(2,4-Difluoro- phenoxy)-5-nitro-pyrimidin-4-yl]-piρeridine-4-carboxylic acid ethyl ester; l-[6-(4-Bromo-2- fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 4-(3- Ethynyl-phenoxy)-5 -nitro-6-(4-ρropyl-piperidin- 1 -yl)-pyrimidine; 4-(4-Chloro-2-fluoro- phenoxy)-5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidine; 4-(2,4-Difluoro-phenoxy)-5-nitro-6- (4-propyl-piperidin-l-yl)-pyrir dine;l-[6-(3-Difiuoromethoxy-benzyloxy)-5-nitro-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; 4-[4-(4-Methyl-benzyl)-ρiperidin-l-yl]-6-(2- methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine; 4-(3-Methanesulfonyl- pyrrolidin-1 -yl)-6-(2-methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5-nitro-pyrimidine; 4-(2- Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-[4-(2-trifluoromethyl-phenoxy)- piperidiή-l-yl]-pyrimidine; 4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-[4- (pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidine; l-[6-(4-Cyclopentyl-phenoxy)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-pyrrol-l-yl- phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 4'-(4-Benzoyl-phenoxy)- S'-nitro-S^^jδ-tetrahydro^H-fl^^bipyridinyM-carboxylic acid ethyl ester; 4-(2-Methyl-5- trifluoromethyl-2H-ρyrazol-3-yloxy)-5-nitro-6-(4-trifluoromethyl-piperidin-l-yl)-pyrimidine; 4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-(4-phenylsulfanyl-piperidin-l- yl)-pyrimidine; 4-(4-Bromo-2-fluoro-phenoxy)-5-nitro-6-(4-ρropyl-piρeridin-l-yl)- 4-[4-(3'-Nitio-4-propyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-2'-yloxy)- phenyl]-butan-2-one; 2,-(4-Benzoyl-phenoxy)-3,-nitro-3,4,5,6-tetrahydro-2H- [l,4']biρyridinyl-4-carboxylic acid ethyl ester; (5-Nitro-6-piperidin-l-yl-pyrimidin-4-yl)-(3- trifluoromethyl-benzyl)-amine; l-[5-Nitro-6-(2-1xifluoromethyl-berιzylarnino)-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-trifluoromethyl-benzylamino)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(3-trifluoromethyl- benzylarmno)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; (5-Nitro-6-piperidin- l-yl-pyrimidin-4-yl)-(2-trifluoromethyl-benzyl)-amine; [4-(3'-Nitro-4-propyl-3 ,4,5,6- tetrahydro-2H-[l,4']bipyridinyl-2'-yloxy)-ρhenyl]-phenyl-methanone; (4-{6-[4-(3-Methyl- [l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitio-pyrirnidin-4-yloxy}-phenyl)-phenyl-methanone; 1 - {6-[4-(4-Fluoro-benzoyl)-phenoxy]-5-nitio-pyrimidin-4-yl} -piperidine-4-carboxylic acid ethyl ester; (4-Fluoro-phenyl)-{4-[5-ni1ro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yloxy]- phenyl} -methanone; 4-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(2-methyl-5- trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine; 4-(4-Methoxymethyl-piperidin-l- yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidine; 4-{4-[6-(4- Methoxymethyl-piperidin-l-yl)-5-nixro-pyrimidin-4-yloxy]-phenyl}-butan-2-one; l-{5-Nitro- 6-[3-(l,l,2,2-tetrafluoro-ethoxy)-phenylamino]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-(5-Nitro-6-phenyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; 1- (6-Naphthalen-2-yl-5-nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; 4-[4-(2- Methoxy-ethyl)-piperidin-l -yl] -6-(2-methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro- pyrimidine; 4-{4-[6-(4-Ethoxymethyl-piperidin-l-yl)-5-nitro-ρyrimidin-4-yloxy]-phenyl}- butan-2-one; 4-[4-(3 '-Nitro-4-propyl-3 ,4,5 ,6-tetrahydro-2H-[l ,2']bipyridinyl-4'-yloxy)- phenyl]-butan-2-one; 3'-Nitro-4-propyl-4,-(4-[l,2,4]triazol-l-yl-phenoxy)-3,4,5,6-tetrahydro- 2H-[l,2']bipyridinyl; l-[3-(4-Benzoyl-phenoxy)-2-nitro-phenyl]-piperidine-4-carboxylic acid ethyl ester; {4-[6-(4-Ethoxy-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-(4-fiuoro- phenyl)-methanone; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro- pyrimidin-4-yl] -piperidin-4-ol; 2- { 1 -[6-(2-Methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 - nitro-pyrimidin-4-yl] -piperidin-4-yl} -ethanol; 3 - { 1 -[6-(2-Methyl-5 -trifluoromethyl-2H- pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}-propionic acid; (l-{6-[4-(4-Fluoro- benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidin-4-yl)-(4-fluoro-phenyl)-methanone; 1- [5-Nitro-6-(4-trifluoromethylsulfanyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(3,4,5-tiimethoxy-benzylamino)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; (5-Nitio-6-piperidin-l-yl-pyrimidin-4-yl)-(4-trifluoromethyl- benzyl)-amine; l-[5-Amino-6-(3-trifluoromethyl-benzylamino)-ρyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Amino-6-(4-trifluoromethyl-benzylamino)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Bromo-phenylamino)-5-nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-trifluoromethyl-phenylamino)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(Methyl-ρhenyl-amino)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-trifluoromethoxy- phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Fluoro- phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[(2,3- Dihydro-benzo[ 1 ,4] dioxin-6-ylmethyl)-amino] -5 -nitro-pyrimidin-4-yl} -piperidine-4- carboxylic acid ethyl ester; l-{6-[(2,3-Dihydro-benzo[l,4]dioxin-2-ylmethyl)-amino]-5-nitro- pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-{6-[(2,3-Dihydro-benzofuran-5- ylmethyl)-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-{6-[(6- Fluoro-4H-benzo[l,3]dioxin-8-ylmethyl)-ardno]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; l-[6-(2,2-Difluoro-benzo[l,3]dioxol-4-ylamino)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(2,2-Difluoro-benzo[l,3]dioxol- 5-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(l,l-Dioxo- lH-lλ6-benzo[b]thiophen-6-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[(Furan-3-ylmethyl)-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-{6-[2-(4-Methoxy-phenoxy)-ethylamino]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-{6-[2-(5-Methoxy-lH-indol-3-yl)-ethylamino]-5- nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; (3,4-Dihydro-2H- benzo[b][l,4]dioxepin-7-yl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-amine; (3- Fluoro-phenyl)-[5-ni1ro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-amine; (3-Methoxy- phenyl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-amine; l-{6-[(3-Fluoro-phenyl)- methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(4- Benzoyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6- (3,5-Bis-trifluoromethyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Dimethoxy-benzylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Hep1yl-phenylamino)-5-nitro-pyrirnidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester; 2'-(4-Benzoyl-phenylamino)-3'-nitro-3,4,5,6-tetrahydro-2H- [l,4']bipyridinyl-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(3,4,5-trimethoxy-phenylamino)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-pentyl- phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(3-Carboxy- propyl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; [5- Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-(3,4,5-trimethoxy-benzyl)-amine; (3,5- Dimethoxy-benzyl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrirnidin-4-yl]-amine; (4-{5-Nitro- 6-[4-(2-trifluoromethyl-phenoxy)-piperidin-l-yl]-pyrimidin-4-ylamino}-phenyl)-phenyl- methanone; l-[6-(3,5-Difluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Dichloro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(2-Bromo-4-trifluoromethoxy-phenylamino)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[(2-Fluoro-phenyl)-methyl- amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(Ethyl-phenyl- amino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[(4-Chloro- phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6- (4-Difluoromethyl-berιzylamino)-5-nitro-pyrimidm-4-yl]-piρeridine-4-carboxylic acid ethyl ester; l-[6-(4-Cyano-phenylamino)-5-nitio-pyrimidin-4-yl]-ρiperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-sec-Butyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-{6-[4-(Cyano-phenyl-methyl)-phenylamino]-5-nitro-pyrimidin- 4-yl}-piperidine-4-carboxylic acid ethyl ester; l-{5-Nitro-6-[4-(4-trifluoromethyl-phenoxy)- phenylamino]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5- phenyl-2H-pyrazol-3-ylamino)-5-ni1xo-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 1 -[6-(4-Benzenesulfonyl-phenylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(2-trifluoromethyl-3H-benzoimidazol-5-ylamino)-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methanesulfonyl-phenyl)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-(6-Benzofuran-5-yl-5-nitro- pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(3-trifluoromethyl- phenyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methoxy-phenyl)-5- nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 4-(4-Butyl-piperidin-l-yl)-6- furan-3 -yl-5 -nitro-pyrimidine; 1 -[6-(3 -Chloro-phenyl)-5-nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[6-(2,6-Dimethoxy-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester; l-(6-Naphthalen-l-yl-5-nixro-pyrimidin-4-yl)-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Methylsulfanyl-phenyl)-5-ni1xo-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-(2',4'-Dihydroxy-5-nitro-[4,5']bipyrimidinyl-6-yl)- piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methanesulfonyl-phenyl)-5-nitro-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Bis-trifluoromethyl-phenyl)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-(6-Dibenzothiophen-4-yl-5-nitro- pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; 4-(2,4-Difluoro-phenoxy)-6-(4- ethoxymethyl-piperidin-l-yl)-5 -nitro-pyrimidine; l-{4-[6-(4-Methoxymethyl-piperidin-l-yl)- 5-nitro-pyrimidin-4-yloxy]-phenyl}-ethanone; 4-{4-[2-Nitro-3-(4-propyl-piperidin-l-yl)- phenoxy]-phenyl}-butan-2-one; l-{4-[2-Nitro-3-(4-propyl-piperidin-l-yl)-phenoxy]-phenyl}- ethanone; {4-[2-Nitro-3 -(4-propyl-piperidin- 1 -yl)-phenoxy] -phenyl} -phenyl-methanone; 3 - {4-[2-Nitro-3-(4-ρropyl-piρeridin-l-yl)-phenoxy]-phenyl}-3-oxo-propionic acid methyl ester; (4-Fluoro-phenyl)-[4-(3'-nitiO-4-propyl-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-4'-yloxy)- phenyl]-methanone; l-[6-(3,5-Dimethyl-isoxazol-4-yl)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-(5-Nitro-6-thiophen-2-yl-pyrimidin-4-yl)-piperidine-4- carboxylic acid ethyl ester; l-[6-(3,5-Dichloro-phenyl)-5-nitro-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-(6-Dibenzoftιran-4-yl-5-nitro-pyrimidin-4-yl)-piρeridine-4- carboxylic acid ethyl ester; l-[6-(3,5-Dimethyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Acetyl-phenyl)-5-nitio-pyrimidin-4-yl]-ρiperidine-4- carboxylic acid ethyl ester; l-[6-(4-Ethanesulfonyl-phenyl)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Fluoro-biphenyl-4-yl)-5-nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3-Methanesulfonyl-phenyl)-5-nitro- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Fluoro-ρhenylethynyl)-5- nitro-pyrirnidin-4-yl]-piperidine-4-carboxylic acid ethyl ester and l-[5-Nitro-6-(3- trifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester.
Pharmaceutical compositions
Some embodiments of the present invention include a method of producing a pharmaceutical composition comprising admixing at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.
A compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically- acceptable carriers, outside those mentioned herein, are available to those in the art; for example, see Remington's Pharmaceutical Sciences, 16th Edition, 1980, Mack Publishing Co., (Oslo et al., eds.) and the most current version.
While it is possible that, for use in the prophylaxis or treatment, a compound of the invention may in an alternative use be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.
The invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and/or prophylactic ingredients. The carrier(s) must be acceptable" in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical formulations and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such χø4
unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl- cellulose; and with lubricants such as talc or magnesium stearate. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.
The dose when using the compounds of Formula (la) can vary within wide limits, and as is customary and is known to the physician, it is to be tailored to the individual conditions in each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the Formula (la). Representative doses of the present invention include, about 0.01 mg to about 1000 mg, about 0.01 to about 750 mg, about 0.01 to about 500 mg, 0.01 to about 250 mg, 0.01 mg to about 200 mg, about 0.01 mg to 150 mg, about 0.01 mg to about 100 mg, and about 0.01 mg to about 75 mg. Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or 4, doses. If appropriate, depending on individual behavior and as appropriate from the patients physician or care-giver it may be necessary to deviate upward or downward from the daily dose.
The amount of active ingredient, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician. In general, one skilled in the art understands how to extrapolate in vivo data obtained in a model system, typically an animal model, to another, such as a human. Typically, animal models include, but are not limited to, the rodents diabetes models as described in Example 6, infra (other animal models have been reported by Reed and Scribner in Diabetes, Obesity and Metabolism, 1, 1999, 75-86). In some circumstances, these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors. Representative factors include the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, on whether an acute or chronic disease state is being treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the Formula (la) and as part of a drug combination. The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety factors as cited above. Thus, the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations. The daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4, part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
The compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
For preparing pharmaceutical compositions from the compounds of the present invention, the selection of a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desire shape and size.
The powders and tablets may contain varying percentage amounts of the active compound. A representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active compound; however, an artisan would know when amounts outside of „-_ -,ΛΛ . ft
WO 2004 0 1 Qg
this range are necessary. Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as an admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and or gelling agents. Lotions may be formulated . with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant. If the compounds of the Formula (la) or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler. Pharmaceutical forms for administration of the compounds of the Formula (la) as an aerosol can be prepared by processes well-known to the person skilled in the art. For their preparation, for example, solutions or dispersions of the compounds of the Formula (la) in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others, and, if appropriate, customary propellants, for example include carbon dioxide, CFC's, such as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.
In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
Alternatively the active ingredients may be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PNP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition , may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number ofany of these in packaged form.
Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and N. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference.
Combination Therapy/Prophylaxis
While the compounds of the invention can be administered as the sole active pharmaceutical agent as described herein above, they can also be used in combination with one or more agents belonging to the class of drugs known as α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrate compounds, LDL catabolism enhancers and angiotensin converting enzyme (ACE) inhibitors. α-Glucosidase inhibitors belong to the class of drugs which competitively inhibit digestive enzymes such as α-amylase, maltase, α-dextrinase, sucrase, etc. in the pancreas and or small infesting. The reversible inhibition by α-glucosidase inhibitors retard, diminish or otherwise reduce blood glucose levels by delaying the digestion of starch and sugars. Some representative examples of α-glucosidase inhibitors include acarbose, N-(l,3-dihydroxy-2- propyl)valiolamine (generic name; voglibose), miglitol, and α-glucosidase inhibitors known in the art.
The class of aldose reductase inhibitors are drugs which inhibit the first-stage rate- limiting enzyme in the polyol pathway that prevent or arrest diabetic complications. In the hyperglycemic state of diabetes, the utilization of glucose in the polyol pathway is increased and the excess csorbitol accumulated intracellularly as a consequence acts as a tissue toxin and hence evokes the onset of complications such as diabetic neuropathy, retinopathy, and nephropathy. Examples of the aldose reductase inhibitors include tolurestat; epalrestat; 3,4- dihydro-2,8-diisopropyl-3-thioxo-2H-l ,4-benzoxazine-4-acetic acid; 2,7-difluorospiro(9H- fluorene-9,4'-imidazolidine)-2',5'-dione (generic name: imirestat); 3-[(4-bromo-2- flurophenyl)methy]-7-chloro-3,4-dihydro-2,4-dioxo-l(2H)-qumazoline acetic acid (generic name: zenarestat); 6-fluoro-2,3-dihydro-2',5'-dioxo-spiro[4H-l-benzopyran-4,4'- imidazolidine]-2-carboxamide (SNK-860); zopolrestat; sorbinil; and l-[(3-bromo-2- benzofuranyl)sulfonyl]-2,4-imidazolidinedione (M- 16209), and aldose reductase inhibitors known in the art.
The biguanides are a class of drugs that stimulate anaerobic glycolysis, increase the sensitivity to insulin in the peripheral tissues, inhibit glucose absorption from the intestine, suppress of hepatic gluconeogenesis, and inhibit fatty acid oxidation. Examples of biguanides include phenformin, metformin, buformin, and biguanides lαiown in the art.
Statin compounds belong to a class of drugs that lower blood cholesterol levels by inhibiting hydroxymethylglutalyl CoA (ΗMG-CoA) reductase. ΗMG-CoA reductase is the rate-limiting enzyme in cholesterol biosynthesis. A statin that inhibits this reductase lowers serum LDL concentrations by upregulating the activity of LDL receptors and responsible for clearing LDL from the blood. Examples of the statin compounds include rosuvastatin, pravastatin and its sodium salt, simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, and ΗMG-CoA reductase inhibitors known in the art.
Squalene synthesis inhibitors belong to a class of drugs that lower blood cholesterol levels by inhibiting synthesis of squalene. Examples of the squalene synthesis inhibitors include (S)-α-[Bis[2,2-dimethyl-l -oxopropoxy)methoxy] phosphinyl]-3- phenoxybenzenebutanesulfonic acid, mono potassium salt (BMS- 188494) and squalene synthesis inhibitors known in the art.
Fibrate compounds belong to a class of drugs that lower blood cholesterol levels by inhibiting synthesis and secretion of triglycerides in the liver and activating a lipoprotein lipase. Fibrates have been known to activate peroxisome proliferators-activated receptors and induce lipoprotein lipase expression. Examples of fibrate compounds include bezafibrate, beclobrate, binifibrate, ciplofϊbrate, clinofibrate, clofibrate, clofibric acid, etofibrate, fenofibrate, gemfibrozil, nicofϊbrate, pirifibrate, ronifibrate, simfibrate, theofϊbrate, and fibrates known in the art.
LDL (low-density lipoprotein) catabolism enhancers belong to a class of drugs that lower blood cholesterol levels by increasing the number of LDL (low-density lipoprotein) receptors, examples include LDL catabolism enhancers known in the art.
Angiotensin converting enzyme (ACE) inhibitors belong to the class of drugs that partially lower blood glucose levels as well as lowering blood pressure by inhibiting angiotensin converting enzymes. Examples of the angiotensin converting enzyme inhibitors include captopril, enalapril, alacepril, delapril; ramipril, lisinopril, imidapril, benazepril, ceronapril, cilazapril, enalaprilat, fosinopril, moveltopril, perindopril, quinapril, spirapril, temocapril, trandolapril, and angiotensin converting enzyme inhibitors known in the art.
Insulin secretion enhancers belong to the class of drugs having the property to promote secretion of insulin from pancreatic β cells. Examples of the insulin secretion enhancers include sulfonylureas (SU). The sulfonylureas (SU) are drugs which promote secretion of insulin from pancreatic β cells by transmitting signals of insulin secretion via SU receptors in the cell membranes. Examples of the sulfonylureas include tolbutamide; chlorpropamide; tolazamide; acetohexamide; 4-chloro-N-[(l-pyrolidinylamino) carbonyl]- benzenesulfonamide (generic name: glycopyramide) or its ammonium salt; glibenclamide (glyburide); gliclazide; l-butyl-3-metanilylurea; carbutamide; glibonuride; glipizide; gliquidone; glisoxepid; glybuthiazole; glibuzole; glyhexamide; glymidine; glypinamide; phenbutamide; tolcyclamide, glimepiride, and other insulin secretion enhancers known in the art. Other insulin secretion enhancers include N-[[4-(l-methylethyl)cyclohexyl)carbonyl]-D- phenylalanine (Nateglinide); calcium (2S)-2-benzyl-3-(cis-hexahydro-2- isoindolinylcarbonyl)propionate dihydrate (Mitiglinide, KAD-1229); and other insulin secretion enhancers known in the art.
Thiazolidinediones belong to the class of drugs more commoningly known as TZDs. Examples of thiazolidinediones include rosiglitazone, pioglitazone, and thiazolidinediones known in the art. Some embodiments of the invention include, a pharmaceutical composition comprising a compound of Formula (la) or a pharmaceutically acceptable salt thereof in combination with at least one member selected from the group consisting of an α-glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a HMG-CoA reductase inhibitor, a squalene synthesis inhibitor, a fibrate compound, a LDL catabolism enhancer and an angiotensin converting enzyme inhibitor. In another embodiment, the pharmaceutical composition is a compound of Formula (la) or a pharmaceutically acceptable salt thereof in combination with a HMG-CoA reductase inhibitor. In still another embodiment, the HMG- CoA reductase inhibitor is selected from the group consisting of prevastatin, simvastatin, lovastatin, atorvastatin, fluvastatin and lipitor.
In accordance with the present invention, the combination can be used by mixing the respective active components either all together or independently with a physiologically acceptable carrier, excipient, binder, diluent, etc., as described herein above, and administering the mixture or mixtures either orally or non-orally as a pharmaceutical composition. When a compound or a mixture of compounds of Formula (la) are administered as a combination therapy or prophylaxis with another active compound the therapeutic agents can be formulated as a separate pharmaceutical compositions given at the same time or at different times, or the therapeutic agents can be given as a single composition.
Other Utility
Another object of the present invention relates to radiolabelled compounds of Formula (la) that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating RUP3 in tissue samples, including human, and for identifying RUP3 ligands by inhibition binding of a radiolabelled compound. It is a further object of this invention to develop novel RUP3 assays of which comprise such radiolabelled compounds.
Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3H (also written as T), nC, 14C, 18F, 1251, 82Br, 1231, 124I, 1251, 1311, 75Br, 76Br, 150, 13N, 35S and 77Br. The radionuclide that is incorporated in the instant radiolabelled compounds will depend on the specific application of that radiolabelled compound. Thus, for in vitro RUP3 labeling and competition assays, compounds that incorporate 3H, 14C, 1251 , 1311, 35S or 82Br will generally be most useful. For radio-imaging applications nC, 18F, ,251, 1231, 1241, 1311, 75Br, 76Br or 77Br will generally be most useful.
It is understood that a "radio-labelled " or "labelled compound" is a compound of Formula (la) that has incorporated at least one radionuclide; In some embodiments, the radionuclide is selected from the group consisting of 3H, 14C, 1251 , 35S and 82Br; In some embodiments, the radionuclide 3H or 14C. Moreover, it should be understood that all of the atoms represented in the compounds of the invention can be either the most commonly occurring isotope of such atoms or the more scarce radio-isotope or nonradio-active isotope.
Synthetic methods for incorporating radio-isotopes into organic compounds including those applicable to those compounds of the invention are well known in the art and include incorporating activity levels of tritium into target molecules include: A. Catalytic Reduction with Tritium Gas - This procedure normally yields high specific activity products and requires halogenated or unsaturated precursors. B. Reduction with Sodium Borohydride [3H] - This procedure is rather inexpensive and requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like. C. Reduction with Lithium Aluminum Hydride [3H ] - This procedure offers products at almost theoretical specific activities. It also requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like. D. Tritium Gas Exposure Labeling - This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst. E. N-Methylation using Methyl Iodide [3H] - This procedure is usually employed to prepare O-methyl or N-methyl (3H) products by treating appropriate precursors with high specific activity methyl iodide (3H). This method in general allows for high specific activity, such as about 80-87 Ci/mmol.
Synthetic methods for incorporating activity levels of 125I into target molecules include: A. Sandmeyer and like reactions - This procedure transforms an aryl or heteroaryl amine into a diazonium salt, such as a tetrafluoroborate salt, and subsequently to 125I labelled compound using Na125I. A represented procedure was reported by Zhu, D.-G. and co-workers in J. Org. Chem. 2002, 67, 943-948. B. Ortho 125Iodination of phenols - This procedure . allows for the incorporation of 125I at the ortho position of a phenol as reported by Collier, T. L. and co-workers in J. Labelled Compd Radiopharm. 1999, 42, S264-S266. C. Aryl and heteroaryl bromide exchange with 125I - This method is generally a two step process. The first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, a Pd catalyzed reaction [i.e. Pd(Ph3P)4] or through an aryl or heteroaryl lithium, in the presence of a xri-alkyltinhalide or hexaalkylditin [e.g., (CH3)3SnSn(CH3)3]. A represented procedure was reported by Bas, M.-D. and co-workers in J. Labelled Compd Radiopharm. 2001, 44, S280-S282.
A radiolabelled RUP3 compound as described herein can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the "radiolabelled compound of Formula (la)" to the RUP3 receptor. Accordingly, the ability of a test compound to compete with the "radio-labelled compound of Formula (la)" for the binding to the RUP3 receptor directly correlates to its binding affinity. The labelled compounds of the present invention bind to the RUP3 receptor. In one embodiment the labelled compound has an IC50 less than about 500 μM, in another embodiment the labelled compound has an IC50 less than about 100 μM, in yet another embodiment the labelled compound has an IC50 less than about 10 μM, in yet another embodiment the labelled compound has an IC50 less than about 1 μM, and in still yet another embodiment the labelled inhibitor has an IC50 less than about 0.1 μM.
Other uses of the disclosed receptors and methods will become apparent to those in the art based upon, inter alia, a review of this patent document.
This application claims priority benefit of U.S. Provisional Application Number 60/440,394, filed January 14, 2003; U.S. Provisional Patent Application Number 60/449,829, filed February 24, 2003, U.S. Provisional Patent Application Number 60/453,390, filed March 6, 2003, and U.S. Non-Provisional Patent Application No. 60/470,875, filed May 14, 2003; wherein each are hereby incorporated by reference in their entirety.
The following examples are given to illustrate the invention and are not intended to be inclusive in any manner:
EXAMPLES
The compounds of the present invention and their syntheses are further illustrated by the following examples. The examples are provided to further define the invention without, however, limiting the invention to the specifics of these examples.
Example 1
96-well Cyclic AMP membrane assay for RUP3
Materials:
1) Adenlyl cyclase Activation Flashplate Assay kit from Perkin Elmer — 96 wells (SMP004B) and 125I tracer (NEX130) which comes with the kit. Keep in refrigerator, in a box, and do not expose the Flashplates to light.
2) Phosphocreatine - Sigma P-7936
3) Creatine Phosphokinase — Sigma C-3755
4) GTP - Sigma G-8877
5) ATP- Sigma A-2383
6) IBMX- Sigma 1-7018
7) Hepes - IM solution in distilled water - Gibco #15630080
8) MgC12 - Sigma M-1028- IM Solution
9) NaCl - Sigma - S6546 - 5M Solution 10) Bradford Protein Assay Kit - Biorad # 5000001
11) Proclin 300- Sigma #4-8126
Binding Buffer - filter through 45- micron Nalgene filter and keep in refrigerator. All buffers and membranes should be kept cold (in ice bucket) while performing assay.
20 mM Hepes, pH7.4 l mM MgC12
100 mM NaCl
2X Regeneration Buffer (make in binding buffer):
20 mM Phosphocreatine (1.02 gm 200 ml binding buffer)
20 units Creatine phosphokinase (4 mg/200 ml)
20 uM GTP (make up 10.46 mg/ml in binding buffer and add 200 ul /200 ml)
0.2 mM ATP (22.04 mg/200 ml)
100 mM IBMX (44.4 mg IBMX dissolved in 1 ml 100% DMSO first and then add the entire amount to 200 ml of buffer).
Regeneration buffer can be aliquotted into 40-45 ml portions (in 50 ml sterile tubes) and kept frozen for up to 2 months. Simply put the tube in a beaker with room temperature water to thaw out the regeneration buffer on the day of the assay.
A. Assay procedure
1) Pipet 50 ul regeneration buffer in all 96 wells using Matrix 1250 8-channel pipettor.
2) Pipet 5 ul DMSO in columns 1 and columns 11 and 12.
3) Pipet 50 ul cAMP standards in columns 11 and 12 in this format: 50 pmole/well for row A, 25 pmole/well for row B, 12.5 pmol/well for row C, 5 picomol/well for row D, 2.5 pmole/well for row E, 1.25 pmole/well for row F, 0.5 pmole/well for row G, and 0 pmole/well (buffer only) for row H.
4) Pipet 5 ul compounds from each well of a compound dilution plate, for IC50s, using the following dilution scheme:
Well H: 400 uM compound (final concentration of compound in reaction mix
= 5/100 x 400 uM = 20 uM Well G: 1:10 dilution of Well H (i.e. 5ul compound from well H + 45 ul
100% DMSO) (final concentration = 2 uM) Well F: 1:10 dilution of well G (final concentration = 0.2 uM) Well E: 1:10 dilution of well F (final concentration = 0.02 uM) Well D: 1:10 dilution of well E (final concentration = 0.002 uM) Well C: 1:10 dilution of well D (final concentration = 0.0002 uM Well B: 1:10 dilution of well C (final concentration = 0.00002 uM) Well A: 1:10 dilution of well B (final concentration = 0.000002 uM)
IC50s or EC50s are done in triplicate. One Flashplate can therefore be set up to handle 3 compounds, (i.e., columns 2, 3, and 4 are for compound #1, columns 5, 6, and 7 are for compound #2, and columns 8, 9, and 10 are for compound #3.)
5) Add 50 ul of RUP3 membranes to all wells in Columns 2 to 10. (Prior to the start of the assay, the frozen membrane pellets for both RUP3 and CMN (cells transfected with an expression plasmid containing no RUP3 sequences), are suspended in binding buffer, usually 1 ml binding buffer for 1 plate of membranes. The membranes are kept in ice all the time, and a polytron (Brinkmann polytron, model # PT-3100) is used (setting 6-7, for 15-20 seconds) to obtain a homogeneous membrane suspension.) Protein concentration is determined by Bradford protein assay kit using instructions given in the kit, using the standard supplied with the kit as a reference. The protein concentration of the membranes is adjusted with binding buffer, so that 50 ul membranes = 15 ug protein (i.e. 0.3 mg/ml protein).
6) In column 1, Wells A, B, C, and D, add 50 ul RUP3 membranes. To wells E, F, G, and H, add 50 ul CMN membranes, (CMN membranes being of the same protein concentration as the RUP3 membranes).
7) Incubate 1 hour at room temperature with agitation on a rotating platform shaker. Cover with foil while shaking.
8) After 1 hour, add (to all 96 wells), 100 ul of the 125I tracer in detection buffer supplied with the Flashplate kit plus proclin, made up in the following manner:
Pipet per 10 ml per Flashplate: 100 ml of detection buffer + 1 ml 125I + 0.2 ml of Proclin ( the proclin helps to stop the production of cAMP). Make a smaller quantity of detection buffer mix if you have fewer plates. „-_ -,ΛΛ . ft
WO 2004 0 1 ! g
9) Shake the plates on a rotating platform shaker for 2 hours, covering the plates with lead sheeting.
10) Seal the plates with the plastic film sealers provided with the Flashplate kit.
11) Count the plates using a TRILUX 1450 Microbeta Counter. See the door of the counter to determine which counting protocol to use.
12) Data is analyzed on the Arena Database according to the RTJP3 non-fusion, IC50 EC50 for 96-well cAMP membrane assay, and the compound numbers and the concentrations of compounds must be entered by the user.
B. Membrane Cyclase Criteria
1) Signal to Noise:
An acceptable signal-to-noise ratio for RUP3 can vary from 4 to 6. The raw cpms are approximately 1800 to 2500 for RUP3 and 3500-4500 for CMN. The cpm (or ultimately pmoles of cAMP/well) cannot be outside the standard curve, and should not approach well A of the standard curve (50 pmole/well) and well H (no cAMP). Generally, the pmoles of cAMP produced by RUP3 receptor are around 11 to 13 pmole/well (for 15 ug/well protein), and for CMN are between 2 to 3 pmole/well (for 15 ug protein /well).
2) Standard curve:
The slope should be linear and the error bars for duplicates should be very small. The receptor and CMN controls cannot be off scale of the standard curve, as described above. If the receptor controls are off the high end of the standard curve,i.e. 50 pmole/well or higher, one must repeat the experiment using less protein. However, such a case has not been observed with transiently transfected RUP3 membranes (10 ug DΝA/ 15 cm plate, using 60 ul Lipofectamine, and preparing membranes after 24 hour of transfection.)
3) The IC50 or EC50 curve should be at 100% (+ or - 20%) of control RUP3 membranes at the top, and should go down to 0 (or up to 20%) at the bottom. The standard error of the triplicate determinations should be + or - 10%. „,„ -,ftft 1
WO 2004 17
C. Stimulation of cAMP in HIT-T15 cells
H1T-T15 (ATCC CRL#1777) is an immortalized hamster insulin-producing cell line. These cells express RUP3 and therefore can be used to assess the ability of RUP3 ligands to stimulate or inhibit cAMP accumulation via its endogenously expressed receptor. In this assay, cells are grown to 80% confluence and then distributed into a 96-well Flashplate (50,000 cells/ well) for detection of cAMP via a "cAMP Flashplate Assay" (NEN, Cat # SMP004). Briefly, cells are placed into anti-cAMP antibody-coated wells that contain either vehicle, the test ligand(s) at a concentration of interest, or 1 uM forskolin. The latter is a direct activator of adenylyl cyclase and serves as a positive control for stimulation of cAMP in HIT-T15 cells. All conditions are tested in triplicate. After a 1 hour incubation to allow for stimulation of cAMP, a Detection Mix containing 125I-cAMP is added to each well and the plate is allowed to incubate for another 1 hour. The wells are then aspirated to remove unbound 125I-cAMP. Bound 125I-cAMP is detected using a Wallac Microbeta Counter. The amount of cAMP in each sample is determined by comparison to a standard curve, obtained by placing known concentrations of cAMP in some wells on the plate.
D. Stimulation of insulin secretion in HIT-T15 cells
It is known that stimulation of cAMP in HIT-T15 cells causes an increase in insulin secretion when the glucose concentration in the culture media is changed from 3mM to 15 mM. Thus, RUP3 ligands can also be tested for their ability to stimulate glucose-dependent insulin secretion (GSIS) in HIT-T15 cells. In this assay, 30,000 cells/well in a 12-well plate are incubated in culture media containing 3 mM glucose and no serum for 2 hours. The media is then changed; wells receive media containing either 3 mM or 15 mM glucose, and in both cases the media contains either vehicle (DMSO) or RUP3 ligand at a concentration of interest. Some wells receive media containing 1 uM forskolin as a positive control. All conditions are tested in triplicate. Cells are incubated for 30 minutes, and the amount of insulin secreted into the media is determined by ELISA, using a kit from either Peninsula Laboratories (Cat # ELIS-7536) or Crystal Chem Inc. (Cat # 90060).
E. Stimulation of insulin secretion in isolated rat islets
As with HIT-T15 cells, it is known that stimulation of c AMP in isolated rat islets causes an increase in insulin secretion when the glucose concentration in the culture media is changed from 60 mg/dl to 300 mg/dl. RUP3 is an endogenously expressed GPCR in the „-_ -,ΛΛ . ft
WO 2004 0 2 8
insulin-producing cells of rat islets. Thus, RUP3 ligands can also be tested for their ability to stimulate GSIS in rat islet cultures. This assay is performed as follows:
A. Select 75-150 islet equivalents (IEQ) for each assay condition using a dissecting microscope. Incubate overnight in low-glucose culture medium. (Optional.)
B. Divide the islets evenly into triplicate samples of 25-40 islet equivalents per sample. Transfer to 40 μm mesh sterile cell strainers in wells of a 6-well plate with 5 ml of low (60 mg/dl) glucose Krebs-Ringers Buffer (KRB) assay medium.
C. Incubate 30 minutes (1 hour if overnight step skipped) at 37°C and 5% C02. Save the supematants if a positive control for the RIA is desired.
D. Move strainers with islets to new wells with 5ml/well low glucose KRB. This is the second pre-incubation and serves to remove residual or carryover insulin from the culture medium. Incubate 30 minutes.
E. Move strainers to next wells (Low 1) with 4 or 5 ml low glucose KRB. Incubate @ 37° C for 30 minutes. Collect supematants into low-binding polypropylene tubes pre-labelled for identification and keep cold.
F. Move strainers to high glucose wells (300mg/dl, which is equivalent to 16.7mM). Incubate and collect supematants as before. Rinse islets in their strainers in low-glucose to remove residual insulin. If the rinse if to be collected for analysis, use one rinse well for each condition (i.e. set of triplicates.)
G. Move strainers to final wells with low-glucose assay medium (Low 2). Incubate and collect supematants as before.
H. Keeping cold, centrifuge supematants at 1800rpm for 5 minutes @ 4-8°C to remove small islets/islet pieces that escape the 40mm mesh. Remove all but lower 0.5 - 1 ml and distribute in duplicate to pre-labelled low-binding tubes. Freeze and store at <-20° C until insulin concentrations can be determined.
I. Insulin determinations are done as above, or by Linco Labs as a custom service, using their rat insulin RIA (Cat. # RI-13K). Example 2
A. RT-PCR analysis of RUP3 expression in human tissues (Figure 1A).
RT-PCR was applied to determine the tissue distribution of RUP3. Ohgonucleotides used for PCR had the following sequences:
ZC47: 5'-CATTGCCGGGCTGTGGTTAGTGTC-3' (forward primer), (SEQ ID NO:3);
ZC48: 5'-GGCATAGATGAGTGGGTTGAGCAG-3' (reverse primer), (SEQ ID NO:4); and the human multiple tissue cDNA panels (MTC, Clontech) were used as templates (1 ng cDNA per PCR amplification). Twenty-two (22) human tissues were analyzed. PCR was performed using Platinum PCR SuperMix (Life Technologies, Inc.; manufacture instructions were followed) in a 50 μl reaction by the following sequences: step 1, 95°C for 4 min; step 2, 95°C for 1 min; step 3, 60°C for 30 sec; step 4, 72°C for 1 min; and step 5, 72°C for 7 min. Steps 2 through 4 were repeated 35 times.
The resulting PCR reactions (15 μl) were loaded on a 1.5% agarose gel to analyze the RT-PCR products, and a specific 466 base-pair DNA fragment representing RUP3 was specifically amplified from cDNA of pancreas origin. Low expression was also evident in subregions of brain.
B. cDNA Dot-Blot analysis of RUP3 expression in human tissues (Figure IB).
Results from RT-PCR analysis were further confirmed in cDNA dot-blot analysis. In this assay, a dot-blot membrane containing cDNA from 50 human tissues (Clontech) was hybridized with a 32P-radiolabelled DNA probe having sequences derived from human RUP3. Hybridyzation signals were seen in pancreas and fetal liver, suggesting these tissues express RTJP3. No significant expression was detected in other tissues analyzed.
C. Analysis of RUP3 by RT-PCR with isolated human pancreatic islets of Langerhans (Figure IC).
Further analysis of RUP3 by RT-PCR with isolated human pancreatic islets of Langerhans showed robust expression of RUP3 in islet cells but not in control samples.
D. Analysis of RUP3 expression with cDNAs of rat origin by RT-PCR (Figure ID).
RUP3 expression was further analyzed with cDNAs of rat origin by RT-PCR technique. Tissue cDNAs used for this assay were obtained from Clontech except those for hypothalamus and islets, which were prepared in house. Concentrations of each cDNA sample were normalized via a control RT-PCR analysis of the house-keeping gene GAPDH before assaying for RUP3 expression. Ohgonucleotides used for PCR had the following sequences: rat RUP3 ("rRUP3") forward: 5'-CATGGGCCCTGCACCTTCTTTG-3' (SEQ ID NO:5); rRUP3 reverse: 5'-GCTCCGGATGGCTGATGATAGTGA-3' (SEQ ID NO:6). PCR was performed using Platinum PCR SuperMix (Life Technologies, Inc.; manufacture instructions were followed) in a 50 μl reaction by the following sequences: step 1, 95°C for 4 min; step 2, 95°C for 1 min; step 3, 60°C for 30 sec; step 4, 72°C for 1 min; and step 5, 72°C for 7 min. Steps 2 through 4 were repeated 35 times.
The resulting PCR reactions (15 μl) were loaded on a 1.5% agarose gel to analyze the RT-PCR products, and a specific 547 base-pair DNA fragment representing rat RUP3 was specifically amplified from cDNA of pancreas origin, revealing a similar expression profile with human. Of particular note, robust expression was seen in isolated islets and hypothalamus.
Example 3
RUP3 protein expression is restricted to β cell lineage of pancreatic islets (Figure 2).
A. A polyclonal anti-RUP3 antibody was prepared in rabbits (Figure 2A). Rabbits were immunized with an antigenic peptide with sequence derived from rat
RUP3 ("rRUP3"). The peptide sequence was RGPERTRESAYHINTISHPELDG and shared 100% identity with mouse RUP3 in the corresponding region. A cysteine residue was incorporated at the Ν-terminal end of this antigenic peptide to facilitate KLH crosslinking before injecting into rabbits. The resulting antisera ("anti-rRUP3") and the corresponding preimmune sera ("pre-rRUP3") were tested for immune reactivity to mouse RUP3 in immunobloting assays (lanes 1 thought 4). In this assay, the GST-RUP3 fusion protein was readily recognized by the anti-rRUP3 antisera (lane 4), but not by the preimmurie sera (lane 2). The immunoreactive signal could be efficiently eliminated when the immunobloting assay was performed in the presence of excess antigenic peptide (lane 6).
B. RUP3 expression in insulin-producing β cells of pancreatic islets (Figure 2B).
Rat pancreas was perfused with 4% paraformaldehyde (PFA) in PBS and embedded in OCT embedding medium. Ten micron sections were prepared, fixed on glass slides, and immunostained with either pre-rRUP3 (Figure 2B, panel a) or with anti-rRUP3 antisera (Figure 2B, panels c and e) followed by secondary staining with donkey anti-rabbit IgG conjugated to the fluorochrome Cy-3. Each section was also co-immunostained with a „-_ „,ftyl /ft«
WO 2004/065 221
monoclonal anti-insulin antibody (Santa Cruz, Figure 2B, panels b and d) in primary staining followed by a secondary staining with donkey anti-mouse IgG conjugated with FITC, or with a goat anti-glucagon antibody (Santa Cruz, Figure 2B, panel f) and donkey anti-goat IgG coupled to FITC. l munofluorescent signals were examined under a fluorescent microscope. RUP3 was found expressed in insulin producing cells (panels c and d), but not in glucagons producing cells (panels e and f). These data demonstrated that RUP3 is expressed in β cells but not in α cells of the rat pancreatic islets. Analogous results were obtained when mouse pancreatic sections were investigated for RUP3 expression.
Example 4
Functional Activities of RUP3 In Vitro (Figure 3).
It was established that RUP3 stimulates the production of cAMP by cotransfection of 293 cells with: (1) a CRE-Luciferase reporter, wherein the ability to stimulate the production of firefly luciferase depends on increased cAMP in cells, and (2) an expression plasmid encoding the human form of RUP3 (Figure 3A). Note that cells co-transfected with an expression plasmid containing no RUP3 sequences ("CMN" in Figure 3A) produce very little luciferase activity, whereas cells transfected with an expression plasmid encoding RUP3 ("RUP3" in Figure 3A) have at least a 10-fold increase in luciferase activity. This indicates that RUP3 stimulates the production of cAMP when introduced into 293 cells. This property of RUP3 is conserved across species, because hamster RUP3 stimulates luciferase activity when introduced into 293 cells in a manner analogous to that described for human RUP3 (Figure 3B).
It is established that, when cAMP is increased in insulin-producing cells of the pancreas, these cells exhibit an enhanced ability to secrete insulin when glucose concentrations rise. To test whether RUP3 might impart enhanced glucose-dependent insulin release, retroviras containing human RUP3 was used to generate Tu6 cells that express high levels of RUP3. Tu6 cells produce insulin, but do not express appreciable levels of RUP3 and do not normally exhibit an increase in insulin release when increased glucose is present in the culture media. As shown in Figure 3C, Tu6 cells transduced with a control virus that contains no receptor are still able to produce insulin, but do not show an increase in insulin secretion when the concentration of glucose in the culture media is shifted from 1 mM to 16 mM. By contrast, Tu6 cells transduced with RUP3-containing retrovirus display significant glucose-dependent insulin secretion (Figure 3C).
Example 5 Functional Activities of RUP3 Agonists In Vitro (Figure 4).
To demonstrate that RUP3 agonists stimulate endogenously expressed RUP3 in insulin-producing cells, two in vitro models can be used. In the first of these, RUP3 agonists are used to stimulate HIT-T15 cells, which express RUP3 at significant levels, as indicated in the Northern blot shown in Figure 4A. Moreover, these cells are known to exhibit enhanced glucose-dependent insulin release when intracellular cAMP concentrations are elevated. In the example shown in Figure 4B, the RUP3 agonist Compound B84 stimulates cAMP production in HIT cells, at a level comparable to that seen with the adenyl cyclase activator forskolin. This indicates that Compound B84 is a very robust stimulator of cAMP in HIT- T15 cells. In the example shown in Figure 4C, Compound B84 also stimulates insulin secretion in HIT cells exposed to 15 mM glucose, once again at a level comparable to that seen with the adenyl cyclase activator forskolin. This indicates that Compound B 84 is a very robust potentiator of insulin secretion in HIT-T15 cells.
Isolated rat islets are the other in vitro model used to demonstrate the efficacy of RUP3 agonists. In this model, agents that induce cAMP are not expected to stimulate insulin secretion when glucose concentrations are low (e.g. 60 mg/dl). However, when glucose concentrations are increased (e.g. to 300 mg/dl), these agents are expected to enhance insulin secretion to levels above those seen with glucose alone. In the example shown in Figure 4D, both RUP3 agonists (Compounds 48 and 51 at 10 uM concentration) enhanced glucose- dependent insulin release. Moreover, the level of enhancement was comparable to that seen with 25 nM GLP-1, a gut hormone known to act on islets in this manner.
Example 6
In vivo effects of RUP3 agonists on glucose homeostasis in mice.
A. Oral Glucose tolerance test (oGTT) (Figure 5A).
Male C57bl/6N mice at age of 8 weeks were fasted for 18 hours and randomly grouped (n=l 1) to receive a RUP3 agonist (Compound B70) at indicated doses, or with control extendin-4 (ex-4, 1 μg/kg), a GLP-1 peptide analog known to stimulate glucose- dependent insulin secretion. Compound B70 was delivered orally via a gavage needle (p.o. volume at 100 μl). Control Ex-4 was delivered intraperitoneally. Thirty minutes after administration of test compound and control ex-4, mice were administered orally with dextrose at 5 g/kg dose. Levels of blood glucose were determined at the indicated time points using Glucometer Elite XL (Bayer). Figure 5A shows the mean glucose concentration averaged from eleven animals in each treatment group. These results demonstrated that the RUP3 agonist, Compound B70, lowered blood glucose in a dose-dependent manner in mice after challenged with glucose.
B. Acute response of db mice to RUP3 agonist (Figure 5B).
Male db mice (C57BL/Ks01ahsd-Leprdb, diabetic, Harlan) at age of 10 weeks were randomly grouped (n=6) to receive vehicle (oral gavage), Compound B70 (60 mg/kg, oral gavage), or Ex-4 (1 μg/kg, intraperitoneally). After compound administration, food was removed and blood glucose levels were determined at indicated times as shown in Figure 5B. Reduction in blood glucose at each time point was expressed as percentage of original glucose levels, averaged from six animals for each group. These animals had blood glucose levels (fed state) of 300-400 mg/dl, significantly higher than non-diabetic wild type animals. Treatment with Compound B70 or Ex-4 significantly reduced glucose levels compared to vehicle control as shown in Figure 5B. These data demonstrated that the RUP3 agonist had efficacy in improving glucose homeostasis in diabetic animals.
Example 7
CRE-Luciferase Assay in 293 Cells
293 cells were plated in 96-well tissue culture plates at a concentration of 20,000 cells per well. The following day, the cells are transfected with a mixture of pCRE-Luc (Stratagene, Cat. # 219076), the indicated expression plasmid, and pEGFP-Nl (Clontech, Cat. # 6085-1) at a ratio of 5:1:0.25 using Lipofectamine Reagent (Invitrogen, Cat. #18324-020) according to the manufacturer's directions. pEGFP-Nl encodes a "green fluorescent protein" and was used as a control to determine that most cells were successfully transfected. After 24-48 hr, the cells were lysed in situ with 100 ul/ well reconstituted Luclite buffer (Luclite- Reporter Gene Assay Kit, Packard, Cat. # 6016911), according to the manufacturer's directions. After a 10 minute incubation in the dark, luminescence was measured using a TRJLUX 1450 Microbeta Counter (Wallac).
Example 8
Generation of Tu6/ RUP3 Stable Lines
To produce Tu6 cells that express RUP3 at high levels, a retrovirus bearing an expression cassette for RUP3 was generated. Briefly, RUP3 coding sequence was cloned into the retroviral vector pLNCX2 (Clontech, Cat # 6102-1). The amphotropic packaging cell line PT-67 (Clontech, K1060-D) was then transfected with either the parental vector pLNCX2 or pLNCX2/RTJP3 using Lipofectamine and stable lines were established using guidelines provided by the PT-67 vendor. Retrovirus-containing supernatant was obtained by collecting media from the resultant stables according to the manufacturer's directions. Tu6 cells, in a 10 cm dish, were then infected with retroviras by incubating in a solution of 1 ml viral supernatant/ 9 ml culture media containing 40 ug/ml polybrene for 24 hours. The medium was then changed to culture media containing 300 ug/ml G418. G418-resistant clones were ultimately created by virtue of the neomycin-resistance gene cassette present in the pLNCX2 vector, thus indicating the successful integration of retroviras into the Tu6 genome. The expression of RUP3 in the Tu6/RUP3 G418-resistant colonies was confirmed by Northern blot.
Example 9
Insulin secretion, Tu6 Stables
To measure insulin secretion from rodent insulin-producing cell lines, cells were first cultured overnight in serum-free, glucose-deficient media. The following morning, the cells were then placed in the same media supplemented with either 1 mM or 16 mM glucose. After an incubation of 4 hours, the media was collected and analyzed for insulin content using a Rat Insulin Enzyme-Immunoassay (EIA) System (Amersham Pharmacia Biotech, Cat. # RPN 2567). Typically, the assay was performed using multiple dilutions of sample media in order to ensure that the sample measurements fell within the boundaries of the standard curve (generated using known amounts of insulin), as recommended by the manufacturer.
Example 10 RUP3 RNA Blot
To determine the expression of RUP3 in insulin-producing or non islet cells, the following cell lines were obtained and cultured according to guidelines provided by American Type Culture Collection or the indicated provider.
Figure imgf000125_0001
Figure imgf000126_0001
Total RNA was isolated from each of these cell lines using TRIZOL (Invitrogen, Cat # 15596-018), subjected to electrophoresis through an agarose/formaldehyde gel and an RNA blot was prepared using standard molecular biological techniques. A radiolabelled RUP3 probe, corresponding to the full-length coding sequence of RUP3, was prepared using a Prime-It II Random Primer Labeling Kit (Stratagene, Cat # 300385). The denatured probe, 10 ml ExpressHyb solution (Clontech, Cat # 8015-2) and the RNA blot were incubated in a hybridization oven, washed and exposed to film using standard molecular biology practices.
Example 11
Receptor Binding Assay
In addition to the methods described herein, another means for evaluating a test compound is by determining binding affinities to the RUP3 receptor. This type of assay generally requires a radiolabelled ligand to the RUP3 receptor. Absent the use of known ligands for the RUP3 receptor and radiolabels thereof, compounds of Formula (la) can be labelled with a radioisotope and used in an assay for evaluating the affinity of a test compound to the RUP3 receptor.
A radiolabelled RUP3 compound as described herein can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the "radiolabelled compound of Formula (la)" to the RUP3 receptor. Accordingly, the ability to compete with the "radio-labelled compound of Formula (la)" or Radiolabelled RUP3 Ligand for the binding to the RUP3 receptor directly correlates to its binding affinity of the test compound to the RUP3 receptor.
ASSAY PROTOCOL FOR DETERMINING RECEPTOR BINDING FOR RUP3: A. RUP3 RECEPTOR PREPARATION
293 cells (human kidney, ATCC), transiently transfected with 10 ug human RUP3 receptor and 60 ul Lipofectamine (per 15-cm dish), were grown in the dish for 24 hours (75% confluency) with a media change and removed with 10 ml/dish of Hepes-EDTA buffer ( 20mM Hepes + 10 mM EDTA, pH 7.4). The cells were then centrifuged in a Beckman Coulter centrifuge for 20 minutes, 17,000 rpm (JA-25.50 rotor). Subsequently, the pellet was resuspended in 20 mM Hepes + 1 mM EDTA, pH 7.4 and homogenized with a 50- ml Dounce homogenizer and again centrifuged. After removing the supernatant, the pellets were stored at -80°C, until used in binding assay. When used in the assay, membranes were thawed on ice for 20 minutes and then 10 mL of incubation buffer (20 mM Hepes, 1 mM MgCl2,100 mM NaCl, pH 7.4) added. The membranes were then vortexed to resuspend the crude membrane pellet and homogenized with a Brinkmann PT-3100 Polytron homogenizer for 15 seconds at setting 6. The concentration of membrane protein was determined using the BRL Bradford protein assay.
B. BINDING ASSAY
For total binding, a total volume of 50ul of appropriately diluted membranes (diluted in assay buffer containing 50mM Tris HCl (pH 7.4), lOmM MgCl2, and ImM EDTA; 5-50ug protein) is added to 96-well polyproylene microtiter plates followed by addition of lOOul of assay buffer and 50ul of Radiolabelled RUP3 Ligand. For nonspecific binding, 50 ul of assay buffer is added instead of lOOul and an additional 50ul of lOuM cold RUP3 is added before 50ul of Radiolabelled RUP3 Ligand is added. Plates are then incubated at room temperature for 60-120 minutes. The binding reaction is terminated by filtering assay plates through a Microplate Devices GF/C Unifilter filtration plate with a Brandell 96-well plate harvester followed by washing with cold 50 mM Tris HCl, pH 7.4 containing 0.9% NaCl. Then, the bottom of the filtration plate are sealed, 50ul of Optiphase Supermix is added to each well, the top of the plates are sealed, and plates are counted in a Trilux MicroBeta scintillation counter. For compound competition studies, instead of adding lOOul of assay buffer, lOOul of appropriately diluted test compound is added to appropriate wells followed by addition of 50ul of Radiolabelled RTJP3 Ligand.
C. CALCULATIONS
The test compounds are initially assayed at 1 and 0.1 μM and then at a range of concentrations chosen such that the middle dose would cause about 50% inhibition of a Radio-RUP3 Ligand binding (i.e., IC50). Specific binding in the absence of test compound (Bo) is the difference of total binding (Bτ) minus non-specific binding (NSB) and similarly specific binding (in the presence of test compound) (B) is the difference of displacement binding (Bp) minus non-specific binding (NSB). IC50 is determined from an inhibition response curve, logit-log plot of % B/B0 vs concentration of test compound.
K; is calculated by the Cheng and Prustoff transformation:
Ki = ιC5o / (i + [Lj κD) where [L] is the concentration of a Radio-RUP3 Ligand used in the assay and KD is the dissociation constant of a Radio-RUP3 Ligand determined independently under the same binding conditions. CHEMISTRY SYNTHESES OF COMPOUNDS OF THE PRESENT INVENTION
EXAMPLE 12
Illustrated syntheses for compounds of Formula (la) are shown in Figure 6 where the symbols have the same definitions as used throughout this disclosure. The preparation of N- oxides is well know in the art, which include, but not limited to pyridines, pyrimidines and the like. For example, N-oxides can be prepared at normal or elevated pressure, in the presence of an oxidizing agent, such as, hydrogen peroxide, peracetic acid, perbenzoic, m- chloroperbenzoic acid (mCPBA), ozone, oxygen and the like, in the presence or absence of solvent, such as chloroform, dichlormethane, acetic acid, trifluoroacetic acid, and the like or mixtures thereof.
Chemistry: Proton nuclear magnetic resonance (XH NMR) spectra were recorded on a Narian Mercury Nx-400 equipped with a 4 nucleus auto switchable probe and z-gradient or a Bruker Avance-400 equipped with a QΝP (Quad Nucleus Probe) or a BBI (Broad Band Inverse) and z-gradient. Chemical shifts are given in parts per million (ppm) with the residual solvent signal used as reference. NMR abbreviations are used as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Microwave irradiations were carried out using the Smith Synthesizer (Personal Chemistry). Thin-layer chromatography (TLC) was performed on silica gel 60 F254 (Merck), preparatory thin-layer chromatography (prep TLC) was preformed on PK6F silica gel 60 A 1 mm plates (Whatman), and column chromatography was carried out on a silica gel column using Kieselgel 60, 0.063-0.200 mm (Merck). Evaporation was done in vacuo on a Buchi rotary evaporator. Celite 545 ® was used during palladium filtrations. '
LCMS specs: 1) PC: HPLC-pumps: LC-IOAD VP, Shimadzu Inc.; HPLC system controller: SCL-10A VP, Shimadzu Inc; UN-Detector: SPD-10A VP, Shimadzu Pnc; Autosampler: CTC HTS, PAL, Leap Scientific; Mass spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex; Software: Analyst 1.2. 2) Mac: HPLC-pumps: LC-8A VP, Shimadzu Inc; HPLC system controller: SCL-10A VP, Shimadzu Inc.
UN-Detector: SPD-10A VP, Shimadzu Inc; Autosampler: 215 Liquid Handler, Gilson Inc; Mass, spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex Software: Masschrom 1.5.2.
Compound Al l-[6-(4-Imidazol-l-yl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester: General Method 1.
A mixture of l-(6-chloro-5-nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester (63 mg, 0.2 mmol), 4-imidazol-l-yl-phenol (42 mg, 0.26 mmol) and potassium carbonate (36 mg, 0.26 mmol, 1 equivalent) in anhydrous DMF (1 ml) was heated to 90 °C overnight. The resulting residue was purified by Flash Chromatography (hexanes: ethyl acetate = 1:1) to give 1 -[6-(4-Imidazol-l -yl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester [Al] as a yellow solid (80 mg, 92 %). H NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80- 1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.38-7.42 (m, 2H), 7.46 (t, IH), 7.55-7.59 (m, 3H), 8.17 (s, IH), 8.90-8.92 (m, IH). Exact mass calculated for
Figure imgf000129_0001
438.17, found 439.2 (MH+).
The intermediate l-(6-chloro-5-nifro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester was prepared by following general method 2.
General Method 2: Addition of Substituted piperidines to dichloro-5-nitropyrimidine. Compound 2,6-dichloro-5-nitropyrimidine (500 mg, 2.57 mmol) was dissolved in dichloromethane (40 ml) and cooled to 0 °C. To this was added diisopropylethyl amine (0.54 ml, 3.08 mmol) followed by a solution of piperidine-4-ethyl-ester (3.69 mmol) in dichloromethane (5 ml) dropwise. The mixture was stirred at 0 °C for 1 hour and then concentrated in vacuo. Flash chromatography (hexanes: ethyl acetate = 1:1) provided Compound Ala, l-(6-chloro-5-nifro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester as a yellow solid (466 mg, 60 %). 1HNMR (DMSO, 400 MHz) δ 1.57-1.63 (m, 2H), 1.91- 1.95 (m, 2H), 2.72-2.74 (m, IH), 3.17(t, 2H), 3.60 (s, 3H), 3.84-3.89 (m, 2H), 8.46 (s, IH). Exact mass calculated for C„H13C1N404 300.06, found 301.2 ( H+). Compounds A2-A155 were prepared in an analogous manner as described for Compound Al, supra.
Compound A2 l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazoI-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester. General Method 3:
4,6-dichloro-5-nitro pyrimidine (5.00 g, 25.7 mmol) and diisopropylethylamine (7.66 ml, 43.9 mmol) were dissolved in dichloromethane (17.0 ml). The mixture was stirred in an ice bath and 4-ethyl ester piperidine (3.33 ml, 43.9 mmol) dissolved in dichloromethane (17.0 ml) was added dropwise. The mixture was warmed to room temperature and after 30 min. the desired product was observed by LCMS m/z 315 (M+H+). The solvent was removed under reduced pressure, the crude dissolved in dioxane (20 ml), sequentially, diisopropylethylamine (6.31 ml, 36.22 mmol) and 2-Methyl-5-trifluoromethyl-2H-3-hydroxypyrazole(3.60 g, 21.73 mmol) were added and the mixture was heated at 90 °C for 18 h. Work up yielded a crude red oil. Purification by Flash Chromatography (0-35% diethyl ether/ hexane). Yield 58.47 % yellow solid. JH NMR 400MHz DMSO δ (ppm): 8.34 (s, IH); 6.71 (s, IH); 4.07 (m, 2H); 3.88 (d, 2H); 3J0 (s, 3H); 3.27 (m, 2H); 2.72 (m, IH); 1.94 (m, 2H); 1.62 (m, 2H); 1.18 (t, 3H). LCMS (ESI) m z 444.3 (M+H*", 100%)
Compound A3 l-[6-(4-Methanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester
Following the general procedure [method 1] compound A3 was obtained as a yellow solid (52%). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.35-4.05 (m, 16H), 4.15 (q, 2H), 7.55-7.58 (m, 2H), 7.62-7.66 (m, IH), 7.88-7.92 (m, 2H), 7.95 (s, IH ). Exact mass calculated for C2 H32N606S 532.21, found 533.3 (MH+).
Compound A4 l-[6-(Benzo[l,2,5]oxadiazol-5-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester
Following the general procedure, [method 1] compound A4 was obtained as a brown solid (65 %). 1HNMR (CDCI3, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 7.22 (d, IH), 7.60 (s, IH), 7.82 (d, IH), 8.16 (s, IH). Exact mass calculated for C18H18N606414.13, found 415.3 (MET1").
Compound A5 l-{6-[4-(2-Methoxycarbonyl-acetyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester: [method 1]
Flash chromatography (hexanes:ethyl acetate = 2: 1) provided compound A5 as a yellow solid (250 mg, 65 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.78-1.88 (m, 2H), 1.95-2.05 (m, 2H), 2.62-2.70 (m, IH), 3.22 (t, 2H), 3.76 (s, 2H), 4.00 (s, 3H), 4.02-4.08 (m, 2H), 4.18 (q, 2H), 7.25 (d, 2H), 8.00 (d, 2H), 8.22 (s, IH). Exact mass calculated for C22H24N408 472.16, found 473.4 (MH+).
Compound A6 l-[5-Anιino-6-(2-methyl-5-trifluoromethyl-2H-pyrazoI-3-yloxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester: General Method 4:
A2 (100 mg, 0.225 mmol) was dissolved in ethanol (8.0 ml), 5% Pd/C (0.1 mmol) was added to the reaction vessel with stirring. The mixture was purged with hydrogen and after 15 min the desired product A6 was observed by LCMS. Filtration followed by solvent removal under reduced pressure yielded a solid that was purified by filtration through a silica plug using 50% ethyl acetate/hexane as solvent. Yield 32.13%. Η NMR 400 MHz DMSO δ (ppm): 8.34 (s, IH); 6.71 (s, IH); 4.07 (m, 2H); 3.88 (d, 2H); 3.70 (s, 2H); 3.30 (s, 3H); 3.23 (m, 2H); 2.72 (m, IH); 1.95 (m, 2H); 1.62 (m, 2H); 1.17 (t, 3H). LCMS (ESI) m/z 415.3 (MΗ", 100%)
Compound A7 l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazoI-3-yloxy)-5-(2,2,2-trifluoro-acetyIamino)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; General Method 5:
A6 (50 mg, 0.12 mmol) and diisopropylamine (0.83 ml, 0.476 mmol) were dissolved in anhydrous dichloromethane (2.0 ml), and excess (CF3CO)20 was added dropwise at 0 °C. Stirring at room temp, was maintained for 12 hours. Purification by RP-HPLC. Yield 46 % white solid. XH NMR 400MHz DMSO δ (ppm): 8.36 (s, IH); 6.73 (s, IH); 4.06 (m, 2H); 3.89 (d, 2H); 3.72 (s, 3H); 3.23 (m, 2H); 2.73 (m, IH); 1.97 (m, 2H); 1.62 (m, 2H); 1.17 (t, 3H).LCMS (ESI) m z 511.3 (MΗ1", 100%)
Compound A8
Propionic acid 1- [2-amino-5-formyl-6-(2-methyl-5-trifluoromethyI-2H-pyr azol-3-yloxy)- pyrimidin-4-yl]-piperidin-4-yl ester;
General Method 6:
4,6-dichloro-2-amino-5-formylpyrimidine (1.90 g, 9.89 mmol) and diisopropylethylamine (3.30 ml, 18.95 mmol) were dissolved in anhydrous 1,4-dioxane (25.0 ml). The mixture was stirred on an ice bath and 4-ethyl ester piperidine (1.46 ml, 9.47 mmol) dissolved in dioxane (25.0 ml) was added dropwise. The mixture attained room temperature and after 30 min. the desired product was observed by LCMS m/z 313 (M+H+). The solvent was removed under reduced pressure, and the crude residue dissolved in dioxane (20 ml), to it were added diisopropylethylamine (6,31 ml, 36.22 mmol) and 2-Methyl-5-trifluoromethyl-2H-pyrazol-3- ol (3.95 g, 23.77 mmol). The mixture heated at 90 °C for 18 h. Aqueous work up yielded a pale orange solid. Recrystalization from ether and hexanes, followed by filtration of the solid yielded white crystals. Yield 50.28%, Η NMR 400MHz DMSO δ (ppm): 9.90 (s, IH); 7.42 (d, 2H); 6.76 (s, IH); 4.09 (m, 2H); 3.95 (d, 2H); 3.76 (s, 3H); 3.09 (m, 2H); 2.63 (m, IH); 1.90 (m, 2H); 1.66 (m, 2H); 1.19 (t, 3H). LCMS (ESI) m/z 443 (M+lf, 100 %)
Compound A9
4-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yI]- piperazine-1-carboxylic acid ethyl ester;
[method 3]. Purification by Flash Chromatography (5-30% ethyl acetate / hexane). Yield 33
% yellow oil. Η NMR 400MHz DMSO δ (ppm): 8.38 (s, IH); 6.71 (s, IH); 4.04 (m, 2H);
3.88 (d, 2H); 3.70 (s, 3H); 3.54 (m, 2H); 3.42 (m, 2H); 3.29 (m, 2H) 1.18 (t, 3H). LCMS
(ESI) m z 446,2 (MΗ", 100%)
Compound AlO l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid methyl ester;
[method 3]. Flash chromatography (hexanes:ethyl acetate = 2:1) provided compound AlO as a yellow solid (173 mg, 30 %). Η NMR (CDC13, 400 MHz) δ 1.80-1.88 (m, 2H), 2.02-2.12
(m, 2H), 2.72-2.74 (m, IH), 3.72 (s, 3H), 3.78 (s, 3H). 3.94-4.06 (m, 2H), 6.49 (s, IH), 8.25
(s, IH). Exact mass calculated for C16H17F3N605430.12, found 431.4 (MET1).
Compound All
2,6-Dimethyl-4-[6-(2-methyI-5-trifluoromethyl-2H-pyrazoI-3-yloxy)-5-nitro-pyrimidin-4- yl]-morpholine;
[method 3]. Purification by Flash Chromatography (0-30% ethyl acetate / hexane).
Yield 57 % yellow oil. Η NMR 400MHz DMSO δ (ppm): 8.37 (s, IH); 6.71 (s, IH); 3.83 (m,
2H); 3.72 (s, 3H); 3.62 (m. 2H); 2.81 (m, 2H); 1.12 (t, 6H). LCMS (ESD m z 403 (MΗ1",
100%)
Compound A12 l-[6-(2-MethyI-5-trifluoromethyl-2H-pyrazoI-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-3-carboxyIic acid ethyl ester;
[method 3]. Purification by Flash Chromatography (0-50% ethyl acetate / hexane).
Yield 50 % yellow oil. Η NMR 400 MHz DMSO δ (ppm): 8.36 (s, IH); 6.72 (s, IH); 4.08
(m, 2H); 3.98 (m, 2H); 3.72 (s, 3H); 3.58 (m, IH); 3.45 (m, IH); 2.69 (m, IH); 1.99 (m, IH);
1.76 (m, 2H); 1.57 (m, IH); 1.17 (t, 3H). LCMS (ESI) m/z 445 (-Λf, 100%)
Compound A13 l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethylamide;
[method 1] . Purification by HPLC. Yield 16 %. Η NMR 400 MHz CDC13 δ (ppm): 8.17 (s, IH); 6.43 (s, IH); 4.06 (m, 2H); 3.72 (s, 3H); 3.12 (m, 2H); 2.58 (m, 3H); 1.88 (m, 4H). LCMS (ESI) m/z 416.1 (M+H÷, 100 %)
Compound A14 l-[6-(2-Methyl-5-phenyl-2H-pyrazoI-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[method 1]. The product was purified by column chromatography on silica (Biotage) using hexane/ ethyl acetate (7:3). Η NMR 400MHz CDC13 δ (ppm): 8.23 (s, IH, pyrimidine); 7.78 (d, 2H), 7.40-7.35 (dd, 2H), 6.50 (s, IH), 4.20 (q, 2H), 4.10-4.00 (m, 2H), 3.78 (s, 3H), 3.30- 3.20 (m, 2H), 2.70-2.60 (m, IH), 2.10-2.00 (m, 2H), 2.95-2.80 (m, 2H), 1.30 (t, 3H). LCMS (ESI) for C22H24N605: m/z 453.2 (M + H+ , 100 %)
Compound A15
4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-piperidin-l-yl-pyrimidine; [method 3]. The product was purified by Preparatory TLC using hexane/ ethyl acetate (7:3). Η NMR 400MHz CDC13 δ (ppm): 8.20 (s,lH, pyrimidine); 6.45 (s, IH); 3.80 (s, 3H, CH3), 3.60-3.50 (m, 4H); 1.75-1.60 (m, 5H). LCMS (ESI) for C14H1SF3N603: m/z 373 (M + H+ , 100 %)
Compound A16 l-[5-Nitro-6-(2-trifluoromethyl-benzyloxy)-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester; General Method 7: l-(6-chloro-5-nitropyrimidine-4-yl)-piperidine-4-carboxylic acid ethyl ester 1 (0.22 g, 0.63 mmol) and 2-(trifluoromethanol) benzyl alcohol (0.11 g, 1.26 mmol) were dissolved in DMF at room temperature. Sodium hydride (30 mg, 1.26 mmol) was added and the mixture was stirred at 40 °C for 30 minutes. Diluted the mixture with 10 % aq. HCl, and extracted twice with EtOAc. The combined organic extracts were washed with water and brine, dried over anhydrous Na2S04, and concentrated in vacuo. The residue was purified by preparatory LCMS. Η NMR, 400MHZ, CDC13, δ (ppm): 8.20 (s, IH); 7.63 (t, 2H); 7.55 (t, IH); 7.39 (t, IH); 5.63 (s, 2H); 4.13 (q, 2H); 3.95 (d, 2H); 3.14 (t, 2H); 2.54 (m, IH); 1.98 (m, 2H); 1.79 (m, 2H); 1.24 (t, 3H). LCMS (ESI) for C20H21F3N4O5: m/z 454 (M+H+, 100 %)
Compound A17 l-[5-Nitro-6-(3-trifluoromethyl-benzyloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 7]. The residue was purified by preparatory TLC using hexane/ethyl acetate (3/1, v/v). ΗNMR, 400MHz, CDC13, δ (ppm): 8.22 (s, IH); 7.66 (s, IH); 7.58 (t, 2H); 7.49 (t, IH); 5.52 (s, 2H); 4.15 (q, 2H); 3.62 (m, 2H); 3.15 (t, 2H); 2.60 (m, IH); 2.00 (m, 2H); 1.80 (m, 2H); 1.27 (t, 3H). LCMS (ESI) for C21H23F3N405: m/z 469 (M+ϊ , 100 %)
Compound A18 l-[5-Nitro-6-(4-trifluoromethyl-benzyloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 7.]. The residue was purified by preparatory TLC using hexane/ethyl acetate(3/l, v/v). 'H NMR, 400MHz, CDC13, δ (ppm): 8.20(s, IH); 7.62(d, 2H); 7.52(d, 2H); 5.52(s, 2H); 4.1 l(q, 2H); 3.96(m, 2H); 3.15(t, 2H); 2.58(m, IH); 2.01(m, 2H); 1.81(m, 2H); 1.25(t, 3H). LCMS (ESI) for C20H21F3N4O5: m/z 454 (M+ϊ , 100 %)
Compound A19 l-[5-Bromo-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]- piperidine-4-carboxyIic acid ethyl ester; General Method 8.
A mixture of l-[6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester (150 mg, 0.37 mmol) andNBS (65 mg, 0.37 mmol) in DMF (3 ml) was stirred at 60 °C for 2 days. The mixture was quenched with sodium thiosulfate, and extracted with ethyl acetate. The combined organic layer was dried with anhydrous sodium sulfate and concentrated in vacuo. Flash chromatography (hexanes:ethyl acetate = 3:1) provided compound A19 as a white solid (100 mg, 57 %). !HNMR (CDC13, 400 MHz) d 1.28 (t, 3H), 1.78-1.88 (m, 2H), 1.95-2.05 (m, 2H), 2.57-2.62 (m, IH), 3.17 (t, 2H), 3.81 (s, 3H), 4.18 (q, 2H), 4.22-4.33 (m, 2H), 6.41 (s, IH), 8.22 (s, IH). Exact mass calculated for C17H19BrF3N5θ3477.06, found 478.0 (MH+).
Compound A20 l-[5-Acetylamino-6-(2-methyl-5-trifluoromethyI-2H-pyrazoI-3-yIoxy)-pyrimidin-4-yI]- piperidine-4-carboxylic acid ethyl ester and
Compound A21 l-[5-Diacetylamino-6-(2-methyl-5-trifluoromethyI-2H-pyrazol-3-yloxy)- pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester
General Method 9:
A mixture of compound A6 (100 mg, 0.24 mmol) and acetic anhydride (0.1 ml, 1 mmol) in pyridine (5 ml) was heated to 60 °C for three days. The mixture was concentrated in vacuo. Flash chromatography (hexanes:ethyl acetate = 1:1) provided compound A20a (7 mg, 7 %) and A20b (40 mg, 34 %) both as a yellow oil. Compound A20a 1HNMR (CDC13, 400 MHz) δ 1.33 (t, 3H), 1.77-1.85 (m, 2H), 1.95-2.05 (m, 2H), 2.22 (s, 3H), 2.55-2.62 (m, IH), 3.16 (t, 2H), 3.76 (s, 3H), 4.06-4.22 (m, 4H), 6.24 (s, IH), 6.50 (s, IH), 8.22 (s, IH). Exact mass calculated for C19H24F3N604456:17, found 457.2 (MH1"). Compound A20b i NMR (CDC13, 400 MHz) δ 1.25 (t, 3H), 1.77-1.85 (m, 2H), 1.95-2.05 (m, 2H), 2.37 (s, 6H), 2.55-
2.62 (m, IH), 3.18 (t, 2H), 3.66 (s, 3H), 4.06-4.22 (m, 4H), 6.24 (s, IH), 6.31 (s, IH), 8.25 (s, IH). Exact mass calculated for C21H25F3N6θ5 498.18, found 499.4 (M+H+).
Compound A22 l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid;
[method 3]. Purification of part of the crude by HPLC. Yield 8.58 % yellow solid. !H NMR
400MHz DMSO δ (ppm): 8.33 (s, H); 6.71 (s, IH); 3.88 (m, 2H); 3.70 (s, 3H); 3.22 (m, 2H);
2.63 (m, IH); 1.93 (m, 2H); 1.59 (m, 2H). LCMS (ESI) m/z 417 (M+H÷, 100 %)
Compound A23 l-{5-Nitro-6-[2-(2-trifluoromethyl-phenyl)-ethoxy]-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[method 7]. The residue was purified by preparatory TLC using hexane/ethyl acetate
(9/l,v/v). *H NMR, 400MHz, CDC13, δ (ppm): 8.63 (s,lH); 7.45 (m, 4H); 4.16 (q,2H); 4.03
(m, 2H); 3.89 ( t, 2H); 3.08 (t, 2H); 3.20 (t, 2H); 2.55 (m, IH); 2.03 (m, 2H); 1.80 (m, 2H);
1.28 (t, 3H). LCMS (ESI) for C21H23F3N405: m/z 468 (M+H÷, 100 %)
Compound A24 l-{5-Nitro-6-[2-(3-trifluoromethyl-phenyl)-ethoxy]-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[method 7]. The residue was purified by preparatory TLC using hexane/ethyl acetate (9/1, v/v). 'H NMR, 400MHZ, CDC13, δ (ppm): 8.63 (s,lH); 7.45 (m, 4H); 4.16 (q,2H); 4.03 (m,
2H); 3.89 ( t, 2H); 3.08 (t, 2H); 3.20 (t, 2H); 2.55 (m, IH); 2.03 (m, 2H); 1.80 (m, 2H); 1.28
(t, 3H). LCMS (ESI) for C21H23F3N405: m/z 468 (M+H+, 100 %)
Compound A25 l-[5-Di-(methanesulfonyl)amino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; General Method 10: Compound A6 (150 mg, 0.36 mmol) was dissolved in dichloromethane (5 ml). To this was added DIEA (0.125 ml) and methane sulfonic anhydride (94 mg, 0.54 mmol). The mixture was stirred at room temperature for 24 hours, quenched with water and extracted with dichloromethane. The combined organic layer was dried in vacuo and purified by HPLC to give compound A25 as a yellow solid (24 mg, 12 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.95 (m, 2H), 2.05-2.15 (m, 2H), 2.60-2.68 (m, IH), 3.38 (t, 2H), 3.50 (s, 6H), 3.79 (s, 3H), 4.17(q, 2H), 4.44-4.55 (m, 2H), 6.24 (s, IH), 8.22 (s, IH). Exact mass calculated for Cι9H25F3N6θ5S2 570.12, found 571.3 (Mϊt).
Compound A26 l-[5-Nitro-6-(3-trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 1]. The residue was purified by column chromatography (Biotage) using 10 % hexane/ethyl acetate. i NMR, 400MHz, CDC13, δ (ppm): 8.16 (s, IH); 7.53 (m, 2H); 7.41 (s, IH); 7.02 (d, IH); 4.16 (q, 2H); 4.01 (m, IH); 3.21 (t, 2H); 2.97 (s, 9H); 2.90 (s, 9H); 2.63 (m, IH); 2.02 (m, 2H); 1.85 (m, 4H); 1.27 (t, 3H). LCMS (ESI) for C19H19F3N4Os: m z 440 (M+H+, 100 %)
Compound A27 l-[5-Methyl-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; General Method 11.
A mixture of A19 (100 mg, 0.21mmol), methyl boronic acid (25 mg, 0.42 mmol), dichlorobis(triphenylphosphine)palladium (π) (15 mg, 0.021 mmol) and potassium carbonate (87 mg, 0.62 mmol) in dry DMF (5 ml) was heated to 100 °C under nitrogen overnight. The mixture was cooled to room temperature, quenched with water and extracted with ethyl acetate. The combined organic layer was dried with anhydrous sodium sulfate and concentrated in vacuo. Flash chromatography (hexanes:ethyl acetate = 3:1) provided compound A27 as an oil (20 mg, 23 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.82-1.94 (m, 2H), 1.97-2.05 (m, 2H), 2.23 (s, 3H), 2.57-2.62 (m, IH), 3.02 (t, 2H), 3.77 (s, 3H), 3.82- 3.88 (m, 2H), 4.18 (q, 2H), 6.34 (s, IH), 8.22 (s, IH). Exact mass calculated for C18H22F3N5θ3413.17, found 414.4 (MH+).
Compound A28 l-[5-Nitro-6-(2-trifIuoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; [method 1]. The residue was purified by column chromatography (Biotage) using 10 % hexane/ethyl acetate. Yield 74 %. !H NMR, 400MHz, CDC13, δ (ppm): 8.14 (s, IH); 7.70 (d, IH); 7.62 (t, IH); 7.38 (t, IH); 7.26 (d, IH); 4.17 (q, 2H); 4.03 (m, 2H); 3.23 (t, 2H); 2.63 (m, IH); 2.04 (m, 2H); 1.85 (m,2H); 1.28 (t, 3H). LCMS (ESI) for C19Hι9F3N4Os: m/z 440 (M+H÷, 100 %)
Compound A29 l-{l-[5-Nitro-6-(4-trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidin-4-carboxylic acid ethyl ester
[method 1]. The residue was purified by column chromatography (Biotage) using 10 % hexane/ethyl acetate. Yield 58 %. *H NMR, 400 MHz, CDC13, δ (ppm): 8.01 (s, IH); 7.47 (d,
2H); 6.93 (d, 2H); 4.16 (q, 2H); 4.05 (m, 2H); 3.23 (t, 2H); 2.66 (m, IH); 2.09 (m, 2H); 1.93
(m ,2H); 1.28 (t, 3H). LCMS (ESI) for C19H191F3N4θ5: m/z 440 (M+H÷, 100 %)
Compound A30 l-[6-(4-Fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 1]. Yield 0.016 g, 16 %. Yellow solid. JH NMR 400MHz CDC13 δ (ppm): 8.17 (s,
IH); 7.10 (m, 4H); 4.18 (q, 2H); 4.03 (m, 2H); 3.22 (m, 2H); 2.63 (m IH); 2.03 (m, 2H); 1.84
(m, 2H); 1.29 (m, 3H) . LCMS (ESI) m/z 391 (M+H+,100%)
Compound A31 l-[6-(2,5-Dimethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 3]. The product was purified by column chromatography on silica (Biotage) using hexane/ ethyl acetate (7:3). 1H NMR 400MHz CDC13 δ (ppm): 8.23 (s,lH, pyrimidine); 5.97 (s, IH), 4.20 (q, 2H), 4.10-4.00 (m,2H), 3.50 (s,3H), 3.30-3.20 (m, 2H), 2.70-2.60 (m, IH), 2.10 (s, 3H), 2.00 (m,2H), 1.95-1.90 (m, 2H), 1.30 (t, 3H). LCMS (ESI) for C17H22N605: m/z 391.3 (M + IT\ 100 %)
Compound A32 l-[6-(4-Bromo-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 1]. The solvent was removed in vacuo and the residue purified by preparatory thin layer chromatography [Si02; EtOAc/hexane; 50:50]. Yield 0.010 g, 9 %. Yellow solid.Η NMR 400MHz CDC13 δ (ppm): 8.17 (s, IH); 7.52 (d, 2H); 7.03 (d, 2H); 4.17 (q, 2H); 4.02 (m, 2H); 3.22 (m, 2H); 2.63 (m, IH); 2.03 (m, 2H); 1.84 (m, 2H); 1.29 (m, 3H) LCMS (ESI) m/z 452, 453 (M+H+,100%)
Compound A33 l-[6-(4-Chloro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 1]. Yield 0.009g, 9%. Yellow solid. JH NMR 400MHz CDC13 δ (ppm): 8.17 (s, IH); 7.37 (d, 2H); 7.08 (d, 2H); 4.17 (m, 2H); 4.03 (m, 2H); 3.22 (m, 2H); 2.64 (m, IH); 2.03 (m, 2H); 1.84 (m, 2H); 1.29 (m, 3H). LCMS (ESI) m/z 407 (M+H+,100%)
Compound A34 l-[6-(4-Carbamoyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
General Method la: A mixture of compound 7 (63 mg, 0.2 mmol), 4-hydroxybenzene carboxamide (35 mg, 0.26 mmol) and potassium carbonate (36 mg, 0.26 mmol) in DMF (1 ml) was heated in microwave for 2 minutes at 80 °C. Following the general procedure, compound A34 was obtained as a yellow solid (65 %). 1HNMR (CDC13, 400 MHz) δ 1.19 (t, 3H), 1.70-1.80 (m, 2H), 1.98-2.03 (m, 2H), 2.65-2.80 (m, IH), 3.22 (t, 2H), 3.82-3.96 (m, 2H), 4.07 (q, 2H), 7.25 (d, 2H), 7.40 (s, IH), 7.92 (d, 2H), 8.00 (s, IH), 8.20 (s, IH). Exact mass calculated for C19H21N506415.15, found 416.2 (MH).
Compound A35 l-{6-[4-(2-Methoxy-ethyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A35 was obtained as a yellow solid (71 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.70-1.80 (m, 2H), 1.98-2.03 (m, 2H), 2.65-2.75 (m, IH), 2.94 (t 2H), 3.22 (t, 2H), 3.37 (s, 3H), 3.62 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.05 (d, 2H), 7.25 (d, 2H), 8.17 (s, IH). Exact mass calculated for C21H26N406430.19, found 431.4 (MIT).
Compound A36 l-[6-(4-Cyclopentyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A36 was obtained as a yellow solid (58%). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.58-1.92 (m, 8H), 1.98-2.15 (m, 4H), 2.65-2.75 (m, IH), 3.00 (quintet, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.04 (d, 2H), 7.25 (d, 2H), 8.18 (s, IH). Exact mass calculated for C23H28N405440.21, found 441.2 (MH+).
Compound A37 l-[5-Nitro-6-(4-pyrrol-l-yl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[method la]. Following the general procedure, compound A37 was obtained as a yellow solid (77 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 6.36 (d, 2H), 7.04 (d, 2H), 7.19 (d, 2H), 7.40 (d, 2H), 8.18 (s, IH). Exact mass calculated for C22H23N5O5 437.17, found 438.2 (MH+).
Compound A38 l-[6-(4-Benzoyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[method la]. Following the general procedure, compound A38 was obtained as a yellow solid (70 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.24-7.28 (m, 2H), 7.46-7.51 (m, 2H), 7.58-7.62 (m, IH), 7.78-7.82 (m, 2H), 7.87-7.90 (m, 2H), 8.21 (s, IH). Exact mass calculated for C25H24N 06476.17, found 477.2 (MH1).
Compound A39 l-{6-[4-(4-Hydroxy-benzenesulfonyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A39 was obtained as a yellow solid (51 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 6.82 (d, 2H), 7.25 (d, 2H), 7.78 (d, 2H), 7.96 (d, 2H), 8.13 (s, IH). Exact mass calculated for C24H24N4OsS 528.13, found 529.2 (Mt ).
Compound A40 l-[6-(4'-Cyano-biphenyl-4-yIoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A40 was obtained as a yellow solid. 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65- 2.75 (m, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.24-7.26 (m, 2H), 7.61-7.78 (m, 6H), 8.19 (s, IH). Exact mass calculated for C25H23N5θ5473.17, found 473.3 (MH4).
Compound A41 l-[6-(2-Amino-4-ethanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A41 was obtained as a yellow solid. 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65- 2.75 (m, IH), 3.14 (q, 2H), 3.40 (t, 2H), 3.96-4.03 (m, 2H), 4.18 (q, 2H), 7.18 (d, 2H), 7.68 (d, IH), 7.72 (d, IH), 8.06 (s, IH), 10.35 (s, 2H). Exact mass calculated for C20H25N5O7S 479.15, found 480.0 (MH+).
Compound A42 l-{6-[4-(5-Hydroxy-pyrimidin-2-yl)-phenoxy]-5-nitro-pyrimidin-4-yI}-piperidine-4- carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A42 was obtained as a yellow solid. 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65- 2.75 (m, IH), 3.14 (q, 2H), 3.40 (t, 2H), 3.96-4.03 (m, 2H), 4.18 (q, 2H), 7.36 (d, 2H), 8.20 (s, IH), 8.38 (d, 2H), 8.77 (s, 2H). Exact mass calculated for C22H22N606466.16, found 467.2 (MH+).
Compound A43 l-[5-Nitro-6-(4-sulfo-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; [method la]. Following the general procedure, compound A43 was obtained as a yellow solid. 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65- 2.75 (m, IH), 3.14 (q, 2H), 3.40 (t, 2H), 3.70-3.82 (m, 2H), 4.05 (q, 2H), 7.12 (d, 2H), 7.60 (d, 2H), 8.20 (s, IH). Exact mass calculated for C18H19N408SNa 474.08, found 475 (M+H+).
Compound A44 l-[5-Nitro-6-(4-[l,2,4]triazol-l-yI-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A44 was obtained as a yellow solid. Η NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-
2.75 (m, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.33 (d, 2H), 7.73 (d, 2H), 8.17 (s,
2H), 8.69 (s, IH). Exact mass calculated for C20H21N7O5439.16, found 440.4 (MH*). Compound A45
1- [6-(4-Carbamoylmethyl-phenoxy)-5-nitro-pyrimidin-4-yl] -piperidine-4-carboxyIic acid ethyl ester;
[method l ]. Following the general procedure, compound A45 was obtained as a yellow solid. Η NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-
2.75 (m, IH), 3.22 (t, 2H), 3.60 (s, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.17(d, 2H), 7.38 (d,
2H), 8.17 (s, IH). Exact mass calculated for C2oH23N506429.16, found 430.3 (MH+).
Compound A46 l-{6-[4-(l,3-Dioxo-l,3-dihydro-isoindoI-2-yl)-phenoxy]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound a46 was obtained as a yellow solid. 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65- 2.75 (m, IH), 3.22 (t, 2H), 3.60 (s, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.26-7.29 (m, 2H), 7.52-7.55 (m, 2H), 7.82 (dd, 2H), 7.94 (dd, 2H), 8.19 (s, IH). Exact mass calculated for C26H23N507 517.16, found 518.3 (MH).
Compound A47
1- [6-(4'-Methoxy-biphenyl-4-yloxy)-5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A47 was obtained as a yellow solid. 'H NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-
2.75 (m, IH), 3.22 (t, 2H), 3.60 (s, 2H), 3.85 (s, 3H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 6.96 (d,
2H), 7.17(d, 2H), 7.54 (d, 2H), 7.60 (d, 2H), 8.17 (s, IH). Exact mass calculated for
C25H26N406478.19, found 479.2 (Mlf).
Compound A48 l-{6-[4-(2,5-Dioxo-imidazolidin-4-yl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A48 was obtained as a yellow solid. Η NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 ( , 2H), 2.65- 2.75 (m, IH), 3.22 (t, 2H), 3.60 (s, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 5.16 (s, IH), 5.30 (s, IH), 5.60 (s, IH), 7.26 (d, 2H), 7.43 (d, 2H), 8.16 (s, IH). Exact mass calculated for C21H22N607470.15, found 471.1 (MH+).
Compound A49 4-(4,4-Difluoro-piperidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5- nitro-pyrimidine;
[method 2 followed by method 3]. Purification by HPLC yielded a yellow solid.
Yield 54.71%. IH NMR 400 MHz CDC13 δ (ppm): 8.29 (s, IH); 6.52 (s, IH); 3.80 (s, 3H);
3.71 (m, 2H); 2.11 (m, 2H); 2.01 (m, 4H). LCMS (ESI) m/z 409.2 (M+H+, 100%)
Compound A50 l-{5-Nitro-6-[4-(4-oxo-cyclohexyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A50 was obtained as a yellow solid (45 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-2.05 (m, 6H), 2.21-2.24 (m, 2H), 2.52-2.56 (m, 2H), 2.65-2.75 (m, IH), 3.22 (t, 2H), 3.60 (s, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.10 (d, 2H), 7.26 (d, 2H), 8.17 (s, IH). Exact mass calculated for C24H283N406 468.2, found 469.2 0017).
Compound A51 l-{5-Nitro-6-[4-(3-oxo-butyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A51 was obtained as a yellow solid (61 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.16 (s, 3H), 2.65-2.75 (m, IH), 2.72-2.78 (m, 2H), 2.82-2.90 (m, 2H), 3.22 (t, 2H), 3.60 (s, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.02 (d, 2H), 7.22 (d, 2H), 8.17 (s, IH). Exact mass calculated for C22H26N406 442.19, found 443.0 (MΕt).
Compound A52
1- [5-Nitro-6-(4-propionyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A52 was obtained as a yellow solid (70 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m,
2H), 2.65-2.75 (m, IH), 3.01 (q, 2H), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.21(d,
2H), 8.02 (d, 2H), 8.17 (s, 2H). Exact mass calculated for C21H24N406428.17, found 429.3
(MH+).
Compound A53 l-[5-Nitro-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester; [method la]. Following the general procedure, compound A53 was obtained as a yellow solid (57 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.22 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 7.28 (d, 2H), 8.10 (d, 2H), 8.19 (s, IH), 8.64 (s, IH). Exact mass calculated for C20H2oN605S 456.12, found 457.2 (M±Ϋ).
Compound A54 l-{6-[4-(2-Hydroxy-ethyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A54 was obtained as a yellow solid. 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65- 2.75 (m, IH), 2.88 (t, 2H), 3.05 (t, 0.5H), 3.22 (t, 2H), 3.87 (t, 2H), 3.96-4.03 (m, 2H), 4.15 (q, 2H), 4.55 (t, 0.5H), 7.07(d, 2H), 7.22 (d, 2H), 8.15 (s, IH). Exact mass calculated for C20H24N4O6416.17, found 417.3 ( H+).
Compound A55
{4-[6-(4,4-Difluoro-piperidin-l-yl)-5-nitro-pyrimidinτ4-yloxy]-phenyI}-phenyl- methanone;
General Procedure 2 followed by method la. Flash column chromatography
[Hexane:Ethyl Acetate=l:l] provided the intermediate as a yellow oil (444 mg, 84 %). JH
NMR 400MHz CDC13 δ(ppm): 8.40(s, IH); 3.70(sb, 4H); 2.1(t, 4H). Exact mass calculated for C9H9C1F2N402278.04, LCMS (ESI) m/z 279.3(M+IT\ 100%).
[method la]. HPLC provided compound A55 as yellow solid (26 mg, 59 %). ΗNMR
400MHz CDC13 δ(ppm): 8.25(s,lH); 7.90(dd,2H);7.80(dd, 2H); 7.61(td, IH); 7.50( td, 2H);
7.26(d,2H); 3.75 (sb, 4H);2.15(qu,4H). Exact mass calculated for C22H18F2N404 440.13,
LCMS (ESI) m z 441.3(M+H+, 100 %).
Compound A56
3-{4-[6-(4,4-Difluoro-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-3-oxo-propionic acid methyl ester;
[method la]. HPLC provided compound A56 as yellow solid (10 mg, 24 %).
Η NMR 400MHz CDC13 δ(ppm): 8.21(s,lH); 8.04(d,2H);7.24(d, 2H); 4.01(s, 2H); 3.75 (sb,
4H);2.15(q.4H); 2.00(sb,3H). Exact mass calculated for C19H18 F2N406 436.12, LCMS (ESI) m/z 437.3 (M+H\ 100 %).
Compound A57 2-[6-(4,4-Difluoro-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-5-ethanesulfonyl- phenylamine;
[method la]. HPLC provided compound A57 as yellow oil (3 lmg, 70 %). !H NMR 400MHz
CDC13 δ (ppm): 10.35 (s,lH); 8.18 (s,lH); 7.85 (s,lH); 7.63 (d, IH); 7.19 ( d, IH); 3.78 (s,
4H); 3.16 (q, 2H); 2.20 (q,4H); 1.21 (sb,3H). Exact mass calculated for C17H19F2N505S
443.11, LCMS (ESI) m/z 444.3 (M+B7, 100 %).
Compound A58
4-(4-Cyclopentyl-phenoxy)-6-(4,4-difluoro-piperidin-l-yl)-5-nitro-pyrimidine; [method la]. HPLC provided compound A58 as yellow solid (20 mg, 50 %). !H NMR 400 MHz CDCI3 δ(ppm): 8.21 (s,lH); 7.25 (d,2H); 7.06 (d, 2H); 3.70 ( s, 4H); 3.03 (q,lH); 2.10 (sb, 4h); 1.80 (d,2H); 1.71 (t,2H); 1.60 (sb, 4H). Exact mass calculated for C20H22F2N4O3 404.17, LCMS (ESI) m/z 405.2 (M+H+, 100%).
Compound A59 l-[6-(2,6-Dichloro-4-methanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A59 was obtained as a yellow solid (52 %). Η NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.35-4.05 (m, 16H), 4.15 (q, 2H), 7.55-7.58 (m, 2H), 7.62-7.66 (m, IH), 7.88-7.92 (m, 2H), 7.95 (s, IH ). Exact mass calculated for C24H32N606S 532.21, found 533.3 (MET).
Compound A60 l-{6-[4-(4-ChIoro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A60 was obtained as a yellow solid (52 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.35-4.05 (m, 16H), 4.15 (q, 2H), 7.55-7.58 (m, 2H), 7.62-7.66 (m, IH), 7.88-7.92 (m, 2H), 7.95 (s, IH ). Exact mass calculated for C24H32N606S 532.21, found 533.3 (MH+).
Compound A61 l-{6-[4-(4-Hydroxy-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; [method la]. Following the general procedure, compound A61 was obtained as a yellow solid (52 %). I MR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.35-4.05 (m, 16H), 4.15 (q, 2H), 7.55-7.58 (m, 2H), 7.62-7.66 (m, IH), 7.88-7.92 (m, 2H), 7.95 (s, IH ). Exact mass calculated for C24H32N606S 532.21, found 533.3 (MH ).
Compound A62 l-[6-(4-Cyanomethyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A62 was obtained as a yellow solid (52 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.35-4.05 (m, 16H), 4.15 (q, 2H), 7.55-7.58 (m, 2H), 7.62-7.66 (m, IH), 7.88-7.92 (m, 2H), 7.95 (s, IH ). Exact mass calculated for C24H32N606S 532.21, found 533.3 (MH+).
Compound A63
(4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-l-yl]-5-nitro-pyrimidin-4-yloxy}-phenyl)- phenyl-methanone;
General Procedure 2 followed by method la. Flash column chromatography [Methanol: Dichloromethane=l:9] provided the intermediate monochloro compound as red oil (124 mg, 35 %). Exact mass calculated for CπH16ClN504S 349.06, LCMS (ESI) m/z 350.1(M+KT, 100 %). [method la]. Flash column chromatography [Hexane: Ethyl Acetate=2:l then Methanol: Dichloromethane=l:9] provided compound A63 as yellow oil (7 mg, 14 %). XH NMR 400MHz CDCI3 δ(ppm): 8.13 (d,2H); 7.91 (d,2H); 7.80 (d, 2H); 7.60 (d, IH); 7.50 (d, 2H); 7.21 (t, IH); 4.03 (m, 2H); 3.71 (db, 6H); 3.31 (sb, 2H); 3.08 (s,3H); 3.00 (s,2H). Exact mass calculated for C24H25N506S 511.15, LCMS (ESI) m z 512.1 (M+H+, 100%).
Compound A64
4-(4-{6-[4-(2-MethanesuIfonyl-ethyl)-piperazin-l-yl]-5-nitro-pyrimidin-4-yloxy}- phenyl)-butan-2-one;
[method la]. Flash column chromatography [Hexane: Ethyl Acetate=2:l then Methanol: Dichloromethane=l:9] provided compound A64 as yellow oil (6 mg, 13 %). *H NMR 400MHz CDCI3 δ(ppm): 8.20 (s,lH); 7.21 (d,2H); 7.05 (d, 2H); 3.63 (s, 4H); 3.20 (d, 2H); 3.03 (s,3H); 2.90 (m, 4H); 2.80 (t, 2H); 2.61 (sb, 4H); 2.18 (s, 3H). Exact mass calculated for C21H27N506S 477.17, LCMS (ESI) m/z 478.1 (M+ET, 100%). Compound A65
3-(4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-l-yl]-5-nitro-pyrimidin-4-yloxy}- phenyl)-3-oxo-propionic acid methyl ester;
[method la]. Flash column chromatography [Hexane: Ethyl Acetate=2:l then Methanol: Dichloromethane=l:9] provided compound A65 as yellow oil (7 mg, 14 %). *H NMR 400MHz CDC13 δ(ppm): 8.20 (s,lH); 8.02 (d, 2H); 7.26 (d,2H); 4.01 (d, 2H); 3.73 (s, 7H); 3.10 (sb, 5H). Exact mass calculated for C21H25N508S 507.14, LCMS (ESI) m/z 508.2 (M+ET, 100%).
Compound A66
4-(4-Methyl-piperidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro- pyrimidine;
[method 2 followed by general method 3]. Purification by HPLC yielded A66 as a yellow solid. Yield: 18 %. H NMR 400MHz CDC13 δ (ppm): 8.10 (s, IH); 6.36 (s, IH); 3.95 (d, 2H);
3.65 (s, 3H); 2.93 (m, 2H); 1.62 (m, 3H); 1.14 (m, 2H); 0.85 (m, 3H). LCMS (ESI) m/z 387
(MTf1", 100%)
Compound A67
4-(4-Bromo-piperidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazoI-3-yloxy)-5-nitro- pyrimidine;
[method 2 followed by general method 3]. Final purification by HPLC yielded an orange solid. Yield 22 %.Η NMR 400MHz CDC13 δ (ppm): 8.31 (s, IH); 6.51 (s, IH); 4.41 (m, IH);
3.84 (m, 2H); 3.81 (s, 3H); 3.66 (m, 2H); 2.17 (m, 2H); 1.98 (m, 2H). LCMS (ESI) m/z 453
(M+H+, 100%)
Compound A68
4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-(4-propyl-piperidin-l-yl)- pyrimidine;
[method la], provided compound A68 as yellow solid (501 mg, 55 % yield). H NMR
400MHz CDC13 δ (ppm): 8.25 (s, IH); 6.51 (s, IH); 4.13 (dt, 2H); 3.80 (s, 3H); 3.07 (td, 2H);
1.82 (d, 2H); 1.63-1.56 (m, IH); 1.40-1.22 (m, 6H); 0.93(t, 3H). Exact mass calculated for
C17H21 F3N603 414.16, LCMS (ESI) m/z 415.3 (M+H7, 100%).
Compound A69 l-[6-(2-MethyI-5-trifluoromethyI-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid amide; [method 3]. Purification by HPLC yielded a yellow solid. Yield 16 %. Η NMR 400 MHz CDCl3 δ (ppm): 8.17 (s, IH); 6.43 (s, IH); 4.06 (m, 2H); 3.72 (s, 3H); 3.12 (m, 2H); 2.58 (m, 3H); 1.88 (m, 4H). LCMS (ESI) m/z 416.1 (M+H+, 100 %)
Compound A70
1- [5-Nitro-6-(2-oxo-2H-chromen-6-yloxy)-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A70 was obtained as a yellow solid (43 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m,
2H), 2.65-2J5 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 6.38 (d, IH), 7.02 (d, IH), 7.10 (s,
IH), 7.42 (d, IH), 7.63 (d, IH), 8.13 (s, IH). Exact mass calculated for C21H20N4O7 440.13, found 441.3 (MH÷).
Compound A71 l-[5-Nitro-6-(2-oxo-benzo[l,3]oxathiol-6-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A71 was obtained as a yellow solid (34 %). INMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m,
2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 7.02 (d, IH), 7.15 (s, IH), 7.40 (d,
IH), 8.14 (s, IH). Exact mass calculated for C19H18N407S 446.09, found 447.0 (MH+).
Compound A72
1- [6-(9H-Carbazol-2-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A72 was obtained as a yellow solid (89 %). JH NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m,
2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 6.90 (d, IH), 7.00 (d, IH), 7.03-7.08
(m, IH), 7.30-7.36 (m, 2H), 7.78-7.82 (m, 2H), 8.12 (s, IH), 8.26 (s, IH). Exact mass calculated for C24H23N505 461.17, found 462.3 (MH+).
Compound A73 l-[5-Nitro-6-(9-oxo-9H-fluoren-2-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A73 was obtained as a yellow solid (84 %). 1HNMR (CDC13, 400 MHz) d 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 7.20-7.25 (m, 3H), 7.40-7.60 (m, 4H), 8.16 (s, IH). Exact mass calculated for C25H22N406474.15, found 475.1 (MET).
Compound A74 l-{5-Amino-6-[4-(3-oxo-butyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester General method 12:
A51 (348 mg, 0.786 mmol) was dissolved in ethyl acetate (10 mL), palladium on activated carbon (lOwt - degussa type) was added and the mixture purged with H2. The reaction was monitored by LCMS and after completion the crude was filtered through celite and activated carbon. Purification by HPLC afforded Compound A74 as a light yellow oil. Yield: 26 %. JH NMR 400MHz CDCl3 δ (ppm): 8.14(s, IH); 7.26 (d, 2H); 7.05 (d, 2H); 6.38 (s, 2H); 4.19 (m, 2H); 3.88 (d, 2H); 3.17 (m, 2H); 2.94 (m, 2H); 2.81 (m, 2H); 2,63 (m, IH); 2.18 (s, 3H); 2.14 (d, 2H); 1.91 (m, 2H); 1.30 (t, 3H). LCMS (ESI) m/z 413.4 (MTf1", 100 %).
Compound A75 l-[6-[4-(3-Oxo-butyl)-phenoxy]-5-(2,2,2-trifluoro-acetylamino)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; General method 13:
A74 (61 mg, 0,148 mmol) and diisopropylethylamine (84 ml, 0.484 mmol) were dissolved in dichloromethane and trifluoroacetic anhydride (0.51 ml, 0.363 mmol) was added. The mixture was stirred at room temperature for 3 hours and LCMS indicated the desired product. Purification by HPLC yielded light yellow oil. Yield 72.97%. Η NMR 400MHz CDC13 δ (ppm): 8.21 (s, IH); 8.14 (s, IH); 7.20 (d, 2H); 7.00 (d, 2H); 4.15 (m, 4H); 3.13 (m, 2H); 2.89 (m, 2H); 2.77 (m, 2H); 2.57 (m, 2H); 2,15 (s, 3H); 1.99 (m, 2H); 1.77 (m, 2H); 1.26 (t, 3H). LCMS (ESI) m z 509.2 (M+H+, 100%)
Compound A76 l-{5-Amino-6-[4-(hydroxy-phenyl-methyl)-phenoxy]-pyrimidin-4-yI}-piperidine-4- carboxylic acid ethyl ester;
[method 12] . Purification by HPLC yielded oil. Yield 8 %. Η NMR 400MHz CDC13 δ
(ppm): 8.05 (s, IH); 7.38 (m, 8H); 7.12 (d, 2H); 5.86 (s, IH); 4.18 (m, 2H); 3.99 (s, 2H); 3.80
(d, 2H); 2.94 (m, 2H); 2.55 (m, IH); 2.09 (m, 2H); 1.88 (m, 2H); 1.29 (t, 3H). LCMS (ESI) nτ/z 449.3 (M+H+, 100%)
Compound A77 l-[6-(2-Benzoyl-5-methoxy-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A77 was obtained as a yellow solid (52 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.35-4.05 (m, 16H), 4.15 (q, 2H), 7.55-7.58 (m, 2H), 7.62-7.66 (m, IH), 7.88-7.92 (m, 2H), 7.95 (s, IH ). Exact mass calculated for C24H32N606S 532.21, found 533.3 (MH+).
Compound A78 l-[6-(6-Chloro-pyridin-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. HPLC provided compound A78 as yellow solid (63 mg, 61 %). Η MR 400MHz CDC13 δ (ppm): 8.20 (d,lH); 8.08 (s, IH); 7.43 (dd,lH); 7.30 (d, IH); 4.09 (q, 2H); 3.95 (dt,2H); 3.15 (td, 2H); 2.55 (m, IH); 1.95 (dt, 2H); 1.77 (td, 2H); 1.19 (t, 3H). Exact mass calculated for C17H18C1N505407.10, LCMS (ESI) m z 408.3 (M+H+, 100 %).
Compound A79 l-[6-(Benzo[l,3]dioxol-5-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A79 was obtained as an oil (46 %). 1HNMR (CDCI3, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 6.00 (s, 2H), 6.57 (d, IH), 6.60 (s, IH), 6.80 (d, IH), 8.16 (s, IH). Exact mass calculated for C19H20N4O7416.13, found 417.0 (MH+).
Compound A80
1- [6-(4-Benzyloxy-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A80 was obtained as a yellow solid (25 %). 'HNMR (CDC13, 400 MHz) d 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m,
2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 5.04 (s, 2H), 6.94-7.05 (m, 4H),
7.27-7.41 (m, 5H), 8.19 (s, IH). Exact mass calculated for C25H26N406478.19, found 479.1
(MET).
Compound A81 l-[6-(3-Morpholin-4-yl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; [method la]. Following the general procedure, compound A81 was obtained as an oil (84 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m, 2H), 2.65-2.75 (m, IH), 3.20-3.35 (m, 6H), 3.82-3.84 (m, 2H), 3.98-4.05(m, 2H), 4.14 (q, 2H), 6.75-6.80 (m, 2H), 6.95-6.99 (m, IH), 7.32-7.38 (m, IH), 8.17 (s, IH). Exact mass calculated for C22H27N506457.20, found 458.3 (MH+).
Compound A82 l-[5-Nitro-6-(4-trifluoromethylsulfanyl-phenoxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A82 was obtained as a yellow solid (32 %). 1HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m,
2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 7.26 (d, 2H), 7.68 (d, 2H), 8.17 (s,
IH). Exact mass calculated for Cι9H19F3N405S 472.1, found 473.1 (MH+).
Compound A83 l-[5-Nitro-6-(4-trifluoromethoxy-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Following the general procedure, compound A83 was obtained as a yellow solid (79 %). !H NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.96 (m, 2H), 2.00-2.08 (m,
2H), 2.65-2.75 (m, IH), 4.02-4.05(m, 2H), 4.14 (q, 2H), 7.18 (d, 2H), 7.26 (d, 2H), 8.17 (s,
IH). Exact mass calculated for Cι9H19F3N406456.13, found 457.1 (MH ).
Compound A84 l-[6-(4-Benzoyl-phenoxy)-5-(2,2,2-trifluoro-acetylamino)-pyrimidin-4-yI]-piperidine-4- carboxylic acid ethyl ester;
[method 13]. Purification by HPLC. JH NMR 400 MHz CDC13 δ (ppm): 8.20 (s, IH); 7.97 (s,
IH); 7.79 (d, 2H); 7.72 (d, 2H); 7.52 (m, IH); 7.41 (m, 2H); 7.13 (d, 2H); 4.09 (m, 4H); 3.11
(m, 2H); 2.53 (m, IH); 1.94 (m, 2H); 1.72 (m, 2H); 1.19 (t, 3H). LCMS (ESI) m z 543.5
(M+B7, 100 %)
Compound A85
{4-[5-Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}-phenyl-methanone; General Procedure 2 followed by method 3.
Intermediate: Η NMR 400MHz CDC13 δ(ppm): 8.26(s, IH); 4.035(d, 2H); 2.94(td, 2H); 1.73(dt, 2H); 1.50 (m, IH); 1.27 ( m, 2H); 1.18 (m, 2H); 1.12 (dd, 2H); 0.84(t, 3H). Exact mass calculated for C12H17ClN4O2284.10, LCMS (ESI) m/z 285.0(M+H+, 100%). [method 1]. HPLC provided compound A85 as yellow oil (77 mg, 69 % yield). JH NMR 400MHz CDC13 δ (ppm): 8.01(s, IH); 7.71 (dd,2H); 7.62 (dd,2H); 7.41 (tt,lH); 7.30 (dt,2H); 7.07 (dt,3H); 3.92 (d, 2H); 2.86 (td,2H); 1.62 (dd, 2H); 1.39 (m, IH); 1.14 (dt, 2H); 1.06 (t,2H); 1.06 (q, 2H); 0.72 (t,3H). Exact mass calculated for C25H26N404 446.20, LCMS (ESI) m/z 447.2 (M+H÷, 100%).
Compound A86
{4-Methoxy-2-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}-phenyl- methanone;
[method 1]. HPLC provided compound A86 as orange oil (67 mg, 57 % yield).
Η NMR 400MHz CDC13 δ(ppm): 7.88 (s, IH); 7.50 (dd,2H); 7.40 (s,lH); 7.37 (tt,lH); 7.30
(t,lH); 7.22 (t,2H); 6.71 (dd,lH); 6.625 (d, IH); 3.81 (d, 2H); 3.71 (s,3H); 2.81 (td,2H); 1.58
(dd, 2H); 1.36 (m, IH); 1.16 (dt, 2H); 1.06 (td,2H); 1.01 (dd, 2H); 0.73 (t,3H). Exact mass calculated for C26H28N405 476.21, LCMS (ESI) m z
Figure imgf000151_0001
100 %).
Compound A87
4-{4-[5-Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}-butan-2-one; [method 1]. HPLC provided compound A87 as yellow solid (62 mg, 59 % yield). *H NMR 400MHz CDCI3 δ(ppm): 8.08 (s, IH); 7.13 (d,2H); 6.95 (d,2H); 4.00 (d, 2H); 2.96 (td,2H); 2.82 (t,2H); 2.69 (t, 2H); 2.07 (s, 3H); 1.71 (dd, 2H); 1.48 (m, IH); 1.27 (m, 2H); 1.17 (m, 4H); 0.83 (t,3H). Exact mass calculated for C22H28N404412.21, LCMS (ESI) m/z 413.4 (M+H÷, 100 %).
Compound A88
5-Nitro-4-(4-propyl-piperidin-l-yl)-6-(4-[l,2,3]thiadiazoI-4-yI-phenoxy)-pyrimidine; [method 1]. HPLC provided compound A88 as yellow solid (61 mg, 56 % yield). *H NMR 400 MHz CDCI3 δ (ppm): 8.56 (s, IH); 8.11 (s, IH); 8.02 (d, 2H); 7.22 (d,2H); 4.03 (d, 2H); 2.96 (td,2H); 1.73 (dd, 2H); 1.48 (m, IH); 1.27 (m, 2H); 1.2 (m, 4H); 0.84 (t,3H). Exact mass calculated for C20H22N6O3 S 426.15, LCMS (ESI) m/z 427.1 (M+H+, 100 %).
Compound A89
3-{4-[5-Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yIoxy]-phenyl}-3-oxo-propionic acid methyl ester;
[method 1]. HPLC provided compound A89 and A89a [enol] as yellow solid (12 mg, 4 mg,
18 % yield).Η NMR 400 MHz CDC13 δ (ppm): A89: 8.08 (s, IH); 7.94 (d, 2H); 7.18 (d, 2H);
4.02 (d, 2H); 3.92 (s,2H); 3.68 (s,3H); 2.96 (td,2H); 1.72 (dd, 2H); 1.50 (m, IH); 1.26 (m, 2H); 1.17 (m, 4H); 0.83 (t,3H). A89a: 8.08(s, 1H); 7.94(d, 2H); 7.75(dd, 2H); 7.12 (dd,2H); 5.57(s, IH); 4.02 (d, 2H); 3.73 (s,3H); 2.96 (t,2H); 1.72 (d, 2H); 1.51(m, IH); 1.26 (m, 2H); 1.18 (m, 4H); 0.83 (t,3H). Exact mass calculated for C22H26N406442.19, LCMS (ESI) m/z 443.3(M+B7, 100%).
Compound A90
5-Ethanesulfonyl-2-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yIoxy]- phenylamine;
[method 1]. HPLC provided compound A92 as yellow solid (60 mg, 53 % yield). Η NMR 400MHz CDC13 δ (ppm): 10.2 (s, IH); 7.97 (s, IH); 7.63 (d, IH); 7.61 (s, IH); 7.11 (d, IH); 3.13 (td, 2H); 3.04 (q, 2H); 1.81 (d, 2H); 1.59 (m, IH); 1.28 (m, 2H); 1.2 (m, 4H); 0.84 (t, 3H). Exact mass calculated for C20H27N5O5 S449.17, LCMS (ESI) m z 450.3 (M+H1", 100 %).
Compound A91
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yI]-6-(4-methanesulfonyl-phenoxy)- pyrimidine-5-carbonitrile;
4,6-Dichloro-pyrimidine-5-carbonitrile (254 mg, 1.47 mmol) was dissolved in DMF (3 mL). K2C03 (203 mg, 1.47 mmol) and phenoxy methyl sulfone (253 mg, 1.47 mmol) were added to the solution at 0 °C. The reaction was stirred for 30 min. The completion of the reaction was judged with TLC (EtOAc: Hex = 1 : 1, R/= 0.82). After the completion of the reaction, were added the oxodiimidazol (340 mg, 1.47 mmol) and K2C03 (406 mg, 2.94 mmol) to the reaction at 0 °C. The reaction was warmed to rt and stirred for 30 min. The reaction was heated to 40 °C and maintained for 1 h. The reaction was cooled to rt, poured in to H20 (50 mL) and extracted with EtOAc (50 mL, two times). The EtOAc was dried over MgS02 and concentrated under vacuum. The crude product was purified over Si02 (EtOAc : Hex = 1 : 1, R/= 0.39) to afford the desired compound ( 523 mg; 76.1%). Η-NMR (DMSO-d6): 8.32 (IH, s), 8.02 (2H, J = 4.3 Hz, d), 8.00 (2H, J = 4.3 Hz, d), 4.68 (2H, m), 3.50 (2H, m), 3.32 (IH, m), 3.44 (3H, s), 3.05 (IH, m), 2.22 (2H, m), 1.83 (2H, J = 17Hz, d), 1.25 (6H, J = 7 Hz, d) ppm. LCMS: 469.4, 384.9, 357.2.
The starting material, 4,6-Dichloro-pyrimidine-5-carbonitrile, used in the preparation of Compound A91 was prepared in the following manner: To a solution of 5-fomyl-4,6- dichloropyrimidine (3.6 g, 20.3 mmol) in EtOAc (50 ml), was added a solution of NH2OH-HCl (1.41 g, 20.3 mmol) in H20 (30 ml) followed by AcONa (1.67 g, 20.3 mmol) at rt. After stirring for 2h, the reaction was washed with H20 (50 ml, two times) and dried over MgS04. The EtOAc was concentrated under vacuum to afford the crude iminohydroxy compound (3.51 g, 90.2%). The crade compound was used for next step without further purification. The iminohydroxy compound (3.51 g, 18.3 mmol) was dissolved in SOCl2 (20 ml) at 0 °C and stirred for 30 min. The reaction was warmed to rt and maintained for 3h. The reaction was poured into H20 (100 g) portionwise and stirred for 30 min. The precipitate was filtered, washed with H20 (100 mL) and dried under vacuum to afford 4,6-DicMoro-pyrirrιidine-5-carbonitrile (2.99g, 91%). 'H-NMR (DMSO-d6): 8.53 ppm; LCMS: not detectable.
Compound A92 l-[6-(4-Difluoromethoxy-benzyloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[Method 7]. The residue was purified by preparatory LCMS. Η NMR, 400 MHz, CDC13, δ
(ppm): 8.19 (s, IH); 7.38 (d, 2H); 7.08 (d, 2H); 6.47 (m, IH); 5.43 (s, 2H); 4.12 (q, 2H); 3.93
(m, 2H); 3.12 (m, 2H); 2.56 (m, IH); 1.96 (m, 2H); 1.76 (m 2H); 1.23 (t, 3H). LCMS (ESI) for C20H22F2N4O6: m/z 452 (M+H÷, 100 %).
Compound A93 l-[6-(3-Difluoromethoxy-benzyloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 7] : The residue was purified by preparatory LCMS. Η NMR, 400MHz, CDC13, δ ,
(ppm): 8.16 (s, IH); 7.29 (t, IH); 7.17 (d, IH); 7.11 (s, IH); 7.00 (d, IH); 6.45 (m, IH); 5.40
(s, 2H); 4.08 (q, 2H); 3.89 (m, 2H); 3.08 (m, 2H); 2.52 (m, IH); 1.92 (m, 2H); 1.74 (m 2H);
1.19 (t, 3H). LCMS (ESI) for C20H22F2N4O6: m/z 452 (M+H\ 100 %).
Compound A94
2-{l-[6-(2-Methyl-5-trifluoromethyI-2H-pyrazol-3-yIoxy)-5-nitro-pyrimidin-4-yl]- piperidin-4-yl}-ethanol;
[methds 2 followed by 3]. Purification by HPLC yielded brownish oil. Yield 21 %. Η NMR
400MHz CDC13 δ (ppm): 8.50 (s, IH); 6.76 (s, IH); 4.37 (d, 2H); 4.04 (s, 3H); 3.99 (m, 2H);
3.33 (t, 2H); 1.82 (m, 8H). LCMS (ESI) m/z 417 (M+H+, 100 %)
Compound A95
3-{l-[6-(2-Methyl-5-trifluoromethyI-2H-pyrazoI-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidin-4-yl}-propionic acid;
[method 2 followed by 3]. Purification by HPLC yielded brownish solid. Yield 21 %. Η
NMR 400 MHz CDC13 δ (ppm): 8.20 (s, IH); 6.45 (s, IH); 4.07 (d, 2H); 3.74 (s, 3H); 3.01
(m, 2H); 2.33 (m, 2H); 2.19 (m, 2H); 1.58 (m, 4H); 1.28 (m, 4H). LCMS (ESI) m/z 459
(M+H+, 100 %)
Compound A96 4-[4-(4-Methyl-benzyl)-piperidin-l-yI]-6-(2-methyI-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-nitro-pyrimidine;
[method 2 followed by 3]. Purification by Flash Chromatography yielded an yellow oil.
Yield 29 %. *H NMR 400MHz CDC13 δ (ppm): 8.25 (s, IH); 7.11 (m, 2H); 7.04 (m, 2H); 6.51
(s, IH); 4.12 (m, 2H); 3.79 (s, 3H); 3.03 (t, 2H); 2.57 (d, 2H); 2.34 (s, 3H); 1.83 (m, 3H); 1.33
(m, 2H). LCMS (ESI) m/z 477 (M+W, 100 %)
Compound A97
4-(3-MethanesulfonyI-pyrrolidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3- yIoxy)-5-nitro-pyrimidine;
[methods 2 and 3]. Purification by HPLC yielded brownish oil. Yield 30 %. LCMS (ESI) m/z 438 (M+H÷, 100%)
Compound A98
4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yIoxy)-5-nitro-6-[4-(2-trifluoromethyl- phenoxy)-piperidin-l-yl]-pyrimidine;
[methods 2 and 3]. Purification by HPLC yielded'orange solid. Yield 77 %. Η NMR 400
MHz CDC13 δ (ppm): 8.29 (s, IH); 7.1 (d, IH); 7.51 (t, IH); 7.02 (m, 2H); 6.54 (s, IH); 3.82
(m, 7H); 2.09 (m, 5H). LCMS (ESI) m/z 533.1 (M+W, 100 %)
Compound A99
4-(2-MethyI-5-trifluoromethyl-2H-pyrazol-3-yIoxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)- piperidin-l-yl]-pyrimidine;
[methods 2 and 3]. Purification by HPLC yielded A99 as a brown oil. Yield 12 %. Η NMR
400MHz CDCl3δ (ppm): 8.31 (s, IH); 6.54 (s, IH); 4.22 (d, 2H); 3.82 (s, 3H); 3.12 (m, 2H);
2.40 (m, IH); 2.03 (m, 2H); 1.72 (m, 2H). LCMS (ESI) m/z 482.1 (M+H+, 100 %)
Compound AlOO
4'-(4-Benzoyl-phenoxy)-3'-nitro-3,4,5,6-tetrahydrό-2H-[l,2']bipyridinyl-4-carboxylic acid ethyl ester;
[method la]. Purification by HPLC provided compound AlOO as yellow solid (43 mg, 41 %). Η NMR 400MHz CDC13 δ(ppm): 7.84 (d,lH); 7.81 (s, 2H); 7.73 ( d, 2H); 7.52 (t,lH); 7.41 (q,2H); 7.17 (d, 2H); 6.57 (d, IH); 4.10 (q, 2H); 3.48 (dt,2H); 3.03 (td, 2H); 2.50 (m, 5H); 1.96 (dd, 2H); 1.81 (td, 2H); 1.21 (t, 3H). Exact mass calculated for C26H25N306475.17 LCMS (ESI) m/z 476.0 (M+W, 100%). Compound AlOl
3'-Nitro-4'-[4-(3-oxo-butyl)-phenoxy]-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-4- carboxylic acid ethyl ester;
[method 1]. Purification by HPLC provided compound AlOl as yellow oil (49 mg, 49 %). *H NMR 400MHz CDC13 δ(ppm): 7.89 (d,lH); 7.21 (d, 2H); 7.05 ( d, 2H); 6.60 (d,lH); 4.19 (q,2H); 3.56 (dt, 2H); 3.12 (td, 2H); 2.91 (t, 2H); 2.78 (t,2H); 2.59 (t, IH); 2.17 (s, 3H); 2.04 (dd, 2H); 1.89 (m, 2H); 1.30 (t, 3H). Exact mass calculated for C23H27N306441.19 LCMS (ESI) m/z 442.5 (M+W, 100%).
Compound A102
4'-[4-(2-Methoxycarbonyl-acetyl)-phenoxy]-3'-nitro-3,4,5,6-tetrahydro-2H-
[l,2']bipyridinyl-4-carboxylic acid ethyl ester;
[method la]. HPLC provided compound A102 as yellow solid (28 mg, 27 %). XH NMR
400MHz CDC13 δ (ppm): 8.03 (d, 2H); 7.92 (d, IH); 7.24 (d, 2H); 6.65 (d, IH); 4.19 (q, 2H);
3.57 (dd, 2H); 3.12 (td, 2H); 2.62 (s, 3H); 2.59 (m, IH); 2.05 (dd, 2H); 1.90 (m, 2H); 1.30(t
3H). Exact mass calculated for C23H25N3θ8471.16 LCMS (ESl) m/z 472.4 (M+H , 100 %).
Compound A103
4'-(2-Amino-4-ethanesuIfonyl-phenoxy)-3'-nitro-3-4,5,6-tetrahydro-2H-[l,2']bipyridinyl- 4-carboxylic acid ethyl ester;
[method la]. HPLC provided compound A103 as brown solid (61 mg, 57 %). JH NMR 400MHz CDCI3 δ(ppm): 9.83 (s,lH); 7.97 (d, IH); 7.45 (dd, IH); 7.10 (d,lH); 6.76 (d, IH); 4.10 (q,2H); 3.45 (d, 2H); 3.16 (m, 4H); 2.69 (m, IH); 1.93 (d,2H); 1.69 (t, 2H); 1.18 (t,3H); 1.12 (t, 3H). Exact mass calculated for C21H26N407 S 478.15 LCMS (ESI) m/z 479.2 (M+H+, 100 %).
Compound A104
4'-(4-Imidazol-l-yl-phenoxy)-3'-nitro-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-4- carboxylic acid ethyl ester;
[method la]. HPLC provided compound A104 as brown oil (64 mg, 65 %). H NMR 400MHz CDCI3 δ (ppm): 8.85 (s, IH); 7.90 (d, IH); 7.57 ( d, IH); 7.53 (dd,2H); 7.45 (d, IH); 7.41 (dd, 2H); 4.20 (q, 2H); 3.56 (d, 2H); 3.13 (td, 2H); 2.60 (m, IH); 2.06 (dd, 2H); 1.90 (td, 2H); 1.30 (t, 3H). Exact mass calculated for C22H23N505437.17 LCMS (ESI) m/z 438.3(M+H+, 100%).
Compound A105 4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-(4-trifluoromethyl- piperidin-l-yl)-pyrimidine;
[method 2 followed by 3]. Purification by HPLC yielded orange oil.. Yield 41 %. *H NMR
400MHz CDC13 δ (ppm): 8.31 (s, IH); 6.54 (s, IH); 4.22 (d, 2H); 3.82 (s, 3H); 3.12 (m, 2H);
2.40 (m, IH); 2.03 (m, 2H); 1.72 (m, 2H). LCMS (ESI) m/z 481.1 (IvlΗ", 100%)
Compound A106
4-(2-Methyl-5-trifluoromethyl-2H-pyrazoI-3-yloxy)-5-nitro-6-(4-phenylsulfanyl- piperidin-l-yl)-pyrimidine;
[method 3]. Purification by HPLC yielded A106 as an orange solid. Yield 55 %. H NMR
400MHz CDCl3δ (ppm): 8.28 (s, 1H);7.47 (m, 2H); 7.34 (m, 2H); 6.53 (s, IH); 4.03 (d, 2H);
3.82 (s, 3H); 3.42 (m, IH); 3.33 (m, 2H); 2.09 (m, 3H); 1.74 (m, 2H). LCMS (ESI) m/z 481.1
(M+W, 100 %)
Compound A107 l-[6-(3-EthynyI-phenoxy)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester;
[method la]. Purification by by semi preparatory HPLC afforded the pure product in 50 %.
ΗNMR, 400MHz, CDC13, δ (ppm): 8.12 (s, IH); 7.30 (m, 2H); 7.19 (s, IH); 7.06 (m, IH);
4.10 (q, 2H); 3.95 (m, 2H); 3.14 (m, 2H); 3.03 (s, IH); 2.56 (m, IH); 1.95 (m, 2H); 1.76 (m,
2H); 1.20 (t, 3H). LCMS (ESI) for C20H20N4O5: m z 396 M+W, 100 %).
Compound A108 l-[6-(4-Chloro-2-fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic cid ethyl ester;
[method la]. Purified by semi preparatory HPLC afforded the pure product in 42 %. H
NMR, 400MHz, CDC13, δ (ppm): 8.00 (s, IH); 7.06 (m, 3H); 4.02 (q, 2H); 3.86 (m, 2H);
3.07 (m, 2H); 2.48 (m, IH); 1.87 (m, 2H); 1.69 (m, 2H); 1.12 (t, 3H). LCMS (ESI) for
Cι8H18ClFN405: m z 424 (M+W, 100 %).
Compound A109 l-[6-(2-4-Difluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[methodla]. purified by semi preparatory HPLC afforded the pure product in 34 %. „-_ -,ΛΛ . ft
WO 2004 0 256
'HNMR, 400MHZ, CDC13, δ (ppm): 8.14 (s, IH); 7.15 (m, IH); 6.89 (m, 2H); 4.14 (q, 2H); 3.98 (m, 2H); 3.19 (m, 2H); 2.60 (m, IH); 2.00 (m, 2H); 1.82 (m, 2H); 1.24 (t, 3H). LCMS (ESI) for C,8H18F2N405: m/z 408 (M+W, 100 %).
Compound A110 l-[6-(4-Bromo-2-fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method la], purified by semi preparatory HPLC afforded the pure product in 41 %. *H
NMR, 400MHz, CDC13, δ (ppm): 8.07 (s, IH); 7.26(m, 2H); 7.02 (t, IH); 4.09(q, 2H); 3.94
(m, 2H); 3.14 (m, 2H); 2.55 (m, IH); 1.95 (m, 2H); 1.76 (m, 2H); 1.19 (t, 3H). LCMS (ESI) for Cι8H18BrFN405: m/z 468 (M+W, 100 %).
Compound All 1
4-(3-Ethynyl-phenoxy)-5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidine;
[method la], purified by semi preparatory HPLC afforded the pure product in 28 %. Η
NMR, 400MHz, CDC13, δ (ppm): 8.07 (s, IH); 7.28 (m, 2H); 7.19 (m, IH); 7.05 (m, IH); :
4.00 (m, 2H); 3.01 (s, IH); 2.93 (m, 2H); 1.71 (m, 2H); 1.48 (m, IH); 1.28 (m, 2H); 1.16 (m,
4H); 0.83 (t, 3H). LCMS (ESI) for C20H22N4O3: m/z 366 (M+H\ 100 %).
Compound A112
4-(4-Chloro-2-fluoro-phenoxy)-5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidine; [method la]. Purified by semi preparatory HPLC afforded the pure product in 39 %. !H NMR, 400MHz, CDC13, δ (ppm): 8.04 (s, IH); 7.13 (m, 3H); 4.01 (m, 2H); 2.94 (m, 2H); 1.71 (m, 2H); 1.49 (m, IH); 1.28 (m, 2H); 1.16 (m, 4H); 0.82 (t, 3H). LCMS (ESI) for Cι8H20ClFN4O3: m/z 394 (M+W, 100 %).
Compound A113
4-(2,4-Difluoro-phenoxy)-5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidine; [method la], purified by semi preparatory HPLC afforded the pure product in 54 %. !H NMR, 400MHz, CDC13, δ (ppm): 8.04 (s, IH); 7.10 (m, IH); 6.85 (m, 2H); 4.00 (m, 2H); 2.94 (m, 2H); 1.71 (m, 2H); 1.49 (m, IH); 1.28 (m, 2H); 1.16 (m, 4H); 0.82 (t, 3H).LCMS (ESI) for Cι8H20F2N4O3: m/z 378(M+H+, 100 %).
Compound A114
4-(4-Bromo-2-fluoro-phenoxy)-5-nitro-6-(4-propyI-piperidin-l-yl)-pyrimidine; [method la], purified by semi preparatory HPLC afforded the pure product in 62 %. !H NMR, 400MHz, CDC13, δ (ppm): 8.15 (s, IH); 7.35 (m, 2H); 7.12 (t, IH); 4.10 (m, 2H); 3.10 (m, 2H); 1.81 (m, 2H); 1.59 (m, IH); 1.36 (m, 2H); 1.26 (m, 4H); 0.93 (t, 3H). LCMS (ESI) for C18H20BrFN4O3: m/z 438 (M.+W, 100 %).
Compound A115
3,-Nitro-2'-[4-(3-oxo-butyl)-phenoxy]-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-4- carboxylic acid ethyl ester; General Procedure 2:
Intermediate monochloro as a yellow oil (128 mg, 80 % yield).Exact mass calculated for C15H13 C1N204320.06, LCMS (ESI) m/z 320.8(M+H+, 100%). [method la]. HPLC provided compound A119 as yellow oil (44 mg, 50 %). !H NMR 400MHz CDC13 δ(ppm): 8.30 (d,lH); 7.42 (d, 2H); 7.18 ( d, 2H); 6.40 (d, IH); 4.34 (q, 2H); 3.95 (dt, 2H); 3.36 (td, 2H); 3.10(t, 2H); 2.96 (t, 2H); 2.74 (m, IH); 2.34 (s, 3H); 2.20 (dt, 2H); 2.05 (td, 2H); 1.44 (t, 3H). Exact mass calculated for C23H27N306441.19 LCMS (ESI) m/z 442.3 (M+W, 100%).
Compound All 6
4-[4-(3'-Nitro-4-propyl-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyI-2'-yloxy)-phenyl]-butan-
2-one;
[method la]. HPLC provided compound A116 as yellow oil (34 mg, 32 %).Η NMR
400MHz CDC13 δ(ppm): 8.09 (d,lH); 7.24 (d, 2H); 7.00 (d, 2H); 6.15 (d,lH); 3.80 (d, 2H);
3.06 (td, 2H); 2.91 (t,2H); 2.77 (t, 2H); 1.77 (d, 2H); 1.51 (m, IH); 1.36-1.22 (m, 6H); 0.8
(t,3H). Exact mass calculated for C23H29N304411.22 LCMS (ESI) m/z 412.4 (M+W, 100 %).
Compound A117
2'-(4-Benzoyl-phenoxy)-3'-nitro-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-4-carboxylic acid ethyl ester;
[method la]. HPLC provided compound A117 as yellow oil (37 mg, 39 %). *H NMR 400MHz CDCI3 δ(ppm): 8.24 (d,lH); 7.97 (d, 2H); 7.86 (d, 2H); 7.68 (t,lH);7.57(t, 2H); 7.27 (d, 2H); 6.36 (d,lH); 4.23 (q, 2H); 3.87 (dt, 2H); 3.23 (td, 2H); 2.66-2.60 (m, IH); 2.08 (dt, 2H); 1.92 (td, 2H); 1.33 (t,3H). Exact mass calculated for C26H25N306475.17 LCMS (ESI) m/z 476.2(M+H+, 100%).
Compound All 8
4-(4-{5-Nitro-6-[4-(pyridin-2-yIsulfanyl)-piperidin-l-yl]-pyrimidin-4-yIoxy}-phenyl)- butan-2-one;
[method la]. The crude was dissolved in dichloromethane and purified by preparative TLC.
[Si02; 20/80 EtOAc/hexanes]. Yield 37 mg, 48 %. Yellow solid. !H-NMR (400 MHz, CDCI3) δ (ppm) 8.36 (d, IH); 8.11 (s, IH); 7.42 (ddd, IH); 7.11 (m, 3H); 6.95 ( , 3H); 4.12 (heptet, IH); 3.94 (tt, 2H); 3.33 (m, 2H); 2.84 (m, 2H); 2.70 (m, 2H); 2.15 (m, 2H); 2.08 (s, 3H); 1.75 (m, 2H). LCMS (ESI), m/z 480 (ML+W, 100%)
Compound A119
[4-(3'-Nitro-4-propyI-3,4,5.6-tetrahydro-2H-[l,4']bipyridinyl-2*-yloxy)-phenyl]-phenyl- methanone;
General Procedure 2: Intermediate monochloro as a yellow oil (142 mg, 80 % yield). Exact mass calculated for C18H„ C1N204354.04, LCMS (ESI) m/z 355.2(M+H+, 100%). [method la]. HPLC provided compound A119 as yellow solid (26 mg, 29 %). *H NMR 400MHz CDCI3 δ(ppm): 8.33 (d,lH); 8.07 (d, 2H); 7.94 ( d, 2H); 7.77 (m,lH); 7.65 (t, 2H); 7.37 (d, 2H); 6.44 (d,lH); 3.96 (d, 2H); 3.28 (td, 2H); 1.95 (d, 2H); 1.71-1.65 (m, IH); 1.51-1.38 (m, 6H); 1.1 (t,3H). Exact mass calculated for C26H27N304445.20 LCMS (ESI) m/z 446.0(M+H+, 100 %).
Compound A120
4-(4-{5-Nitro-6-[4-(2-trifluoromethyI-phenoxy)-piperidin-l-yl]-pyrimidin-4-yloxy}- phenyI)-butan-2-one;
[method 2 followed by method 1]. Yield 0.173 g, 83 %. Yellow solid. !H NMR 400MHz
CDCI3 d (ppm): 8.30 (s, IH); 7.53 (m, IH); 7.42 (m, 1H);6.93 (m, 2H); 4.75 (m, IH); 3.77 (m,
2H); 3.56 (m, 2H); 1.95 (m, 4H). LCMS (ESI) m/z 403 (M+^,100%)
[method la]. Compound A120 purified through a silica plug [Si02; EtOAc/hexane; 20:80].
Yield 0.067 g, 85 %. Yellow oil. Η NMR 400MHz CDC13 δ (ppm): 8.12 (s. IH); 7.53 (m,
IH); 7.42 (m, IH); 7.15 (m, 2H); 6.97 (m, 4H); 3.72 (m, 2H); 3.60 (m, 2H); 2.82 (m, 2H);
2.70 (m, 3H); 2.08 (m, 4H); 1.97 (m, 4H). LCMS (ESI) m/z 531 (M+H+,100 %)
Compound A121
4-(4-{6-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yI]-5-nitro-pyrimidin-4-yloxy}- phenyI)-butan-2-one;
[method 1]. Purification by HPLC. Yield 52 %. Yellow solid. Η NMR 400MHz CDC13 δ
(ppm): 8.11 (s, IH);); 7.17 (d, 2H); 6.98 (d, 2H); 4.06 (d, 2H); 3.23 (t, 2H); 3.12 (d, 2H); 3.00
(m, 2H); 2,85 (t, 2H); 2.72 (t, 2H); 2.10 (s, 3H); 1.81 (m, 4H); 1,28 (m, 2H); 0.84 (t, 6H).
LCMS (ESI) m/z 453 (M+-B7", 100 %)
[method la]. Purification by HPLC yielded a yellow solid. Yield 62 %. Η NMR 400MHz
CDCl3δ (ppm): 8.13 (s, IH); 7.15 (d, 2H); 6.98 (d, 2H); 4.02 (d, 2H); 3.22 (m, 3H); 2.83 (t, 2H); 2,70 (t, 2H); 2.33 (s, 3H); 2.10 (m, 5H); 1.04 (m, 2H). LCMS (ESI) m/z 453.2 (M+H÷, 100 %)
Compound A122
(4-{6-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yloxy}- phenyl)-phenyl-methanone;
Purification by HPLC yielded yellow solid. Yield 68 %. *H NMR 400MHz CDC13 δ (ppm): 8.04 (s, IH); 7.71 (d, 2H); 7.61 (d, 2H); 7.41 ( , IH); 7.30 (m,2H); 7.08 (m, 2H); 3.92 (d, 2H); 3.13 (m, 3H); 2.21 (s, 3H); 2,02 (m, 2H); 1.83 (m, 2H). LCMS (ESI) m/z 487.1 (M+W, 100 %)
Compound A123 l-{6-[4-(4-Fluoro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method 1]. HPLC provided compound A123 as yellow solid (85 mg, 86 % yield). *H NMR
400MHz CDC13 δ (ppm): 8.13 (s,lH); 7.79 (d, 2H); 7.76 (d, 2H); 7.20 (d, 2H); 7.10 (d,2H);
4.09 (q, 2H); 3.96 (dt,2H); 3.15 (td, 2H); 2.59-2.52 (m, IH); 1.96 (dt, 2H); 1.77 (td, 2H); 1.19
(t,3H). Exact mass calculated for C25H23 FN406 494.16, LCMS (ESI) m/z 495.1 (M+H+, 100
Compound A124
(4-FIuoro-phenyl)-{4-[5-nitro-6-(4-propyI-piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}- methanone;
[method 1]. HPLC provided compound A124 as yellow solid (69 mg, 84 % yield). *H NMR 400MHz CDCI3 δ(ppm): 8.10 (s, IH); 7.78 (d, 2H); 7.76 (d, 2H); 7.19 (d, 2H); 7.09 (tt, 2H); 4.03 ( d, 2H); 2.96 (td, 2H); 1.73 (dd, 2H); 1.51(m, IH); 1.37 ( m, 2H); 1.21 (m, 2H); 1.15( m, 2H); 0.83 (t, 3H). Exact mass calculated for C25H25FN404 464.19, LCMS (ESI) m/z 465.2 (M+H÷, 100%).
Compound A125
4-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(2-methyl-5-trifluoromethyI-2H- pyrazol-3-yIoxy)-5-nitro-pyrimidine;
[method 3]. Purification by HPLC yielded yellow oil. Yield 38 %. Η NMR 400MHz CDC13 δ (ppm): 8.16 (s, IH); 6.38 (s, IH); 3.98 (d, 2H); 3.65 (s, 3H); 3.21 (m, 3H); 2.26 (s, 3H);
2.08 (m, 2H); 1.89 (m, 2H). LCMS (ESI) m/z 417 (M+W, 100 %) „-_ -,ΛΛ . ft
WO 2004 0 260
Compound A126
4-(4-Methoxymethyl-piperidin-l-yl)-6-(2-methyI-5-trifluoromethyl-2H-pyrazol-3-yloxy)-
5-nitro-pyrimidine;
[method 3]. Purification by HPLC yielded A126 as a yellow oil. Yield 21 %. Η NMR
400MHz CDCl3δ (ppm): 8.05 (s, IH); 6.30 (s, IH); 3.93 (d, 2H); 3.59 (s, 3H); 3.15 (s, 3H);
3.07 (m, 2H); 2,89 (m, 2H); 1.69 (m, 3H); 1.15 (m, 2H). LCMS (ESI) m/z 417 (M+H+, 100%)
Compound A127
4-{4-[6-(4-Methoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyI}-butan-2- one;
[method la]. Purification by HPLC yielded A127 as a yellow solid. Yield 19 %. Η NMR
400 MHz CDC13 δ (ppm): 8.04 (s, IH); 7.07 (d, 2H); 6.91 (d, 2H); 3.98 (d, 2H); 3.22 (s, 3H);
3.14 (d, 2H); 2.92 (m, 2H); 2,76 (m, 2H); 2.64 (m, 2H); 2.02 (s, 3H); 1.74 (m, 3H); 1,20 (m,
2H). LCMS (ESI) m/z 414.45 (M+H , 100 %)
Compound A128 <
4-[4-(2-Methoxy-ethyl)-piperidin-l-yl]-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-nitro-pyrimidine;
[method 2 followed by la]. Purification by HPLC yielded orange solid. Yield 41 %. H
NMR 400 MHz CDC13 δ (ppm): 8.11 (s, IH); 6.36 (s, IH); 3.97 (d, 2H); 3.65 (s, 3H); 3.33
(m, 2H); 3.22 (s, 3H); 2,93 (m, 2H); 1.69 (m, 3H); 1.43 (m, 2H); 1.16 (m, 2H). LCMS (ESI) m/z 431.1 (M+H1-, 100 %)
Compound A129
4-{4-[6-(4-Ethoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-butan-2- one;
[method la] A129 was purified by HPLC. Η NMR 400MHz CDC13 δ (ppm): 8.00 (s, IH),
7.10 (d, 2H), 6.80 (d, 2H), 3.90 (m, 2H), 3.30 (q, 2H), 3.15 (d, 2H), 2.90 (m, 2H),2.70 (t, 2H),
2.60 (t, 2H), 2.00 (s, 3H) 1.70 (m, 3H), 1.20 (m, 2H), 1.00 (t, 2H). LCMS (ESI) for
C22H28N405: m/z 429.0 (M + H , 100 %)
Compound A130
4-(2,4-Difluoro-phenoxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidine; [method la] A130 was purified by semi preparatory HPLC afforded the pure product in 73 %. Η NMR, 400MHz, CDC13, δ (ppm): 8.67 (d, IH); 8.10(s, IH); 7.80 (t, IH); 7.42 (d, IH); , ,, lol
7.3 l(t, IH); 7.11 (m, IH); 6.88 (m, 2H); 4.12 (m, IH); 3.99 (m, 2H); 3.29 (m, 2H); 2.14 (m, 2H); 1.76 (m, 2H). LCMS (ESI) for C20H17F2N5O3S: m/z 445 (M+W, 100 %).
Compound A131
(4-Methoxy-2-{5-nitro-6-[4-(pyridin-2-yIsuIfanyl)-piperidin-l-yI]-pyrimidin-4-yIoxy}- phenyl)-phenyl-methanone;
[method la] Purified by semi preparatory LCMS afforded the pure product in 38 %. :H NMR, 400 MHz, CDC13, δ (ppm): 8.55 (d, IH); 7.98 (s, IH); 7.62 (m, 3H); 7.46 (m, 2H); 7.31 (m, 3H); 7.15 (m, IH); 6.80 (m, IH); 6.72 (d, IH); 4.05 (m, IH); 3.86 (m, 2H); 3.82 (s, 3H, -OCH3); 3.22 (m, 2H); 2.09 (m, 2H); 1.70 (m, 2H). LCMS (ESI) for C28H25N505S: m/z 543 (M+W, 100 %).
Compound A132
4-(2,4-Difluoro-phenoxy)-6-(4-ethoxymethyl-piperidin-l-yl)-5-nitro-pyrimidine; [method 1]. crude product was purified by HPLC to afford yellow oil (35.4 mg, 27 %). *H NMR 400MHz CDC13 δ (ppm): 8.20 (s, IH), 7.20 (m, IH), 6.80 (d, 2H),7.00-6.90 (m, 2H),4.10 (m, 2H), 3.50 (d, 2H), 3.10 (m, 2H), 2.00 (m, IH), 1.90 (m, 2H), 1.40 (m, 2H), 1.20 (t, 3H). LCMS (ESI) for Cι8H2oFN404: m/z 395.1 (M + H+ , 100 %)
Compound A133
4-{4-[6-(4-CycIopropyImethoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]- phenyI}-butan-2-one;
[method 2 followed by method la]. Purification by HPLC yielded yellow solid. Yield 53 %. Η NMR 400 MHz CDC13 δ (ppm): 7.97 (s, IH);); 7.02 (d, 2H); 6.84 (d, 2H); 3.92 (d, 2H); 3.13 (m, 2H); 3.07 (m, 2H); 2.86 (m, 2H); 2,71 (m, 2H); 2.57 (m, 2H); 1.56 (s, 3H); 1.70 (m, 3H); 1.13 (m, 2H); 0.85 (m, IH); 0.34 (m, 2H); 0.01 (m, 2H). LCMS (ESI) m/z 455.2 (M+W, 100 %)
Compound A134
4-{4-[5-Nitro-6-(4-propoxymethyl-piperidin-l-yl)-pyrimidin-4-yIoxy]-phenyl}-butan-2- one;
[method 2 followed by la]. Purification by HPLC yielded yellow solid. Yield 22 %. *H
NMR 400MHz CDC13 δ (ppm): 8.03 (s, IH);); 7.08 (d, 2H); 6.90 (d, 2H); 3.98 (d, 2H); 3.24
(t, 2H); 3.16 (d, 2H); 2.92 (m, 2H); 2,76 (m, 2H); 2.63 (m, 2H); 2.01 (s, 3H); 1.74 (m, 3H);
1.45 (m, 2H); 1.19 (m, 2H); 0.78 (t, 3H). LCMS (ESI) m/z 443.3 M+W, 100 %) „,„ -,ftft 1
WO 2004 2 2
Compound A135 l-{4-[6-(4-MethoxymethyI-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-ethanone; [method la]. Yield 12 %. Η NMR 400MHz CDC13 δ (ppm): 8.03 (s, IH);); 7.89 (d, 2H); 7.10 (d, 2H); 3.99 (d, 2H); 3.21 (t, 3H); 3.13 (m, 2H); 2.93 (m, 2H); 2,47 (s, 3H); 1.75 (m, 3H); 1.19 (m, 2H). LCMS (ESI) m z 387 (IvTΗ4, 100%)
Compound A136 4-{4-[2-Nitro-3-(4-propyl-piperidin-l-yl)-phenoxy]-phenyl}-butan-2-one;
Following general procedure 1, compound A136 was obtained as a yellow oil (70 %). 'HNMR (CDC13, 400 MHz) δ 0.70 (t, 3H), 1.04-1.17 (m, 7H), 1.53(d, 2H), 1.97 (s, 3H), 2.54- 2.70 (m, 6H), 3.10(d, 2H), 6.36 (d, 2H), 6.69 (d, IH), 6.77 (d, 2H), 6.96 (d, 2H ), 7.04(t,lH). Exact mass calculated for C24H30N2O4410.22, found 411.2 (MH+).
Compound A137 l-{4-[2-Nitro-3-(4-propyl-piperidin-l-yI)-phenoxy]-phenyl}-ethanone;
Following the general procedure 1, compound A137 was obtained as a yellow solid (11 %) 1HNMR (CDCI3, 400 MHz) δ 0.82 (t, 3H), 1.17-1.28 (m, 7H), 1.64 (d, 2H), 2.50 (s, 3H), 2.67 (t, 2H), 3.20 (d, 2H), 6.58 (d, IH), 6.89 (d, IH), 6.98 (d, 2H), 7.24 (t, IH ), 7.88 (d, 2H). Exact mass calculated for C22H26N204382.19, found 383.3 (MH4).
Compound A138 {4-[2-Nitro-3-(4-propyl-piperidin-l-yl)-phenoxy]-phenyl}-phenyl-methanone;
The intermediate monofluoro was made by method 2. It was obtained as a yellow solid (88 % yield). 'HNMR (CDC13, 400 MHz) δ 0.88 (t, 3H), 1.24-1.33 (m, 7H), 1.71 (m, 2H), 2.74 (t, 2H), 3.23 (d, 2H), 6.77(t, IH), 6.87 (d, IH), 7.30 (d, IH). Exact mass calculated for CMH19FN202266.14, found 297.0 (MH+).
Following the general procedure 2, compound A138 was obtained as a yellow oil (72 %). 'HNMR (CDCI3, 400 MHz) δ 0.75 (t, 3H), 1.10-1.24 (m, 7H), 1.59-1.62 (m, 2H), 2.67 (t, 2H), 3.20 (d, 2H), 6.59 (d, IH), 6.88 (d, IH), 6.95 (d, 2H), 7.21 (t, IH), 7.34 (t, 2H ), 7.44 (t,lH), 7.63 (d, 2H), 7.68 (d, 2H). Exact mass calculated for C27H28N204444.20, found 445.1(MH+).
Compound A139
3-{4-[2-Nitro-3-(4-propyl-piperidin-l-yl)-phenoxy]-phenyl}-3-oxo-propionic acid methyl ester;
[method 1]. Following the general procedure, compound A139 was obtained as a yellow solid (6 %). !HNMR (CDC13, 400 MHz) δ 0.71 (t, 3H), 0.99-1.16 (m, 7H), 1.54 (m, 2H), 2.33-2.35 (m, 2H), 2.62 (m, 2H), 3.68 (s, 3H), 6.74 (d, IH), 6.96 (d, 2H), 7.06 (d, IH), 7.37 (t, IH ), 7.83( d, 2H). Exact mass calculated for C24H28N206440.19, found 399.2 (TVuT").
Compound A140
4-{4-[6-(4-Butoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyI}-butan-2- one;
[method la]. Purification by HPLC yielded yellow oil. Yield 41 %. Η NMR 400MHz CDC13 δ (ppm): 8.03 (s, IH);); 7.08 (d, 2H); 6.89 (d, 2H); 3.97 (d, 2H); 3.27 (t, 2H); 3.16 (d, 2H);
2.90 (m, 2H); 2,76 (t, 2H); 2.63 (t, 2H); 2.02 (s, 3H); 1.74 (m, IH); 1,70 (d, 2H); 1,41 (m,
2H); 1,22 (m, 4H); 0.78 (t, 3H). LCMS (ESI) m/z 457 M+W, 100%)
Compound A141
4-{4-[6-(4-Isobutoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yIoxy]-phenyI}-butan-2- one;
[method la]. Purification by HPLC yielded yellow oil. Yield 45 %. Η NMR 400MHz
CDCl3δ (ppm): 8.11 (s, IH);); 7.17 (d, 2H); 6.98 (d, 2H); 4.06 (d, 2H); 3.23 (t, 2H); 3.12 (d, .
2H); 3.00 (m, 2H); 2,85 (t, 2H); 2.72 (t, 2H); 2.10 (s, 3H); 1.81 (m, 4H); 1,28 (m, 2H); 0.84 (t,
6H). LCMS (ESI) m z 457 (M+W, 100 %)
Compound A142
(4-Fluoro-phenyI)-[4-(3'-nitro-4-propyl-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-4'- yloxy)-phenyl]-methanone;
General Procedure 2 provided the monochloro intermediate as yellow crystal (484 mg, 66 % yield). 1H NMR 400MHz CDC13 δ (ppm): 8.21 (d, IH); 6.91(d, IH); 3.62(d, 2H); 3.09 (td,
2H); 1.89 (d,2H); 1.61 (m, IH); 1.50-1.34 (m,6H); 1.03 (t, 3H). Exact mass calculated for
C13Hi8 C1N302283.11, LCMS (ESI) m/z 284.3(M+H+, 100%).
[method la]. HPLC provided compound A142 as tan solid (34 mg, 37 % yield). Η NMR
400MHz CDC13 δ (ppm): 7.83 (d, IH); 7.78 (d, 2H); 7.75 (d, 2H); 7.15 (d, 2H); 7.11 (d, 2H);
6.58 ( d, IH); 3.51 (d, 2H); 2.97 (td, 2H); 1.73 (dd, 2H); 1.49-1.42 (m, IH); 1.31-1.17 (m,
6H); 0.84 (t, 3H). Exact mass calculated for C26H26FN304 463.19, LCMS (ESI) m/z
464.0(M+H+, 100%).
Compound A143
4-[4-(3'-Nitro-4-propyI-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-4'-yIoxy)-phenyl]-butan-
2-one; [method la]. HPLC provided compound A143 as yellow solid (57 mg, 70 % yield). Η NMR 400MHz CDC13 δ(ppm): 7.75 (d, IH); 7.11 (d, 2H); 6.95 (d, 2H); 6.46 (d, 2H); 3.46 (d, 2H); 2.90 ( td, 2H); 2.81 (t, 2H); 2.68(t, 2H); 2.07 (s, 3H); 1.69 (m, 2H); 1.43-1.38 (m, IH); 1.29- 1.16 ( m, 6H); 0.83 (t,3H). Exact mass calculated for C23H29N304 411.22, LCMS (ESI) m/z 412.0 (M+W, 100%).
Compound A144
3'-Nitro-4-propyl-4'-(4-[l,2,4]triazoI-l-yl-phenoxy)-3,4,5,6-tetrahydro-2H-
[l,2']bipyridinyl;
[method la]. HPLC provided compound A144 as yellow solid (46 mg, 56 % yield). *H NMR
400MHz CDCI3 δ (ppm): 8.62(s, IH); 8.08 (s, IH); 7.72(d, IH); 7.58 (d, 2H); 7.18 (d, 2H);
6.49 (d, IH); 3.43(d, 2H); 2.89 (td, 2H); 1.66 (d, 2H); 1.42-1.35 (m, IH); 1.25-1.11 (m, 6H);
0.79 (t,3H). Exact mass calculated for C21H24N603 408.19, LCMS (ESI) m/z 409.0 (M+H+,
100%).
Compound A145 l-{2-Nitro-3-[4-(3-oxo-butyl)-phenoxy]-phenyl}-piperidine-4-carboxy!ic acid ethyl ester;
The intermediate monofluoro was made by method 2. It was obtained as a yellow solid (90 % yield). !HNMR (CDC13, 400 MHz) δ 1.20 (t, 3H), 1J7-1.93 (m, 4H), 2.35 (m, IH), 2J3-2.79 (t, 2H), 3.18-3.22 (m, 2H), 4.08 (q, 2H), 6.77-6.86 (m, 2H), 7.25-7.31 (m, IH). Exact mass calculated for Cι4H17FN20 296.12, found 297.2. Following general procedure 1, compound A145 was obtained as a yellow oil (61 %). 'HNMR (CDC13, 400 MHz) δ 1.19 (t, 3H), 1.77- 1.83(m, 2H), 1.88-1.92(m, 2H), 2.07(s, 3H), 2.30-2.33 (m, IH), 2.66-2.82(m, 6H), 3.18- 3.22(m, 2H), 4.07 (q, 2H), 6.50 (d, IH), 6.79 (d, IH ), 6.88(d, 2H), 7.08(d, 2H), 7.16(t,lH). Exact mass calculated for C24H28N206440.19, found 441.1 (MH).
Compound A146 l-[3-(4-Benzoyl-phenoxy)-2-nitro-phenyl]-piperidine-4-carboxylic acid ethyl ester; [method 2]. Intermediate was obtained as a yellow solid (90 % yield). 'HNMR (CDC13, 400 MHz) δ 1.20 (t, 3H), 1.77-1.93 (m, 4H), 2.35 (m, IH), 2.73-2.79 (t, 2H), 3.18-3.22 (m, 2H), 4.08 (q, 2H), 6.77-6.86 (m, 2H), 7.25-7.31 (m, IH). Exact mass calculated for C14H17FN204 296.12, found 297.2 (MH+). Following the general procedure 1, compound A146 was obtained as a yellow solid (44 %). 'HNMR (CDC13, 400 MHz) δ 1.20 (t, 3H), 1.80-1.91 (m, 4H), 2.37(m, IH), 2.74-2.81(m, 2H), 3.22-3.25 (m, 2H), 4.10 (q, 2H), 6.68(d, IH), 6.93 (d, IH), 7.02 (d, 2H), 7.29 (t, IH ), 7.42(t, IH), 7.52(d, IH), 7.70(d, 2H), 7.76(d, 2H). Exact mass calculated for C27H26N206474.18, found 475.2 (MB*). Compound A147
{4-[6-(4-Ethoxy-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-(4-fluoro-phenyl)- methanone;
[method la]. Purification by HPLC. Yield 24 %. Η NMR 400MHz CDC13 δ (ppm): 8.03 (s, IH);); 7.66 (m, 4H); 7.07 (m, 2H);6.98 (m, 2H); 3.65 (m, 2H); 3.48 (m, IH); 3.39 (q, 2H); 3.25 (m, 2H); 1.77 (m, 2H); 1.56 (m, 2H); 1.06 (t, 3H). LCMS (ESI) m/z 467 ( W, 100%)
Compound A148 l-[6-(2-Methyl-5-trifluoromethyI-2H-pyrazoI-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidin-
4-ol
[method 3]. Purification by HPLC. Yield 35 % yellow oil. Η NMR 400MHz DMSO δ
(ppm): 8.26 (s, IH); 6.67 (s, IH); 4.82 (s, IH); 3.75 (m, 2H); 3.68 (s, 3H); 3.31 (m, 2H); 1.76
(m, 2H); 1.41 (m, 2H). LCMS (ESI) m/z 389 (M H+, 100%)
Compound A149 l-[6-(4-Acetyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester, [method la]. The mixture was purified by HPLC to give compound A149 as a yellow solid (57 mg, 70 %). !HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.80-1.90 (m, 2H), 1.98-2.03 (m, 2H), 2.62 (s, 3H), 3.22 (t, 2H), 3.97-4.03 (m, 2H), 4.17 (q, 2H), 7.25 (d, 2H), 8.02 (d, 2H), 8.17 (s, IH). Exact mass calculated for C20H22N4O6414.15, found 415.2 (MH ).
Compound A150
(l-{6-[4-(4-Fluoro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidin-4-yI)-(4-fluoro- phenyl)-methanone
[method la]. Purification by HPLC. Yield 40 % of a yellow solid as TFA salt. Η NMR
400MHz CDCI3 δ (ppm): 10.0 (s, IH); 8.19 (s, IH); 8.01 (m, 2H); 7.91 (m, 2H); 7.76 (m,
4H); 7.19 (m, 2H); 7.09 (m, 4H); 4.06 (d, 2H); 3.52 (m, IH); 3.25 (m, 2H); 1.88 (m, 4H).
LCMS (ESI) m/z 545.4 (Mtf, 100 %)
Compound A151
4-(4-{6-[4-(4-Fluoro-benzoyI)-piperidin-l-yl]-5-nitro-pyrimidin-4-yIoxy}-phenyl)-butan-
2-one
[method la]. Purification by HPLC yielded yellow solid. Yield 62 %. Η NMR 400MHz
CDCl3δ (ppm): 8.25 (s, IH); 8.04 (m, 2H); 7.26 (m, 4H); 7.10 (d, 2H); 4.19 (m, 2H); 3.61 (m, 1H);3.35 (m, 2H); 2.96(t; 2H); 2.83 (t, 2H); 2.21 (s, 3H); 2.00 (m, 4H). LCMS (ESI) m/z 493.4 (MΗ, 100%)
Compound A152
4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)-cycIohexyl]- pyrimidine
[method la]. The crade was dissolved in DMF and purified by HPLC.Yellow solid. Yield 66 mg, 72 %. 'H-NMR (400 MHz, CDC13) δ(ppm): 8.43 (m, IH); 8.12 (s, IH); 7.94 (tt, 2H);
7.49 (ddd, IH); 7.28 (tt, 2H), 7.15 (m, IH); 7.01 (m, IH); 4.10 (heptet, IH); 3.96 (tt, 2H);
3.34 (m, 2H); 3.00 (s, 3H); 2.15 (m, 2H); 1.75 (m, 2H). LCMS (ESI), m/z 488 (M+H+, 100%)
Compound A153
4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-[4-(pyridin-4-ylsulfanyl)-cyclohexyI]- pyrimidine
[method la]. The crude was dissolved in dichloromethane and purified by HPLC. Yellow solid. Yield 85 mg, 87 %. 'H-NMR (400 MHz, CDC13) δ(ppm): 8.41 (m, 2H); 8.10(s, IH); . -
7.94 (m, 2H); 7.79 (m, 2H); 7.33 (m, 2H); 4.02 (m, 3H); 3.37 (m, 2H); 3.06 (s, 3H); 2.20 (m,
2H); 1.78 (m, 2H). LCMS (ESI), m/z 488 (M+H+, 100 %)
Compound A154
4-(4-MethanesuIfonyl-phenoxy)-5-nitro-6-(4-phenylsulfanyl-cyclohexyl)-pyrimidine [method la]. The crude was dissolved in dichloromethane and purified by HPLC. Yellow solid. Yield 80 mg, 83 %. Η-NMR (400 MHz, CDC13) δ(ppm): 7.97 (s, IH); 7.78 (m, 2H); 7.21 (m, 2H); 7.15 (m, 3H); 7.08 (m, 2H); 3.80 (m, 2H); 3.16 (heptet, IH); 3.06 (m, 2H); 2.86 (s, 3H); 1.87 (m, 2H); 1.50 (m, 2H). LCMS (ESI), m/z 487 (M+H÷, 100%)
Compound A155 l-[5-Nitro-6-(4-trifluoromethylsulfanyl-phenoxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester
[method la], yellow solid (92 %). Η NMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.79 (m, 2H),
1.98 (m, 2H), 2.58 (m, IH), 3.18 (t, 2H), 3.85 (m, 2H), 4.10 (q, 2H), 7.58 (d, 2H), 7.67 (d,
IH), 8.09 (s, IH), 10.13 (s, IH). Exact mass calculated for C19H2oF3N504S 471.45, found
472.1 (MH+).
Compound A156 5-[l,3]Dioxolan-2-yl-4-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methanesulfonyl-phenoxy)-pyrimidine
Using the method described herein Compound A156 was prepared. The crade mixture was purified by flash chromatography, eluted with 50% ethyl acetate/hexane to afford Compound A156 (316.5mg, 67.8%). 1H MR400MHz CDC13 δ (ppm): 8.24 (s, IH), 7.93 (d, 2H), 7.26(d, 2H), 5.95(s, IH), 4.10 (m, 2H), 3.96 (m, 2H), 3.17 (q, IH), 3.02 (s,3H), 2.14 (m, 2H), 1.95 (m, 2H), 1.28 (d, 6H). LCMS (ESI) for C24H29N506S: m z 516.3 (M + H1", 100%)
Compound A157
4-[4-(3-IsopropyI-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methanesulfonyl-phenoxy)- pyrimidine-5-carbaIdehyde
Compound A156 was hydrolyzed using HCl aq in a mixture of acetone/acetonitrile to give Compound A157 (30.0mg, 93.72%); 1HNMR400MHz CDC13 δ (ppm):10.3(s,lH), 8.17 (s, IH), 7.96 (d, 2H), 7.32(d, 2H), 4.12 (m, 2H),3.30 (m, 2H),3.22 (m,lH), 3.00(s, 3H), 3.00 (q,lH), 2.06 (m, 2H), 2.00 (m, 2H), 1.27 (d, 6H). LCMS (ESI) for C22H25N505S: m/z 472:2 (M + H+, 100%).
Compound A158
5-[l,3]Dioxolan-2-yl-4-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-
[l,2,3]thiadiazoI-4-yI-phenoxy)-pyrimidine
White solid, Η NMR 400MHz CDC13 δ (ppm): 8.62 (s, IH), 8.3 l(s,lH), 8.08(d, 2H), 7.28(d, 2H), 6.06(s, IH), 4.24 (m, 2H), 4.13 (m, 2H), 4.04 (m, 2H), 3.23 (m, 2H), 3.07(q, IH), 2.20 (m, 2H), 2.02 (m, 2H), 1.33 (d, 6H); LCMS (ESI) for C2SH27N704S: m/z 522.3 (M + H+, 100%).
The intermediate 4-chloro-5-[l,3]dioxolan-2-yl-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)- pyrimidine was prepared using the following method: Phosphorus Oxychoride (200 mL, 2184.8mmol) was added drop wise (additional funnel) in DMF at 0 °C, and stirred for 1 hour, treated with 4,6 dihydroxypyridimidine (50. Og, 446.1 mmol) and stirred for half hour at room temperature. The heterogeneous mixture was refluxed for 3 hours. The volatiles were removed at reduce pressure, and the residue was poured in ice water and extract with chloroform and diethylether, wash with sodium bicarbonate and concentrate under high vacuum. The resulting mixture was purified on silica (CH2C12) to afford 4,6-dichloro- pyrimidine-5-carbaldehyde as a yellow solid (54.0 g). !H NMR 400MHz CDC13 δ (ppm): 10.3 (s, IH, aldehyde), 8.7 (s,lH, pyrimidine).
Compound 4,6-Dichloro-pyrimidine-5-carbaldehyde (8.6g, 0.049mmol), anhydrous ethylene glycol (8.2ml) and τ Toluene-sulfonic acid (150mg) were mixture in benzene (200 mL) and heated under reflux for 3 hours. Concentrate under high vacuun worked up with chloroform, water, sodium bicarbonate and sodium chloride, concentrate. The reaction mixture was purified on silica (CH2C12) to give 4,6-Dichloro-5-[l,3]dioxolan-2-yl-pyrimidine (8.86g, 82.5%). Η NMR 400MHz CDC13 δ (ppm): 8.8 (s, IH), 6.3 (s,lH), 4.3 (m, 2H,), 4.1(m, 2H).
To a mixture of 4,6-dichloro-5-[l,3]dioxolan-2-yl-pyrimidine (100.0 mg, 0.45mmol) and added Potassium Carbonate (80.62mg, 0.45mmol) in DMF (5mL) cooled to 0° C was added a solution of 4-[l,2,3]-thiadiazol-4-yl-phenol (DMF) drop wise. The resulting mixture was stirred at room temperature for 30 minutes to give 4-chloro-5-[l,3]dioxolan-2-yl-6-(4- [l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine. LCMS (ESI) for Cι5HπClN403S: m/z 362.9 (M + H1-, 100%).
Compound A159
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-[l,2,3]thiadiazol-4-yl- phenoxy)-pyrimidine-5-carbaldehyde
White solid (18.01 mg, 25.9%); 1H NMR 400MHz CDC13 δ (ppm):10J(s, IH), 8.67 (s, IH), 8.26(s,lH), 8.14(d, 2H), 7.34(d, 2H), 4.19 (m, 2H), 3.40 (m, 2H), 3.26 (m, IH), 3.07(q, IH), ,..
2.20 (m, 2H), 2.02 (m, 2H), 1.33 (d, 6H). LCMS (ESI) for C23H23N703S: m/z 478.2 (M + H* , 100%).
Compound A160
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yI)-piperidin-l-yI]-6-(4-[l,2,3]thiadiazol-4-yl- phenoxy)-pyrimidine-5-carboxylic acid
White solid (3.8 mg, 13.63%); Η NMR 400 MHz MeOD δ (ppm): 9.23 (s, IH), 8.13(d, 2H) 8.06(s,lH)„ 7.29(d, 2H), 4.61 (m.2H), 3.30 (m, 2H), 3.05(q, IH), 2.15 (m, 2H), 1.97 (m, 2H), 1.32 (d, 6H); LCMS (ESI) for C23H23N704S: m/z 494.3 (M + H+, 100%).
Compound A161
[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-[l,2,3]thiadiazol-4-yl- phenoxy)-pyrimidin-5-yl]-methanol
Yellow solid (17.5mg, 85.03%); Η NMR400MHz CDC13 δ (ppm): 8.63 (s, IH), 8.31(s,lH), 8.1 l(d, 2H), 7.27(d, 2H),4.77 (s,2H), 4.23 (m, 2H), 3.28 (m, 2H), 3.28 (m, IH), 3.07(q, IH),
2.21 (m, 2H), 2.03 (m, 2H), 1.34 (d, 6H); LCMS (ESI) for C23H25N703S: m/z 480.3 (M + H+, 100%)
Compound A162
[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yI]-6-(4-[l,2,3]thiadiazol-4-yI- phenoxy)-pyrimidin-5-yImethyI]-dimethyl-amine White solid, (4.2mg, 15.83%), LCMS (ESI) for C25H30N8O2S: m/z 507.3 (M + it, 100%).
Compound A163
4-[4-(3-tert-Butyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(6-methanesulfonyl-pyridin-3- yloxy)-5-nitro-pyrimidine
Compound A163 was prepared using the general procedure for the addition of amine to pyrimidine; yellow solid (82mg, 81%). JH NMR 400MHz CDC13 δ(ppm): 8.60(s, IH); 8.19(s, IH); 8.18(d,lH); 7J9(d,lH); 4.12(db,2H); 3.39-3.29(m,3H); 3.26(s,3H); 2.22(db,2H); 2.06-2.02(m, 2H); 1.36(s,9H).Exact mass calculated for C21H25N 706S 503.16, LCMS (ESI) m/z 504.2(M+H+, 100%).
Compound A164
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methanesuIfonyl-phenoxy)-
2-methyI-pyrimidine-5-carbonitrile
1 To a solution of 4-chloro-6-(4-methanesulfonyl-phenoxy)-2-methyl-pyrimidine-5- carbonitrile (80.0 mg, 0.25 mmol) and 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine (107.1 mg, 0.50 mmol) in DMF (1 mL) was added potassium carbonate (68.3 mg, 0.50 mmol) and the resulting mixture was left stirring for 2 hours at room temperature. Worked up with ethyl acetate, sodium bicarbonate, dried with magnesium sulfate and evaporated. The crade product was crystallized with ethyl acetate/hexane over night and filtered off to afford Compound A164 as a yellow solid (30.6mg). LCMS (ESI) for C23H26N604S: m/z 483.3 (M + H+, 100%), Η NMR 400MHz CDC13 δ (ppm): 8.00 (d, 2H), 7.38 ( d, 2H), 4.82 (m, 2H), 3.45 (m, 2H), 3.31 (m, IH), 3.10 (s, 3H), 3.08 (m, IH), 2.35 (s, 3H), 2.24(m, 2H), 2.03 (m, 2H), 1.34(d, 6H).
Compound A165 l-[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methanesulfonyl- phenoxy)-pyrimidin-5-yl]-ethanone
To a solution of l-[4-chloro-6-(4-methanesulfonyl-phenoxy)-pyrimidin-5-yl]- ethanone (0.21 mmol, 70 mg) and 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine (0.21 mmol, 49 mg) in N,N-dimethyl formamide (500 uL) was added potassium carbonate (.21 mmol, 29 mg). The mixture was microwaved at 100 °C for 150 seconds. Its progress was monitored by thin layer chromatography and LCMS. The reaction was treated with water and the desired compound was extracted in ethyl acetate. Organic layer was evaporated in vacuo. Purification by HPLC provided Compound A165 as a white solid (20 mg, 20%). Η-NMR (400 MHz, CDC13) δ(ppm): 8.24 (s, IH); 8.01 (d, 2H); 7.32 (d, 2H); 4.02 (m, 2H); 3.22 (m, 3H); 3.10 (m, IH); 3.08 (s, 3H); 2.69 (s, 3H), 2.18 (m, 2H), 2.02 (m, 2H); 1.35 (d, 6H). LCMS (ESI), m/z 486.3 (M+H+, 100%).
EXAMPLE 13
SYNTHESES OF COMPOUNDS OF THE PRESENT INVENTION
Compound Bl l-{6-[(Benzo[l,3]dioxol-5-ylmethyI)-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; General Method 14.
Starting material, {6-chloro-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester was prepared by general method 2. A mixture of 6-chloro-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester (63 mg,0.2 mmol), amine (1.1 eqv, 33 mg, 0.22 mmol) and potassium carbonate (1.1 eqv, 31 mg,0.22 mmol) in DMF (1 ml) was stirred at 100 °C for 3 minutes in Smith microwave Synthesiser. HPLC purification afforded compound Bl as yellow oil (59 mg, 54 %). Η NMR 400MHz CDC13 δ (ppm): 8.58 (s, IH); 8.01 (s, IH); 6.63 (d, 2H); 6.61 (s, IH); 5.79 (s, 2H); 4.51 (d, 2H); 3.99 (q, 2H) 3.70 (dt, 2H); 3.10 (td, 2H); 2.48 (m, IH); 1.88 (dt, 2H); 1.70 (td, 2H); 1.09 (t, 3H). Exact mass calculated for C20H23, N506 429.16, LCMS (ESI) m/z 430.0 (M+W, 100%).
Compound B2 l-[5-Nitro-6-(3,4,5-trimethoxy-benzylamino)-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester;
[method 14]. Filtered the reaction mixture and the filtrate was purified by semi preparatory HPLC afforded the pure product in 28 % yield. Η NMR, 400MHz, CDC13, δ (ppm): 8.71 (m, IH); 8.07 (s, IH); 7.10 (s, 2H); 6.42 (s, 2H); 4.56 (d, 2H); 4.02 (q, 2H); 3.71 (s, 6H); 3.69 (s, 3H); 3.16 (m, 2H); 2.52 ( , IH); 1.91 (m, 2H); 1.74 (m, 2H); 1.12 (t, 3H). LCMS (ESI) for C22H29N507: m/z 475(M+H+, 100 %).
Compound B3
(5-Nitro-6-piperidin-l-yl-pyrimidin-4-yl)-(3-trifluoromethyl-benzyl)-amine; [method 14]. The product was purified by Preparatory TLC using hexane/ ethyl acetate (9:1). Η NMR 400MHz CDC13 δ (ppm): 8.65 (s); 8.05 (s, IH, pyrimidine); 7.65 (d, IH); 7.50 (m, 2H); 7.40 (d, IH); 5.00(s, 2H); 3.50 (m, 4H), 1.80 (s, NH); 1.75-1.60 (m, 5H)
Compound B4 l-[5-Nitro-6-(2-trifluoromethyl-benzylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; ,„^„„
WO 2004/06538 271
[method 14]. The residue was filtered through a silica plug [Si02; EtOAc/hexane; 50:50] and solvent removed in vacuo. Yield 0.143 g, 50 %. Yellow oil. JH NMR 400MHz CDC13 δ(ppm): 8.63 (m, IH); 8.07 (s, IH); 7.68 (m, IH); 7.53 (m, 2H); 7.40 (m, IH); 5.01 (m, 2H); 4.17 (m, 2H); 3.89 (m, 2H); 3.21 (m, 2H); 2.63 (m, IH); 2.03 (m, 2H); 1.85 (m, 2H); 1.28 (m, 3H). LCMS (ESI) m/z 390 (M+W, 100 %)
Compound B5 l-[5-Nitro-6-(4-trifluoromethyl-benzylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 14]. Solvent was removed in vacuo and residue was purified by preparatory TLC.
[Si02; EtOAc/hexane; 10:90]. Yield 0.227 g, 73 %. Yellow oil. Η NMR 400MHz CDC13 δ (ppm): 8.69 (m, IH); 8.06 (s, IH); 7.60 (d, 2H); 7.45 (d, 2H); 4.87 (m, 2H); 4.17 (m, 2H);
3.90 (m, 2H); 3.22 (m, 2H); 2.64 (m, IH); 2.03 (m, 2H); 1.85 (m, 2H); 1.28 ( , 3H)
Compound B6 l-[5-Nitro-6-(3-trifluoromethyI-benzylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 14]. Solvent was removed in vacuo and residue was purified by preparatory TLC. [Si02; EtOAc/hexane; 10:90. Yield 0.177g, 65 %. Yellow solid. Η NMR 400MHz CDC13 δ(ppm): 8.69 (m, IH); 8.06 (s, IH); 7.61 (m, IH); 7.54 (m, 2H); 7.48 (m, IH); 4.87 (m, 2H); 4.17 (m, 2H); 3.90 (m, 2H); 3.22 (m, 2H); 2.64 (m, IH); 2.03 (m, 2H); 1.85 (m, 2H); 1.28 (m, 3H)
Compound B7
(5-Nitro-6-piperidin-l-yl-pyrimidin-4-yI)-(2-trifluoromethyl-benzyl)-amine; [method 14]. The product was purified by Preparatory TLC using hexane/ ethyl acetate (9:1). Η NMR 400MHz CDC13 δ (ppm): 8.65 (s); 8.05 (s, IH, pyrimidine); 7.65 (d, IH); 7.50 (m, 2H); 7.40 (d, IH); 5.00(s, 2H); 3.50 (m, 4H,), 1.80 (s, NH),1.75-1.60 (m, 5H)
Compound B8 (5-Nitro-6-piperidin-l-yI-pyrimidin-4-yl)-(4-trifluoromethyl-benzyl)-amine;
The product was purified by Preparatory TLC using hexane/ ethyl acetate/dichloromethane (8:1: 1). Η NMR 400MHz CDC13 δ (ppm): 9.05 (s); 8.05 (s, IH, pyrimidine); 7J0 (d, 2H); 7.50 (d, 2H); 4.90 (s, 2H); 3.40 (m,4H,), 1.75-1.60 (.m, 6H).
Compound B9 l-[5-Amino-6-(3-trifluoromethyl-benzylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; General Method 15.
Di-substituted-5-nitropyrimidine (180 mg, 0.4 mmol) was dissolved in ethyl acetate (5 mL) and flushed with N2 gas. Palladium catalyst [5 %, Pd/C] was added and hydrogen gas was introduced into the mixture. The reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was filtered through Celite and the solvent was removed under vacuo. Yield 0.158 g, 94 %. White solid. Η NMR 400MHz CDC13 δ(ppm): 8.69 (m, IH); 8.06 (s, IH); 7.61 (m, IH); 7.54 (m, 2H); 7.48 (m, IH); 4.87 (m, 2H); 4.17 (m, 2H); 3.90 (m, 2H); 3.22 (m, 2H); 2.64 (m, IH); 2.03 (m, 2H); 1.85 (m, 2H); 1.28 (m, 3H). LCMS (ESI) m/z 424 (M+H+,100%)
Compound B10 l-[5-Amino-6-(4-trifluoromethyl-benzylamino)-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[method 15]. Yield 0.121 g, 72 %. White solid. lH NMR 400MHz CDC13 δ(ppm): 8.13 (s,
IH); 7.58 (d, 2H); 7.46 (d, 2H); 4.75 (m, 2H); 4.17 (m, 2H); 3.43 (m, 2H); 2.86 (m, 2H); 2.49
(m, IH); 2.05 (m, 2H); 1.86 (m, 2H); 1.29 (m, 3H). LCMS (ESI) m/z 424 (M+H+, 100%)
Compound Bll l-[6-(4-Bromo-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; General Method 16.
[6-chloro-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester (415 mg, 1.32 mmol) and 4-bromoaniline (309 mg, 1.80 mmol) were dissolved in anhydrous 1,4-dioxane (0.5-1 ml) and irradiated in a sealed microwave reaction tube at 250 °C for 300 seconds. The reaction mixture was passed through a silica plug [Si02; EtOAc/hexane; 20:80]. Yield 0.070 g, 12 %. Yellow solid. Η NMR 400MHz CDC13 δ (ppm): 9.98 (s, IH); 8.03 (s, IH); 7.41 (m, 2H); 7.17 (m, 2H); 4.09 (m, 2H); 3.83 (m, 2H); 3.16 (m, 2H); 2.77 (m, IH); 1.97 (m, 2H); 1.78 (m, 2H); 1.20 (m, 3H). LCMS (ESI) m/z 451, 452 (M+H+, 100 %)
Compound B12 l-[5-Nitro-6-(4-trifluoromethyl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[Method 16]. Yield O.OlOg, 14%. Yellow solid. Η NMR 400MHz CDC13 δ (ppm): 10.11 (s,
IH); 8.07 (s, IH); 7.69 (d, 2H); 7.54 (d, 2H); 4.09 (m, 2H); 3.84 (m, 2H); 3.17 (m, 2H); 2.58
(m, IH); 1.97 (m, 2H); 1.79 (m, 2H); 1.20 (m, 3H). LCMS (ESI) m/z 440 (M+H÷, 100 %) Compound B13 l-[6-(Methyl-phenyl-amino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[method 16] Yield 0.062 g, 93 %. Yellow solid. Η NMR 400MHz CDC13 δ(ppm): 8.09 (s,
IH); 7.33 (m, 2H); 7.17 (m, 3H); 4.14 (m, 2H); 3.92 (m, 2H); 3.54 (s, 3H); 3.19 (m, 2H); 2.58
(m, IH); 1.99 (m, 2H); 1.83 (m, 2H); 1.26 (m, 3H). LCMS (ESI) m/z 386 (M+H÷, 100 %)
Compound B14 l-[5-Nitro-6-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. Yield 0.066 g, 92 %. Yellow solid. !H NMR 400MHz CDC13 δ(ppm): 10.09 (s,
IH); 8.11 (s, IH); 7.63 (d, 2H); 7.22 (d, 2H); 4.17 (m, 2H); 3.91 (m, 2H); 3.25 (m, 2H); 2.66
(m, IH); 2.05 (m, 2H); 1.86 (m, 2H); 1.28 (m, 3H). LCMS (ESI) m/z 456 (M+H+,100%)
Compound B15 l-[6-(4-Fluoro-phenylamino)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. Yield 0.071 g, 100 %. Yellow solid. Η NMR 400MHz CDC13 δ(ppm): 10.01
(s, IH); 8.08 (s, IH); 7.50 (m, 2H); 7.06 ( , 2H); 4.16 (m, 2H); 3.90 (m, 2H); 3.23 (m, 2H);
2.65 (m, IH); 2.03 (m, 2H); 1.86 (m, 2H); 1.27 (m, 3H). LCMS (ESI) m/z 390 (M+H+,100%)
Compound B16 l-[6-(3,5-Difluoro-phenyIamino)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. Yield 0.066 g, 89 %. Yellow solid. Η NMR 400MHz CDC13 δ(ppm): 10.13 (s, IH); 8.15 (s, IH); 7.29 (m, 2H); 6.60 (m, IH); 4.16 (m, 2H); 3.90 (m, 2H); 3.22 (m, 2H); 2.64 (m, IH); 2.03 (m, 2H); 1.84 ( , 2H); 1.27 (m, 3H). LCMS (ESI) m/z 408 (M+H+,100%)
Compound B17 l-[6-(3,5-Dichloro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic cid ethyl ester;
[Method 16]. Yield 0.023 g, 33 %. Yellow solid. JH NMR 400MHz CDC13 δ(ppm): 10.08 (s,
IH); 8.16 (s, IH); 7.62 ( , 2H); 7.15 (m, IH); 4.17 (m, 2H); 3.91 (m, 2H); 3.23 (m, 2H); 2.66
(m, IH); 2.05 (m, 2H); 1.85 (m, 2H); 1.28 (m, 3H). LCMS (ESI) m z 440 (M+H+, 100%)
Compound B18 1 - [6-(Benzo [1 ,3] dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.063 g, 70 %. Orange oil. Η NMR400MHz CDC13 δ(ppm): 9.96 (s, IH); 8.09 (s, IH); 7.17 (s, IH); 6.81 (m, 2H); 5.98 (s, 2H); 4.16 (q, 2H); 3.91 (m, 2H); 3.24 (m, 2H); 2.64 (m, IH); 2.04 (m, 2H); 1.86 (m, 2H); 1.27 (m, 3H). LCMS (ESI) m/z 416 (M+H+, 100 %)
Compound B19 l-[6-(2-Bromo-4-trifluoromethoxy-phenyIamino)-5-nitro-pyrimidin-4-yI]-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. The reaction mixture was passed through a silica plug [Si02; EtOAc/hexane; 10:90]. Yield 0.020 g, 24 %. Yellow solid. Η NMR 400MHz CDC13 δ(ppm): 10.21 (s, IH); 8.28 (m, IH); 8.06 (s, IH); 7.42 (m, IH); 7.17 (m, IH); 4.09 (m, 2H); 3.85 (m, 3.85); 3.18 (m, 2H); 2.55 (m, IH); 1.98 (m, 2H); 1.79 (m, 2H); 1.20 (m, 3H). LCMS (ESI) m/z 535, 536 (M+H+, 100 %)
Compound B20 l-[6-(2-Fluoro-phenyIamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic cid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue was purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.016 g, 22 %. Yellow oil. Η NMR 400MHz CDCl3δ(ppm): 10.11 (s, IH); 8.16 (m, 2H); 7.15 (m, 3H); 4.16 (m, 2H); 3.92 (m, 2H); 3.25 (m, 2H); 2.65 (m, IH); 2.03 (m, 2H); 1.86 (m, 2H); 1.28 (m, 3H). LCMS (ESI) m/z 390 (M+H+,100%)
Compound B21 l-[6-(3-Fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[Method 16]. The reaction mixture was passed through a silica plug [Si02; EtOAc/hexane; 20:80]. Yield 0.034 g, 43 %. Yellow solid. Η NMR400MHz CDC13 δ(ppm): 10.12 (s, IH); 8.14 (s, IH); 7.63 (m, IH); 7.31 (m, IH); 7.23 (m, IH); 6.87 (m, IH); 4.17 (m, 2H); 3.91 (m, 2H); 3.24 (m, 2H); 2.65 (m, IH); 2.05 (m, 2H); 1.86 (m, 2H); 1.28 (m, 3H). LCMS (ESI) m z 390 (M+H1", 100%)
Compound B22 l-{6-[(2-FIuoro-phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.018 g, 23 %. Yellow oil. Η NMR 400MHz CDC13 δ(ppm): 8.09 (s, IH); 7.14 (m, 2H); 7.03 (m, 2H); 4.15 (m, 2H); 3.93 (m, 2H); 3.51 (s, 3H); 3.20 (m, 2H); 2.60 ( , IH); 2.00 (m, 2H); 1.83 (m, 2H); 1.27 (m, 3H). LCMS (ESI) m z 404 (M+H+,100%)
Compound B23 l-[6-(Ethyl-phenyl-amino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.008 g, 8 %. Yellow oil. Η NMR400MHz CDC13 δ(ppm): 8.13 (s, IH); 7.32 (m, 2H); 7.20 (m, 2H); 7.12 (m, IH); 4.14 (m, 4H); 3.86 (m, 2H); 3.14 (m, 5H); 2.57 (m, IH); 1.98 (m, 2H); 1.83 (m, 2H); 1.24 (m, 4H). LCMS (ESI) m/z 400 (M+H+,100%)
Compound B24 l-{6-[(4-Chloro-phenyl)-methyI-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxyIic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.008 g, 8 %. Yellow oil. 1HNMR400MHz CDC13 δ(ppm): 8.10 (s, IH); 7.29 (d, 2H); 7.10 (d, 2H); 4.15 (m, 2H); 3.93 (m, 2H); 3.52 (s, 3H); 3.21 (m, 2H); 2.56 (m, IH); 2.01 (m, 2H); 1.85 (m, 2H); 1.26 (m, 3H) . LCMS (ESI) m z 420 (M+H+,100%)
Compound B25 l-[6-(4-Difluoromethyl-benzyIamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 14]. HPLC provided compound B25 as yellow oil (58 mg, 64 %). *H NMR 400
MHz CDC13 δ (ppm): 8.48 (s, IH); 8.13 (s, IH); 7.27 (d, 2H); 7.05 (d, 2H); 4.72 (d, 2H); 4.10
(q, 2H); 3.80 (dt, 2H); 3.25 (td, 2H); 2.60 (m, IH); 2.00 (dt, 2H); 1.84 (td, 2H); 1.19 (t, 3H).
Exact mass calculated for C20H23 F 2N505 451.17, LCMS (ESI) m/z 452.1 (M+H+, 100%).
Compound B26 l-{6-[(2,3-Dihydro-benzo[l,4]dioxin-6-yImethyl)-amino]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; [method 14]. HPLC provided compound B26 as yellow solid (62 mg, 56 %). Η NMR 400MHz CDC13 δ (ppm): 8.86 (s,lH); 8.28 (s, IH); 6.95 (d,lH); 6.93 (s, IH); 6.89 (d, IH); 4.75 (d,2H); 4.25 (q, 2H); 3.96 (dt, 4H); 3.87 (dt, 2H); 3.38 (td, 2H); 2.75 (m,lH); 2.15 (dt,2H); 1.98 (td, 2H); 1.35 (t, 3H). Exact mass calculated for C21H25N506 443.18, LCMS (ESI) m/z 444.6(M+H+, 100%).
Compound B27 l-{6-[(2,3-Dihydro-benzo[l,4]dioxin-2-ylmethyI)-amino]-5-nitro-pyrimidin-4-yI}- piperidine-4-carboxylic acid ethyl ester;
[method 14]. HPLC provided compound B27 as yellow solid (62 mg, 56 %). H NMR 400MHz CDCI3 δ(ppm): 8.86 (s, IH); 8.28 (s, IH); 6.95 (d, IH); 6.93 (s, IH); 6.89 (d, IH); 4.75 (d, 2H); 4.25 (q, 2H); 3.96 (dt, 4H); 3.87 (dt, 2H); 3.38 (td, 2H); 2.75 (m, IH); 2.15 (dt, 2H); 1.98 (td, 2H); 1.35 (t, 3H). Exact mass calculated for C21H25N506 443.18, LCMS (ESI) m/z 444.6(M+H+, 100%).
Compound B28 l-{6-[(2,3-Dihydro-benzofuran-5-ylmethyl)-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[method 14]. HPLC provided compound B28 as yellow solid (62 mg, 57 %). *H NMR 400MHz CDCI3 δ(ppm): 8.47(s,lH); 8.02(s, IH); 7.12(s, IH); 7.02(d, IH); 6.68(d,lH); 4.62(d, 2H); 4.50(t, 2H); 4.09(q, 2H); 3.81(dt, 2H); 3.15(d, 2H); 3.12(t, 2H); 2.55(m, IH); 1.95(dt, 2H); 1.77(td, 2H); 1.19(1, 3H). Exact mass calculated for C21H25N505427.19, LCMS (ESI) m/z 428.1(M+H+, 100%).
Compound B29 l-{6-[(6-Fluoro-4H-benzo[l,3]dioxin-8-ylmethyl)-amino]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester;
[method 14]. HPLC provided compound B29 as yellow solid (77 mg, 67 %). Η NMR 400MHz CDCI3 δ(ppm): 8.92 (s,lH); 8.09 (s, IH); 6.88 (dd, IH); 6.58 (dd,lH); 5.22 (s,2H); 4.80 (s, 2H); 4.68 (d, 2H); 4.09 (q, 2H); 3.80 (d, 2H); 3.19 (td, 2H); 2.57 (m, IH); 1.96 (dt, 2H); 1.79 (td, 2H); 1.19 (t, 3H). Exact mass calculated for C21H24FN506461.17, LCMS (ESI) m/z 462.3 (M+H+, 100 %).
Compound B30 l-[6-(3,4-Dihydro-2H-benzo[b][l,4]dioxepin-7-ylamino)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; [Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.069 g, 71 %. Yellow oil. lηΑ NMR 400 MHz CDC13 δ (ppm): 9.96 (s, IH); 8.09 (s, IH); 7.24 (m, IH); 7.04 (m, IH); 6.95 (m, IH); 4.22 (m, 6H); 3.90 (m, 2H); 3.22 (m, 2H); 2.63 (m, IH); 2.19 (m, 2H); 2.03 (m, 2H); 1.85 (m, 2H); 1.26 ( , 3H). LCMS (ESI) m/z 444 (M+H+,100 %)
Compound B31 l-{6-[4-(Morpholine-4-sulfonyI)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.030 g, 29 %. Yellow oil. Η NMR 400MHz CDC13 δ (ppm): 10.29 (s, IH); 8.19 (s, IH); 7.89 (d, 2H); 7.74 (d, 2H); 4.17 (m, 2H); 3.91 (m, 2H); 3.75 (m, 3.75); 3.27 (m, 2H); 3.02 (m, 6H); 2.66 (m, IH); 2.07 (m, 2H); 1.87 (m, 2H); 1.28 (m, 4H). LCMS (ESI) m/z 521 (M+H+, 100%)
Compound B32 l-[6-(2,2-Difluoro-benzo[l,3]dioxol-4-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.069 g, 74
%. Yellow solid. Η NMR 400MHz CDC13 δ (ppm): 10.06 (s, IH); 8.10 (s, IH); 7.61 (s, IH);
7.25 (s, IH); 7.04 (m, 2H); 4.17 (m, 2H); 3.91 (m, 2H); 3.25 (m, 2H); 2.65 (m, IH); 2.05 (m,
2H); 1.87 ( . 2H); 1.28 (m, 3H). LCMS (ESI) m/z 452 (M+H+, 100 %)
Compound B33 l-[6-(2,2-Difluoro-benzo[l,3]dioxol-5-yIamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. Preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.048g, 50%. Yellow solid. Η NMR 400MHz CDCl3 δ(ppm): 9.87 (s, IH); 8.13 (s, IH); 7.67 (m, IH); 7.25 (s, IH);
7.09 (m, IH); 6.92 (m, IH); 4.17 (m, 2H); 3.92 (m, 2H); 3.26 (m, 2H); 2.66 (m, IH); 2.06 (m,
2H); 1.88 (m, 2H); 1.58 (m, 2H); 1.28 (m, 3H). LCMS (ESI) m/z 452 (M+H+, 100 %)
Compound B34 l-[6-(l,l-Dioxo-lH-lλ6-benzo[b]thiophen-6-ylamino)-5-nitro-pyrimidin-4-yI]-piperidine-
4-carboxylic acid ethyl ester;
[Method 16]. preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.021 g, 22 %. Yellow solid. Η NMR 400MHz CDC13 δ (ppm): 10.23 (s, IH); 8.35 (m, IH); 8.07 (s, IH); 7.51 (m, ,„^„„
WO 2004/06538 278
IH); 7.21 (m, IH); 7.08 (m, IH); 6.57 (m, 1H); 4.05 (q, 2H); 3.79 (m, 2H); 3.13 (m, 2H); 2.53 (m, IH); 1.93 (m, 2H); 1.74 (m, 2H); 1.15 (m, 3H). LCMS (ESI) m/z 460 (M+H+,100%)
Compound B35 l-{6-[(Furan-3-yImethyl)-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method 14]. HPLC provided compound B35 as yellow solid (46 mg, 61 %). *H NMR 400MHz CDC13 δ(ppm): 8.71(s,lH); 8.16(s, IH); 7.44(s,lH); 7.37(d, IH); 6.35(d, IH); 4.59(d,2H); 4.11(q,2H); 3.82(dt, 2H); 3.26(td, 2H); 2.61(m, IH); 2.00(dt, 2H); 1.84(td, 2H); 1.20(t, 3H). Exact mass calculated for CπH21 N5O5375.15, LCMS (ESI) m/z 376.1 (M+H+, 100%).
Compound B36 l-{6-[2-(4-Methoxy-phenoxy)-ethylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[method 14]. HPLC provided compound B36 as yellow solid (77 mg, 69 %). *H NMR 400MHz CDCI3 δ (ppm): 9.22 (s,lH); 8.26 (s, IH); 6.90 (d,2H); 6.87 (d, 2H); 4.20 (t,2H); 4.19 (t,2H); 4.04 (q, 2H); 3.93 (dt,2H); 3.79 (s,3H); 3.39 (td, 2H); 2.72 (m, IH); 2.11 (dt, 2H); 1.94 (td, 2H); 1.30 (t, 3H). Exact mass calculated for C21H27N5O6445.20, LCMS (ESI) m/z 446.2 (M+H+, 100 %).
Compound B37 l-{6-[2-(5-Methoxy-lH-indol-3-yI)-ethylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[method 14]. HPLC provided compound B37 as yellow solid (63 mg, 54 %). *H NMR 400MHz CDCI3 δ (ppm): 8.47 (s,lH); 8.04 (s, IH); 7.91 ( s, IH); 7.19 (d,lH); 7.01 (dd,2H); 6.80 (dd, IH); 4.08 (q, 2H); 3.84 (dt,2H); 3.78 (s, 3H); 3.13 (td, 2H); 3.03 ( t,2H); 2.54 (m, 5H); 1.94 (dt, 2H); 1.76 (td, 2H); 1.18 (t, 3H). Exact mass calculated for C23H28N6θ5468.21 (ESI) m/z 469.2, 100 %).
Compound B38
(3,4-Dihydro-2H-benzo[b][l,4]dioxepin-7-yl)-[5-nitro-6-(4-propyl-piperidin-l-yl)- pyrimidin-4-yl] -amine;
[Method 16]. preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.003 g, 3 %. Yellow oil.
Η NMR 400MHz CDC13 δ (ppm): 9.78 (s, IH); 7.87 (s, IH); 6.85 (m, IH); 6.74 (m, IH); 4.00 (m, 4H); 3.71 (m, 2H); 2.86 (m, 2H); 1.97 (m, 2H); 1.58 (m, 2H); 1.12 (m, 2H); 1.03 (m, 6H); 0.69 (m, 3H). LCMS (ESI) m z 414 (M+H+, 100 %)
Compound B39
(3-Fluoro-phenyl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-amine; [Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.007 g, 9 %. Yellow oil. Η NMR 400MHz CDC13 δ(ppm): 10.11 (s, IH); 8.08 (s, IH); 7.59 (m, IH); 7.26 (m, IH); 7.20 (m, IH); 6.82 (m, IH); 3.90 (m, 2H); 3.04 (m, 2H); 1.76 (m, 2H); 1.56 (m, IH); 1.29 (m, 2H); 1.20 (m, 4H); 0.86 (m, 3H). LCMS (ESI) m/z 360 (M+H+, 100 %)
Compound B40
(3-Methoxy-phenyl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-amine; [Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.002 g, 2 %. Yellow oil. Η NMR 400MHz CDC13 δ(ppm): 10.04 (s, IH); 8.04 (s, IH); 7.21 (m, 2H); 7.04 (m, IH); 6.67 (m, IH); 3.87 (m, 2H); 3.75 (s, 3H); 3.02 (m, 2H); 1.74 (m, 2H); 1.49 (m, IH); 1.27 (m, 2H); 1.19 (m, 4H); 0.84 (m, 3H). LCMS (ESI) m/z 404 (M+H+,100%) •
Compound B41 l-{6-[(3-Fluoro-phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yI}-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.023 g, 30%. Light brown oil. 1H NMR 400MHz CDC13 δ(ppm): 8.13 (s, IH); 7.26 (m, IH); 6.88 (m, 3H); 4.13 (q, 2H); 3.91 (m, 2H); 3.53 (s, 3H); 3.19 (m, 2H); 2.58 (m, IH); 1.99 (m, 2H); 1.81 (m, 2H); 1.24 (m, 3H). LCMS (ESI) m/z 404 (M+H+,100%)
Compound B42
1- [6-(4-Benzoyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC
[Si02; EtOAc/hexane; 20:80]. Yield 0.059 g, 65 %. Light yellow solid. Η NMR 400MHz
CDCl3 δ (ppm): 10.31 (s, IH); 8.21 (s, IH); 7.89 (m, 2H); 7.82(m, 4H); 7.61 (m, IH); 7.50
(m, 2H); 4.19 (q, 2H); 3.94 (m, 2H); 3.27 (m, 2H); 2.67 (m, IH); 2.08 (m, 2H); 1.89 (m, 2H);
1.29 (m, 3H). LCMS (ESI) m/z 476 (M+H+,100%) Compound B43 l-{6-[4-(l,l-Dioxo-lλ6-thiomorpholin-4-yImethyl)-phenylamino]-5-nitro-pyrimidin-4- yl}-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 50:50]. Yield 0.055 g, 56 %. Yellow oil. JH NMR400MHz CDC13 δ(ppm): 10.09 (s, IH); 8.11 (s, IH); 7.55 (d, 2H); 7.31 (d, 2H); 5.29 (s, IH); 4.15 (m, 2H); 3.89 (m, 2H); 3.63 (m, 2H); 3.22 (m, 2H); 3.01 (m, 6H); 2.64 (m, IH); 2.03 (m, 2H); 1.84 (m, 2H); 1.25 (m, 4H). LCMS (ESI) m/z 519 (M+H+,100%)
Compound B44 l-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 50:50]. Yield 0.032 g, 37 %. Yellow solid. !H NMR 400MHz CDC13 δ (ppm): 10.21 (s, IH); 8.11 (s, IH); 7.83 (m, 4H); 4.09 (m, 2H); 3.84 (m, 2H); 3.18 (m, 2H); 2.99 (s, 3H); 2.59 (m, IH); 1.98 (m, 2H); 1.79 (m, 2H); 1.20 (m, 3H). LCMS (ESI) m/z 450 (M+H+,100%)
Compound B45 l-[6-(4-Dimethylsulfamoyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. The solvent was removed in vacuo and the residue purified by preparatory TLC [Si02; EtOAc/hexane; 40:60]. Yield 0.060 g, 57 %. Yellow solid. Η NMR 400MHz CDC13 δ(ppm): 10.20 (s, IH); 8.10 (s, IH); 7.79 (d, 2H); 7.68 (d, 2H); 4.09 (q, 2H); 3.84 (m, 2H); 3.18 (m, 2H); 2.64 (s, 6H); 2.57 (m, IH); 1.98 (m, 2H); 1.79 (m, 2H); 1.20 (m, 3H). LCMS (ESI) m/z 479 (M+H+,100%)
Compound B46 l-[6-(3-Methoxy-phenylamino)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. purified by preparatory TLC. [Si02; 2:3 EtOAc/hexanes]. Yield 75 mg, 84 %.
Yellow solid. Η-NMR (400 MHz, CDC13) δ(ppm): 10.15 (s, IH); 8.16 (s, IH); 7.24 (m, 2H);
7:il (m, IH); 6.88 (m, IH); 4.10 (q, 2H); 3.92 (m, 2H); 3.82 (s, IH); 3.17 (m, 2H); 2.62
(heptet, IH); 2.09 (m, 2H); 1.95 (m, 2H); 1.25 (t, 3H). LCMS (ESI), m/z 401 (M+H+, 100%) Compound B47 l-[6-(2-Methoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic cid ethyl ester;
[Method 16]. purified by preparatory TLC. [Si02; 15/85 EtOAc/hexanes]. Yield 56 mg, 63
%. Yellow solid. TLNMR (400 MHz, CDC13) δ(ppm): 10.57 (s, IH); 8.41 (m, IH); 8.18 (s,
IH); 7.15 (m, IH); 7.0 (m, IH); 4.21 (q, 2H); 3.92 (m, 5H); 3.25 (m, 2H); 2.63 (m, 2H); 2.08
(m, 2H); 1.88 (m, 2H); 1.24 (m, 3H). LCMS (ESI), m/z 401 (M+H+, 100%)
Compound B48 l-[6-(3,5-Bis-trifluoromethyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. Purified by flash chromatography. [Silica Gel 60; 20/80 EtOAc/hexanes].
Yield 89 mg, 80 %. Yellow solid. Η-NMR (400 MHz, CDC13) δ (ppm): 10.23 (s, IH); 8.20
(m, 3H); 7.65 (s, IH); 4.20 (m, 2H); 3.92 (m, 2H); 3.15 (m, 2H); 2.68 (heptet, IH); 2.10 (m,
2H); 1.94 (m, 2H); 1.30 (t, 3H). LCMS (ESI), m/z 507 (M+H+, 100%)
Compound B49 l-[6-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. purified by preparatory TLC. [Si02; 20/80 EtOAc/hexanes]. Yield 61 mg, 64 %. Orange solid. Η-NMR (400 MHz, CDC13) δ (ppm): 10.61 (s, IH); 8.24 (s, IH); 8.17 (s, IH); 6.84 (d, IH); 6.62 (dd, IH); 4.17(q, 2H); 3.92 (m, 5H); 3.80 (s, 3H); 3.23 (m, 2H); 2.63 (heptet, IH); 2.10 (m, 2H); 1.84 (m, 2H); 1.25 (t, 3H). LCMS (ESI), m/z 431 (M+H+, 100 %)
Compound B50 l-[6-(3,5-Dimethoxy-benzylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 14]. Semi preparatory HPLC afforded the pure product in 28 %. Η NMR, 400MHz, CDC13, δ (ppm): 8.85 (m, IH); 8.32 (s, IH); 7.50 (s, IH); 6.73 (d, 2H); 6.63 (t, IH); 4.96 (d, 2H); 4.40 (q, 2H); 4.13 (m, 2H); 4.03 (s, 6H); 3.45 (m, 2H); 2.86 (m, IH); 2.26 (m, 2H); 2.08 (m, 2H); 1.50 (t, 3H). LCMS (ESI) for C22H29N507: m/z 475(M+H+, 100 %).
Compound B51
[5-Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-(3,4,5-trimethoxy-benzyl)-amine; [method 14]. semi preparative HPLC afforded the pure product in 16 %. :H NMR, 400MHz, CDCI3, δ (ppm): 8.81(m, IH); 8.05(s, IH); 7.07 (s, IH); 6.39 (s, 2H); 4.53 (d, 2H); 3.76 (m, IH); 3.67 (s, 6H); 3.66 (s, 3H); 3.01 (m, 2H); 1.68 (d, 2H); 1.12 (m, 6H); 0.72 (t, 3H). LCMS (ESI) for C22H3ιN505: m/z 445 (M+W, 100 %).
Compound B52
(3,5-Dimethoxy-benzyl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-amine; [method 14]. Semi preparative HPLC afforded the pure product in 20 %. ]H NMR, 400MHz, CDC13, δ (ppm): 8.66 (m, IH); 8.11 (s, IH); 7.30 (s, IH); 6.54 (d, 2H); 6.43 (t, IH); 4.76 (d, 2H); 3.96 (m, IH); 3.83 (s, 6H); 3.12 (m, 2H); 1.84 (m, 2H); 1.38 (m 2H); 1.30 (m 4H); 0.95 (t, 3H). LCMS (ESI) for C21H29N504: m/z 415 (M+H+, 100 %).
Compound B53
(4-{5-Nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4-ylamino}-phenyl)- phenyl-methanone;
[Method 16]. purified by preparative TLC. [Si02; 30/70 EtOAc/hexanes] .Yield 42 mg, 51 %. Yellow solid. Η-NMR (400 MHz, CDC13) δ(ppm): 10.3 (s, IH); 8.44 (d, IH); 8.20 (s, IH); 7.87 (m, 2H); 7.81 (m, 4H); 7.59 (m, IH); 7.50 (m, 3H); 7.18 (d, IH); 7.01 (d, IH); 4.22 (heptet, IH); 3.92 (m, 2H); 3.45 (dt, 2H); 2.26 (m, 2H); 1.86 (m, 2H). LCMS (ESI), m/z 513 (M+H+, 100%)
Compound B54
(4-{5-Nitro-6-[4-(2-trifluoromethyl-phenoxy)-piperidin-l-yI]-pyrimidin-4-ylamino}- phenyl)-phenyl-methanone;
[Method 16]. residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.057 g, 68 %. Yellow solid. Η NMR 400 MHz CDC13 δ (ppm): 10.24 (s, IH); 8.13 (s, IH); 7.80
(m, 2H); 7.74 (m, 4H); 7.52 (m, 2H); 7.42 (m, 4H); 6.95 (m, 2H); 4.78 (m, IH); 3.64 (m, 4H);
2.02 (m, 4H). LCMS (ESI) m/z 564 (M+H+, 100 %)
Compound B55 l-[6-(4-Cyano-phenyIamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[Method 16]. residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.035 g, 40 %. Yellow solid. Η NMR 400MHz CDC13 β(ppm): 10.19 (s, IH); 8.10 (s, IH); 7.76 (d,
2H); 7.58 (d, 2H); 4.09 (q, 2H); 3.83 (m, 2H); 3.17 (m, 2H); 2.58 (m, IH); 1.97 (m, 2H); 1.78
(m, 2H); 1.19 (m, 3H) LCMS (ESI) m/z 397 (M+H+,100%)
Compound B56 l-[6-(3,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.070 g, 73 %. Orange solid. Η NMR 400MHz CDC13 δ (ppm): 9.84 (s, IH); 7.91 (s, IH); 6.60 (d, 2H); 6.10 (t, IH); 3.954 (q, 2H); 3.69 ( , 2H); 3.58 (s, 6H); 3.01 (m, 2H); 2.42 (m, IH); 1.82 (m, 2H); 1.63 (m, 2H); 1.05 (m, 3H). LCMS (ESI) m/z 432 (M+H+,100%)
Compound B57 l-[6-(4-sec-Butyl-phenylamino)-5-nitro-pyrimidin-4-yI]-piperidine-4-carboxyIic acid ethyl ester;
[Method 16]. residue purified by preparatory TLC [SiOz; EtOAc/hexane; 20:80]. Yield 0.088 g, 93 %. Orange oil. Η NMR 400MHz CDC13 δ (ppm): 10.10 (s, IH); 8.14 (s, IH); 7.50 (d, 2H); 7.21 (d, 2H); 4.19 (q, 2H); 3.94 (m, 2H); 3.26 (m, 2H); 2.63 (m, 2H); 2.06 (m, 2H); 1.87 (m, 2H); 1.61 (m, 2H); 1.27 (m, 6H); 0.86 (m, 3H). LCMS (ESI) m/z 428 (M+H+, 100 %)
Compound B58 l-[6-(4-Heptyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.092 g, 89 %. Orange oil. 1H NMR400MHz CDCl3 δ(ppm): 10.05 (s, IH); 8.09 (s, IH); 7.43 (d,
2H); 7.18 (d, 2H); 4.16 (q, 2H); 3.90 (m, 2H); 3.22 (m, 2H), 2.60 (m, 3H); 2.02 (m, 2H); 1.84
(m, 2H); 1.27 (m, 13H); 0.87 (m, 3H). LCMS (ESI) m/z 470 (M+H+, 100 %)
Compound B59
2'-(4-Benzoyl-phenylamino)-3'-nitro-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-4- carboxylic acid ethyl ester. General Method 17.
A mixture of 2, 4-dichloro-3-nitro-pyridine (77 mg, 0.4 mmol), 4-benzoyl-aniline (1.0 eqv, 7 9mg, 0.4 mmol) and potassium carbonate (1.4 eqv, 78 mg, 0.56 mmol) in DMF (1 ml) was stirred in a sealed vessel at 150 °C for 30 mins under microwave irradiation. HPLC provided intermediate compound 2-[4-benzoyl-anilino]-4-dichloro-3-nitro-pyridine as brown solid (58 mg, 41 % yield). Exact mass calculated for Cι8H12ClN303 353.06, LCMS (ESI) m/z 353.6(M+H+, 100%).
[method 14]. RP-HPLC provided compound B59 as orange solid (26 mg, 27 % yield). Η NMR 400MHz CDC13 δ (ppm): 9.55 (s, IH); 7.89 (d, 3H); 7.74 (d, 2H); 7.57 (t, IH); 7.46 (t, 2H); 7.32 ( d, 2H); 6.50 (d, IH); 4.12 (q, 2H); 3.63 (d, 2H); 3.26 ( t, 2H); 2.63-2.58 (m, IH); 2.04( d, 2H); 1.94 (td, 2H); 1.21(1, 3H). Exact mass calculated for C26H26N405 474.19, LCMS (ESI) m/z 475.3 (M+W, 100%).
Compound B60 l-[5-Nitro-6-(3,4,5-trimethoxy-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. purified by preparatory TLC. [Si02; 30/70 EtOAc/hexanes] .Yield 42 mg, 41
%. Orange oil. Η-NMR (400 MHz, CDC13) δ(ppm): 9.97 (s, IH); 8.05 (s, IH); 6.77 (s, 2H);
4.08 (q, 2H); 3.81 (m, 11H); 3.17 (t, 2H); 2.58 (heptet, IH); 1.97 (t, 2H); 1.78 (q, 2H); 1.19 (t,
3H). LCMS (ESI), m/z 462 (M+H+, 100%)
Compound B61 l-[5-Nitro-6-(4-pentyl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. purified by preparatory TLC. [Si02; 20/80 EtOAc/hexanes]. Yield 79 mg, 81
%. Yellow oil. Η-NMR (400 MHz, CDC13) δ (ppm): 9.99 (s, IH); 8.00 (s, IH); 7.38 (d, 2H);
7.12 (d, 2H); 4.09 (q, 2H); 3.83 (m, 2H); 3.15 (m, 2H); 2.55 (m, 3H); 1.95 (m, 2H); 1.79 (m,
2H); 1.53 (m, 2H); 1.24 (m, 7H); 0.81 (t, 3H). LCMS (ESI), m/z 442 (M+H+, 100 %)
Compound B62 l-{6-[4-(3-Carboxy-propyl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. purified by preparatory TLC. [Si02; 30/70 EtOAc/hexanes]. Yield 67 mg,
67%. Yellow solid. Η-NMR (400 MHz, CDC13) δ (ppm): 10.08 (s, IH); 8.13 (s, IH); 7.49
(d, 2H); 7.22 (d, 2H); 4.18 (q, 2H); 3.92 (m, 2H); 3.25 (m, 2H); 2.68 (m, 3H); 2.40 (t, 2H);
2.06(m, 2H); 1.96 (m, 2H); 1.88 (m, 2H); 1.27 (t, 3H). LCMS (ESI), m/z 458 (M+W, 100 %)
Compound B63 l-{6-[4-(Cyano-phenyI-methyl)-phenylamino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. Dry crade B63 was purified by Biotage Horizon 2 [12+M column; 30/70 EtOAc/hexanes]. Yield 93 mg, 87 %. Yellow film. Η-NMR (400 MHz, CDC13) δ(ppm): 10.13 (s, IH); 8.13 (s, IH); 7.64 (tt, 2H); 7.36 (m, 7H); 5.31 (s, IH); 4.17 (q, 2H); 3.92 (m, 2H); 3.25 (m, 2H); 2.66 (heptet, IH); 2.06 (m, 2H); 1.88(m, 2H); 1.28 (t, 3H). LCMS (ESI), m/z 486 (M+H+, 100 %) Compound B64 l-[6-(4-CycIohexyI-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. Crude B64 was purified by preparatory TLC [Si02; 20/80 EtOAc/hexanes]. Yield 55 mg, 55 %. Yellow solid. !H-NMR (400 MHz, CDC13) δ(ppm): 9.99 (s, IH); 8.04 (s, IH); 7.38 (tt, 2H); 7.16 (m, 2H); 4.09 (m, 2H); 3.84 ( , 2H); 3.16 (m, 2H); 2.56 (heptet, IH); 2.43(m, IH); 1.95 (m, 2H); 1.79 (m, 8H); 1.31 (m, 2H), 1.20(t, 5H). LCMS (ESI), m/z 453 (M+H+, 100%)
Compound B65 l-[5-Nitro-6-(4-[l,2,4]triazol-l-yl-phenylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[Method 16]. Crude B65 was purified by flash chromatography [Silica Gel 60; 30/70 EtOAc/hexanes]. Yield 53 mg, 55 %. Yellow solid. Η-NMR (400 MHz, CDC13) δ(ppm): 10.42 (s, IH); 8.56 (s, IH); 8.15 (s, IH); 8.11 (s, IH); 7.79 (tt, 2H); 7.71 (tt, 2H); 4.17 (q, 2H); 3.93 ( , 2H); 3.26 (m, 2H); 2.66(heptet, IH); 2.05 (m, 2H); 1.87 (m, 2H); 1.27 (m, 3H). LCMS (ESI), m/z 438 (M+H+, 100 %)
Compound B66 l-[5-Nitro-6-(4-trifluoromethanesuIfonyl-phenylamino)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. Purified by flash chromatography [Silica Gel 60; 30/70 EtOAc/hexanes].
Yield 34 mg, 31 %. Yellow solid. Η-NMR (400 MHz, CDC13) δ(ppm): 10.72 (s, IH); 8.16 (s,
IH); 7.98 (m, 4H); 4.10 (q, 2H); 3.85 (m, 2H); 3.20 (m, 2H); 2.60 (heptet, IH); 1.99 (m, 2H);
1.81(m, 2H); 1.19 (m, 3H). LCMS (ESI), m/z 503 (M+H+, 100 %)
Compound B67 l-[5-Nitro-6-(4-[l,2,3]thiadiazol-4-yl-phenylamino)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
[Method 16]. purified by flash chromatography [Silica Gel 60; 30/70 EtOAc/hexanes].
Yield 39 mg, 39 %. Yellow solid. Η-NMR (400 MHz, CDC13) δ (ppm): 10.48 (s, IH); 8.65
(s,lH); 8.18 (s, IH); 8.08 (ft, 2H); 7.80 (tt, 2H); 4.16 (q, 2H); 3.94 (m, 2H); 3.26 (m, 2H);
2.66(heptet IH); 2.06 (m, 2H); 1.89 (m, 2H); 1.28 (t, 3H).
Compound B68 [6-(4-Ethoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)- amine;
[Method 16]. purified by HPLC [Semi-Prep]. Yield 13 mg, 17 %. Yellow solid. Η-NMR
(400 MHz, CDC13) δ(ppm): 10.13 (s, IH); 7.99 (s,lH); 7.73 (m, 4H); 3.79 (m, 2H); 3.3 (q,
2H); 3.11 (d, 2H); 2.95 (m, 2H); 2.86 (s, 3H); 1.77(m, 3H); 1.18 (m, 2H); 1.02 (m, 3H).
LCMS (ESI), m/z 436 (M+H+, 100 %)
Compound B69
[5-Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-(4-[l,2,4]triazol-l-yl-phenyl)- amine;
[Method 16]. purified by preparatory TLC [Si02; 50/50 EtOAc/hexanes]. Yield 27 mg, 27 %.
Yellow solid. JH-NMR (400 MHz, CDC13) δ (ppm): 10.17 (s, IH); 8.47 (s,lH); 8.07 (s, IH);
8.04 (s, IH); 7.73 (tt, 2H); 7.63 (tt, 2H); 3.89 (m, 2H); 3.05 (m, 2H); 1.76(m, 2H); 1.40 (m,
IH); 1.24 (m, 6H); 0.85 (t, 3H). LCMS (ESI), m/z 408 (M+H+, 100%)
Compound B70
{5-Nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4-yl}-(4-[l,2,4]triazol-l-yI- phenyl)-amine;
[Method 16]. The crude was purified by HPLC. Yield 52 mg, 55 %. Yellow solid. Η-NMR (400 MHz, CDCI3) δ (ppm): 10.18 (s, IH); 8.47 (s, IH); 8.37 (m, IH); 8.09 (s, IH); 8.04 (s, IH); 7.72 (tt, 2H); 7.63 (tt, 2H); 7.43 (ddd, IH); 7.12 (tt, IH); 6.94 (m, IH); 4.15 (heptet, IH); 3.85 (m, 2H); 3.37 (m, 2H); 2.19 (m, 2H); 1.79 (m, 2H). LCMS (ESI), m/z 476 (M+H+, 100 % )
Compound B71
(2-Fluoro-phenyI)-{6-[4-(3-methyI-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro- pyrimidin-4-yl}-amine;
[Method 16]. Purified by HPLC. Yield 33 mg, 38%. Yellow solid. Η-NMR (400 MHz,
CDCI3) δ (ppm): ): 10.01 (s, IH); 8.09 (s, IH); 7.63 (t, IH); 7.28 (m, IH); 7.16 (m, 2H); 3.98
(m, 2H); 3.41 (m, 2H); 3.33 (heptet, IH); 2.36 (s, 3H); 2.23 (m, 2H); 2.05 (m, 2H). LCMS
(ESI), m/z 399 (M+H+, 100% )
Compound B72
(4-Methanesulfonyl-phenyl)-{6-[4-(3-methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5- nitro-pyrimidin-4-yI}-amine; [Method 16]. yellow solid.Yield 15.2%. *H NMR 400MHz CDC13 δ (ppm): 10.5 (s, IH); 8.49 (s, IH); 8.2 (dd, 4H); 4.26 (d, 2H); 3.64 (m, 2H); 3.60 (m, IH); 3.33 (s, 3H); 2,67 (s, 3H); 2.5 (d, 2H); 2.33 (m, 2H). LCMS (ESI) m/z 460,2 (M+H+, 100%)
Compound B73
{6-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4-
[l,2,4]triazol-l-yl-phenyl)-amine;
[Method 16]. yellow solid. Yield 11 %. *H NMR 400MHz CDC13 δ (ppm): 10 (s, IH); 8.41
(s, IH);); 8.02 (s, IH); 7.97 (s, IH); 7.64 (d, 2H); 7.55 (d, 2H); 3.84 (d, 2H); 3.24 (m, 2H);
3.20 (m, IH); 2.25 (s, 3H); 2,09 (d, 2H); 1.90 (m, 2H). LCMS (ESI) m/z 449,2 (M+H+, 100%)
Compound B74 l-{5-Nitro-6-[4-(4-trifluoromethyl-phenoxy)-phenylamino]-pyrimidin-4-yl}-piperidine-
4-carboxylic acid ethyl ester;
[Method 16]. residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]
Yield 0.057g, 56 %. Yellow solid. !H NMR 400MHz CDCL3 δ (ppm): 10.23 (s, IH); 8.25 (s,
IH); 7.72 (m, 4H); 7.20 (m, 4H); 4.30 (q, 2H); 4.05 (m, 2H); 3.37 (m, 2H); 2.78 (m, IH); 2.18
(m, 2H); 2.00 (m, 2H); 1.40 (m, 3H). LCMS (ESI) m/z 532 (M+H+,100%)
Compound B75
{6- [4-(3-Ethyl- [1 ,2,4] oxadiazol-5-yl)-piperidin-l-yl] -5-nitro-pyrimidin-4-yl}-(2-fluoro- phenyl)-amine;
[Method 16]. The desired product was observed by LCMS m/z 414 (M+H+). Purification by
RP-HPLC.Yield 69 %.1HNMR400MHz CDCl3δ (ppm): 10.00 (s, IH); 8.11 (s,lH); 8.09 (m,
1); 7.12 (m, 3H); 3.97 (d, 2H); 3.29 (m, 2H); 3.26 (m, IH); 2.69 (m, 2H); 2.18 (m, 2H); 2.06
(m, 2H); 1.29 (t, 3H). LCMS (ESI) m/z 414 (M+H+, 100%)
Compound B76
{6-[4-(2-Methoxy-phenylsuIfanyI)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4-
[l,2,4]triazol-l-yl-phenyl)-amine;
[Method 16]. Yield 43 %. Yellow solid. Η NMR 400MHz CDC13 δ (ppm): 9.98 (s, IH); 8.33
(s, IH);); 7.91 (d, 2H); 7.57 (d, 2H); 7.47 (d, 2H); 7.20 (m, IH); 7.09 (m, 2H); 6.70 (m, 2H);
3.69 (s, 3H); 3.33 (m, IH); 3.10 (m, 2H); 1.85 (m, 2H); 1.51 (m, 4H). LCMS (ESI) m/z 505
(M+H+, 100 %)
Compound B77 , sβ loo
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl}-amine
Crade B77 was purified by flash chromatography [Silica gel 60; 50/50 EtOAc/hexanes]. Yield 49 mg, 50 %. Yellow solid. 'H-NMR (400 MHz, CDC13) δ(ppm): ): 10.25 (s, IH); 8.13 (s, IH); 7.85 (m, 4H); 7.64 (tt, IH); 7.43 (m. IH); 7.11 (d, IH); 6.95 (m, IH); 4.15 (m, IH); 3.85(m, 2H); 3.38 (m, 2H); 2.99 (s, 3H); 2.19 (m, 2H); 1.79 (m, 2H). LCMS (ESI), m/z 487 (M+H+, 100% )
Compound B78
(3-Methoxy-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yI]-pyrimidin-4-yl}- amine
[Method 16]. The crude mixture was purified by preparatory TLC [Si02; 20/80
EtOAc/hexanes].
Yield 70 mg, 87 %. Yellow solid. Η-NMR (400 MHz, CDC13) δ (ppm): 10.25 (s, IH); 8.55
(m, IH); 8.25 (s, IH); 7.60 (ddd, IH); 7.40 (m, 2H); 7.38 (s, IH); 7.29 (d, IH); 7.22 (d, IH);
7.12 (m, IH); 4.33 (heptet, IH); 4.01 (m, 2H); 3.94 (s, 3H); 3.54 (m, 2H); 2.36 (m, 2H); 1.98
(m, 2H). LCMS (ESI), m/z 439 (M+H+, 100% )
Compound B79
Benzo[l,3]dioxol-5-yl-[5-nitro-6-(4-propyl-piperidin-l-yI)-pyrimidin-4-yI]-amine. [Method 16]. Residue purified by preparatory TLC [Si02; EtOAc/hexane; 20:80]. Yield 0.005 g, 6 %. Yellow oil. 1HNMR400MHz CDCl3δ(ppm): 9.92 (s, IH); 8.01 (s, IH); 7.13 (m, IH); 6.78 (m, IH); 6.72 (m, IH); 5.92 (s, 2H); 3.87 (m, 2H); 3.02 (m, 2H); 1.74 (m, 2H); 1.48 (m, IH); 1.27 (m, 2H); 1.18 (m, 4H); 0.84 (m, 3H). LCMS (ESI) m/z 386 (M+H+,100%)
Compound B80
(4-Fluoro-phenyl)-{l-[5-nitro-6-(4-[l,2,4]triazol-l-yl-phenylamino)-pyrimidin-4-yl]- piperidin-4-yl}-methanone
Purification by HPLC. Yield 56 %. yellow solid TFA salt. Η NMR 400MHz CDC13 δ (ppm): 11.61 (s, 3H); 10.3 (s, IH); 9.18 (s,lH); 8.39 (s, IH); 8.18 (s, IH); 8.01 (m, 2H); 7.84 (d, 2H); 7.74 (d, 2H); 7.19 (t, 2H); 4.07 (d, 2H); 3.67 (m, IH); 3.47 (m, 2H); 2.05 (m, 4H). LCMS (ESI) m/z 489.4 (M+H+, 100%)
Compound B81
[5-Nitro-6-(4-phenylsuIfanyl-piperidin-l-yl)-pyrimidin-4-yI]-(4-[l,2,4]triazol-l-yl- phenyl)-amine [Method 16]. product precipitated from the crade as a yellow solid. It was filtered and washed with hexane. Yield 36 %. !H NMR 400MHz CDC13 δ (ppm): 10.17 (s, IH); 8.57 (s, IH); 8.10 (d, 2H); 7.76 (d, 2H); 7.66 (d, 2H); 7.42 (m, 2H); 7.29 (m, 3H); 3.89 (m, 2H); 3.39 (m, 1H);3.27 (m, 2H); 2.06(m; 2H); 1.71 ( , 2H). LCMS (ESI) m/z 475.3 (M+H+, 100%)
Compound B82
(4-Fluoro-phenyl)-{l-[6-(2-fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yI}- methanone
[Method 16]. Purification by HPLC. Yield 17 %. red oil. Η NMR 400MHz CDC13 δ (ppm):
9.92 (s, IH); 7.96 (s, IH); 7.79 (m, 2H); 7.46 (m, IH); 7.17 (m, IH); 7.02 (m, 4H); 3.86 (d,
2H); 3.46 (m, IH); 3.31 (m, 2H); 1.86 (m, 4H). LCMS (ESI) m/z 440.4 (M+H+, 100%)
Compound B83 l-[6-(2-MethyI-5-phenyI-2H-pyrazol-3-yIamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester
[Method 16]. Purification by HPLC yielded orange solid. Yield 30 %. Η NMR 400MHz
CDC13 δ (ppm):, 8.34 (s, IH); 7.90 (m, 2H); 7.68 (d, 3H); 7.04 (s, IH); 4.32 (m, 2H); 4.11 (s,
3H); 4.06 (m, 2H); 3.44 (m, 2H); 2.83 (m, IH); 2.22 (m, 2H); 2.04 (m, 2H); 1.41 (t, 3H).
LCMS (ESI) m/z 452 (M+H+, 100%)
Compound B84
(4-Methanesulfonyl-phenyI)-[5-nitro-6-(4-phenylsulfanyl-piperidin-l-yl)-pyrimidin-4- yl]-amine
[Method 16]. Purification by HPLC yielded yellow solid. Yield 9 %. Η NMR 400MHz
CDCI3 δ (ppm): 10.0 (s, IH); 8.00 (s, IH); 7.75 (d, 2H); 7.68 (d, 2H); 7.26 (m, 2H); 7.14 (m,
3H); 3.73 (d, 2H); 3.22 (m, IH); 3.13 (m, 2H); 2.87 (s, 3H); 1.91 (m, 2H); 1.55 (m, 2H).
LCMS (ESI) m/z 486 (M+H+, 100%)
Compound B85
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-2-yIoxy)-piperidin-l-yl]-pyrimidin-4- yl}-amine
[Method 16]. as yellow solid (68 mg, 72 %). Η NMR 400MHz CDC13 δ(ppm): 10.2 (s, IH);
8.13 (s, IH); 8.12 (d, IH); 7.87 (d, 2H); 7.83 (d, 2H); 7.60 (t, IH); 6.87 (t,lH); 6J3 (d,lH);
5.29 (m,lH); 3.76-3.70 (m,2H); 3.56-3.51 (m,2H); 2.99 (s,3H); 2.10-2.05 (m, 2H); 1.95-1.90
(m,2H). Exact mass calculated for C2lH22N6O5S470.14, LCMS (ESI) m/z 471.4(M+H+,
100%). Compound B86
{6-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl- phenyl)-amine
[method 16] afforded compound B86 as yellow solid (58 mg, 60 %). !H NMR 400MHz
CDC13 δ(ppm): 10.2 (s, IH); 8.13 (s, IH); 7.87 (d, 2H); 7.81 (d, 2H); 6.92(m, 2H); 6.82
(m,2H); 4.50 (m,lH); 3.71-3.65 (m,2H); 3.54-3.51 (m,2H); 2.99 (s,3H); 1.99-1.91 (m 2H).
Exact mass calculated for C22H22 FN5O5S 487.13, LCMS (ESI) m/z 488.3(M+H+, 100%).
Compound B87
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-4-yloxy)-piperidin-l-yl]-pyrimidin-4- yl}-amine
Method 16 afforded compound B87 as yellow solid (56 mg, 60 %). Η NMR 400MHz CDC13 δ(ppm): 10.2(s, IH); 8.68 (d, 2H); 8.17(s,lH); 7.88 (d, 2H); 7.83(d, 2H); 7.26 (d, 2H); 4.96 (m,lH); 3.76-3.69 (m,2H); 3.62-3.57 (m,2H); 3.00 (s,3H); 2.21-2.15 (m 2H); 2.03-1.99 (m,2H). Exact mass calculated for C21H22 N6O5S470.14, LCMS (ESI) m/z 471.2(M+H+, 100%).
Compound B88
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyrimidin-2-yloxy)-piperidin-l-yl]- pyrimidin-4-yl}-amine
Method 16 afforded compound B88 as a yellow solid (69 mg, 73 %). Η NMR 400MHz CDCI3 δ(ppm): 10.2 (s, IH); 8.52 (d, 2H); 8.14(s,lH); 7.88 (d, 2H); 7.83 (d, 2H); 6.96(t, IH); 5.34 (m,lH); 3J9-3J2 (m,2H); 3.58-3.52 (m,2H); 2.99 (s,3H); 2.14-2.08 (m 2H); 2.02-1.93 (m,2H). Exact mass calculated for C20H21 N705S 471.13, LCMS (ESI) m/z 472.0(M+H+, 100%).
Compound B89
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-4-ylsulfanyl)-piperidin-l-yI]- pyrimidin-4-yl}-amine
Method 16 afforded compound B89 as a yellow solid (52 mg, 54 %). Η NMR 400MHz CDCI3 δ(ppm): 10.1(s, IH); 8.56(d, 2H); 8.17(s,lH); 7.89 (d, 2H); 7.83(d, 2H); 7.53(d, 2H); 3.92-3.89(m,2H); 3.84(m,lH); 3.44-3.38(m,2H); 3.00(s,3H); 2.26-2.22(m 2H); 1.94- 1.88(m,2H). Exact mass calculated for C21H22N604S2 486.11, LCMS (ESI) m/z 487.2 (M+H+, 100%). Compound B90
(4-MethanesulfonyI-phenyl)-{6-[4-(4-methoxy-phenyIsulfanyl)-piperidin-l-yl]-5-nitro- pyrimidin-4-yl}-amine
Method 16 afforded compound B90 as a as yellow solid (50 mg, 49 %). Η NMR 400MHz CDC13 δ(ppm): 10.2(s, IH); 8.11(s,lH); 7.87 (d, 2H); 7.80(d, 2H); 7.34(d, 2H); 6J9(d,2H); 3.86-3.83(m,2H); 3J4(s,3H); 3.22-3.12(m,3H); 2.99(s,3H); 1.99-1.95(m 2H); 1.66- 1.57(m,2H). Exact mass calculated for C23H25N5θ5S2 515.13, LCMS (ESI) m/z 516.1(M+H+, 100%).
Compound B91
[6-(4-BenzenesulfonyI-piperidin-l-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl- phenyl)-amine
Method 16 afforded compound B91 a as yellow solid (51 mg, 50 %). Η NMR 400MHz
CDCI3 δ(ppm): 10.2(s, IH); 8.12(s,lH); 7.87 (d, 2H); 7.81(d,2H); 7.79(d, 2H); 7.64(t, IH);
7.53(t,lH); 4.01(m,2H); 3.17(m,lH); 3.08-3.04(m,2H); 2.99(s,3H); 2.08-2.04(m 2H); 1.82-
1.78(m,2H). Exact mass calculated for C22H23N506S2 517.11, LCMS (ESI) m/z 518.3(M+H+,
100%).
Compound B92
{4-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperazin-l-yl}-acetic acid ethyl ester
[Method 16]. afforded compound B92 as a yellow solid (45 mg, 48 %). Η NMR 400MHz
CDCI3 δ (ppm): 10.2(s, IH); 8.18(s,lH); 7.88 (d, 2H); 7.81 (d, 2H); 4.21(q,2H); 3.86-3.83
(m,6H); 3.46-3.43 (m, 4H); 3.00 (s,3H); 1.23 (t, 3H). Exact mass calculated for C19H24N606S
464.15, LCMS (ESI) m/z 465.3 (M+H+, 100%).
Compound B93
(2-FIuoro-phenyI)-{5-nitro-6-[4-(pyridin-2-ylsulfanyI)-cycIohexyI]-pyrimidin-4-yl}- amine
[Method 16]. The crade was dissolved in dichloromethane and purified by preparative TLC. [Si02; 15/85 EtOAc/hexanes] .Yellow solid. Yield 7 mg, 10 %. Η-NMR (400 MHz, CDC13) δ (ppm): 10.07 (s, IH); 8.37 (d, IH); 8.13(m, IH); 8.08 (s, IH); 7.43 (ddd, IH); 7.07 (m, 4H); 6.94 (m, IH); 4.15 (heptet, IH); 3.85 (m, 2H); 3.36 (m, 2H); 2.18 (m, 2H); 1.79 (m, 2H). LCMS (ESI), m/z 427 (M+H+, 100 %)
Compound B94 (2-Methoxy-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsuIfanyl)-cyclohexyl]-pyrimidin-4-yl}- amine
[Method 16]. purified by preparative TLC. [Si02; 15/85 EtOAc/hexanes]. Yellow solid.
Yield 42 mg, 56 %. Η-NMR (400 MHz, CDC13) δ (ppm): 10.51 (s, IH); 8.36 (d, 2H); 8.10(s,
IH); 7.42 (ddd, IH); 7.10 (d, IH); 7.03 (ddd, IH); 6.87 (d, IH); 4.14 (heptet, IH); 3.85 (m,
5H); 3.35 (m, 2H); 2.17 (m, 2H); 1.78 (m, 2H). LCMS (ESI), m/z 438 (M+H+, 100%)
Compound B95
(4-Methanesulfonyl-phenyl)-(5-nitro-6-{4-[3-(3-trifluoromethyl-phenyI)-
[l,2,4]oxadiazol-5-yl]-piperidin-l-yI}-pyrimidin-4-yl)-amine
Following the general procedure 16, compound B95 was obtained as a yellow solid (61 %). Η NMR (CDC13, 400 MHz) δ 2.06-2.10 (m, 2H), 2.23-2.27 (m, 2H), 2.99 (s, 3H), 3.31-3.38 (m, 3H), 3.96-3.99 (m, 2H), 7.55 (t, IH), 7.70 (d, IH), 7.86 (dd, 4H), 8.16 (s, IH), 8.20 (d, IH), 8.28 (s, IH), 10.2 (s, IH). Exact mass calculated for C25H22F3N705S 589.1, found 590.4 (MH+).
Compound B96
{6-[4-(3-EthyI-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4- methanesulfonyl-phenyl)-amine
Following the general procedure 16, compound B96 was obtained as a yellow solid (31 %). *H NMR (CDCI3, 400 MHz) δ 1.25 (t, 3H), 2.06-2.10 (m, 2H), 2.23-2.27 (m, 2H), 2.70 (q, 2H), 2.99 (s, 3H), 3.31-3.38 (m, 3H), 3.96-3.99 (m, 2H), 7.84 (dd, 4H), 8.14 (s, IH), 10.2 (s, IH). Exact mass calculated for C20H23N7O5S 473.1, found 474.2 (MH+).
Compound B97
(6-{4- [5-(4-Fluoro-phenyl)- [1 ,3,4] oxadiazoI-2-yl] -piperidin-l-yl}-5-nitro-pyrimidin-4-yl)-
(4-methanesulfonyl-phenyl)-amine
Following the general procedure 16, compound B97 was obtained as a yellow solid (93 %). *H MR (CDCI3, 400 MHz) δ 2.06-2.10 (m, 2H), 2.23-2.27 (m, 2H), 2.99 (s, 3H), 3.31-3.38 (m, 3H), 3.96-3.99 (m, 2H), 7.24 (dd, 2H), 7.96 (dd, 4H), 8.04-8.08 (m, 2H), 8.25 (s, IH), 10.3 (s, IH). Exact mass calculated for C24H22FN705S 539.14, found 540.3 (MH+).
Compound B98
(4-Methanesulfonyl-phenyl)-[5-nitro-6-(4-pyridin-2-ylmethyl-piperidin-l-yl)-pyrimidin- 4-yl] -amine Following the general procedure 16, Compound B98 was obtained as a yellow solid (95 %). 'HNMR (CDC13, 400 MHz) δ 1.36-1.47 (m, 2H), 1.69-1.72 (m, 2H), 2.12-2.18 (m, IH), 2.99 (s, 3H), 3.00-3.05 (m, 2H), 3.91-3.94 (m, 2H), 7.52 (d, IH), 7.65 (dt, IH), 7.85 (dd, 4H), 8.11 (s, IH), 8.17 (dt, IH), 8.82 (d, IH), 10.2 (s, IH). Exact mass calculated for C22H24N604S 468.1, found 469.4 (MH+).
Compound B99
4-[4-(3-IsopropyI-[l,2,4]oxadiazoI-5-yl)-piperidin-l-yl]-6-(4-methyIsuIfanyl- phenylamino)-pyrimidine-5-carbonitrile
Following the general procedure, Compound B99 was prepared. 'H-NMR (DMSO-d6): 9.38 (IH, s), 8.21 (IH, s), 7.47 (2H, J = 4.3 Hz, d), 7.23 (2H, J = 4.3 Hz, d), 4.50 (2H, m), 3.35 (2H, m), 3.02 (IH, m), 2.51 (3H, s), 2.18 (2H, m), 1.79 (2H, m) 1.83 (6H, J = 7Hz, d) ppm. LCMS: 436.3, 351.9, 324.4, 270.2.
Compound B100 l-{6-[4-(4,5-DichIoro-imidazoI-l-yl)-phenyIamino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester
[Method 16]. yellow solid (40 mg, 49 %). 'HNMR (CDC13, 400 MHz) δ 1.28 (t, 3H), 1.87
(m, 2H), 2.06 (m, 2H), 2.66 (m, IH), 3.26 (t, 2H), 3.93 (m, 2H), 4.17 (q, 2H), 7.37 (m, 2H),
7.54 (s, IH), 7.82 (m, 2H), 8.17 (s, IH), 10.23 (s, IH). Exact mass calculated for
C21H21C12N704506.34, found 506.2 (MH+).
Compound B101
Benzo[l,3]dioxoI-5-yl-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4- yl}-amine
[Method 16]. orange solid (9 mg, 14 %). 'HNMR (CDC13, 400 MHz) δ 1.78 (m, 2H), 2.17
(m, 2H), 3.35 (m, 2H), 3.83 (m, 2H), 4.14 (m, IH), 5.92 (m, 2H), 6.75 (m, 2H), 6.94 (m, IH),
7.11 (m, IH), 7.19 (m, IH), 7.42 (m, IH), 8.02 (s, IH), 8.36 (m, IH), 9.91 (s, IH). Exact mass calculated for C24H24N408S 452.49, found 453.2 (MH+).
Compound B102
(4-FIuoro-phenyl)-{l-[6-(2-fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}- methanone
[Method 16]. yellow solid (16mg, 44%). ]HNMR (CDC13, 400 MHz) δ 1.89 (m, 4H), 3.26
(m, 2H), 3.51 (m, IH), 3.96 (m, 2H), 7.10 (m, 5H), 7.92 (m, 2H), 8.08 (s, IH), 8.13 (m, IH),
10.06 (s, IH). Exact mass calculated for C24H24N408S 439.41, found 440.3 (MH+). Compound B103
{1- [6-(Benzo [1 ,3] dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl] -piperidin-4-yl}-(4-fluoro- phenyl)-methanone
[Method 16]. orange solid (20 mg, 53 %). 1HNMR (CDC13, 400 MHz) δ 1.89 (m, 4H), 3.26
(m, 2H), 3.51 (m, IH), 3.96 (m, 2H), 5.92 (s, 2H), 6.76 (m, 2H), 7.10 (m, 3H), 7.92 (m, 2H),
8.03 (s, IH), 9.91 (s, IH). Exact mass calculated for C23H2oFN5Os 465.43, found 466.3
(MH+).
Compound B104
(2,3-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4- yl}-amine
[Method 16]. yellow solid (5 mg, 8 %). 1HNMR (CDC13, 400 MHz) δ 1.78 (m, 2H), 2.17 (m,
2H), 3.35 (m, 2H), 3.83 (m, 2H), 4.14 (m, IH), 6.94 (m, 2H), 7.03 (m, IH), 7.10 (m, IH),
7.42 (m, IH), 7.89 (m, IH), 8.08 (s, IH), 8.37 (m, IH), 10.05 (s, IH). Exact mass calculated for C20H18F2N6O2S 444.46, found 444.9 (M+H+).
Compound B105
(2,4-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4- yl}-amine
[Method 16]. yellow solid (12 mg, 19 %). 1HNMR (CDC13, 400 MHz) δ 1.78 (m, 2H), 2.17
(m, 2H), 3.35 (m, 2H), 3.83 (m, 2H), 4.14 (m, IH), 6.85 (m, 2H), 6.93 (m, IH), 7.10 (m, IH),
7.42 (m, IH), 7.89 (m, IH), 8.05 (s, IH), 8.37 (m, IH), 9.91 (s, IH). Exact mass calculated for C20HιSF2N6O2S 444.46, found 445.4 (M+H+).
Compound B106
(2,5-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyI)-piperidin-l-yl]-pyrimidin-4- yl}-amine
[Method 16]. yellow solid (3 mg, 5 %). 'HNMR (CDC13, 400 MHz) δ 1.78 (m, 2H), 2.17 (m,
2H), 3.35 (m, 2H), 3.83 (m, 2H), 4.14 (m, IH), 6.73 (m, IH), 6.93 (m, IH), 7.03 (m, IH), "
7.11 (m, IH), 7.42 (m, IH), 8.13 (s, IH), 8.25 (m, IH), 8.37 (m, IH), 10.25 (s, IH). Exact mass calculated for C20H18F2N6O2S 444.46, found 445.3 (M+H+).
Compound B107 l-[6-(4-BenzenesulfonyI-phenyIamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester
[Method 16]. yellow solid (32 mg, 39 %). !HNMR (CDC13, 400 MHz) δ 1.22 (t, 3H), 1.80 (m, 2H), 2.00 (m, 2H), 2.60 (m, IH), 3.20 (t, 2H), 3.85 (m, 2H), 4.12 (q, 2H), 7.48 (m, 3H), 7.78 (d, 2H), 7.90 (m, 4H), 8.11 (s, IH), 10.19 (s, IH). Exact mass calculated for C24H25N506S 511.55, found 512.3 (MW).
Compound B108 l-[5-Nitro-6-(2-trifluoromethyl-3H-benzoimidazoI-5-yIamino)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester
[Method 16]. yellow solid (1 lmg, 14%). 'HNMR (CDC13, 400 MHz) δ 1.40 (t, 3H), 2.00 (m,
2H), 2.18 (m, 2H), 2J9 (m, IH), 3.39 (t, 2H), 4.06 (m, 2H), 4.30 (q, 2H), 7.43 (m, IH), 7.65
(m, IH), 7.95 (m, IH), 8.26 (m, 2H), 10.40 (s, IH). Exact mass calculated for C2oH20F3N704
479.41, found 480.3 (MW).
Compound B109 l-{5-Nitro-6-[3-(l,l,2,2-tetrafluoro-ethoxy)-phenylamino]-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester
[Method 16]. yellow solid (65 mg, 84 %). 1HNMR (CDC13, 400 MHz) δ 1.36 (t, 3H), 1.96
(m, 2H), 2.14 (m, 2H), 2.74 (m, IH), 3.34 (m, 2H), 4.01 (m, 2H), 4.26 (q, 2H), 6.02 (m, IH),
7.14 (m, IH), 7.47 (m, IH), 7.56 (m, IH), 7.77 (m, IH), 8.24 (s, IH), 10.23 (s, IH). Exact mass calculated for C20H21F4N5θ5487.40, found 488.2 (MH+).
Compound B110
{6-[4-(4-Iodo-phenoxy)-piperidin-l-yI]-5-nitro-pyrimidin-4-yl}-(4-methanesulfonyl- phenyl)-amine
Yellow solid; yield 82.6%. Η NMR 400MHz CDC13 δ (ppm): 10.2 (s, IH); 8.13 (s, IH); 7.86 (m, 4H); 7.50 (m, 2H); 6.64 (m, 2H); 4.55 (m, IH); 3.65 (m, 2H); 3.55 (ni, 2H); 2.98 (s, 3H); 1.96 (m, 4H). LCMS (ESI) m/z 596 (M+H+, 100%).
Compound Bill
(2-FIuoro-4-methanesuIfonyl-phenyl)-{6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin- l-yl]-5-nitro-pyrimidin-4-yI}-amine
Following the general procedure, Compound Bill was obtained as a yellow solid (38%). 'H NMR 400MHz CDC13 δ 10.3(s, IH); 8.74(t,lH); 8.17(s, IH); 7.70 (d, IH); 7.67(d, IH); 3.95-3.92(m,2H); 3.33-3.27(m,2H); 3.29-3.23(m,lH); 3.00(s,3H); 3.03-2.96(m, IH); 2.19-2.11(m, 2H); 2.03-1.96(m, 2H); 1.26(d, 6H). Exact mass calculated for C21H24FN705S 505.15, LCMS (ESI) m/z 506.2(M+H+, 100%).
Compound B112
{6-[4-(3-Ethyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(2-fluoro-4- methanesulfonyl-phenyl)-amine
Following the general procedure, Compound B112 was obtained as a yellow solid (31%). 1HNMR (CDC13, 400 MHz) δ 1.25 (t, 3H), 2.06-2.10 (m, 2H), 2.23-2.27 (m, 2H), 2.70 (q, 2H), 2.99 (s, 3H), 3.31-3.38 (m, 3H), 3.96-3.99 (m, 2H), 7.84 (dd, 4H), 8.14 (s, IH), 10.2 (s, IH). Exact mass calculated for C20H23N7O5S 473.1, found 474.2 (MW).
Compound Bl 13
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(3-propyl-[l,2,4]oxadiazol-5-yl)-piperidin-l- yl]-pyrimidin-4-yl}-amine '
Following the general procedure, Compound B113 was obtained as a yellow solid (44%). Η NMR 400MHz CDC13 δ 10.2(s, IH); 8.13(s, IH); 7.87 (d, 2H); 7.83(d, 2H); 3.92(m,2H); 3.32-3.29(m,2H); 3.26-3.23(m,lH); 2.99(s,3H); 2.62(t, 2H); 2.19-2.15(m, 2H); 2.01-1.95(m, 2H); 1.69(se, 2H); 0.91(t, 3H). Exact mass calculated for C21H25N705S 487.16, LCMS (ESI) m/z 488.2(M+H+, 100%).
Compound B114
{6-[4-(3-Cyclopropylmethyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4- yl}-(4-methanesulfonyl-phenyl)-amine
Following the general procedure, Compound B114 was obtained as a yellow solid (45%). !H NMR 400MHz CDC13 δ 10.2(s, IH); 8.15(s, IH); 7.87 (d, 2H); 7.78(d, 2H); 3.95(m,2H); 3.34-3.30(m,2H); 3.30-3.27(m,lH); 3.00(s,3H); 2.57(d, 2H); 2.21-2.17(m, 2H); 2.04-1.96(m, 2H); 1.06-1.02(m, IH); 0.53-0.48(m, 2H); 0.25-0.16(m, 2H). Exact mass calculated for C22H25N705S 499.16, LCMS (ESI) m/z 500.5(M+H+, 100%).
Compound B115
{6-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4- methanesulfonyl-phenyl)-amine
Following the general procedure, Compound B115 was obtained as a yellow solid (76%). !H NMR 400MHz CDC13 δ 10.2 (s, IH); 8.14 (s, IH); 7.85 (dd, 4H); 3.92 (d, 2H); 3.27 (m, 3H); 3.0 (s, 3H); 2,14 (m, 2H); 1.99 (m, 2H); 1.25 (d, 6H). LCMS (ESI) m/z 488 (M+H+, 100%)
Compound Bl 16
{6-[4-(3-Cyclopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4- methanesulfonyl-phenyl)-amine
Following the general procedure, Compound B116 was obtained as a yellow solid (83.6%). Η NMR 400MHz CDC13 δ 10.2 (s, IH); 8.14 (s, IH); 7.86 (dd, 4H); 3.90 (d, 2H); 3.30 (m, 2H); 3.27 (m, IH); 3.00 (s, 3H); 2.13 (m, 2H); 1.98 (m, 3H); 0.97 (m, 4H). LCMS (ESI) m/z 486 (M+H+, 100%)
Compound Bl 17
(4-Methanesulfonyl-phenyl)-(5-nitro-6-{4-[3-(3-trifluoromethyl-phenyl)-
[l,2,4]oxadiazol-5-yl]-piperidin-l-yl}-pyrimidin-4-yl)-amine
Following the general procedure, Compound B117 was obtained as a yellow solid (61%). 1HNMR (CDC13, 400 MHz) δ 2.06-2.10 (m, 2H), 2.23-2.27 (m, 2H), 2.99 (s, 3H), 3.31-3.38 (m, 3H), 3.96-3.99 (m, 2H), 7.55 (t, IH), 7.70 (d, IH), 7.86 (dd, 4H), 8.16 (s, IH), 8.20 (d, IH), 8.28 (s, IH), 10.2 (s, IH). Exact mass calculated for C2SH22F3N705S 589.1, found 590.4 (MH+).
Compound B118
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methanesulfinyl- phenylamino)-pyrimidine-5-carbonitrile
Compound B99 was selectively oxidized using mCPBA to give Compound B118 as the sulfoxide. Η-NMR (DMSO-d6): 9.65 (IH, s), 8.26 (IH, s), 7.75 (2H, m), 7.63 (2H, m), 4.52 (2H, m), 3.45 (IH, m), 3.32 (2H, m), 3.04 (IH, m), 2.73 (3H, s), 2.18 (2H, m), 1.79 (2H, m) 1.18 (6H, J = 7Hz, d) ppm. LCMS: 468.4, 384.1, 356.2, 302.1.
Compound B119
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(4-trifluoromethoxy-phenoxy)-piperidin-l-yl]- pyrimidin-4-yl}-amine
A mixture of compound (6-chloro-5-nitro-pyrimidin-4-yl)-(4-methanesulfonyl-phenyl)-amine (400 mg, 1.22 mmol), 4-(4-trifluoromethoxy-phenoxy)-piperidine (399 mg, 1.34 mmol) and potassium carbonate (336 mg, 2.44 mmol) in DMF (8 ml) was heated in an oil bath at 60°C for 2 hours. The crude mixture was cooled to 0°C and quenched with water. The solid was filtered off, rinsed with water and dried in vacuum oven to give product B119 as a yellow solid (604 mg, 90%). 1HNMR (CDCI3, 400 MHz) d 2.01-2.08 (m, 4H), 3.06 (s, 3H), 3.64- 3.66 (m, 2H), 3.73-3.75 (m, 2H), 4.62-4.66 (m, IH), 6.93 (d, 2H), 7.17 (d, 2H), 7.93 (dd, 4H), 8.21 (s, IH), 10.2 (s, IH). Exact mass calculated for C23H22F3N506S 553.1, found 554.3
(MH+).
Compound B120
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methanesulfonyl- phenylamino)-pyrimidine-5-carbonitrile
Compound B99 was oxidized using mCPBA to give Compound B120 as the sulfone. !H NMR (DMSO-d6): 9.86 (IH, s), 8.34 (IH, s), 7.93 ~ 7.84 (4H, m), 4.54 (2H, m), 3.50 ~ 3.39 (3H, m), 3.21 (3H, s) 3.05 (IH, m), 2.21 (2H, m), 1.83 (2H, m) 1.27 (6H, J = 7Hz, d) ppm. LCMS: 452.1, 437.2, 368.1, 340.0.
Compound B121 l-{l-[6-(2-Fluoro-4-methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidin-4- yl}-hexan-l-one
The general procedure for the addition of Amine to pyrimidine afforded Compound 121; !H NMR, 400MHz, CDC13, δ (ppm): 10.48(s, NH); 8.84(s, IH); 8.23(s, IH); 7.75(m, 2H); 3.98(m, 2H); 3.22(m, 2H); 3.06 (s, CH3); 2.69(m, IH); 2.48(m, 2H); 1.99(m, 2H); 1.77(m, 2H), 1.59(m, 2H), 1.29(m, 4H), 0.89(t, 3H); LCMS (ESI) for C22H28FN505S: m/z 493(M+H+, 100 %).
Compound B122 l-{l-[6-(4-Methanesulfonyl-phenyIamino)-5-nitro-pyrimidin-4-yl]-piperidin-4-yl}- hexan-1-one
The general procedure for the addition of Amine to pyrimidine afforded Compound 122; *H NMR, 400MHz, CDC13, δ (ppm): 10.2(s, NH); 8.20(s, IH); 7.92(m, 4H); 3.98(m, 2H); 3.22(m, 2H); 3.06 (s, CH3); 2.69(m, IH); 2.48(m, 2H); 1.99(m, 2H); 1.77(m, 2H), 1.59(m, 2H), 1.29(m, 4H), 0.89(t, 3H); LCMS (ESI) for C22H29N505S: m/z 476(M+H+, 100 %).
Compound B123
{6-[4-(3-tert-Butyl-[l,2,4]oxadiazoI-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(2- fluoro-4-methanesuIfonyl-phenyl)-amine
The general procedure for the addition of Amine to pyrimidine afforded Compound B123 as yellow oil (40mg, 51%). !H NMR 400MHz CDC13 d(ppm): 10.4(s,NH); 8.83(t, IH); 8.25(s, IH); 7.76 (t, 2H); 4.01(d,2H); 3.41-3.34(m, 2H); 3.32-3.28(m, IH); 3.08(s,3H); 2.27-2.22(m, 2H); 2.11-2.04(m, 2H); 3.36(s, 9H). Exact mass calculated for: C23H27FN 6OsS 518.17, LCMS (ESI) m/z 520.4(M+H+, 100%).
Compound B124
{6-[4-(3-tert-Butyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yI}-(4- methanesulfonyI-phenyl)-amine
The general procedure for the addition of amine to pyrimidine afforded Compound 124 as a yellow solid, yield 90%; Η NMR 400MHz CDC13 δ (ppm): 10.2 (s, IH); 8.23 (s, IH); 7.97 (d, 2H); 7.76 (d, 2H); 4.02 (d, 2H); 3.44 (m, 3H); 3.2 (s, 3H); 2,27 (m, 2H); 2.03 (m, 2H); 1.37 (s, 9H); LCMS (ESI) m/z 502 (M+H+, 100%)
Compound B125
[6-(4-Benzofuran-2-yl-piperidin-l-yl)-5-nitro-pyrimidin-4-yl]-(4-methanesulfonyl- phenyl)-amine
The general procedure for the addition of amine to pyrimidine afforded Compound B125 as a yellow solid (82mg, 91%). !H NMR (CDC13, 400 MHz) δ 1.00 (s, IH), 1.54 (m, 2H), 1.93 (m, 2H), 2.97 (s, 3H), 3.09 (m, 2H), 3.74 (m, 2H), 6.42 (s, IH), 6.98 (m, 3H), 7.27 (d, IH), 7.32 (d, IH), 7.66 (m, 4H), 7.97 (s, IH). Exact mass calculated for C20H21F2N7O3 493.53, found 494.4 ( +W .
Compound B126
4-(3-Fluoro-4-methanesulfonyl-phenylamino)-6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)- piperidin-l-yl]-pyrimidine-5-carbonitrile
Compound B126 was obtained as a solid (90%). 1HNMR (CDC13, 400 MHz) δ 1.34 (d, 6H), 2.01-2.08 (m, 2H), 2.23-2.27 (m, 2H), 3.06 (heptet, IH), 3.22 (s, 3H), 3.30-3.34 (m, IH), 3.46-3.50 (m, 2H), 4.70-4.77 (m, 2H), 7.33 (dd, IH), 7.40 (s, IH), 7.90 (t, IH), 8.08 (dd, IH), 8.38 (s, IH). Exact mass calculated for C22H24FN703S 485.2, found 486.3 (MW).
Compound B127
{6-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(5- methanesulfonyl-pyridin-2-yl)-amine
Compound B127 was prepared by the general procedure for the addition of pyridinylsulfone to pyrimidine to give a solid (4 mg, 4%). !H NMR 400MHz CDC13 δ(ppm): 10.5(s, NH); 8.86(s,lH); 8.74(d, IH); 8.29(s,lH); 8.20(d, IH); 4.02-3.99(m,2H); 3.40-3.28(m, 3H); 3.11(s,3H); 3.11-3.06(m, IH); 2.26-2.22(m, 2H); 2.09-2.03(m, 2H); 1.33(d, 6H). Exact mass calculated for C20H24N 8OsS 488.16, LCMS (ESI) m/z 489.3(M+H+, 100%). Compound B128
(3-Fluoro-4-methanesulfonyl-phenyl)-{6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin- l-yl]-5-nitro-pyrimidin-4-yl}-amine
Compound B128 was prepared using the general procedure for the oxidation of a sulfide to sulfone; yellow solid (9 mg, 36%). Η NMR 400MHz CDC13 δ(ppm): 10.3(s,NH); 8.25(s, IH); 8.13(d, IH); 7.92(t,lH); 7.40(d,lH); 4.00(db,2H); 3.41-3.29(m,3H); 3.23(s,3H);3.10-3.07(m, IH); 2.26-2.24(m,2H); 2.10-2.02(m,2H); 1.34(d,6H). Exact mass calculated for C21H24FN 705S 505.15, LCMS (ESI) m/z 506.3(M+H+, 100%).
Compound B129
{6-[4-(3-IsopropyI-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yI}-(6- methanesulfonyl-pyridin-3-yl)-amine
Compound B129 was prepared using the general procedure for the oxidation of a sulfide to sulfone; yellow solid (6 mg, 67%). *H NMR 400MHz CDC13 δ(ppm): 10.3(s,NH); 8.93(s, IH); 8.52(d, IH); 8.22(s,lH); 8.10(d,lH); 4.00(db,2H); 3.41-3.3 l(m,3H); 3.23(s,3H); 3.08(qu, IH); 2.27-2.23 (m,2H); 2.10-2.04(m,2H); 1.33(d,6H).Exact mass calculated for C20H24N 8OsS 488.16, LCMS (ESI) m/z 489.2(M+H+, 100%).
Compound B130
4-(2,3-Difluoro-phenylamino)-6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]- pyrimidine-5-carbonitrile
To a solution of 4,6-dic oro-pyrimidine-5-carbonitrile (254 mg, 1.47 mmol) and 2,3- difluoroaniline (190 mg, 1.47 mmol) in DMF (3 mL) at 0 °C was added K2C03 (203 mg, 1.47 mmol). The completion of the reaction was monitored by TLC (EtOAc:Hex 1:1, R/= 0.90). After the completion of the reaction, 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine (340 mg, 1.47 mmol) and K2C03 (406 mg, 2.94 mmol) were added at 0°C. The reaction was warmed to rt and stirred for 30 min. The reaction was heated to 40°C and maintained for 1 h. The reaction was cooled to rt ,' oured in to H20 (50 mL) and extracted with EtOAc (50 mL, two times). The EtOAc was dried over MgS02 and concentrated under vacuum. The crade product was purified over Si02 (EtOAc:Hex = 1:1, Rf= 0.49) to afford Compound B130 ( 501 mg; 76J %). Η-NMR (DMSO-d5): 9.60 (IH, s), 8.28 (IH, s), 7.45-7.29 (3H, m), 4.64 (2H, m), 3.59-3.52 (4H, m), 3.41-3.49 (2H, m), 2.29-2.25 (2H, b), 1.96-1.86 (2H, m), 1.39 (6H, d) ppm. LCMS: 426.43.
Compound B131
4-(2,5-Difluoro-phenylamino)-6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]- pyrimidine-5-carbonitrile To a solution of 4,6-Dic oro-pyrimidine-5-carbonitrile (254 mg, 1.47 mmol) and 2,5- difluoroaniline (190 mg, 1.47 mmol) in DMF (3 mL) at 0°C was added K2C03 (203 mg, 1.47 mmol). The completion of the reaction was monitored by TLC (EtOAc:Hex = 1:1, R/= 0.90). After the reaction was complete, 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine (340 mg, 1.47 mmol) and K2C03 (406 mg, 2.94 mmol) were added at 0°C. The reaction was warmed to rt and stirred for 30 min. The reaction was heated to 40°C and maintained for 1 h. The reaction was cooled to rt, poured in to H20 (50 mL) and extracted with EtOAc (50 mL, two times). The EtOAc was dried over MgS02 and concentrated under vacuum. The crade product was purified over Si02 (EtOAc:Hex = 1:1, Rf= 0.44) to afford the desired Compound B131 ( 465 mg; 71.1 %). Η-NMR (DMSO-ds): 9.32 (IH, s), 8.19 (IH, s), 7.40-7.08 (3H, m), 4.54 (2H, m), 3.48-3.32 (4H, m), 3.07-3.01 (2H, m), 2.18-2.14 (2H, b), 1.96-1.86 (2H, m), 1.27 (6H, d) ppm. LCMS: 426.43.
Compound B132
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yI)-piperidin-l-yl]-6-(4-methyIsulfanyl-phenylamino)- pyrimidine-5-carbonitrile
Compound B132 was prepared by the general procedure for the addition of amine to pyrimidine as described herein using 4-chloro-6-(4-methylsulfanyl-phenylamino)-pyrimidine-5- carbonitrile and 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine. 'H-NMR (DMSO-d6): 9.38 (IH, s), 8.21 (IH, s), 7.47 (2H, J = 4.3 Hz, d), 7.23 (2H, J = 4.3 Hz, d), 4.50 (2H, m), 3.35 (2H, m), 3.02 (IH, m), 2.51 (3H, s), 2.18 (2H, m), 1.79 (2H, m) 1.83 (6H, J = 7Hz, d) ppm. LCMS: 436.3, 351.9, 324.4, 270.2. termediate4-chloro-6-(4-memylsulfanyl-pta prepared in a similar manner as described herein using 4,6-dicUoro-pyrimidine-5-carbonitrile and 4-methylsulfanyl-phenylamine. T NMR (DMSO-d6): 10.22 (IH, s), 8.53 (IH, s) 7.43 (2H, m), 7.40 (2H, m), 2.49 (3H, s) ppm. LCMS: 277.0, 234.0, 149.0.
Compound B133
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methanesulfonyl- phenylamino)-pyrimidine-5-carbonitrile
To a solution of 4-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methylsulfanyl-phenylanιmo)-pyrinιicrme-5-carbonitrile (200mg, 0.46 mmol) in dichloromethane (5 mL) at 0°C was added 216 mg of »z-CPBA (0.94 mmol). The reaction was stirred for 10 min and warmed to room temperature. The reaction was maintained for 2h at the same temperature and the completion of the reaction was judged by TLC. The reaction was concentrated under vacuum and purified over Si02 (ethyl acetate/ Hex = 1/lm R/= 0.69) to afford Compound B133 (167 mg, 80%). Η-NMR (DMSO-d6): 9.86 (IH, s), 8.34 (IH, s), 7.93 - 7.84 (4H, m), 4.54 (2H, m), 3.50 - 3.39 (3H, m), 3.21 (3H, s) 3.05 (IH, m), 2.21 (2H, m), 1.83 (2H, m) 1.27 (6H, J = 7Hz, d) ppm. LCMS: 452.1, 437.2, 368.1, 340.0.
Compound B134
4-(4-Hexanoyl-piperidm-l-yl)-6-(6-methylsulfanyl-pyridm-3-ylamino)-pyrimicline-5- carbonitrile
4-Chloro-6-(4-methylsulfanyl-phenylamino)-pyrimidine-5-carbonitrile (150.00mg, 0.54mmol) in DMF (2ml) was mixture with Potassium Carbonate (82.1mg, 0.59mmol), added l-piperidin-4-yl-hexan-l-one hydrochloride (237.4mg, 1.08 mmol) in DMF (1ml) and left stirring at room temperature for 1 hour. Reaction was worked up with ethyl acetate, sodium bicarbonate, dried with magnesium sulfate, filtered and concentrate under high vacuum to afford a lithe yellow solid as product. Compound was recrystalized using hexane in ethyl acetate to afford Compound B134 (157mg). LCMS (ESI) for C22H28N6OS: m/z 425.4 (M + H+, 100%). !H NMR 400MHz CDC13 δ (ppm): 8.72 (d, IH), 8.40 (s, 1H),7.97 (q,lH), 7.21 (s,lH,NH), 4.92 (m, 2H), 3.42 (m, 2H), 2.86 (m, IH), 2.75 (s, 3H), 2.65 (t, 2H), 2.15 (m, 2H), 1.77 (m, 2H), 1.50(m, 2H), 1.50 (m, 2H), 1.07 (t, 3H).
Compound B135
4-(4-Hexanoyl-piperidin-l-yl)-6-(6-methanesulfonyl-pyridin-3-ylamino)- pyrimidine-S-carbonitrile
4-(4-Hexanoyl-piperidin-l-yl)-6-(6-methylsulfanyl-pyridin-3-ylamino)-pyrimidine-5- carbonitrile (100 mg, 0.236mmol) in chloroform was mixture with wzCPBA (122.0mg, OJlmmol) at 0 C under stirring, left reaction warmed up to room temperature and reacted for an additional 12 hours. Worked up with water (pH=10 using ammonium hydroxide as base), chloroform, sodium bicarbonate, dried with magnesium sulfate, concentrate under high vacuum and crystallized using hexane and ethyl acetate to afford Compound B135 as a solid (90mg, 84%). LCMS (ESI) for C22H28N603S: m/z 457.2 (M + H+ , 100%). Η NMR 400MHz CDC13 δ (ppm): 8.87 (d, IH), 8.46 (q, IH), 8.32 (s,lH), 8.07(d,lH), 7.42 (s,lH, NH), 4.74 (m, 2H), 3.48 (m, 2H),3.21(s, 3H), 2.70 (m, IH), 2.48 (t, 2H), 1.98 (m. 2H), 1.58 (m, 2H), 1.27(m, 2H), 1.27 (m, 2H), 0.89 (t, 3H).
Compound B136
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(6-methylsulfanyl-pyridin-3- ylamino)-pyrimidine-5-carbonitrile
4-Chloro-6-(6-methylsulfanyl-pyridin-3-ylamino)-pyrimidine-5-carbonitrile (80.00mg, 0.29mmol) in DMF (2ml) was mixture with Potassium Carbonate (79.62mg, 0.58mmol), added 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine hydrochloride (237.4 mg, 1.08 or 1.02 mmol) in DMF (1ml) and left stirring at room temperature for 1 hour. Reaction was worked up with ethyl acetate, sodium bicarbonate, dried with magnesium sulfate, filtered and concentrate under high vacuum. Compound was recrystallized using hexane in ethyl acetate to afford Compound B136. Η NMR 400MHz DMSO δ (ppm): 9.48 (s,lH), 8.55 (d, IH), 8.35 (s, IH), 8.19 (s, IH), 7.77 (d, IH), 7.26 (d,lH), 4.52(m, 2H), 3.48 (m, IH), 3.37 (m, 2H), 3.32 (s, 3H), 3.04 (m, IH), 2.14 (m, 2H), 1.75 (m, 2H), 1.33 (d, 6H).
Compound B137
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(6-methanesulfonyl- pyridin-3-ylamino)-pyrimidine-5-carbonitrile
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(6-methylsulfanyl-pyridin- 3 -ylamino)-pyrimidine-5 -carbonitrile (26.0mg, 0.06mmol) in chloroform was mixture with wzCPBA (41.1mg, 0.24mmol) at 0 C under stirring, left reaction warmed up to room temperature and reacted for an additional 12 hours. Worked up with water (pH=10 using ammonium hydroxide as base), chloroform, sodium bicarbonate, dried with magnesium sulfate, concentrate under high vacuum and crystallized using hexane and ethyl acetate to afford Compound B137 as a solid (7.5 mg). !H NMR 400MHz DMSO δ (ppm): 8.88 (d, IH), 8.55 (d, IH), 8.35 (s, IH), 8.08 (d, IH), 7.44 (s, IH), 4.72 (m, 2H), 3.48 (m, IH), 3.30 (m, IH), 3.22 (s, 3H), 3.08 (m, IH), 2.23 (m, 2H), 2.03 (m, 2H), 1.33 (d, 6H).
Compound B138 l-[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methanesulfonyl- phenylamino)-pyrimidin-5-yl]-ethanone
To a solution of l-[4-Chloro-6-(4-methanesulfonyl-phenylamino)-pyrimidin-5-yl]- ethanone (0.21 mmol, 70 mg) and 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine hydrochloride (0.21 mmol, 49 mg) in N,N-dimethyl formamide (500 uL) was added potassium carbonate (0.21 mmol, 29 mg). The resulting mixture was microwaved at 100 °C for 150 seconds. Its progress was monitored by thin layer chromatography and LCMS. The reaction was treated with water and the desired compound was extracted in ethyl acetate. Organic layer was evaporated in vacuo. Purification by HPLC provided Compound B138 as a white solid (15 mg, 15%). Η-NMR (400 MHz, CDC13) δ(ppm): 10.85 (s, IH); 8.32 (s, IH); 7.92 (s, 4H); 4.07 (m, 2H); 3.40 (m, 2H); 3.29 (h, IH); 3.09 (m, IH); 3.07 (s, 3H); 2.47 (s, 3H); 2.18 (m, 2H); 2.03 (m, 2H), 1.33 (d, 6H). LCMS (ESI), m/z 485.3 (M+H+, 100%).
Compound B139 l-[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(6-methanesulfonyl- pyridin-3-ylamino)-pyrimidin-5-yl]-ethanone
To a solution of l-[4-cUoro-6-(6-methanesulfonyl-pyridin-3-ylamino)-pyrimidin-5- yl]-ethanone (0.21 mmol, 70 mg) and 4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidine hydrochloride (0.21 mmol, 49 mg) in N,N-dimethyl formamide (500 uL) was added potassium carbonate (.21 mmol, 29 mg). The mixture was microwaved at 100 °C for 150 seconds. Its progress was monitored by thin layer chromatography and LCMS. The reaction was treated with water and the desired compound was extracted in ethyl acetate. Organic layer was evaporated in vacuo. Purification by HPLC provided Compound B139 as a white solid (31 mg, 31%). Η-NMR (400 MHz, CDC13) δ(ppm): 10.9 (s, IH); 8.90 (d, IH); 8.58 (d, IH); 8.32 (s, IH); 8.05 (d, IH); 4.09 (m, 2H); 3.41 (m, 2H); 3.29 (h, IH); 3.23(s, 3H); 3.09 (h, IH); 2.48 (s, 3H), 2.18 (m, 2H), 2.02 (m, 2H), 1.35 (d, 6H)LCMS (ESI), m/z 486.3 (M+H+, 100%).
EXAMPLE 14
SYNTHESES OF COMPOUNDS OF THE PRESENT INVENTION
Compound Cl l-(5-Nitro-6-phenyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester General Method 17. A mixture of l-(6-chloro-5-nitropyrimidine-4-yl)-piperidine-4- carboxylic acid ethyl ester (0.157 g, 0.49 mmol), phenyl boronic acid (62.1 mg, 0.50 mmol), tetrakistriphenylphosphinepalladium(O) (11.6 mg), 2MNa2C03 (375 μL), DME/H20/ethanol (7/3/2) (1239 μL) was heated in a microwave tube at 140 °C for 120 s in a microwave reactor. The reaction mixture was cooled and filtered and the filtrate was partitioned between ethyl acetate and water. The organic layer was washed with IN NaOH (2x) and brine, dried (Na2C03) and evaporated. Flash column chromatography (Biotage, silica, 20 % EtOAc/hexane) afforded the desired product Cl in 47 % yield. Η NMR, 400MHz, CDC13, δ (ppm): 8.63(s, IH); 7.45(m, 5H); 4.16(q, 2H); 4.07(m, 2H); 3.20(t, 2H); 2.62(m, IH); 2.03(m, 2H); 1.84(m, 2H); 1.28(t, 3H). LCMS (ESI) for C18H20N4O4: m/z 356 (M+H+, 100 %)
Compound C2 l-(6-Naphthalen-2-yl-5-nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester [method 17]. Purification of the crude product by HPLC afforded the pure product. !H NMR, 400MHz, CDC13, δ (ppm): 8.62(s, IH); 7.93(s, IH); 7.80 (m, 3H); 7.50(m, 3H); 4.10(q, 2H); 3.99(m, 2H); 3.16 (t, 2H); 2.58(m, IH); 1.98 (m, 2H); 1.21(t, 3H). LCMS (ESI) for C22H22N404: m/z 406 (M+H+, 100 %) Compound C3
1- [6-(4-Methanesulf onyl7phenyl)-5-nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester;
[method 17]. Purification of the crade product by preparatory LCMS afforded the pure product in 7 %. !H NMR, 400 MHz, CDC13, δ (ppm): 8.66(s, IH); 8.02(d, IH); 7.66(d, IH);
4.18(q, 2H); 4.05(m, 2H); 3.27(t, 2H); 3.09(s, 3H); 2.66(m, IH); 2.06(m, 2H); 1.88(m, 2H);
1.28(t, 3H). LCMS (ESI) for C19H22N406S: m/z 434 (M+H+, 100 %)
Compound C4 l-(6-Benzofuran-5-yl-5-nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; [method 17]. Flash column chromatography (Biotage, silica, 20 % EtOAc/hexane) afforded the product in 61 % yield. Η NMR, 400MHz, CDC13, δ (ppm): 8.63(s, IH); 7.66(d, IH); 7.57(s, IH); 7.54(d, IH); 7.39(t, IH); 7.28(t, IH); 4.15(m, 4H); 3.22(t, 2H); 2.63(m, IH); 2.04(m, 2H); 1.85(m, 2H); 1.28(t, 3H). LCMS (ESI) for C22H20N4O5: m/z 396 (M+H+, 100 %)
Compound C5 l-[5-Nitro-6-(3-trifluoromethyl-phenyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 17] . Purification of the crude product by HPLC afforded the pure product in 11 %. Η NMR, 400MHz, CDC13, δ (ppm): 8.65 (s, IH); 7.46 (q, IH); 4.18 (q, 2H); 4.05 (m, 2H); 3.24 (m, 3H); 2.65 (m, IH); 2.05 (m, 2H); 1.86 (m, 2H); 1.27 (t, 3H). LCMS (ESI) for C19H22N404: m/z 370 (M+H+, 100 %)
Compound C6 l-[6-(4-Methoxy-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyIic acid ethyl ester;
[method 17]. Flash column chromatography (Biotage, silica, 20 % EtOAc/hexane) afforded the product in 24 % yield. Η NMR, 400MHz, CDC13, δ (ppm): 8.60(s, IH); 7.47(d, IH);
6.94(, 2H); 4.15(q, 2H); 4.03(m, 2H); 3.84(s, 2H); 3.17(m, 2H); 2.61(m, IH); 1.96(m, 2H);
1.83(m, 2H); 1.27(t, 3H). LCMS (ESI) for C19H22N405: m/z 386 (M+H+, 100 %)
Compound C7
4-(4-Butyl-piperidin-l-yl)-6-furan-3-yl-5-nitro-pyrimidine;
[method 17]. Flash column chromatography (Biotage, silica, 20 % EtOAc/hexane) afforded the product in 35 % yield. Η NMR, 400MHz, CDC13, δ (ppm): 8.55(s, IH); 7.97(s, IH); 7.46(s, IH); 6.73(s, 2H); 4.16(q, 2H); 3.18 (m, 2H); 2.61(m, IH); 2.01(m, 2H); 1.83(m, 2H); 1.27(t, 3H). LCMS (ESI) for C16H18N405: m/z 346 (M+H+, 100 %)
Compound C8 l-[6-(3-Chloro-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester [method 17]. Purification of the crude product by HPLC afforded the pure product in 14 %. 1NMR, 400MHz, CDC13, δ (ppm): 8.67(s, IH); 7.47(m, IH); 7.38(t, IH); 7.32(m, IH); 4.18(q, 2H); 4.05 (m, 2H); 3.28 (t, 2H); 2.67(m, IH); 2.07(m, 2H); 1.88(m, 2H); 1.28(t, 3H). LCMS (ESI) for Cι8H19ClN404: m/z 390 (M+H+, 100 %)
Compound C9 l-[6-(2,6-Dimethoxy-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 17]. Purification of the crade product by HPLC afforded the pure product in 28 %. ΗNMR, 400MHZ, CDC13, δ (ppm): 8.79(s, IH); 7.95(s, 3H); 7.40(t, IH); 6.59(d, 2H); 4.18(q, 2H); 4.07 (m, 2H); 3.74 (s, 6H); 3.38 (t, 2H); 2.70(m, IH); 2.10(m, 2H); 1.95(m, 2H); 1.28(t, 3H). LCMS (ESI) for C,8H19C1N404: m/z 390 (M+W, 100 %)
Compound CIO l-(6-Naphthalen-l-yl-5-nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; [method 17]. The reaction mixture was filtered through Celite and activated carbon and purified by preparatory LCMS. Η NMR 400MHz CDC13 δ(ppm): 8.75 (s, IH); 7.96 (m, IH); 7.90 (m, 2H); 7.51 (m, 3H); 7.40 (m, IH); 4.19 (m, 2H); 4.11 (m, 2H); 3.31 (m, 2H); 2.68 (m, IH); 2.08 (m, 2H); 1.91 (m, 2H); 1.29 (m, 3H). LCMS (ESI) m/z 407 (M+H+,100%)
Compound Cll l-[6-(4-Methylsulfanyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 17]. The reaction mixture was filtered through Celite and activated carbon and purified by preparatory LCMS. lH NMR 400MHz CDC13 δ(ppm): 8.68 (s, IH); 7.41 (m, 2H);
7.28 (m, 2H); 4.18 (m, 2H); 4.07 (m, 2H); 3.27 (m, 2H); 2.66 (m, IH); 2.52 (s, 3H); 2.03 (m,
2H); 1.85 (m, 2H); 1.29 (m, 3H). LCMS (ESI) m/z 403 (M+H+,100%)
Compound C12 l-(2',4'-Dihydroxy-5-nitro-[4,5']bipyrimidinyl-6-yl)-piperidine-4-carboxylic acid ethyl ester; [method 17]. The reaction mixture was filtered through Celite and activated carbon and purified by HPLC w/TFA. Yield 0.015 g, 11 %. Yellow solid. Η NMR 400MHz CDC13 D(ppm): 8.48, 7.33 (s, IH); 8.02 (s, IH); 4.07 (m, 2H); 3.86 (m, 2H); 3.13 (m, 2H); 2.65 (s, 2H); 2.55 (m, IH); 1.93 (m, 2H); 1.74 (m, 2H); 1.18 (m, 3H). LCMS (ESI) m/z 391 (M+H+,100%)
Compound C13 l-[6-(4-Methanesulfonyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 17] Yield: 6 mg (4 %). Η NMR, 400MHz, CDC13, δ (ppm): 8.66(s, IH); 8.02(d, IH); 7.66(d, IH); 4.18(q, 2H); 4.05(m, 2H); 3.27(t, 2H); 3.09(s, 3H); 2.66(m, IH); 2.06(m, 2H); 1.88(m, 2H); 1.28(t, 3H). LCMS (ESI) for C19H22N406S: m/z 434 (M+H+, 100 %)
Compound C14 l-[6-(3,5-Bis-trifluoromethyI-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 17]. Purification of the crude product by preparatory LCMS afforded the pure product in 23 %. i NMR, 400MHz, CDC13, δ (ppm): 8.64(s, IH); 7.96(s, 3H); 4.18(q, 2H);
4.05(m, 2H); 3.25(t, 2H); 2.65(m, IH); 2.05(m, 2H); 1.85(m, 4H); 1.28(t, 3H). LCMS (ESI) for C20HιSF6N4O4: m/z 492 (M+H+, 100 %)
Compound C15 l-(6-Dibenzothiophen-4-yl-5-nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester;
[method 17]. Purification of the crude product by preparatory LCMS afforded the pure product in 24 %. XH NMR, 400MHz, CDC13, δ (ppm): 8.72(s, IH); 8.20(d, IH); 8.12 (m, IH); 7.76(m, IH); 7.45(m, 4H); 7.37(m, IH); 4.14(q, 2H); 4.05(m, 2H); 3.27(t, 2H); 2.64(m, IH); 2.03(m, 2H); 1.86(m, 2H); 1.25(t, 3H). LCMS (ESI) for C24H22N404S: m/z 462 (M+H+, 100 %)
Compound C16 l-[6-(3,5-Dimethyl-isoxazol-4-yI)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic cid ethyl ester;
[method 17]. Purification of the crade product by preparatory LCMS afforded the pure product in 12 %. ΗNMR, 400MHz, CDC13, δ (ppm): 8.64(s, IH); 4.18(q, 2H); 4.05(m, 2H); 3.25(t, 2H); 2.66(m, IH); 2.35(s, 3H); 2.21(s, 3H); 2.05(m, 2H); 1.86(m, 2H); 1.28(t, 3H). LCMS (ESI) for C17H21N505: m/z 375 (M+H+, 100 %) Compound C17 l-(5-Nitro-6-thiophen-2-yl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; [method 17]. Purification of the crude product by preparatory LCMS afforded the pure product in 23%. ]H NMR, 400MHz, CDC13, δ (ppm): 8.56(s, IH); 7.58(d, IH); 7.47(d, IH); 7.10(t, IH); 4.17(q, 2H); 4,09(d, 2H); 3.21(t, 2H); 2.62(m, IH); 2.03(m, 2H); 1.85(m, 2H); 1.28(t, 3H). LCMS (ESI) for C16H,8N404S: m/z 362 (M+H+, 100 %)
Compound C18
1- [6-(3,5-Dichloro-phenyI)-5-nitro-pyrimidin-4-yI] -piperidine-4-carboxylic acid ethyl ester;
[method 17]. Purification of the crade product by preparatory LCMS afforded the pure product in 7 %. !H NMR, 400MHz, CDC13, δ (ppm): 8.59(s, IH); 7.44(s, IH); 7.30(s, 2H);
7.23(s, IH); 4.14(q, 2H); 4.00(m, 2H); 3.21(m, 2H); 2.61(m, IH); 2.02(m, 2H); 1.81(m, 2H);
1.25(1, 3H). LCMS (ESI) for C16H18N404S: m/z 362 (M+H+, 100 %)
Compound C19 l-(6-Dibenzofuran-4-yl-5-nitro-pyrimidin-4-yI)-piperidine-4-carboxylic acid ethyl ester; [method 17]. Purification of the crude product by preparatory LCMS afforded the pure product in 17 %. !H NMR, 400MHz, CDC13, δ (ppm): 8.77(s, IH); 8.07(d, IH); 7.96(d, IH); 7.45(m, 4H); 7.36(t, IH); 4.18(q, 2H); 4.08(m, 2H); 3.31(t, 2H); 2.69(m, IH); 2.07(m, 2H); 1.92(m, 2H); 1.29(t, 3H). LCMS (ESI) for C24H22N405: m/z 446 (M+H+, 100 %)
Compound C20
1- [6-(3,5-Dimethyl-phenyl)-5-nitro-pyrimidin-4-yl] -piperidine-4-carboxyIic acid ethyl ester;
[method 17]. Purification of the crude product by preparatory LCMS afforded the pure product in 23 %. Η NMR, 400MHz, CDC13, δ (ppm): . 8.46(s, IH); 6.93(s, 3H); 4.02(q, 2H);
3.89(m, 2H); 3.05(m, 2H); 2.47(m, IH); 2.20(s, 6H); 1.88(m, 2H); 1.70(m, 4H); 1.18(t, 3H).
LCMS (ESI) for Cι8H18ClN404: m/z 384 (M+H+, 100 %)
Compound C21 l-[6-(4-Acetyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
Filtered the reaction mixture and the filtrate was purified by semi preparatory HPLC afforded the pure product in 21 %. Η NMR, 400MHz, CDC13, δ (ppm): 8.63(s, IH); 8.00(d, 2H); 7.57(d, 2H); 4.16(q, 2H); 4.03(m, 2H); 3.22(m, 2H); 2.64(s, 3H); 2.03(m, 2H); 1.85(m, 4H); 1.27(t, 3H). LCMS (ESI) for C20H22N4Os: m/z 398 (M+W, 100 %) Compound C22 l-[6-(4-Ethanesulfonyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyli2 acid ethyl ester;
' [method 17]. Purification of the crade product by preparatory TLC using 20 % EtOAc/hexane afforded the pure product in 21 %. Η NMR, 400MHz, CDC13, δ (ppm): 8.63(s, IH); 7.97(d, 2H); 7.67(d, 2H); 4.18(q, 2H); 3.22(m, 2H); 3.12(m, 3H); 2.65(m, IH); 2.04(m, 2H); 1.85(m, 2H); 1.28(t, 3H). LCMS (ESI) for C20H24N4O6S: m/z 448 (M+H+, 100 %)
Compound C23 l-[6-(2-Fluoro-biphenyl-4-yl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 17]. purified by semi preparatory HPLC afforded the pure product in 14 %. lH
NMR, 400MHz, CDC13, δ (ppm): 8.54(s, IH); 7.35(m, 8H); 4.07(q, 2H); 3.96(m, 2H); 3.13(t,
2H); 2.53(m, IH); 1.95(m, 2H); 1.77(m, 2H); 1.19(t, 3H). LCMS (ESI) for C20H22N4O5: m/z
398 (M+H+, 100 %)
Compound C24 l-[6-(3-Methanesulfonyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 17]. Purification of the crade product by flash column chromatography (Biotage,silica, 20 % EtOAc/hexane) afforded the pure product in 5 %. Η NMR, 400MHz, CDC13, δ (ppm): 8.67(s, IH); 8.07(m, 2H); 7.69(m, 2H); 4.18(q, 2H); 4.09(m, 2H); 3.29(t, 2H); 3.08(s, 3H); 2.71(m, IH); 2.06(m, 2H); 1.87(m, 2H); 1.27(t, 3H). LCMS (ESI) for C19H22N406S: m/z 434(M+H+, 100 %)
Compound C25 l-{6-[4-(2-Carboxy-ethyl)-phenyl]-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester;
[method 17]. C25 was purified by preparatory HPLC afforded the pure product in 24 %. H NMR, 400MHz, CDC13, δ (ppm): 8.52(s, IH); 7.33(d, 2H); 7.17(d, 2H); 4.07(m, 2H); 3.94(m, 2H); 3.10(t, 2H); 2.94(t, 2H); 2.64(t, 2H); 2.52(m, IH); 1.40(t, 3H). LCMS (ESI) for C21H24N406: m/z 428(M+H+, 100 %)
Compound C26 l-{6-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid methyl ester
[method 17]. Purification of the residue by column chromatography (silica, 20 % EtOAc/hexane) afforded the pure product in 14 %. ]H NMR, 400MHz, CDC13, δ (ppm): 8.55(s, IH); 7.36(d, 2H); 7.19(d, 2H); 3.95(m, 2H); 3.64(s, 3H); 3.60(s, 3H); 3.1 l(m, 2H); 2.92(t, 2H); 2.57(t, 2H); 2.54(m, IH); 1.95(m, 2H); 1.76(m, 2H). LCMS (ESI) for C21H24N406: m/z 428 (M+H+, 100 %).
Compound C27 l-{6-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester.
[method 17]. Purification of the residue by preparatory TLC (silica, 20 % EtOAc/hexane) afforded the pure product in 16 %. *H NMR, 400MHz, CDC13, δ (ppm): 8.55(s, IH); 7.35(d, 2H); 7.19(d, 2H); 4.09(q, 2H); 3.96(m, 2H); 3.60(s, 3H); 3.1 l(m, 2H); 2.92(t, 2H); 2.57(t, 2H); 1.94(s, 3H); 1.77(m, 2H); 1.19ft 3H). LCMS (ESI) for C22H26N406: m/z 442 (M+H+, 100 %).
EXAMPLE 15
SYNTHESES OF COMPOUNDS OF THE PRESENT INVENTION
Compound Dl l-[5-Nitro-6-(2-trifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester. General Method 18. l-{6-chloro-5-nitro-pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester (100 mg, 0.317 mmol), Pd(PPh3)2Cl2 (12 mg, 0.017 mmol) and copper(l)iodide (5 mg, 0.026 mmol) were dissolved in diisopropylethylamine and stirred for 2 min. o-ethynyl-trifluoromethylbenzene (100 ul, 0.072 mmol) was added and the mixture stirred under N2 at 70 °C for 18 hours. The yellow suspension turned black. After cooling to room temperature, the reaction mixture was diluted with chloroform (12 ml), passed through a celite plug and concentrated under vacuo. Purification by Flash Chromatography (0-30% Ethyl acetate / Hexanes) gave Compound Dl. Yield 35 %. lH NMR 400MHz CDC13 δ (ppm): 8.58 (s, IH); 7.78 (d, IH); 7.71 (d, IH); 7,56 (m, 2H); 4.16 (m, 2H); 4.01 (d, 2H); 3.21 (m, 2H); 2.63 (m, IH); 2.03 (m, 2H); 1.84 (m, 2H); 1.26 (t, 3H). LCMS (ESI) m z 449 (M+H+, 100 %)
Compound D2 l-(5-Nitro-6-phenylethynyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester [method 18]. Purification by HPLC yielded red oil. Yield 9 %. *H NMR 400MHz CDC13 δ (ppm): 8.49 (s, IH); 7.54 (d, 2H); 7.32 (d, 3H); 4.11 (m, 2H); 3.95 (d, 2H); 3.20 (m, 2H); 2.58 (m, IH); 2.01 (m, 2H); 1.80 (m, 2H); 1.21 (t, 3H). LCMS (ESI) m/z 381 (M+H+, 100 %)
Compound D3 l-[5-Nitro-6-(4-trifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 18]. Purification by HPLC. Yield 30 % brown solid. *H NMR 400MHz CDC13 δ
(ppm): 8.55 (s, IH); 1.1 (d, 2H); 7.65 (d, 2H); 4.17 (m, 2H); 4.00 (d, 2H); 3.24 (m, 2H); 2.64
(m, IH); 1.96 (m, 4H); 1.28 (t, 3H). LCMS (ESI) m/z 449 (M+H+, 100%)
Compound D4 l-(5-Nitro-6-m-toIylethynyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester;
Purification by HPLC. Yield 60 % brown solid. Η NMR 400MHz CDC13 δ (ppm): 8.55 (s, IH); 7.44 (d, 2H); 7.27 (d, 2H); 4.18 (m, 2H); 4.00 (d, 2H); 3.24 (m, 2H); 2.64 ( , IH); 2.37 (s, 3H); 2.04 (m, 2H); 1.87 (m, 2H); 1.28 (t, 3H). LCMS (ESI) m/z 395 (M+H+, 100 %)
Compound D5
1- [6-(2-FIuoro-phenylethynyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxyiic acid ethyl ester;
Η NMR 400MHz CDC13 δ (ppm): 8.58 (s, IH); 7.78 (d, IH); 7.71 (d, IH); 7,56 (m, 2H); 4.16 (m, 2H); 4.01 (d, 2H); 3.21 (m, 2H); 2.63 (m, IH); 2.03 (m, 2H); 1.84 (m, 2H); 1.26 (t, 3H). LCMS (ESI) m/z 449 (M+H+, 100 %)
Compound D6 l-[5-Nitro-6-(3-trifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
[method 18]. Purification by Flash Chromatography (20-30 % Ethyl acetate/ Hexanes). Yield
42 %. *H NMR 400MHz CDC13 δ (ppm): 8.55 (s, IH); 7.87 (s, IH); 7.78 (d, IH); 7.68 (d,
IH); 7.55 (m, IH); 4.19 (m, 2H); 4.00 (d, 2H); 3.23 (m, 2H); 2.65 (m, IH); 2.04 (m, 2H); 1.86
(m, 2H); 1.27 (t, 3H). LCMS (ESI) m/z 449 (M+H+, 100%)
EXAMPLE 16
SYNTHESES OF COMPOUNDS OF THE PRESENT INVENTION
5-Nitro-4-(5-phenyl-[l,3,4]oxadiazol-2-ylsulfanyl)-6-[4-(pyridin-2-yIsulfanyl)-piperidin- l-yl]-pyrimidine Compound El
[Method 16]. yellow solid (56 mg, 80 %). 1HNMR (CDC13, 400 MHz) δ 1.61 ( , 2H), 2.02 (m, 2H), 3.22 (m, 2H), 3.69 ( , 2H), 3.98 (m, 2H), 6.87 (m, IH), 6.94 (m, IH), 7.30 (m, 4H), 7.72 (m, 2H), 7.89 (m, IH), 8.20 (m, IH). Exact mass calculated for C22Hι9N703S2493.56, found 494.5 (MW).
The compounds in the above examples were screened in the Membrane Cyclase Assay. Representative compounds are shown in the table below:
Figure imgf000213_0001
The other compounds in the Examples showed IC50 activities in the membrane cyclase assay less than about 500 μM.
Those skilled in the art will recognize that various modifications, additions, substitutions, and variations to the illustrative examples set forth herein can be made without departing from the spirit of the invention and are, therefore, considered within the scope of the invention. All documents referenced above, including, but not limited to, printed publications, and provisional and regular patent applications, are incorporated herein by reference in their entirety.

Claims

CLAIMS We claim:
A compound of Formula (la):
Figure imgf000214_0001
(la) or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:
A and B are independently Cι-3 alkylene optionally substituted with 1 to 4 methyl groups;
D is O, S, S(O), S(0)2, CR2R3 orN-R2;
V is selected from the group consisting of Cι-3 alkylene, ethynylene and Cι-2 heteroalkylene wherein each are optionally substituted with 1 to 4 substituents selected from the group consisting of C1-3 alkyl, Cι_ alkoxy, carboxy, cyano, -3 haloalkyl and halogen; or
V is absent;
W is NR4, O, S, S(O) or S(0)2; or W is absent; X is N or CR5;
V is N or CRs;
Z is selected from the group consisting of Cι-5 acyl, Cι-5 acyloxy, C alkoxy, Cι-8 alkyl, C alkylcarboxamide, Cι-4 alkylthiocarboxamide, CH alkylsulfonamide, CM alkylsulfinyl, CM alkylsulfonyl, CM alkylthio, - alkylthioureyl, CM alkylureyl, amino, Cι-2 alkylamino, C2-t dialkylamino, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, C .8 diacylamino, C2-g dialkylcarboxamide, Cι-4 dialkylthiocarboxamide, C2-6 dialkylsulfonamide, -4 dialkylsulfonylamino, formyl, CM haloalkoxy, CM haloalkyl, CM haloalkylcarboxamide, C1-4 haloalkylsulfinyl, - haloalkylsulfonyl, - haloalkylthio, halogen, aryl, heterocyclic, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl, wherein Cι-8 alkyl and Cι-5 acyl are each optionally substituted with 1, 2, 3 or 4 groups selected from the group consisting of Ci-5 acyl, Cι-5 acyloxy, CM alkoxy, C alkylcarboxamide, CM alkylsulfonamide, C alkylsulfinyl, CM alkylsulfonyl, CM alkylthio, C alkylureyl, amino, Cι-2 alkylamino, C2 dialkylamino, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, formyl, CM haloalkoxy, CM haloalkylsulfinyl, C haloalkylsulfonyl, C haloalkylthio, halogen, hydroxyl, hydroxylamino and nitro; or Z is a group of Formula (A):
Figure imgf000215_0001
(A) wherein:
R7 is H, Ci-8 alkyl or C3-6 cycloalkyl; and R8 is H, nitro or nitrile; Ari is aryl or heteroaryl wherein each are optionally substituted with R9-Ri3;
Ri is selected from the group consisting of H, C1-5 acyloxy, C2-6 alkenyl, CM alkoxy, Cι-8 alkyl, -4 alkylcarboxamide, C2.6 alkynyl, CM alkylsulfonamide, CM alkylsulfinyl, C1- alkylsulfonyl, CM alkylthio, CM alkylureyl, amino, CM alkylamino, C2.8 dialkylamino, carboxamide, cyano, C3.6 cycloalkyl, C2-6 dialkylcarboxamide, C2.6 dialkylsulfonamide, halogen, _4 haloalkoxy, CM haloalkyl, CM haloalkylsulfinyl, C haloalkylsulfonyl, C haloalkylthio and hydroxyl;
R2 is selected from the group consisting of H, C1-5 acyl, -5 acyloxy, CM alkoxy, Cι-8 alkyl, -4 alkylcarboxamide, CM alkylthiocarboxamide, CM alkylsulfinyl, CM alkylsulfonyl, C alkylthio, amino, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, C3.6-cycloalkyl, C2-6 dialkylcarboxamide, C haloalkoxy, C haloalkyl, halogen, heteroaryl, hydroxyl and phenyl; and wherein Ci- s alkyl, heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected from the group consisting of C1-5 acyl, C1-5 acyloxy, CM alkoxy, Cι-8 alkyl, CM alkylamino, -4 alkylcarboxamide, CM alkylthiocarboxamide, CM alkylsulfonamide, CM alkylsulfinyl, Cw alkylsulfonyl, CM alkylthio, C alkylthioureyl, Cι-4 alkylureyl, amino, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, C3.6-cycloalkyl, C3-6-cycloalkyl-Cι-3-alkylene, C3-6-cycloalkyl-C1-3- heteroalkylene, C2-8 dialkylamino, C2.6 dialkylcarboxamide, C dialkylthiocarboxamide, C2.6 dialkylsulfonamide, CM allcylthioureyl, C haloalkoxy, CM haloalkyl, C haloalkylsulfinyl, CM haloalkylsulfonyl, CM haloalkyl, C haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro; or
R2 is -Ar2-Ar3 wherein Ar2 and Ar3 are independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of H, -5 acyl, C1-5 acyloxy, Cι-4 alkoxy, Cι-8 alkyl, CM alkylcarboxamide, CM alkylthiocarboxamide, CM alkylsulfinyl, CM alkylsulfonyl, CM alkylthio, amino, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, C3-6-cycloalkyl, C2-6 dialkylcarboxamide, CM haloalkoxy, CM haloalkyl, halogen, hydroxyl and nitro; or R2 is a group of Formula (B):
Figure imgf000216_0001
(B) wherein:
Rι4 is Cι-8 alkyl or C3.6 cycloalkyl; and R15 is F, Cl, Br or CN; or R2 is a group of Formula (C):
Figure imgf000216_0002
(C) wherein:
G is C=0, CR16Rπ, O, S, S(O), S(0)2; where R16 and R17 are independently H or Cι-8 alkyl; and
Ar4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of Cι-5 acyl, Cι-5 acyloxy, CM alkoxy, Cι_8 alkyl, CM alkylcarboxamide, CM alkylthiocarboxamide, CM alkylsulfonamide, CM alkylsulfinyl, Cι- alkylsulfonyl, C alkylthio, CM alkylthioureyl, C alkylureyl, amino, carbo-Ci-β-alkoxy, carboxamide, carboxy, cyano, C3.6- cycloalkyl, C2.6 dialkylcarboxamide, - dialkylthiocarboxamide, C2- 6 dialkylsulfonamide, CM allcylthioureyl, CM haloalkoxy, C haloalkyl, CM haloalkylsulfinyl, C haloalkylsulfonyl, CM haloalkyl, CM haloalkylthio, halogen, heteroaryl, hydroxyl, hydroxylamino and nitro;
R3 is H, Ci-s alkyl, CM alkoxy, halogen or hydroxyl;
Ri is H or Cι-8 alkyl;
R5 and Re are independently H, Cι-8 alkyl or halogen;
R9 is selected from the group consisting of C1-5 acyl, C1-5 acyloxy, C2-6 alkenyl, CM alkoxy, Cι-8 alkyl, CM alkylamino, CM alkylcarboxamide, C2.6 alkynyl, CM alkylsulfonamide, C alkylsulfinyl, CM alkylsulfonyl, CM alkylthio, Cι-4 alkylureyl, amino, arylsulfonyl, carbo-Cι-5-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, C2-5 dialkylamino, C2-6 dialkylcarboxamide, C2.6 dialkylsulfonamide, halogen, CM haloalkoxy, CM haloalkyl, CM haloalkylsulfinyl, CM haloalkylsulfonyl, C haloalkylthio, heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxyl, nitro, C4-7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide and sulfonic acid, and wherein C,-5 acyl, -4 alkoxy, Cι-8 alkyl, C1 alkylsulfonamide, alkylsulfonyl, arylsulfonyl, heteroaryl, phenoxy and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cι-5 acyl, Cι_5 acyloxy, C2.6 alkenyl, C alkoxy, C,-8 alkyl, CM alkylcarboxamide, C2-6 alkynyl, C alkylsulfonamide, CM alkylsulfinyl, C1- alkylsulfonyl, CM alkylthio, CM alkylureyl, . carbo-Ci-β-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, C2_β dialkylcarboxamide, halogen, C haloalkoxy, CM haloalkyl, CM haloalkylsulfinyl, CM haloalkylsulfonyl, CM haloalkylthio, heteroaryl, heterocyclic, hydroxyl, nitro and phenyl; or
R9 is a group of Formula (D):
Figure imgf000217_0001
(D) wherein:
"p" and "r" are independently 0, 1, 2 or 3; and Ris is H, Ci-5 acyl, C2-6 alkenyl, Cι-8 alkyl, CM alkylcarboxamide, C2.6 alkynyl, CM alkylsulfonamide, carbo-Cι.6- alkoxy, carboxamide, carboxy, cyano, C3-6 cycloalkyl, C2-6 dialkylcarboxamide, halogen, heteroaryl or phenyl, and wherein the heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of CM alkoxy, amino, CM alkylamino, C2.6 alkynyl, C2-8 dialkylamino, halogen, CM haloalkoxy, CM haloalkyl and hydroxyl; and R10-R13 are independently selected form the group consisting of C1-5 acyl, C1-5 acyloxy, C2.6 alkenyl, CM alkoxy, Cι-8 alkyl, C alkylcarboxamide, C2-6 alkynyl, C alkylsulfonamide, CM alkylsulfinyl, C alkylsulfonyl, CM alkylthio, C alkylureyl, carbo-Cι_6-alkoxy, carboxamide, carboxy, cyano, C3-6 cycloalkyl, C2-6 dialkylcarboxamide, halogen, CM haloalkoxy, CM haloalkyl, CM haloalkylsulfinyl, CM haloalkylsulfonyl, C haloalkylthio, hydroxyl and nitro; or two adjacent R10-Rπ groups together with Ari form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
2. The compound according to claim 1 wherein W is NR).
3. The compound according to claim 2 wherein R is H.
4. The compound according to claim 2 wherein R4 is CH3 or CH2CH3.
5. The compound according to claim 1 wherein W is O.
6. The compound according to claim 1 wherein W is S.
7. The compound according to claim 1 wherein W is absent.
8. The compound according to claim 1 wherein W is absent and V is ethynylene.
9. The compound according to any one of claims 1 to 7 wherein V is -CH2- or - CH2CH2-.
10. The compound according to any one of claims 1 to 7 wherein V is -OCH2CH2-.
11. The compound according to any one of claims 1 to 7 wherein V is absent.
12. The compound according to any one of claims 1 to 11 wherein A is ethylene and B is methylene.
13. The compound according to any one of claims 1 to 11 wherein A is propylene and B is methylene.
14. The compound according to any one of claims 1 to 11 wherein A and B are both ethylene wherein A and B are optionally substituted with 1 to 4 methyl groups.
15. The compound according to any one of claims 1 to 14 wherein D is O, S, S(O) or S(O)2.
16. The compound according to any one of claims 1 to 14 wherein D is CR2R3.
17. The compound according to claim 16 wherein R2 is selected from the group consisting of H, Cι-5 acyl, Cι-5 acyloxy, C alkoxy, Cι-8 alkyl, -4 alkylcarboxamide, C alkylthiocarboxamide, CM alkylsulfinyl, C alkylsulfonyl, CM alkylthio, amino, carbo- -6-alkoxy, carboxamide, carboxyl, C3-6 cycloalkyl, CM haloalkoxy, C haloalkyl, halogen and hydroxyl.
18. The compound according to claim 17 wherein R2 is selected from the group consisting of C(0)CH3, C(0)CH2CH3, C(0)CH2CH2CH3, C(0)CH(CH3)2, C(0)CH2CH2CH2CH3, OC(0)CH3, OC(0)CH2CH3, OC(0)CH2CH2CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, OCH2(CH2)2CH3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3, CH2(CH2)3CH3, C(0)NH2, C02CH3, C02CH2CH3, C02CH2CH2CH3, C02CH(CH3)2, C02CH2(CH2)2CH3, and C02H.
19. The compound according to claim 17 wherein R2 is selected from the group consisting of S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, S(0)2CH2(CH2)2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, hydroxyl, and F.
20. The compound according to claim 16 wherein R2 is Cι-8 alkyl, or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of Ci-5 acyloxy, -4 alkoxy, Cι-8 alkyl, CM alkylsulfonyl, carbo-Ci-β-alkoxy, carboxamide, carboxy, C3-6-cycloalkyl, C3.6-cycloalkyl-Cι-3-alkylene, C3-6-cycloalkyl- Cι-3-heteroalkylene, and hydroxyl.
21. The compound according to claim 20 wherein R2 is selected from the group consisting of CH2OCH3, CH2CH2OCH3, CH2OCH2CH3, CH2OCH2CH2CH3, CH2CH2OCH2CH3, CH2CH2OCH2CH2CH3, CH2OCH(CH3)2, CH2OCH2CH(CH3)2, CH2C02H, CH2CH2C02H, CH2OH, CH2CH2OH and CH2CH2CH2OH.
22. The compound according to claim 20 wherein R2 is selected from the group consisting of CH2S(0)2CH3, CH2S(0)2CH2CH3, CH2S(0)2CH2CH2CH3, CH2S(0)2CH(CH3)2, CH2S(0)2CH2(CH2)2CH3, CH2CH2S(0)2CH3, CH2CH2S(0)2CH2CH3, CH2CH2S(0)2CH2CH2CH3, CH2CH2S(0)2CH(CH3)2, CH2CH2S(0)2CH2(CH2)2CH3, CH2OCH2-cyclopropyl, CH2OCH2-cyclobutyl, CH2OCH2-cyclopentyl, and CH2OCH2-cyclohexyl.
23. The compound according to claim 20 wherein R2 is selected from the group consisting of l,2,4-oxadiazol-3-yl, l,2,4-oxadiazol-5-yl, l,3,4-oxadiazol-2-yl, 3- methyl-l,2,4-oxadiazol-5-yl, 3-ethyl-l,2,4-oxadiazol-5-yl, 3-isopropyl-l,2,4- oxadiazol-5-yl, 3-propyl-l,2,4-oxadiazol-5-yl, 3-t-butyl-l,2,4-oxadiazol-5-yl, and 3- cyclopropyl-l,2,4-oxadiazol-5-yl.
24. The compound according to claim 16 wherein R2 is -Ar2-Ar3 wherein Ar2 and Ar3 are independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of Cι-5 acyl, -5 acyloxy, CM alkoxy, Cι-8 alkyl, CM alkylcarboxamide, CM alkylthiocarboxamide, C alkylsulfinyl, CM alkylsulfonyl, CM alkylthio, amino, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, C3-6-cycloalkyl, C2.6 dialkylcarboxamide, C haloalkoxy, CM haloalkyl, halogen, hydroxyl and nitro.
25. The compound according to claim 24 wherein Ar2 is a heteroaryl and Ar3 is phenyl.
26. The compound according to claim 16 wherein R2 is Formula (C):
Figure imgf000220_0001
(C) wherein:
G is C=0, CR16R17, O, S, S(O), S(0)2; wherein R16 and R17 are independently H or Cι-2 alkyl; and
Ar4 is phenyl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of CM alkoxy, Cι-8 alkyl, CM haloalkoxy, CM haloalkyl, and halogen.
27. The compound according to claim 26 wherein G is C=0, CH2 or O.
28. The compound according to claim 26 wherein G is S, S(O) or S(0)2.
29. The compound according to any one of claims 26 to 28 wherein Ar is selected from the group consisting of pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
30. The compound according to any one of claims 26 to 29 wherein Ar4 is 2-pyridyl.
31. The compound according to any one of claims 26 to 30 wherein R,6 and R17 are both H.
32. The compound according to any one of claims 16 to 31 wherein R3 is H.
33. The compound according to any one of claims 1 to 14 wherein D is N-R2.
34. The compound according to claim 33 wherein R2 is H, or carbo-Cι-6-alkoxy.
35. The compound according to claim 34 wherein R2 is selected from the group consisting of C02CH3, C02CH2CH3, C02CH2CH2CH3, C02CH(CH3)2 and C02CH2(CH2)2CH3.
36. The compound according to claim 33 wherein R2 is Cι.s alkyl optionally substituted with 1 to 5 substituents selected from the group consisting of CM alkylsulfonyl, carbo-Cι-6-alkoxy, and carboxy.
37. The compound according to claim 36 wherein R2 is CH2C02Et, or CH2CH2C02H.
38. The compound according to claim 36 wherein R2 is selected from the group consisting of CH2CH2S(0)2CH3, CH2CH2S(0)2CH2CH3, CH2CH2S(0)2CH2CH2CH3, CH2CH2S(0)2CH(CH3)2 and CH2CH2S(0)2CH2(CH2)2CH3.
39. The compound according to any one of claims 1 to 38 wherein Z is selected from the group consisting of C,-5 acyl, Cι-8 alkyl, CM alkylcarboxamide, amino, cyano, C4-8 diacylamino, C2-6 dialkylsulfonamide, formyl, halogen, heterocyclic, and nitro wherein Cι.8 alkyl and Cι-5 acyl are each optionally substituted with 1, or 2 groups selected from the group consisting of C2-4 dialkylmino, hydroxy, and halogen.
40. The compound according to claim 39 wherein Z is selected from the group consisting of nitro, amino, formyl, NHC(0)CF3, Br, NHC(0)CH3, N(C(0)CH3)2, N(S(0)2CH3)2, CH3, [l,3]dioxolan-2-yl, CH2OH, CH2N(CH3)2, and C(0)CH3.
41. The compound according to any one of claims 1 to 40 wherein Ri is selected from the group consisting of H, Cι-8 alkyl, and amino.
42. The compound according to any one of claims 1 to 41 wherein Ari is phenyl optionally substituted with R9-Rι3.
43. The compound according to claim 42 wherein R9 is selected from the group consisting of Cι.5 acyl, CM alkoxy, C s alkyl, C alkylcarboxamide, C2-6 alkynyl, Ci- 4 alkylsulfonamide, C2-6 dialkylsulfonamide, CM alkylsulfinyl, CM alkylsulfonyl, CM alkylthio, amino, arylsulfonyl, C2-6 dialkylamino, C2-6 dialkylsulfonamide, and carboxamide.
44. The compound according to claim 43 wherein R9 is selected from the group consisting of C(0)CH3, C(0)CH2CH3, C(0)CH2CH2CH3, C(0)CH(CH3)2, C(0)CH2CH2CH2CH3. OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, OCH2CH2CH2CH3, CH3, CH2CH3, GH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3, CH2(CH2)3CH3, CH2(CH2)4CH3, CH2(CH2)5CH3, C(0)NHCH3, C(0)NHCH2CH3, C(0)NHCH2CH2CH3, C(0)NHCH(CH3)2, C≡CH, S(0)2NHCH3, S(0)2NHCH2CH3, S(0)2NHCH2CH2CH3, S(0)2NHCH(CH3)2, S(0)2NHCH2(CH2)2CH3, S(0)2NHCH(CH3)CH2CH3, S(0)2N(CH3)2, S(0)2N(Et)(CH3), S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, S(0)2CH2(CH2)2CH3, S(0)2CH(CH3)CH2CH3, SCH3, SCH2CH3, SCH2CH2CH3, SCH(CH3)2, SCH2(CH2)2CH3, amino, S(0)2Ph, N(CH3)2, N(CH3)(Et), N(Et)2 and C(0)NH2.
45. The compound according to claim 42 wherein R9 is selected from the group consisting of cyano, C3-6 cycloalkyl, halogen, CM haloalkoxy, CM haloalkyl, CM haloalkylsulfonyl, and CM haloalkylthio.
46. The compound according to claim 45 wherein R9 is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cl, F, Br, OCF3, OCHF2, OCH2CF3, CF3, CHF2, CH2CF3, SCF3, SCHF2 and SCH2CF3.
47. The compound according to claim 42 wherein R9 is selected from the group consisting of heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxy, C -7 oxo- cycloalkyl, phenoxy and phenyl.
48. The compound according to claim 47 wherein R9 is selected from the group consisting of morpholin-4-yl, thiomo holin-4-yl, l-oxo-lλ4-thiomorpholin-4-yl, 1,1- Dioxo-lλ6-thiomorpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-l-yl, 4-ethyl- piperazin-1-yl, 4-propyl-piperazin-l-yl, piperidin-1-yl, pyrrolidin-1-yl, 2,5-dioxo- imidazolidin-4-yl, 2,4-dioxo-thiazolidin-5-yl, 4-oxo-2-thioxo-thiazolidin-5-yl, 3- methyl-2,5-dioxo-imidazolidin-4-yl, 3-methyl-2,4-dioxo-thiazolidin-5-yl, 3-methyl-4- oxo-2-thioxo-thiazolidin-5-yl, 3-ethyl-2,5-dioxo-imidazolidin-4-yl, 3-ethyl-2,4-dioxo- thiazolidin-5-yl, and 3-ethyl-4-oxo-2-thioxo-thiazolidin-5-yl.
49. The compound according to claim 47 wherein R9 is selected from the group consisting of lH-imidazol-4-yl, [l,2,4]triazol-l-yl, [l,2,3]triazol-l-yl, [l,2,4]triazol- 4-yl, pyrrol-1-yl, pyrazol-1-yl, lH-pyrazol-3-yl, imidazol-1-yl, oxazol-5-yl, oxazol-2- yl, [l,3,4]oxadiazol-2-yl, [l,3,4]thiadiazol-2-yl, [l,2,4]oxadiazol-3-yl, [l,2,4]thiadiazol-3-yl, tetrazol-1-yl, pyrimidin-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl, l,3-dioxo-l,3-dihydro-isoindol-2-yl and [l,2,3]thiadiazol-4-yl.
50. The compound according to claim 42 wherein R9 is Cι-8 alkyl or Cι-4 alkoxy optionally substituted with 1 to 5 substituents selected independently from the group consisting of Cι-5 acyl, CM alkoxy, CM alkylcarboxamide, CM alkylsulfonyl, carbo- Cι-6-alkoxy, carboxamide, carboxy, cyano, and hydroxyl.
51. The compound according to claim 50 wherein R9 is selected from the group consisting of CH2OCH3, CH2OCH2CH3, CH2OCH2CH2CH3, CH2OCH(CH3)2, CH2OCH2(CH2)2CH3, CH2CH2OCH3, CH2CH2OCH2CH3, CH2CH2OCH2CH2CH3, CH2CH2OCH(CH3)2 and CH2CH2OCH2(CH2)2CH3.
52. The compound according to claim 42 wherein R9 is of Formula (D):
Figure imgf000223_0001
(D) wherein:
"p" and "r" are independently 0, or 1; and Rι8 is H, carbo-Cι.6-alkoxy, heteroaryl or phenyl, and wherein the heteroaryl and phenyl are each optionally substituted with 1 to 5 substituents selected independently from the group consisting of CM alkoxy, amino, CM alkylamino, C2-6 alkynyl, C2-s dialkylamino, halogen, CM haloalkoxy, CM haloalkyl and hydroxyl.
53. The compound according to claim 52 wherein p = 0 and r = 0.
54. The compound according to claim 53 wherein R18 is phenyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of CM alkoxy, amino, CM alkylamino, C2.6 alkynyl, C2-8 dialkylamino, halogen, CM haloalkoxy, CM haloalkyl and hydroxyl.
55. The compound according to claim 52 wherein p = 0 and r = 1.
56. The compound according to claim 55 wherein R18 is carbo- -β-alkoxy or carboxy.
57. The compound according to any one of claims 43 to 56 wherein R9 is substituted at the para position on the phenyl.
58. The compound according to any one of claims 42 to 57 wherein R10-R13 are independently selected from the group consisting of C1-5 acyl, CM alkoxy, Cι-8 alkyl, CM alkylcarboxamide, CM alkylureyl, carbo-Cj-g-alkoxy, carboxamide, carboxy, cyano, C3-6 cycloalkyl, halogen, C haloalkoxy and CM haloalkyl.
59. The compound according to any one of claims 42 to 57 wherein one or two R10-R13 groups are independently halogen.
60. The compound according to any one of claims 42 to 59 wherein two adjacent R10-R.1 groups together with the phenyl form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
61. The compound according to claim 60 wherein the heterocyclic group together with the phenyl group is a 2,3-dihydro-benzofuran-5-yl, benzo[l,3]dioxol-5-yl group, 2,3- dihydro-benzo[l,4]dioxin-6-yl, 2,3-dihydro-benzo[l,4]dioxin-2-yl group, 3,4- dihydro-2H-benzo [b] [ 1 ,4] dioxeρin-7-yl group.
62. The compound according to any one of claims 1 to 41 wherein Ari is heteroaryl optionally substituted with R9-Rι3.
63. The compound according to claim 62 wherein R9 is selected from the group consisting of CM alkoxy, Cι_8 alkyl, CM alkylcarboxamide, CM alkylsulfonyl, -4 haloalkyl, hydroxy, halogen, and phenyl.
64. The compound according to claim 63 wherein R9 is selected from the group consisting OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, OCH2CH2CH2CH3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH(CH3)(CH2CH3), CH2(CH2)2CH3, CH2(CH2)3CH3, CH2(CH2)4CH3, CH2(CH2)5CH3, C(0)NHCH3, C(0)NHCH2CH3, C(0)NHCH2CH2CH3, C(0)NHCH(CH3)2, C(0)NHCH2(CH2)2CH3, S(0)2CH3, S(0)2CH2CH3, S(0)2CH2CH2CH3, S(0)2CH(CH3)2, Cl, F, Br, CF3, CHF2, CH2CF3, and hydroxy.
65. The compound according to any one of claims 62 to 64 wherein R10-R13 are independently C1-5 acyl, Q-4 alkoxy, Q-8 alkyl, C alkylcarboxamide, CM alkylureyl, carbo-Cι-6-alkoxy, carboxamide, carboxy, cyano, C3.6 cycloalkyl, halogen, CM haloalkoxy and CM haloalkyl.
66. The compound according to any one of claims 62 to 64 wherein one or two R10-R.3 groups are independently halogen.
67. The compound according to any one of claims 1 to 66 wherein X is N and Y is CH.
68. The compound according to any one of claims 1 to 66 wherein X is N and Y is CF.
69. The compound according to any one of claims 1 to 66 wherein X is CH and Y is N.
70. The compound according to any one of claims 1 to 66 wherein X and Y are N.
71. The compound according to any one of claims 1 to 66 wherein X and Y are CH.
72. The compound according to any one of claims 1 to 66 wherein X is CH and Y are CF.
73. The compound according to claim 1 wherein said compound is selected from the group consisting of: l_[6-(4-Irnidazol-l-yl-phenoxy)-5-nifro-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; 1 -[6-(2-Methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(Benzo[l,2,5]oxadiazol-5-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-{6-[4-(2-Methoxycarbonyl-acetyl)-phenoxy]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester;
' l-[5-Amino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-(2,2,2-trifluoro- acetylamino)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
Propionic acid l-[2-amino-5-formyl-6-(2-methyl-5-trifluoromethyl-2H- pyrazol-3 -yloxy)-pyrimidin-4-yl] -piperidin-4-yl ester;
4-[6-(2-Methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro-pyrimidin-4- yl]-piperazine-l -carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nifro-pyrimidin-4- yl]-piperidine-4-carboxylic acid methyl ester;
2,6-Dimethyl-4-[6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro- pyrimidin-4-yl] -moφholine; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4- yl]-piperidine-3 -carboxylic acid ethyl ester; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethylamide; l-[6-(2-Methyl-5-phenyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester;
4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-piperidin-l-yl- pyrimidine; l-[5-Nifro-6-(2-trifluoromethyl-benzyloxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nitio-6-(3-tiifluoromethyl-benzyloxy)-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nitro-6-(4-trifluoromethyl-benzyloxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Bromo-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; 1 -[5 -Acetylamino-6-(2-methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Diacetylamino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)- pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Methyl-5-frifluoromethyl-2H-ρyrazol-3-yloxy)-5-nifro-pyrimidin-4- yl]-piperidine-4-carboxylic acid; l-{5-Nifro-6-[2-(2-1rifluoromethyl-phenyl)-ethoxy]-pyriιriidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-{5-Nitro-6-[2-(3-trifluoromethyl-phenyl)-ethoxy]-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-[5-Di-(methanesulfonyl)amino-6-(2-methyl-5-trifluoromethyl-2H-pyrazol- 3-yloxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nifro-6-(3-trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Methyl-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nifro-6-(2-trifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nifro-6-(4-t ifluoromethyl-phenoxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(2,5-Dimethyl-2H-pyrazol-3-yloxy)-5-nifro-pyrimidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester; l-[6-(4-Bromo-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Chloro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Carbamoyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(2-Methoxy-ethyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Cyclopentyl-phenoxy)-5-nifro-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -[5 -Nitro-6-(4-pyrrol- 1 -yl-phenoxy)-ρyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Benzoyl-phenoxy)-5-nifro-pyrirnidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(4-Hydroxy-benzenesulfonyl)-ρhenoxy]-5-nifro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-[6-(4'-Cyano-biphenyl-4-yloxy)-5-nifro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(2-Amino-4-ethanesulfonyl-phenoxy)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(5-Hydroxy-pyrir din-2-yl)-phenoxy]-5-nifro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester;
1 -[5 -Nitro-6-(4-sulfo-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-[l,2,4]triazol-l-yl-phenoxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -[6-(4-Carbamoylmethyl-phenoxy)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-{6-[4-(l,3-Dioxo-l,3-dihydro-isoindol-2-yl)-phenoxy]-5-nifro-pyrimidin-4- yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(4'-Methoxy-biphenyl-4-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 - {6-[4-(2,5-Dioxo-imidazolidin-4-yl)-phenoxy] -5 -nitro-pyrimidin-4-yl} - piperidine-4-carboxylic acid ethyl ester;
4-(4,4-Difluoro-piperidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-nitro-pyrimidine; \
1 - {5-Nitro-6-[4-(4-oxo-cyclohexyl)-phenoxy]-pyrimidin-4-yl} -piperidine-4- carboxylic acid ethyl ester; l-{5-Nitro-6-[4-(3-oxo-butyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; l-[5-Nitro-6-(4-propionyl-phenoxy)-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 - {6-[4-(2-Hydroxy-ethyl)-phenoxy]-5-nitro-pyrimidm-4-yl} -piperidine-4- carboxylic acid ethyl ester;
{4-[6-(4,4-Difluoro-piperidin-l-yl)-5-nifro-pyrimidin-4-yloxy]-ρhenyl}- - phenyl-methanone; 3 - {4-[6-(4,4-Difluoro-piperidin- 1 -yl)-5-nitro-pyrimidin-4-yloxy] -phenyl} -3 - oxo-propionic acid methyl ester;
2-[6-(4,4-Difluoro-piperidin-l -yl)-5 -nifro-pyrimidin-4-yloxy] -5 - ethanesulfonyl-phenylamine;
4-(4-Cyclopentyl-phenoxy)-6-(4,4-difluoro-piperidin-l-yl)-5-nitro- pyrimidine; l-[6-(2,6-Dichloro-4-methanesulfonyl-phenoxy)-5-nifro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(4-Chloro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-ρiperidine-4- carboxylic acid ethyl ester; l-{6-[4-(4-Hydroxy-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine- 4-carboxylic acid ethyl ester;
1 -[6-(4-Cyanomethyl-phenoxy)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester;
(4- {6-[4-(2-Methanesulfonyl-ethyl)-piperazin- 1 -yl]-5-nitro-pyrimidin-4- yloxy}-phenyl)-phenyl-methanone;
4-(4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-l-yl]-5-nifro-pyrimidin-4- yloxy} -ρhenyl)-butan-2-one;
3-(4-{6-[4-(2-Methanesulfonyl-ethyl)-piperazin-l-yl]-5-nitro-pyrimidin-4- yloxy}-phenyl)-3 -oxo-propionic acid methyl ester;
4-(4-Methyl-piperidin- 1 -yl)-6-(2-methyl-5 -trifluoromethyl-2H-pyrazol-3 - yloxy)-5 -nitro-pyrimidine;
4-(4-Bromo-piρeridin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3- yloxy)-5-nitro-pyrimidine;
4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-(4-propyl- piperidin-1 -yl)-pyrimidine;
1 -[6-(2-Methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid amide; l-[5-Nitro-6-(2-oxo-2H-chromen-6-yloxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -[5-Nitro-6-(2-oxo-benzo[ 1 ,3]oxathiol-6-yloxy)-pyrimidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester; l-[6-(9H-Carbazol-2-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nifro-6-(9-oxo-9H-fluoren-2-yloxy)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-{5-Amino-6-[4-(3-oxo-butyl)-phenoxy]-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; l-[6-[4-(3-Oxo-butyl)-phenoxy]-5-(2,2,2-1rifluoro-acetylarmno)-pyrirnidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-{5-Amino-6-[4-(hydroxy-phenyl-methyl)-phenoxy]-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Benzoyl-5-methoxy-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(6-Chloro-pyridin-3-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(Benzo[l,3]dioxol-5-yloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Benzyloxy-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
1 -[6-(3 -Morpholin-4-yl-phenoxy)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester;
1 -[5 -Nitro-6-(4-trifluoromethylsulfanyl-phenoxy)-pyrimidin-4-yl] -piperidine- 4-carboxylic acid ethyl ester;
1 -[5 -Nitro-6-(4-trifluoromethoxy-phenoxy)-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Benzoyl-phenoxy)-5-(2,2,2-frifluoro-acetylamino)-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester;
{4-[5-Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}-phenyl- methanone;
{4-Methoxy-2-[5 -nitro-6-(4-propyl-piperidin- 1 -yl)-pyrimidin-4-yloxy] - phenyl} -phenyl-methanone;
4-{4-[5-Nifro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yloxy]-phenyl}-butan- 2-one;
5-Nitro-4-(4-propyl-piperidin-l-yl)-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)- pyrimidine;
3 - {4-[5 -Nitro-6-(4-propyl-piperidin- 1 -yl)-pyrimidin-4-yloxy] -phenyl} -3 -oxo- propionic acid methyl ester;
5-Ethanesulfonyl-2-[5-nifro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yloxy]- phenylamine; l-[6-(4-Difluoromethoxy-benzyloxy)-5-nifro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(3-Difluoromethoxy-benzyloxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
2- { 1 -[6-(2-Methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro-pyrimidin- 4-yl] -piperidin-4-yl} -ethanol;
3 - { 1 -[6-(2-Methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro-pyrimidin- 4-yl]-piperidin-4-yl}-propionic acid;
4-[4-(4-Methyl-benzyl)-piperidin-l-yl]-6-(2-methyl-5-trifluoromethyl-2H- pyrazol-3 -yloxy)-5 -nitro-pyrimidine;
4-(3-Methanesulfonyl-pyrrolidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H- pyrazol-3-yloxy)-5-nitro-pyrimidine;
4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-[4-(2- 1rifluoromethyl-phenoxy)-piperidin-l-yl]-pyrimidine;
4-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-6-[4-(pyridin-2- ylsulfanyl)-piperidin- 1 -yl] -pyrimidine;
4,-(4-Benzoyl-phenoxy)-3,-nitro-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-4- carboxylic acid ethyl ester;
3,-Nitro-4'-[4-(3-oxo-butyl)-phenoxy]-3,4,5,6-tetrahydro-2H- [l,2']bipyridinyl-4-carboxylic acid ethyl ester;
4'-[4-(2-Methoxycarbonyl-acetyl)-phenoxy]-3,-nitro-3,4,5,6-tetrahydro-2H- [l,2']bipyridinyl-4-carboxylic acid ethyl ester;
4'-(2-Amino-4-ethanesulfonyl-phenoxy)-3'-nitro-3,4,5,6-tetrahydro-2H- [l,2']bipyridinyl-4-carboxylic acid ethyl ester;
4'-(4-Imidazol- 1 -yl-phenoxy)-3 '-nitro-3 ,4,5 ,6-tetrahydro-2H- [l,2']bipyridinyl-4-carboxylic acid ethyl ester;
4-(2-Methyl-5 -trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro-6-(4- trifluoromethyl-piperidin-l-yl)-ρyrimidine;
4-(2-Methyl-5 -trifluoromethyl-2H-ρyrazol-3 -yloxy)-5 -nitro-6-(4- phenylsulfanyl-piperidin-l-yl)-pyrimidine; l-[6-(3-Ethynyl-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Chloro-2-fluoro-phenoxy)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(2,4-Difluoro-phenoxy)-5-nifro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Bromo-2-fluoro-phenoxy)-5-nifro-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
4-(3-Ethynyl-phenoxy)-5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidine; 4-(4-Chloro-2-fluoro-phenoxy)-5 -nitro-6-(4-propyl-piperidin- 1 -yl)- pyrimidine;
4-(2,4-Difluoro-phenoxy)-5 -nitro-6-(4-propyl-piperidin- 1 -yl)-pyrimidine;
4-(4-Bromo-2-fluoro-phenoxy)-5-nitro-6-(4-propyl-piperidin-l-yl)- pyrimidine;
3'-Nitro-2'-[4-(3-oxo-butyl)-phenoxy]-3,4,5,6-tetrahydro-2H- [l,4']bipyridinyl-4-carboxylic acid ethyl ester;
4-[4-(3'-Nitro-4-propyl-3,4,5,6-tetrahydro-2H-[l,4,]bipyridinyl-2'-yloxy)- phenyl]-butan-2-one;
2'-(4-Benzoyl-phenoxy)-3'-nitro-3,4,5,6-tetrahyάiO-2H-[l,4']bipyridinyl-4- carboxylic acid ethyl ester;
4-(4-{5-Nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4- yloxy } -phenyl)-butan-2-one;
[4-(3'-Nifro- -propyl-3,4,5,6-tetrahydro-2H-[l,4]bipyri<linyl-2'-yloxy)- phenyl]-phenyl-methanone;
4-(4-{5-Nifro-6-[4-(2-trifluoromethyl-phenoxy)-piperidin-l-yl]-pyrimidin-4- yloxy} -phenyl)-butan-2-one;
4-(4-{6-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro- pyrimidin-4-yloxy}-phenyl)-butan-2-one;
(4-{6-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin- 4-yloxy}-phenyl)-phenyl-methanone; l-{6-[4-(4-Fluoro-benzoyl)-phenoxy]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester;
(4-Fluoro-phenyl)-{4-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4- yloxy] -phenyl} -methanone;
4-[4-(3-Methyl-[l,2,4]oxadiazol-5-yl)-ρiperidin-l-yl]-6-(2-methyl-5- trifluoromethyl-2H-pyrazol-3 -yloxy)-5 -nitro-pyrimidine;
4-(4-Methoxymethyl-piperidin-l-yl)-6-(2-methyl-5-trifluoromethyl-2H- pyrazol-3 -yloxy)-5 -nitro-pyrimidine;
4-{4-[6-(4-Methoxymethyl-piperidin-l-yl)-5-nifro-pyrimidin-4-yloxy]- phenyl} -butan-2-one;
4-[4-(2-Methoxy-ethyl)-piperidin-l-yl]-6-(2-methyl-5-trifluoromethyl-2H- pyrazol-3 -yloxy)-5 -nitro-pyrimidine;
4- {4-[6-(4-Ethoxymethyl-piperidin- 1 -yl)-5 -nitro-pyrimidin-4-yloxy] - phenyl} -butan-2-one;
4-(2,4-Difluoro-phenoxy)-5-nifro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidine; (4-Methoxy-2-{5-nifro-6-[4-φyridin-2-ylsulfanyl)-piρeridin-l-yl]-pyrirnidin- 4-yloxy}-phenyl)-ρhenyl-methanone;
4-(2,4-Difluoro-phenoxy)-6-(4-ethoxymethyl-piperidin-l-yl)-5-nitro- pyrimidine;
4-{4-[6-(4-Cyclopropylmethoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4- yloxy]-phenyl}-butan-2-one;
4- {4-[5 -NitiO-6-(4-propoxymethyl-piperidin- 1 -yl)-pyrimidin-4-yloxy] - phenyl} -butan-2-one;
1 - {4-[6-(4-Methoxymethyl-piperidin- 1 -yl)-5 -nitro-pyrimidin-4-yloxy] - phenyl } -ethanone;
4- {4-[2-Nitro-3 -(4-propyl-piperidin- 1 -yl)-phenoxy] -phenyl} -butan-2-one; l-{4-[2-Nitro-3-(4-propyl-piperidin-l-yl)-phenoxy]-phenyl}-ethanone;
{4-[2-Nitro-3 -(4-propyl-piperidin- 1 -yl)-phenoxy] -phenyl } -phenyl- methanone;
3 - {4-[2-Nitro-3 -(4-propyl-piperidin- 1 -yl)-phenoxy] -phenyl} -3 -oxo-propionic acid methyl ester;
4-{4-[6-(4-Butoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]- phenyl} -butan-2-one;
4-{4-[6-(4-Isobutoxymethyl-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]- phenyl}-butan-2-one;
(4-Fluoro-phenyl)-[4-(3'-nitro-4-propyl-3,4,5,6-tetrahydro-2H- [1 ,2']bipyridinyl-4'-yloxy)-phenyl]-methanone;
4-[4-(3'-Nitro-4-propyl-3,4,5,6-tetrahydro-2H-[l,2,]bipyridinyl-4'-yloxy)- phenyl]-butan-2-one;
3'-Nitro-4-propyl-4,-(4-[l,2,4]triazol-l-yl-phenoxy)-3,4,5,6-tetrahydro-2H- [l,2']bipyridinyl;
1 - {2-Nitro-3 -[4-(3 -oxo-butyl)-phenoxy]-phenyl} -piperidine-4-carboxylic acid ethyl ester; l-[3-(4-Benzoyl-phenoxy)-2-nitro-phenyl]-piperidine-4-carboxylic acid ethyl ester;
{4-[6-(4-Ethoxy-piperidin-l-yl)-5-nitro-pyrimidin-4-yloxy]-phenyl}-(4- fluoro-phenyl)-methanone; l-[6-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yloxy)-5-nitro-pyrimidin-4- yl]-piperidin-4-ol; l-[6-(4-Ace1yl-phenoxy)-5-nifro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; ( 1 - {6-[4-(4-Fluoro-benzoyl)-phenoxy]-5 -nitro-pyrimidin-4-yl} -piperidin-4- yl)-(4-fluoro-phenyl)-methanone;
4-(4-{6-[4-(4-Fluoro-benzoyl)-piperidm-l-yl]-5-nifro-pyrimidin-4-yloxy}- phenyl)-butan-2-one;
4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-[4-(pyridin-2-ylsulfanyl)- cyclohexyl]-pyrimidine;
4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-[4-(ρyridin-4-ylsulfanyl)- cyclohexyl]-pyrimidine;
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methanesulfonyl-phenoxy)-pyrimidine-5-carbonitrile;
5-[l,3]Dioxolan-2-yl-4-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l- yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidine;
4-[4-(3-Isoρropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methanesulfonyl-phenoxy)-pyrimidine-5-carbaldehyde;
5-[l,3]Dioxolan-2-yl-4-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l- yl]-6-(4-[l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine;
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- [l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine-5-carbaldehyde;
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- [l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidine-5-carboxylic acid;
[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-ρiperidin-l-yl]-6-(4- [l,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-5-yl]-methanol;
[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- [ 1 ,2,3]thiadiazol-4-yl-phenoxy)-pyrimidin-5 -ylmethyl]-dimethyl-amine;
4-(4-Methanesulfonyl-phenoxy)-5-nitro-6-(4-ρhenylsulfanyl-cyclohexyl)- pyrimidine;
4-[4-(3-tert-Butyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(6- methanesulfonyl-pyridin-3 -yloxy)-5 -nitro-pyrimidine;
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methanesulfonyl-phenoxy)-2-methyl-pyrimidine-5-carbonitrile; and l-[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methanesulfonyl-ρhenoxy)-pyrimidin-5 -yl] -ethanone; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
The compound according to claim 1 wherein said compound is selected from the group consisting of: l-{6-[(Benzo[l,3]dioxol-5-ylmethyl)-amino]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-[5-Nifro-6-(3,4,5-trimethoxy-benzylarmno)-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
(5-Nifro-6-piperidin-l-yl-pyrimidin-4-yl)-(3-trifluoromethyl-benzyl)-amine; l-[5-Nifro-6-(2-trifluoromethyl-benzylannno)-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nifro-6-(4-1rifluoromethyl-benzylamino)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nifro-6-(3-trifluoromethyl-benzylamino)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
(5 -Nifro-6-piperidin- 1 -yl-pyrimidin-4-yl)-(2-trifluoromethyl-benzyl)-amine;
(5-Nitro-6-piperidin-l-yl-pyrimidin-4-yl)-(4-trifluoromethyl-benzyl)-amine;
1 -[5 -Amino-6-(3 -trifluoromethyl-benzylamino)-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[5-Amino-6-(4-trifluoromethyl-benzylamino)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Bromo-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
1 -[5 -Nifro-6-(4-trifluoromethyl-phenylanήno)-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[6-(Methyl-phenyl-amino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-trifluoromethoxy-phenylamino)-pyrimidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester; l-[6-(4-Fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Difluoro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(3,5-Dichloro-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(Benzo[l,3]dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(2-Bromo-4-frifluoromethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2-Fluoro-phenylar no)-5-nifro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(3-Fluoro-phenylar no)-5-nifro-pyrirnidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[(2-Fluoro-phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine- 4-carboxylic acid ethyl ester; l-[6-(Ethyl-ρhenyl-ar no)-5-nifro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[(4-Chloro-phenyl)-methyl-amino]-5-nitro-pyrimidin-4-yl}-piperidine- 4-carboxylic acid ethyl ester;
1 -[6-(4-Difluoromethyl-benzylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-{6-[(2,3-Dihydro-benzo[l,4]dioxin-6-ylmethyl)-amino]-5-nitro-pyrimidin- 4-yl}-piperidine-4-carboxylic acid ethyl ester; l-{6-[(2,3-Dihydro-benzo[l,4]dioxin-2-ylmethyl)-amino]-5-nitro-pyrimidin- 4-yl}-piperidine-4-carboxylic acid ethyl ester; l-{6-[(2,3-Dihydro-benzofuran-5-ylmethyl)-amino]-5-nifro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-{6-[(6-Fluoro-4H-benzo[l,3]dioxin-8-ylmethyl)-amino]-5-nitro-pyrimidin- 4-yl}-piperidine-4-carboxylic acid ethyl ester;
1 -[6-(3 ,4-Dihydro-2H-benzo [b] [ 1 ,4] dioxepin-7-ylamino)-5 -nitro-pyrimidin- 4-yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(Morpholine-4-sulfonyl)-phenylamino]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; l-[6-(2,2-Difluoro-benzo[l,3]dioxol-4-ylamino)-5-nifro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2,2-Difluoro-benzo[l,3]dioxol-5-ylamino)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester;
1 -[6-(l , 1 -Dioxo-lH-1 λ6-benzo[b]thiophen-6-ylamino)-5 -nitro-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester; l-{6-[(Furan-3-ylmethyl)-amino]-5-nitro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; l-{6-[2-(4-Methoxy-phenoxy)-ethylamino]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester;
1 - {6-[2-(5 -Methoxy- lH-indol-3 -yl)-ethylamino] -5 -nitro-pyrimidin-4-yl} - piperidine-4-carboxylic acid ethyl ester;
(3,4-Dihydro-2H-benzo[b][l,4]dioxepin-7-yl)-[5-nitro-6-(4-propyl-piperidin- l-yl)-pyrimidin-4-yl]-amine; (3-Fluoro-phenyl)-[5-nifro-6-(4-propyl-ρiperidin-l-yl)-ρyrimidin-4-yl]- amine;
(3-Methoxy-ρhenyl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]- amine; l-{6-[(3-Fluoro-phenyl)-methyl-amino]-5-nitro-ρyrimidin-4-yl}-piperidine- 4-carboxylic acid ethyl ester;
1 -[6-(4-Benzoyl-phenylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-{6-[4-(l,l-Dioxo-lλ6-thiomorpholin-4-ylmethyl)-phenylamino]-5-nitro- pyrimidin-4-yl}-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methanesulfonyl-phenylamino)-5-nifro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Dimethylsulfamoyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester;
1 -[6-(3 -Methoxy-phenylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester;
1 -[6-(2-Methoxy-phenylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[6-(3,5-Bis-trifluoromethyl-phenylamino)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester; l-[6-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -[6-(3 ,5 -Dimethoxy-benzylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester;
[5-Nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]-(3,4,5-trimethoxy- benzyl)-amine;
(3,5-Dimethoxy-benzyl)-[5-nitro-6-(4-propyl-piperidin-l-yl)-pyrimidin-4-yl]- amine;
(4-{5-Nifro-6-[4-φyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4- ylamino}-phenyl)-phenyl-methanone;
(4-{5-Nitro-6-[4-(2-trifluoromethyl-phenoxy)-piperidin-l-yl]-pyrimidin-4- ylamino}-phenyl)-phenyl-methanone;
1 -[6-(4-Cyano-phenylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Dimethoxy-phenylanιino)-5-nifro-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-sec-Butyl-phenylan- no)-5-nitio-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Heptyl-phenylannno)-5-nifro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
2'-(4-Berj-zoyl-phenylarnino)-3l-nitro-3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl- 4-carboxylic acid ethyl ester;
1 -[5 -Nitro-6-(3 ,4,5 -trimethoxy-phenylamino)-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester;
1 -[5 -Nifro-6-(4-pentyl-phenylamino)-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester;
1 - {6-[4-(3 -Carboxy-propyl)-phenylamino] -5 -nitro-pyrimidin-4-yl} - piperidine-4-carboxylic acid ethyl ester; l-{6-[4-(Cyano-phenyl-methyl)-phenylamino]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester;
1 -[6-(4-Cyclohexyl-phenylamino)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[5-Nifro-6-(4-[l,2,4]1riazol-l-yl-phenylamino)-pyrimidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester;
1 -[5 -Nifro-6-(4-trifluoromethanesulfonyl-phenylamino)-pyrimidin-4-yl] - piperidine-4-carboxylic acid ethyl ester; l-[5-Nitro-6-(4-[l,2,3]thiadiazol-4-yl-phenylamino)-pyrimidin-4-yl]- piρeridine-4-carboxylic acid ethyl ester;
[6-(4-Ethoxymethyl-piperidin- 1 -yl)-5 -nitro-pyrimidin-4-yl] -(4- methanesulfonyl-phenyl)-amine;
[5-Nitro-6-(4-propyl-piperidin- 1 -yl)-pyrimidin-4-yl] -(4-[ 1 ,2,4]triazol- 1 -yl- phenyl)-amine;
{5-Nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidin-4-yl}-(4- [ 1 ,2,4]triazol- 1 -yl-phenyl)-amine;
(2-Fluoro-phenyl)- {6-[4-(3 -methyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl] -5 - nitro-pyrimidin-4-yl} -amine;
(4-Methanesulfonyl-phenyl)-{6-[4-(3-methyl-[l,2,4]oxadiazol-5-yl)- piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-amine;
{6-[4-(3 -Methyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl]-5 -nitro-pyrimidin-4- yl}-(4-[l,2,4]triazol-l-yl-phenyl)-amine; l-{5-Nifro-6-[4-(4-trifluoromethyl-phenoxy)-phenylamino]-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; {6-[4-(3-Ethyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4- yl} -(2-fluoro-phenyl)-amine;
{6-[4-(2-Methoxy-phenylsulfanyl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}- (4-[l,2,4]triazol-l-yl-phenyl)-amine;
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l- yl]-pyrimidin-4-yl} -amine;
(3-Methoxy-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine;
Benzo [ 1 ,3]dioxol-5 -yl-[5 -nitro-6-(4-propyl-piperidin- 1 -yl)-pyrimidin-4-yl] - amine;
(4-Fluoro-phenyl)-{l-[5-nitiO-6-(4-[l,2,4]triazol-l-yl-phenylamino)- pyrimidin-4-yl] -piperidin-4-yl} -methanone;
[5-Nitro-6-(4-phenylsulfanyl-piperidin-l-yl)-pyrimidin-4-yl]-(4- [ 1 ,2,4]triazol- 1 -yl-phenyl)-amine;
(4-Fluoro-phenyl)-{l-[6-(2-fluoro-phenylamino)-5-nitio-pyrimidin-4-yl]- piperidin-4-yl } -methanone; l-[6-(2-Methyl-5-phenyl-2H-pyrazol-3-ylamino)-5-nitro-pyrimidin-4-yl]- piperidine-4-carboxylic acid ethyl ester;
(4-Methanesulfonyl-phenyl)-[5-nitro-6-(4-phenylsulfanyl-piperidin-l-yl)- pyrimidin-4-yl] -amine;
(4-Methanesulfonyl-phenyl)- { 5 -nitro-6-[4-(pyridin-2-yloxy)-piperidin- 1 -yl] - pyrimidin-4-yl} -amine;
{6-[4-(4-Fluoro-phenoxy)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4- methanesulfonyl-phenyl)-amine;
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-4-yloxy)-piperidin-l-yl]- pyrimidin-4-yl} -amine;
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyrimidin-2-yloxy)-piperidin-l- yl]-pyrimidin-4-yl} -amine;
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(pyridin-4-ylsulfanyl)-piperidin-l- yl]-pyrimidin-4-yl} -amine;
(4-Methanesulfonyl-phenyl)-{6-[4-(4-methoxy-phenylsulfanyl)-piperidin-l- yl]-5-nitro-pyrimidin-4-yl} -amine;
[6-(4-Benzenesulfonyl-piperidin- 1 -yl)-5 -nitro-pyrimidin-4-yl] -(4- methanesulfonyl-phenyl)-amine;
{4-[6-(4-Methanesulfonyl-phenylar no)-5-nifro-pyrimidin-4-yl]-piperazin-l- yl} -acetic acid ethyl ester; (2-Fluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine;
2-Methoxy-phenyl)- {5 -nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin- 1 -yl] - pyrimidin-4-yl} -amine;
(4-Methanesulfonyl-phenyl)-(5-nitro-6-{4-[3-(3-trifluoromethyl-phenyl)- [1 ,2,4]oxadiazol-5-yl]-piperidin-l -yl} -pyrimidin-4-yl)-amine;
{6-[4-(3 -Ethyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl] -5 -nitro-pyrimidin-4- yl}-(4-methanesulfonyl-phenyl)-amine;
(6-{4-[5-(4-Fluoro-phenyl)-[l,3,4]oxadiazol-2-yl]-piperidin-l-yl}-5-nitro- pyrimidin-4-yl)-(4-methanesulfonyl-phenyl)-amine;
(4-Methanesulfonyl-phenyl)-[5 -nitro-6-(4-pyridin-2-ylmethyl-piperidin- 1 -yl)- pyrimidin-4-yl]-amine; '
1 - {6-[4-(4,5 -Dichloro-imidazol- 1 -yl)-phenylamino] -5 -nitro-pyrimidin-4-yl} - piperidine-4-carboxylic acid ethyl ester;
Benzo[l,3]dioxol-5-yl-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine;
(4-Fluoro-phenyl)-{l-[6-(2-fluoro-phenylamino)-5-nitro-pyrimidin-4-yl]- piperidin-4-yl} -methanone;
{ 1 -[6-(Benzo [ 1 ,3] dioxol-5 -ylamino)-5 -nitro-pyrimidin-4-yl] -piperidin-4-yl } - (4-fluoro-phenyl)-methanone;
(2,3-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine;
(2,4-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine;
(2,5-Difluoro-phenyl)-{5-nitro-6-[4-(pyridin-2-ylsulfanyl)-piperidin-l-yl]- pyrimidin-4-yl} -amine; l-[6-(4-Benzenesulfonyl-phenylamino)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[5-Nifro-6-(2-trifluoromethyl-3H-benzoimidazol-5-ylaιnino)-pyrimidin-4- yl]-piperidine-4-carboxylic acid ethyl ester;
1 - {5 -Nitro-6-[3 -(1,1 ,2,2-tetrafluoro-ethoxy)-phenylamino] -pyrimidin-4-yl} - piperidine-4-carboxylic acid ethyl ester;
{6-[4-(4-Iodo-phenoxy)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-(4- methanesulfonyl-phenyl)-amine;
(2-Fluoro-4-methanesulfonyl-phenyl)-{6-[4-(3-isopropyl-[l,2,4]oxadiazol-5- yl)-piperidm-l-yl]-5-nifro-pyrimidin-4-yl}-amine; {6-[4-(3-Ethyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin-4- yl} -(2-fluoro-4-methanesulfonyl-phenyl)-amine;
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(3-ρropyl-[l,2,4]oxadiazol-5-yl)- piperidin- 1 -yl] -pyrimidin-4-yl} -amine;
{6-[4-(3-Cyclopropylmethyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro- pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
{6-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin- 4-yl}-(4-methanesulfonyl-phenyl)-amine;
{6-[4-(3-Cyclopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro- pyrimidin-4-yl}-(4-methanesulfonyl-phenyl)-amine;
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4-methylsulfanyl- phenylamino)-pyrimidine-5-carbonitrile;
4-[4-(3 -Isopropyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl] -6-(4- methanesulfinyl-phenylamino)-pyrimidine-5-carbonitrile;
(4-Methanesulfonyl-phenyl)-{5-nitro-6-[4-(4-trifluoromethoxy-phenoxy)- piperidin-1 -yl]-pyrimidin-4-yl} -amine;
4-[4-(3 -Isopropyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl] -6-(4- methanesulfonyl-phenylamino)-pyrimidine-5-carbonitrile;
1 - { 1 -[6-(2-Fluoro-4-methanesulfonyl-phenylamino)-5 -nitro-pyrimidin-4-yl] - piperidin-4-yl} -hexan-1 -one; l-{l-[6-(4-Methanesulfonyl-phenylarnino)-5-nitro-pyrimidin-4-yl]-piperidin- 4-yl} -hexan-1 -one;
{6-[4-(3-tert-Butyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin- 4-yl}-(2-fluoro-4-methanesulfonyl-phenyl)-amine;
{6-[4-(3-tert-Butyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin- 4-yl}-(4-methanesulfonyl-phenyl)-amine;
[6-(4-Benzofuran-2-yl-piperidin- 1 -yl)-5 -nitro-pyrimidin-4-yl] -(4- methanesulfonyl-phenyl)-amine;
4-(3-Fluoro-4-methanesulfonyl-phenylamino)-6-[4-(3-isopropyl- [ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl] -pyrimidine-5 -carbonitrile;
{6-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nifro-pyrimidin- 4-yl}-(5-methanesulfonyl-pyridin-2-yl)-amine;
(3-Fluoro-4-methanesulfonyl-phenyl)-{6-[4-(3-isopropyl-[l,2,4]oxadiazol-5- yl)-piperidin-l-yl]-5-nitro-pyrimidin-4-yl}-amine;
{6-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-5-nitro-pyrimidin- 4-yl}-(6-methanesulfonyl-pyridin-3-yl)-amine; 4-(2,3-Difluoro-phenylamino)-6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)- piperidin-l-yl]-pyrimidine-5-carbonitrile;
4-(2,5-Difluoro-phenylamino)-6-[4-(3-isopropyl-[l,2,4]oxadiazol-5-yl)- piperidin-l-yl]-pyrimidine-5-carbonitrile;
4-[4-(3 -Isopropyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin-l -yl] -6-(4-methylsulfanyl- phenylamino)-pyrimidine-5-carbonitrile;
4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methanesulfonyl-phenylamino)-pyrimidine-5-carbonitrile;
4-(4-Hexanoyl-piperidin-l-yl)-6-(6-methylsulfanyl-pyridin-3-ylamino)- pyrimidine-5 -carbonitrile;
4-(4-Hexanoyl-piperidin- 1 -yl)-6-(6-methanesulfonyl-pyridin-3 -ylamino)- pyrimidine-5 -carbonitrile;
4-[4-(3 -Isopropyl-[ 1 ,2,4] oxadiazol-5 -yl)-piperidin- 1 -yl] -6-(6-methylsulfanyl- pyridin-3 -ylamino)-pyrimidine-5 -carbonitrile;
4-[4-(3 -Isopropyl-[ 1 ,2,4]oxadiazol-5 -yl)-piperidin- 1 -yl] -6-(6- methanesulfonyl-pyridin-3-ylamino)-pyrimidine-5-carbonitrile; l-[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(4- methanesulfonyl-phenylamino)-pyrimidin-5-yl]-ethanone; and l-[4-[4-(3-Isopropyl-[l,2,4]oxadiazol-5-yl)-piperidin-l-yl]-6-(6- methanesulfonyl-pyridin-3 -ylamino)-pyrimidin-5 -yl] -ethanone; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
The compound according to claim 1 wherein said compound is selected from the group consisting of: l-(5-Nitro-6-phenyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-(6-Naphthalen-2-yl-5-nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methanesulfonyl-phenyl)-5-nifro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -(6-Benzofuran-5 -yl-5 -nifro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester;
1 -[5 -Nitro-6-(3 -trifluoromethyl-phenyl)-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[6-(4-Methoxy-phenyl)-5-nifro-pyriτnidin-4-yl]-piperidine-4-carboxylic acid ethyl ester;
4-(4-Butyl-piperidin- 1 -yl)-6-furan-3 -yl-5 -nitro-pyrimidine; l-[6-(3-Chloro-phenyl)-5-nifro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(2,6-Dimethoxy-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-(6-Naphthalen-l-yl-5-nifro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methylsulfanyl-phenyl)-5-nifro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-(2',4,-Dihydroxy-5-nitro-[4,5']bipyrimidinyl-6-yl)-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Methanesulfonyl-phenyl)-5-nifro-pyrirnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -[6-(3 ,5 -Bis-trifluoromethyl-phenyl)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-(6-Dibenzothiophen-4-yl-5-nitiO-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Dimethyl-isoxazol-4-yl)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -(5-Nitro-6-thiophen-2-yl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester;
1 -[6-(3 ,5 -Dichloro-phenyl)-5 -nitro-pyrimidin-4-yl] -piperidine-4-carboxylic acid ethyl ester;
1 -(6-Dibenzofuran-4-yl-5 -nitro-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[6-(3,5-Dimethyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Acetyl-phenyl)-5-nifro-pyrimidin-4-yl]-piperidine-4-carboxylic acid ethyl ester; l-[6-(4-Ethanesulfonyl-phenyl)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-[6-(2-Fluoro-biphenyl-4-yl)-5-nitro-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -[6-(3 -Methanesulfonyl-phenyl)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-{6-[4-(2-Carboxy-ethyl)-phenyl]-5-nifro-pyrimidin-4-yl}-piperidine-4- carboxylic acid ethyl ester; l-{6-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-5-nitro-pyrimidin-4-yl}- piperidine-4-carboxylic acid methyl ester; and l-{6-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-5-nifro-pyrimidin-4-yl}- piperidine-4-carboxylic acid ethyl ester; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
76. The compound according to claim 1 wherein said compound is selected from the group consisting of: l-[5-Nifro-6-(2-trifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester;
1 -(5 -Nitro-6-phenylethynyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester; l-[5-Nifro-6-(4-frifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; l-(5-Nifro-6-m-tolylethynyl-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester;
1 -[6-(2-Fluoro-phenylethynyl)-5 -nitro-pyrimidin-4-yl] -piperidine-4- carboxylic acid ethyl ester; l-[5-Nifro-6-(3-trifluoromethyl-phenylethynyl)-pyriιnidin-4-yl]-piperidine-4- carboxylic acid ethyl ester; and l-[5-Amino-6-(3-frifluoromethyl-phenylethynyl)-pyrimidin-4-yl]-piperidine- 4-carboxylic acid ethyl ester; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
77. The compound according to claim 1 wherein said compound is 5-Nitro-4-(5-phenyl- [l,3,4]oxadiazol-2-ylsulfanyl)-6-[4-φyridin-2-ylsulfanyl)-piperidin-l-yl]-pyrimidine or a pharmaceutically acceptable salt, hydrate or solvate thereof.
78. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 77 and a pharmaceutically acceptable carrier.
79. A method for prophylaxis or treatment of a metabolic disorder in an individual comprising administering to the individual a therapeutically effective amount of a compound according to any one of claims 1 to 77 or a pharmaceutical composition of claim 78.
80. The method according to claim 79 wherein the metabolic disorder is type I, type π diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X or metabolic syndrome.
81. The method according to claim 79 wherein the metabolic disorder is type II diabetes.
82. A method for controlling or decreasing weight gain of an individual comprising administering to the individual a therapeutically effective amount of a compound according to any one of claims 1 to 77 or pharmaceutical composition of claim 78.
83. A method of modulating a RUP3 receptor comprising contacting the receptor with a compound according to any one of claims 1 to 77.
84. A method of modulating a RUP3 receptor in an individual comprising contacting the receptor with a compound according to any one of claims 1 to 77.
85. The method of modulating the RUP3 receptor according to claim 83 or 84 wherein the compound is an agonist.
86. The method of modulating the RUP3 receptor according to claim 83 or 84 wherein the compound is an inverse agonist.
87. The method of modulating the RUP3 receptor according to any one of claims 84 to 86 wherein the modulation of the RUP3 receptor is prophylaxis or treatment of a metabolic disorder.
88. The method of modulating the RUP3 receptor according to claim 87 wherein the metabolic disorder is type I, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X or metabolic syndrome.
89. The method of modulating the RUP3 receptor according to claim 87 wherein the metabolic disorder is type II diabetes.
90. The method of modulating the RUP3 receptor according to any one of claims 84 to 86 wherein the modulation of the RUP3 receptor controls or reduces weight gain of the individual.
91. The method according to any one of claims 84 to 90 wherein the individual is a mammal.
92. The method according to claim 91 wherein the mammal is a human.
93. Use of a compound' according to any one of claims 1 to 77 for production of a medicament for use in prophylaxis or treatment of a metabolic disorder.
94. The use of a compound according to claim 93 wherein the metabolic disorder is type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X or metabolic syndrome.
95. Use of a compound according to any one of claims 1 to 77 for production of a medicament for use in controlling or decreasing weight gain in an individual.
96. The use according to claim 95 wherein the individual is a mammal.
97. The use according to claim 96 wherein the mammal is a human.
98. A compound according to any one of claims 1 to 77 or a pharmaceutical composition according to claim 78 for use in a method of treatment of the human or animal body by therapy.
99. A compound according to any one of claims 1 to 77 or a pharmaceutical composition according to claim 78 for use in a method of prophylaxis or treatment of a metabolic disorder of the human or animal body by therapy.
100. The method of producing a pharmaceutical composition comprising admixing at least one compound according to any one of claims 1 to 77 and a pharmaceutically acceptable carrier.
PCT/US2004/001267 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia WO2004065380A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
EP04702248A EP1599468B1 (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
SI200430529T SI1599468T1 (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
BR0406761-4A BRPI0406761A (en) 2003-01-14 2004-01-14 1,2,3-Trisubstituted aryl and heteroaryl derivatives as metabolism modulators and the prophylaxis and treatment of related disorders such as diabetes and hyperglycemia
DK04702248T DK1599468T3 (en) 2003-01-14 2004-01-14 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders associated therewith such as diabetes and hyperglycemia
EA200501132A EA011009B1 (en) 2003-01-14 2004-01-14 1,2,3-substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DE602004009295T DE602004009295T2 (en) 2003-01-14 2004-01-14 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM FOR THE PREVENTION AND TREATMENT OF METABOLISM-CONDITIONAL DISEASES SUCH AS DIABETES OR HYPERGLYKEMIA
CA002512899A CA2512899A1 (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
NZ540612A NZ540612A (en) 2003-01-14 2004-01-14 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US10/541,657 US8293751B2 (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
MXPA05007485A MXPA05007485A (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia.
YUP-2005/0532A RS20050532A (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CN2004800022039A CN1835943B (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and uses thereof
JP2006501019A JP2006516572A (en) 2003-01-14 2004-01-14 Prevention and treatment of 1,2,3-trisubstituted aryl derivatives and 1,2,3-trisubstituted heteroaryl derivatives as metabolic modulators and disorders associated with these derivatives such as diabetes and hyperglycemia
AU2004205642A AU2004205642C1 (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
IL169081A IL169081A (en) 2003-01-14 2005-06-08 4,5,6-trisubstituted pyrimidine compounds, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for modulating metabolism
HR20050696A HRP20050696B1 (en) 2003-01-14 2005-08-03 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
NO20053803A NO20053803L (en) 2003-01-14 2005-08-11 1,2,3-trisubstituted aryl and heteroaryl derivatives such as metabolism modulators and prophylaxis and treatment of related disorders such as diabetes and hyperglycemia
IS7979A IS2713B (en) 2003-01-14 2005-08-12 1,2,3-triple aryl and heteroaryl derivatives as metabolic regulators and prevention and treatment of related diseases such as diabetes and hyperglycaemia
HK05111332A HK1076815A1 (en) 2003-01-14 2005-12-09 1,2,3-trisubstitued aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such asdiabetes and hyperglycemia
US12/945,712 US20110082134A1 (en) 2003-01-14 2010-11-12 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2010257356A AU2010257356A1 (en) 2003-01-14 2010-12-21 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US13/618,592 US8933083B2 (en) 2003-01-14 2012-09-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US44039403P 2003-01-14 2003-01-14
US60/440,394 2003-01-14
US44982903P 2003-02-24 2003-02-24
US60/449,829 2003-02-24
US45339003P 2003-03-06 2003-03-06
US60/453,390 2003-03-06
US47087503P 2003-05-14 2003-05-14
US60/470,875 2003-05-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/541,657 A-371-Of-International US8293751B2 (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US12/945,712 Continuation US20110082134A1 (en) 2003-01-14 2010-11-12 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US13/618,592 Continuation US8933083B2 (en) 2003-01-14 2012-09-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Publications (2)

Publication Number Publication Date
WO2004065380A1 true WO2004065380A1 (en) 2004-08-05
WO2004065380A8 WO2004065380A8 (en) 2004-10-21

Family

ID=32777226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001267 WO2004065380A1 (en) 2003-01-14 2004-01-14 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Country Status (30)

Country Link
US (3) US8293751B2 (en)
EP (1) EP1599468B1 (en)
JP (2) JP2006516572A (en)
KR (2) KR20110010824A (en)
CN (1) CN102558155A (en)
AT (1) ATE374766T1 (en)
AU (2) AU2004205642C1 (en)
BR (1) BRPI0406761A (en)
CA (1) CA2512899A1 (en)
CO (1) CO5640119A2 (en)
CY (1) CY1107085T1 (en)
DE (1) DE602004009295T2 (en)
DK (1) DK1599468T3 (en)
EA (1) EA011009B1 (en)
EC (1) ECSP055916A (en)
ES (1) ES2295816T3 (en)
GE (1) GEP20084540B (en)
HK (1) HK1076815A1 (en)
HR (1) HRP20050696B1 (en)
IL (1) IL169081A (en)
IS (2) IS2713B (en)
MA (1) MA27707A1 (en)
MX (1) MXPA05007485A (en)
NO (1) NO20053803L (en)
NZ (1) NZ540612A (en)
PL (1) PL377847A1 (en)
PT (1) PT1599468E (en)
RS (1) RS20050532A (en)
SG (1) SG182004A1 (en)
WO (1) WO2004065380A1 (en)

Cited By (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006067531A1 (en) * 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006076243A1 (en) * 2005-01-10 2006-07-20 Arena Pharmaceuticals, Inc. Processes for preparing 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidine-1-carboxylic acid derivatives and related compounds
WO2006076231A2 (en) * 2005-01-10 2006-07-20 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
JP2006522143A (en) * 2003-04-04 2006-09-28 アイアールエム・リミテッド・ライアビリティ・カンパニー Novel compounds and compositions as protein kinase inhibitors
WO2007027225A2 (en) 2005-04-27 2007-03-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2007120689A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7335672B2 (en) 2004-09-13 2008-02-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
JP2008526724A (en) * 2004-12-31 2008-07-24 プロシディオン・リミテッド Derivatives of pyridine, pyrimidine, and pyrazine as GPCR agonists
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009055331A2 (en) 2007-10-22 2009-04-30 Schering Corporation Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010009195A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010013849A1 (en) 2008-08-01 2010-02-04 日本ケミファ株式会社 Gpr119 agonist
WO2010029089A2 (en) * 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010075269A1 (en) 2008-12-23 2010-07-01 Schering Corporation Pyrimidine derivatives as gpcr modttlators for use in the treatment of obesity and diabetes
WO2010075271A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
WO2010114957A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
WO2010114958A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bridged bicyclic heterocycle derivatives and methods of use thereof
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
WO2010146605A1 (en) * 2009-06-18 2010-12-23 Cadila Healthcare Limited Novel gpr 119 agonists
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011025006A1 (en) 2009-08-31 2011-03-03 日本ケミファ株式会社 Gpr119 agonist
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7928230B2 (en) 2007-07-17 2011-04-19 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
EP2316457A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011062885A1 (en) 2009-11-23 2011-05-26 Schering Corporation Fused bicyclic pyrimidine derivatives and methods of use thereof
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
WO2011127106A1 (en) 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
US8093257B2 (en) 2007-05-04 2012-01-10 Bristol-Myers Squibb Company [6,5]-bicyclic GPR119 G protein-coupled receptor agonists
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8153635B2 (en) 2007-09-20 2012-04-10 Irm Llc Compounds and compositions as modulators of GPR119 activity
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US20120157443A1 (en) * 2009-09-04 2012-06-21 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN101123964B (en) * 2004-12-24 2012-11-28 普罗西迪恩有限公司 G-protein coupled receptor(GPR116) agonists and use thereof for treating obesity and diabetes
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
JP2012533546A (en) * 2009-07-15 2012-12-27 イーライ リリー アンド カンパニー GPR119 agonist
US8372837B2 (en) 2008-07-16 2013-02-12 Bristol-Myers Squibb Company Pyridone and pyridazone analogues as GPR119 modulators
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8399485B2 (en) 2006-12-14 2013-03-19 Merck Sharp & Dohme Corp. Acyl bipiperidinyl compounds useful as GPR 119 agonists
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US8551957B2 (en) 2007-08-16 2013-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US8815876B2 (en) 2008-07-16 2014-08-26 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9067891B2 (en) 2007-03-07 2015-06-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
KR20150126564A (en) 2014-05-02 2015-11-12 현대약품 주식회사 Novel cyclohexene derivatives, preparation method thereof and pharmaceutical composition for prevention or treatment of the metabolic diseases containing the same as an active ingredient
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9737533B2 (en) 2009-05-12 2017-08-22 Janssen Pharmaceuticals. Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US20180185291A1 (en) 2011-03-07 2018-07-05 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
WO2018236896A1 (en) 2017-06-19 2018-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US10618887B2 (en) 2012-06-08 2020-04-14 Sunesis Pharmaceuticals, Inc. Pyrimidinyl tyrosine kinase inhibitors
US10723699B2 (en) 2015-11-04 2020-07-28 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11071729B2 (en) 2007-09-14 2021-07-27 Addex Pharmaceuticals S.A. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
PL378295A1 (en) * 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of glucose metabolism and the prophylaxis and treatment of disorders thereof
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
WO2007035355A2 (en) * 2005-09-16 2007-03-29 Arena Pharmaceuticals, Inc. Modulators of metabolism and the treatment of disorders related thereto
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2164846A2 (en) 2007-05-22 2010-03-24 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles and their use as antiviral agents.
CN101801930B (en) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
AU2008297876B2 (en) 2007-09-14 2011-07-07 Addex Pharma S.A. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
ES2637794T3 (en) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Imidazo [1,2-A] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2010313397B2 (en) * 2009-10-30 2015-07-02 Janssen Pharmaceutica Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
US20110269759A1 (en) * 2009-10-30 2011-11-03 Coats Steven J Pyrimidine compounds as delta opioid receptor modulators
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
PL2649069T3 (en) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN103261195B (en) 2010-11-08 2015-09-02 杨森制药公司 The purposes of 1,2,4-triazolo [4,3-a] pyridine derivate and the positive allosteric modulators as MGLUR2 acceptor thereof
JP2014094886A (en) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Gpr119 agonist
WO2013052395A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
US9353078B2 (en) * 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
CN115340526B (en) * 2021-05-12 2024-02-02 中国科学院上海药物研究所 Phthalimide compound, pharmaceutical composition, preparation method and application thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2341925A1 (en) * 1973-08-20 1975-03-06 Thomae Gmbh Dr K 2,4, (opt.5-), 6-substd. pyriminidines as antithrombic agents - e.g. 6-methyl-5-nitro-2-piperazino-4-thiomorpolino-pyrimidine
DE2831850A1 (en) * 1978-07-20 1980-02-07 Basf Ag Diuretic n-carboxy:phenyl:sulphonyl pyrrole derivs. - prepd. from substd. 3-sulphonamido:benzoic acid
EP0556889A1 (en) * 1992-02-18 1993-08-25 Duphar International Research B.V Method of preparing aryl(homo)piperazines
RU938559C (en) * 1980-12-12 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе S-derivatives of 5-amyno-6-mercaptopyrimidine possessing antitumoral and cytostatic activity
EP0667343A1 (en) * 1994-01-18 1995-08-16 Sandoz Ltd. Alpha-pyrimidinyl acrylic acid derivatives with fungicidal activity
WO1996033994A1 (en) * 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Amino-substituted derivatives, process for the preparation thereof, and herbicide
WO1996036613A1 (en) * 1995-05-19 1996-11-21 Nippon Soda Co., Ltd. Substituted benzoic acid derivatives, process for the production thereof, and herbicides
WO1997026252A1 (en) * 1996-01-19 1997-07-24 Fmc Corporation Insecticidal n-heterocyclylalkyl- or n-[(polycyclyl)-alkyl]-n'-substituted piperazines
EP0801059A1 (en) * 1994-11-29 1997-10-15 Dainippon Pharmaceutical Co., Ltd. Indole derivative
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
EP0940387A1 (en) * 1995-10-26 1999-09-08 Tokyo Tanabe Company Limited Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2001027107A2 (en) * 1999-10-12 2001-04-19 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2001049677A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S Phenylpiperazinyl derivatives
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
WO2002002549A1 (en) * 2000-07-05 2002-01-10 Taisho Pharmaceutical Co., Ltd. Tetrahydropyridino or piperidino heterocyclic derivatives
WO2002006274A1 (en) * 2000-07-17 2002-01-24 Wyeth N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2002098864A1 (en) * 2001-06-01 2002-12-12 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
WO2003077656A1 (en) * 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
WO2004000843A1 (en) * 2002-06-24 2003-12-31 Astrazeneca Ab NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY
WO2004000819A1 (en) * 2002-06-24 2003-12-31 Astrazeneca Ab New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines

Family Cites Families (320)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH389134A (en) 1960-03-15 1965-03-15 Ciba Geigy Process for the production of new anthraquinone vat dyes
CH478818A (en) * 1965-10-22 1969-09-30 Ciba Geigy Process for the preparation of new N, N'-di- (pyrimidyl- (4) -aminoalkyl) -diazacycloalkanes
CH480410A (en) 1967-01-09 1969-10-31 Geigy Ag J R Process for the preparation of water-soluble azopyrimidine dyes
CA961052A (en) * 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (en) 1967-10-17 1970-06-01
US3608087A (en) * 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) * 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
BE756953A (en) 1969-10-02 1971-04-01 Merck & Co Inc POTENTIALIZATION OF ANTIBIOTICS
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) * 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en) * 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
US3690834A (en) * 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (en) * 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazoles and thiodiazole azo dyes
CH560197A5 (en) 1971-05-17 1975-03-27 Ciba Geigy Ag 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (en) 1971-05-17 1975-01-31 Ciba Geigy Ag MEANS OF INFLUENCING PLANT GROWTH.
US3966764A (en) * 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) * 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (en) 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (en) * 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azo dyes
AT340933B (en) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K PROCESS FOR THE PRODUCTION OF NEW PYRIMIDE DERIVATIVES AND THEIR ACID ADDITIONAL SALTS
JPS5517382Y2 (en) 1973-11-14 1980-04-22
US4101541A (en) * 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
CH584739A5 (en) 1973-12-21 1977-02-15 Ciba Geigy Ag
FR2258841B1 (en) 1974-01-29 1977-11-04 Ugine Kuhlmann
AT327605B (en) 1974-05-06 1976-02-10 Ciba Geigy Ag AGENTS FOR INHIBITING PLANT GROWTH
AU492126B2 (en) 1974-05-14 1975-11-20 Ciba-Geigy Ag Nitropyrimidine derivatives
FR2306697A1 (en) 1975-04-10 1976-11-05 Sogeras NEW PYRIMIDINES FOR USE AS ANTIDIABETIC AND HYPOCHOLESTEROLEMANT MEDICINAL PRODUCTS
US4139705A (en) 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
US4189579A (en) 1977-05-20 1980-02-19 The Dow Chemical Company Aminoalkylthiopurines
DE2731264A1 (en) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh NEW 1-ACYL-2-CYANAZIRIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
JPS6038696B2 (en) * 1977-12-09 1985-09-02 コニカ株式会社 Silver halide color photographic material
US4242507A (en) * 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
JPS556283A (en) 1978-06-29 1980-01-17 Sanyo Electric Co Ltd Electronic wrist watch
DE2831580C2 (en) 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Method and reagent for the determination of glycerin
DE2906603A1 (en) * 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-SUBSTITUTED AZIRIDINE-2-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
DE3070304D1 (en) 1980-04-28 1985-04-25 Teijin Ltd Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (en) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyano pyrazoles, herbicides containing them, process for their preparation and their use as herbicides
DOP1981004033A (en) 1980-12-23 1990-12-29 Ciba Geigy Ag PROCEDURE TO PROTECT CROP PLANTS FROM PHYTOTOXIC ACTION OF HERBICIDES.
DE3334455A1 (en) 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen GUANIDIN DERIVATIVES
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (en) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt PYRIDONE
JPS6157587A (en) 1984-08-29 1986-03-24 Shionogi & Co Ltd Condensed heterocyclic derivative and antiulcerative
PH22302A (en) 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
AU601145B2 (en) 1985-03-01 1990-09-06 Duphar International Research B.V. Benzoyl urea derivatives having anti-tumor activity
DE3601196A1 (en) 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-DIHYDROPYRIDINE
JPH0533359Y2 (en) 1986-08-04 1993-08-25
CA1340284C (en) 1987-03-19 1998-12-22 Zeneca Inc. Herbicidal substituted cyclic diones
DE68926687T2 (en) 1988-01-11 1997-03-06 Fuji Photo Film Co Ltd Process for the generation of extremely high-contrast negative images
NZ238863A (en) 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
WO1992012976A1 (en) 1991-01-16 1992-08-06 Yoshitomi Pharmaceutical Industries, Ltd. Use of pyridine compound as selective drug and novel pyridine compound
CA2070978A1 (en) 1991-06-11 1992-12-12 William J. Greenlee Cyclic renin inhibitors
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JPH0533359A (en) 1991-08-02 1993-02-09 Kubota Corp Small-sized back hoe of full swing type
DE4208254A1 (en) 1992-03-14 1993-09-16 Hoechst Ag SUBSTITUTED PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL AND FUNGICIDE
TW237456B (en) 1992-04-09 1995-01-01 Ciba Geigy
FR2692575B1 (en) 1992-06-23 1995-06-30 Sanofi Elf NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
DE4241632A1 (en) 1992-12-10 1994-06-16 Thomae Gmbh Dr K New (aza)aromatic or alicyclic carboxylic acid cpds. - used e.g. for treating thrombosis, inflammation, osteoporosis, cardiac infarct or tumour metastasis
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
JPH0753546B2 (en) 1992-12-28 1995-06-07 山本 優 Manufacturing method of coreless paper roll, device used for it and winding shaft
JPH0753546A (en) 1993-08-09 1995-02-28 Kuraray Co Ltd Diaryl-substituted heterocyclic compound and its medical use
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
DE69430581D1 (en) * 1993-10-14 2002-06-13 Abbott Lab CHINOLIZINONE TYPE COMPOUNDS
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
HU221855B1 (en) 1994-09-09 2003-02-28 Nippon Shinyaku Co., Ltd. Substituted piridin-, pyrimidin- and triazine derivatives and pharmaceutical compositions containing such compounds
WO1996028427A1 (en) 1995-03-10 1996-09-19 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH10506126A (en) 1995-05-12 1998-06-16 ニューロゲン コーポレイション Novel deazapurine derivatives; a new class of CRF1 specific ligands
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR0169813B1 (en) 1995-07-12 1999-01-15 김종인 4-amino-3-acylnaphthyridine derivatives
US6248571B1 (en) 1995-08-31 2001-06-19 Lonza Ag Method of producing dihydroxypyrimidine derivatives
JP4022271B2 (en) 1995-10-31 2007-12-12 富士フイルム株式会社 Pyrazolylazophenol dye
DE19602095A1 (en) 1996-01-22 1997-07-24 Bayer Ag Halopyrimidines
AU708055B2 (en) 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
PL191271B1 (en) 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pyrazole pyrimidines as antagonists of crf receptor
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
DE19624659A1 (en) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkene and pyridylalkanoic acid amides
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
JP3565864B2 (en) 1996-09-12 2004-09-15 シエーリング アクチエンゲゼルシヤフト Benzamidine derivatives substituted by cyclic amino acids or cyclic hydroxy acid derivatives and their use as anti-pseudo-solids
US6008234A (en) 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DZ2376A1 (en) 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
CA2229123A1 (en) 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
WO1998035967A2 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
ATE250035T1 (en) 1997-04-22 2003-10-15 Janssen Pharmaceutica Nv QUINOLINE AND QUINAZOLINE DERIVATIVES AS CRF ANTAGONISTS
JP2002501493A (en) 1997-04-22 2002-01-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Thiophenopyridines as CRF antagonists
JPH11193277A (en) 1997-05-14 1999-07-21 Nippon Soda Co Ltd Pyrimidine derivative, its production and harmful organism controller
DE19737723A1 (en) 1997-08-14 1999-02-18 Bayer Ag New methoximino:methyl-di:hydro-1,2,4-oxadiazine derivatives
BR9811939A (en) 1997-08-14 2000-09-05 Bayer Ag Methoxyiminomethyloxadiazines as pesticides
NL1010018C2 (en) 1997-09-09 1999-03-10 Duphar Int Res Quinoline and quinazoline derivatives with corticotropin releasing factor (CRF) antagonistic effect.
EP1068206A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors
JP2000038350A (en) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd Diabetes therapeutic drug
AU5777299A (en) 1998-08-21 2000-03-14 Du Pont Pharmaceuticals Company Isoxazolo(4,5-d)pyrimidines as CRF antagonists
KR100658489B1 (en) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. HIV replication inhibiting pyrimidines
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
CA2645717A1 (en) 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Human orphan g protein-coupled receptors
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
AU3123500A (en) 1998-12-17 2000-07-03 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1areceptor activity
US6239126B1 (en) 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US6867200B1 (en) 1998-12-18 2005-03-15 Axys Pharmaceuticals, Inc. (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
CZ27399A3 (en) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
PT1163237E (en) 1999-03-17 2004-08-31 Astrazeneca Ab AMIDA DERIVATIVES
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
EP1074549B1 (en) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DK1212327T3 (en) 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
JP2001089452A (en) 1999-09-22 2001-04-03 Sankyo Co Ltd Pyrimidine derivative
PT1225874E (en) 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv ANTIVIRAL COMPOSITIONS.
IL148905A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
DE60026155T2 (en) 1999-09-30 2006-08-10 Neurogen Corp., Branford SOME ALKYLENDIAMINE-SUBSTITUTED HETEROCYCLES
OA12049A (en) 1999-09-30 2006-05-02 Neurogen Corp Amino substituted pyrazoloÄ1,5,-aÜ-1,5-pyrimidinesand pyrazoloÄ1,5,-aÜ-1,3,5-triazines.
DE19947154A1 (en) 1999-10-01 2001-10-04 Bayer Ag Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
CO5271670A1 (en) 1999-10-29 2003-04-30 Pfizer Prod Inc ANTIGONISTS OF THE CORTICITROPINE RELEASE FACTOR AND RELATED COMPOSITIONS
GR990100388A (en) 1999-11-09 2001-07-31 PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND A FIBRIC ACID DERIVATIVE, PROVIDING FOR PATIENT'S COMPLIANCE AND ANTIPATED TO RETAIN EFFICACY, IMPROVE SAFETY AND REDUCE....
JP2003518128A (en) 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー Aromatic phosphonates as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
DE19962936A1 (en) 1999-12-24 2001-06-28 Bayer Ag New beta-aminoacid amide derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological disorders e.g. asthma, diabetes or rheumatoid arthritis
OA12157A (en) 2000-01-18 2006-05-08 Pfizer Prod Inc Corticotropin releasing factor antagonists.
IL150841A0 (en) 2000-02-09 2003-02-12 Hokuriku Pharmaceutical 1h-imidazopyridine derivatives
WO2001060870A1 (en) 2000-02-15 2001-08-23 Foster Miller, Inc. No voc radiation curable resin compositions
AU784722B2 (en) 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1326604A2 (en) 2000-04-12 2003-07-16 Novartis AG Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
WO2001085699A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
DE10024319A1 (en) 2000-05-17 2001-11-22 Merck Patent Gmbh New bis-acylguanidine compounds are subtype-1 cellular sodium ion-proton antiporter inhibitors useful e.g. for treating arrhythmia, angina pectoris, infarction and insulin-independent diabetes mellitus
WO2001087892A1 (en) 2000-05-18 2001-11-22 Neurocrine Biosciences, Inc. Crf receptor antagonists
ATE348162T1 (en) 2000-05-18 2007-01-15 Bayer Healthcare Ag REGULATION OF A HUMAN DOPAMINE-LIKE G-PROTEIN COUPLED RECEPTOR.
YU89002A (en) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Substituted 1-aminoalkyl-lactams and their use as muscarinic receptors antagonists
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
MXPA02012795A (en) * 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
WO2002002539A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
CN1441783A (en) 2000-07-18 2003-09-10 山之内制药株式会社 Medicine comprising dicyanopyridine derivative
ATE362468T1 (en) 2000-07-25 2007-06-15 Merck & Co Inc N-SUBSTITUTED INDOLES WITH APPLICATION IN THE TREATMENT OF DIABETES
WO2002019975A1 (en) 2000-09-05 2002-03-14 Taisho Pharmaceutical Co., Ltd. Hair growth stimulants
AU2001262945B2 (en) 2000-09-20 2006-02-02 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
PE20020507A1 (en) 2000-10-17 2002-06-25 Schering Corp NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
DK1333833T3 (en) 2000-10-23 2011-12-12 Glaxosmithkline Llc New trisubstituted 8H-pyridol [2,3-d] pyrimidin-7-one compound for the treatment of CSBP / RK / p38 kinase-mediated diseases
EP1347755A2 (en) 2000-10-31 2003-10-01 Merck &amp; Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP2004529075A (en) 2000-11-03 2004-09-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド CRF receptor antagonists and methods related thereto
US20020058026A1 (en) 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical Isoxazole derivatives
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
CA2448729A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab Piperazinyl and piperidyl substituted heterocyclic compounds
US20030180813A1 (en) 2000-12-01 2003-09-25 Takahide Ohishi Method of screening remedy for diabetes
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
AU2002231139B2 (en) 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
CZ305202B6 (en) 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Pharmaceutical composition
EP1357908A4 (en) 2001-01-30 2009-07-15 Merck & Co Inc Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
WO2002098878A1 (en) 2001-02-08 2002-12-12 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10110754A1 (en) 2001-03-07 2002-09-19 Bayer Ag Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
WO2002072101A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP4323810B2 (en) 2001-04-20 2009-09-02 ワイス Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
HUP0402352A2 (en) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Pyrimidine derivatives for use as phosphodiesterase (pde)7 inhibitors and pharmaceutical compositions containing them
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003026661A1 (en) 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Insulin secretion accelerator and novel pyrimidine derivative
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (en) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
JP2005518408A (en) 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Combination use of GLP-1 compounds and other drugs to treat dyslipidemia
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US20070225351A1 (en) 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
GB0201850D0 (en) 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
WO2003076418A1 (en) 2002-03-07 2003-09-18 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
AR039090A1 (en) 2002-03-22 2005-02-09 Novartis Ag COMBINATION OF ORGANIC COMPOUNDS
WO2003088962A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
EP1499598A1 (en) 2002-04-18 2005-01-26 Ucb, S.A. Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
DE10219435A1 (en) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituted pyrazolo-pyrimidin-4-ones
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2488617A1 (en) 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
JP4831965B2 (en) 2002-06-10 2011-12-07 エラン ファーマ インターナショナル，リミティド Nanoparticle formulations comprising HMG-CoA reductase inhibitor derivatives ("statins"), novel combinations thereof, and the manufacture of these pharmaceutical compositions
AR040241A1 (en) 2002-06-10 2005-03-23 Merck & Co Inc INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA
WO2003103632A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
ATE494002T1 (en) 2002-06-14 2011-01-15 Amylin Pharmaceuticals Inc PREVENTION AND/OR TREATMENT OF ULCEROSAL COLITIS WITH PYY OR PYYÄ3-36Ü
DE10226943A1 (en) 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidines and their use
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
EP1531832B1 (en) 2002-06-28 2009-04-15 Glykos Finland Oy Therapeutic compositions for use in prophylaxis or treatment of diarrheas
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
AU2003254053A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as protein kinase inhibitors
EP1534389A2 (en) 2002-07-23 2005-06-01 SmithKline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
JP2005536517A (en) 2002-07-23 2005-12-02 スミスクライン ビーチャム コーポレーション Pyrazolopyrimidines as kinase inhibitors
EP1527345A2 (en) 2002-07-29 2005-05-04 Axxima Pharmaceuticals AG Method for isolating atp binding proteins by means of immobilized protein inhibitors
EP1539136B1 (en) 2002-07-30 2008-07-09 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
DE60332738D1 (en) 2002-07-30 2010-07-08 Merck Sharp & Dohme PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
BR0313255A (en) 2002-08-08 2005-07-12 Amgen Inc Compound, pharmaceutical composition, use of a compound and methods of making a medicament and preparing a compound
DE10237722A1 (en) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
WO2004017896A2 (en) 2002-08-21 2004-03-04 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
CN100457730C (en) 2002-08-29 2009-02-04 默克公司 Indoles having anti-diabetic activity
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2489405A1 (en) 2002-09-11 2004-03-25 Yamanouchi Pharmaceutical Co., Ltd. Screening method of agents for increasing insulin content
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
WO2004033710A2 (en) 2002-10-09 2004-04-22 Genaissance Pharmaceuticals, Inc. Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
EP1551842A1 (en) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
JP2006507302A (en) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド Kinase inhibitor
US20040110241A1 (en) 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
DE60336264D1 (en) 2002-12-20 2011-04-14 Bayer Pharmaceuticals Corp INDIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AND INTERMEDIATE PRODUCTS AND METHODS FOR THEIR MANUFACTURE
GB0230021D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
GB0230020D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP1583531B1 (en) 2003-01-16 2007-04-18 SB Pharmco Puerto Rico Inc Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists
JP2007504285A (en) 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド N-cyclohexylaminocarbonylbenzenesulfonamide derivative
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
PL378295A1 (en) 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of glucose metabolism and the prophylaxis and treatment of disorders thereof
JP2004269469A (en) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
JP2004269468A (en) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
MXPA05010456A (en) 2003-03-28 2006-03-21 Pfizer Prod Inc 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity.
TWI393560B (en) 2003-05-02 2013-04-21 Japan Tobacco Inc Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an hmg coa reductase inhibitor
DK1475094T3 (en) 2003-05-06 2010-11-22 Univ Palackeho Pyrazolo [4,3-d] pyrimidines, processes for their preparation and their use
SE0301368D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
AU2003902882A0 (en) 2003-06-10 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Piperidyl derivatives
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
CN100509798C (en) 2003-07-11 2009-07-08 艾尼纳制药公司 Trisubstituted aryl and heteroaryl derivatives as modulatorsof metabolism and the prophylaxis and treatment of disorders related thereto
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP2287156B1 (en) 2003-08-15 2013-05-29 Novartis AG 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US20050043327A1 (en) 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
CN100457108C (en) 2003-09-02 2009-02-04 默克公司 Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005023762A1 (en) 2003-09-04 2005-03-17 Abbott Laboratories Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
PE20050374A1 (en) 2003-09-05 2005-05-30 Vertex Pharma SERINE PROTEASE INHIBITORS, IN PARTICULAR HCV PROTEASE NS3-NS4A
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005025554A2 (en) 2003-09-09 2005-03-24 Japan Tobacco Inc. Dipeptidyl peptidase iv inhibitor
AU2004275719B2 (en) 2003-09-23 2010-08-19 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US20060089335A1 (en) 2003-10-14 2006-04-27 Guosong Liu Compositions and methods for enhancing cognitive function and synaptic plasticity
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
PE20050444A1 (en) 2003-10-31 2005-08-09 Takeda Pharmaceutical PYRIDINE COMPOUNDS AS PEPTIDASE INHIBITORS
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
KR20070054762A (en) 2003-11-12 2007-05-29 페노믹스 코포레이션 Heterocyclic boronic acid compounds
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
WO2005058849A1 (en) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
DE10360835A1 (en) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
KR101154830B1 (en) 2003-12-24 2012-06-18 프로시디온 리미티드 Heterocyclic derivatives as GPCR receptor agonists
EP1708571A4 (en) 2004-01-16 2009-07-08 Merck & Co Inc Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
CA2556239A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
JP4609080B2 (en) 2004-03-10 2011-01-12 富士ゼロックス株式会社 Fixing device and image forming apparatus using the same
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
MXPA06011799A (en) 2004-04-12 2006-12-15 Sankyo Co Thienopyridine derivatives.
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2005121121A2 (en) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080167321A1 (en) 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
ATE481969T1 (en) 2004-10-01 2010-10-15 Merck Sharp & Dohme AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
JP4862654B2 (en) 2004-10-08 2012-01-25 アステラス製薬株式会社 Aromatic ring fused pyrimidine derivatives
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
AR051596A1 (en) 2004-10-26 2007-01-24 Irm Llc CONDENSED HETEROCICLIC COMPOUNDS NITROGENATED AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FOOD DISORDERS
ES2498972T3 (en) 2004-11-03 2014-09-26 Arena Pharmaceuticals, Inc. GPR41 and its modulators for the treatment of insulin-related disorders
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
BRPI0516407A (en) 2004-12-24 2008-09-02 Prosidion Ltd G-protein coupled receptor agonists (gpr116) and their use for the treatment of obesity and diabetes
JP5065908B2 (en) 2004-12-24 2012-11-07 プロシディオン・リミテッド G protein-coupled receptor agonist
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000010A (en) 2005-01-10 2006-07-31 Arena Pharm Inc PROCEDURE TO PREPARE AROMATIC ETERES
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
DOP2006000009A (en) 2005-01-13 2006-08-15 Arena Pharm Inc PROCEDURE TO PREPARE ETERES OF PIRAZOLO [3,4-D] PYRIMIDINE
WO2006078992A2 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
CA2611446A1 (en) 2005-06-09 2006-12-14 Banyu Pharmaceutical Co., Ltd. Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea
CA2613236A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
CN101213192B (en) 2005-07-01 2012-06-06 Irm责任有限公司 Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
WO2007035355A2 (en) 2005-09-16 2007-03-29 Arena Pharmaceuticals, Inc. Modulators of metabolism and the treatment of disorders related thereto
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AU2006337137B2 (en) 2005-12-29 2012-06-14 Tersera Therapeutics Llc Multicyclic amino acid derivatives and methods of their use
JP5237115B2 (en) 2006-01-19 2013-07-17 オーキッド リサーチ ラボラトリーズ リミテッド New heterocycles
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
KR101281962B1 (en) 2006-04-11 2013-07-08 아레나 파마슈티칼스, 인크. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
AU2007291252A1 (en) 2006-08-30 2008-03-06 Inovacia Ab Pyridine compounds for treating GPR119 related disorders
UA97817C2 (en) 2006-12-06 2012-03-26 Глаксосмиткляйн Ллк Heterocyclic derivatives of 4-(methylsulfonyl)phenyl and use thereof
JP2010513272A (en) 2006-12-14 2010-04-30 メルク エンド カムパニー インコーポレーテッド Acylbipiperidinyl compounds, compositions containing such compounds, and therapeutic methods
WO2009038974A1 (en) 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity
KR20100137561A (en) 2008-04-07 2010-12-30 아이알엠 엘엘씨 Compounds and compositions as modulators of gpr119 activity
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
JP2012513470A (en) 2008-12-23 2012-06-14 シェーリング コーポレイション Bicyclic heterocyclic derivatives and methods of use thereof
WO2010074271A1 (en) 2008-12-26 2010-07-01 武田薬品工業株式会社 Therapeutic agent for diabetes
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AR077638A1 (en) 2009-07-15 2011-09-14 Lilly Co Eli COMPOSITE OF (METHANOSULPHONYL -PIPERIDIN) - (ALCOXI-ARIL) -TETRAHIDRO- PYRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES OR OBESITY
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
US20130023494A1 (en) 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2341925A1 (en) * 1973-08-20 1975-03-06 Thomae Gmbh Dr K 2,4, (opt.5-), 6-substd. pyriminidines as antithrombic agents - e.g. 6-methyl-5-nitro-2-piperazino-4-thiomorpolino-pyrimidine
DE2831850A1 (en) * 1978-07-20 1980-02-07 Basf Ag Diuretic n-carboxy:phenyl:sulphonyl pyrrole derivs. - prepd. from substd. 3-sulphonamido:benzoic acid
RU938559C (en) * 1980-12-12 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе S-derivatives of 5-amyno-6-mercaptopyrimidine possessing antitumoral and cytostatic activity
EP0556889A1 (en) * 1992-02-18 1993-08-25 Duphar International Research B.V Method of preparing aryl(homo)piperazines
EP0667343A1 (en) * 1994-01-18 1995-08-16 Sandoz Ltd. Alpha-pyrimidinyl acrylic acid derivatives with fungicidal activity
EP0801059A1 (en) * 1994-11-29 1997-10-15 Dainippon Pharmaceutical Co., Ltd. Indole derivative
WO1996033994A1 (en) * 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Amino-substituted derivatives, process for the preparation thereof, and herbicide
WO1996036613A1 (en) * 1995-05-19 1996-11-21 Nippon Soda Co., Ltd. Substituted benzoic acid derivatives, process for the production thereof, and herbicides
EP0940387A1 (en) * 1995-10-26 1999-09-08 Tokyo Tanabe Company Limited Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
WO1997026252A1 (en) * 1996-01-19 1997-07-24 Fmc Corporation Insecticidal n-heterocyclylalkyl- or n-[(polycyclyl)-alkyl]-n'-substituted piperazines
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2001027107A2 (en) * 1999-10-12 2001-04-19 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2001049677A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S Phenylpiperazinyl derivatives
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
WO2002002549A1 (en) * 2000-07-05 2002-01-10 Taisho Pharmaceutical Co., Ltd. Tetrahydropyridino or piperidino heterocyclic derivatives
WO2002006274A1 (en) * 2000-07-17 2002-01-24 Wyeth N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
WO2002098864A1 (en) * 2001-06-01 2002-12-12 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
WO2003077656A1 (en) * 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
WO2004000843A1 (en) * 2002-06-24 2003-12-31 Astrazeneca Ab NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY
WO2004000819A1 (en) * 2002-06-24 2003-12-31 Astrazeneca Ab New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NORMAN M.H.: "Structure-activity relationships of a series of pyrrolo(3,2-d)pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 22, 2000, pages 4288 - 4312, XP002285195 *

Cited By (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP2006522143A (en) * 2003-04-04 2006-09-28 アイアールエム・リミテッド・ライアビリティ・カンパニー Novel compounds and compositions as protein kinase inhibitors
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EA010690B1 (en) * 2003-07-11 2008-10-30 Арена Фармасьютикалз, Инк. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1923390A1 (en) * 2003-07-11 2008-05-21 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7335672B2 (en) 2004-09-13 2008-02-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2316457A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
CN101123964B (en) * 2004-12-24 2012-11-28 普罗西迪恩有限公司 G-protein coupled receptor(GPR116) agonists and use thereof for treating obesity and diabetes
WO2006067531A1 (en) * 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
JP4916452B2 (en) * 2004-12-31 2012-04-11 プロシディオン・リミテッド Derivatives of pyridine, pyrimidine, and pyrazine as GPCR agonists
JP2008526724A (en) * 2004-12-31 2008-07-24 プロシディオン・リミテッド Derivatives of pyridine, pyrimidine, and pyrazine as GPCR agonists
EP2322152A1 (en) * 2005-01-10 2011-05-18 Arena Pharmaceuticals, Inc. Method of preparing a composition comprising a GPR119 agonist
EP2322157A1 (en) 2005-01-10 2011-05-18 Arena Pharmaceuticals, Inc. Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
JP2008195733A (en) * 2005-01-10 2008-08-28 Arena Pharmaceuticals Inc Combined curing method for diabetes, symptom related to diabetes and symptom to be improved by increase of blood glp-1 level
EA011883B1 (en) * 2005-01-10 2009-06-30 Арена Фармасьютикалз, Инк. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
AU2006205164B2 (en) * 2005-01-10 2011-09-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
JP2012017330A (en) * 2005-01-10 2012-01-26 Arena Pharmaceuticals Inc Combination therapy for treating diabetes and condition related to diabetes, and treating condition to be improved with increase in blood glp-1 level
EP2322151A2 (en) * 2005-01-10 2011-05-18 Arena Pharmaceuticals, Inc. Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor
EP2322150A3 (en) * 2005-01-10 2011-11-16 Arena Pharmaceuticals, Inc. Method of identifying GLP-1 secretagogues
EP1997484A3 (en) * 2005-01-10 2009-02-11 Arena Pharmaceuticals, Inc. Method of identifying GLP-1 secretagogues
EP2322151A3 (en) * 2005-01-10 2012-01-18 Arena Pharmaceuticals, Inc. Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor
WO2006076231A3 (en) * 2005-01-10 2007-01-18 Arena Pharm Inc Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
JP2011184458A (en) * 2005-01-10 2011-09-22 Arena Pharmaceuticals Inc Combination therapy for treatment of diabetes and conditions related thereto and for treatment of conditions ameliorated by increasing blood glp-1 level
EP1808168A1 (en) * 2005-01-10 2007-07-18 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
EA014156B1 (en) * 2005-01-10 2010-10-29 Арена Фармасьютикалз, Инк. Process for preparing 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperedine-1-carboxylicacid derivatives and related compounds
WO2006076243A1 (en) * 2005-01-10 2006-07-20 Arena Pharmaceuticals, Inc. Processes for preparing 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidine-1-carboxylic acid derivatives and related compounds
WO2006076231A2 (en) * 2005-01-10 2006-07-20 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
JP2008110964A (en) * 2005-01-10 2008-05-15 Arena Pharmaceuticals Inc Combination therapy for treatment of diabetes and condition related thereto and for treatment of condition ameliorated by increasing blood glp-1 level
KR101016890B1 (en) * 2005-01-10 2011-02-22 아레나 파마슈티칼스, 인크. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
EP2322156A1 (en) * 2005-01-10 2011-05-18 Arena Pharmaceuticals, Inc. Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
WO2007027225A2 (en) 2005-04-27 2007-03-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
WO2007120689A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2007120702A3 (en) * 2006-04-11 2008-05-22 Arena Pharm Inc Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
EP2369341A2 (en) * 2006-04-11 2011-09-28 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
EP2402750A1 (en) 2006-04-11 2012-01-04 Arena Pharmaceuticals, Inc. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
EP2369341A3 (en) * 2006-04-11 2012-01-04 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
CN103536924A (en) * 2006-04-11 2014-01-29 艾尼纳制药公司 Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
EP2253311A3 (en) * 2006-04-11 2011-06-22 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
EP2325182A1 (en) 2006-12-06 2011-05-25 Glaxosmithkline LLC Bicyclic compounds and use as antidiabetics
US8399485B2 (en) 2006-12-14 2013-03-19 Merck Sharp & Dohme Corp. Acyl bipiperidinyl compounds useful as GPR 119 agonists
US9067891B2 (en) 2007-03-07 2015-06-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
US8076322B2 (en) 2007-05-04 2011-12-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
US8513265B2 (en) 2007-05-04 2013-08-20 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
US8314095B2 (en) 2007-05-04 2012-11-20 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
US8093257B2 (en) 2007-05-04 2012-01-10 Bristol-Myers Squibb Company [6,5]-bicyclic GPR119 G protein-coupled receptor agonists
US8476283B2 (en) 2007-05-04 2013-07-02 Bristol-Myers Squibb Company [6,5]—bicyclic GPR119 G protein-coupled receptor agonists
US8232404B2 (en) 2007-07-17 2012-07-31 Bristol-Myers Squibb Company Pyridone GPR119 G protein-coupled receptor agonists
US7928230B2 (en) 2007-07-17 2011-04-19 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
US8178561B2 (en) 2007-07-17 2012-05-15 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
US8513424B2 (en) 2007-07-17 2013-08-20 Bristol-Myers Squibb Company Pyridone GPR119 G protein-coupled receptor agonists
US8003796B2 (en) 2007-07-17 2011-08-23 Bristol-Myers Squibb Company Pyridone GPR119 G protein-coupled receptor agonists
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
US8551957B2 (en) 2007-08-16 2013-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US11071729B2 (en) 2007-09-14 2021-07-27 Addex Pharmaceuticals S.A. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8153635B2 (en) 2007-09-20 2012-04-10 Irm Llc Compounds and compositions as modulators of GPR119 activity
US8258156B2 (en) 2007-09-20 2012-09-04 Irm Llc Compounds and compositions as modulators of GPR119 activity
WO2009055331A2 (en) 2007-10-22 2009-04-30 Schering Corporation Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2009126245A1 (en) * 2008-04-07 2009-10-15 Arena Pharmaceuticals, Inc. Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010009195A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8815876B2 (en) 2008-07-16 2014-08-26 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
US8372837B2 (en) 2008-07-16 2013-02-12 Bristol-Myers Squibb Company Pyridone and pyridazone analogues as GPR119 modulators
WO2010013849A1 (en) 2008-08-01 2010-02-04 日本ケミファ株式会社 Gpr119 agonist
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
WO2010029089A3 (en) * 2008-09-10 2010-05-06 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
WO2010029089A2 (en) * 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010075271A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8722882B2 (en) 2008-12-23 2014-05-13 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010075269A1 (en) 2008-12-23 2010-07-01 Schering Corporation Pyrimidine derivatives as gpcr modttlators for use in the treatment of obesity and diabetes
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US12115179B2 (en) 2009-02-13 2024-10-15 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2010114957A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
WO2010114958A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bridged bicyclic heterocycle derivatives and methods of use thereof
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
US10071095B2 (en) 2009-05-12 2018-09-11 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
US9737533B2 (en) 2009-05-12 2017-08-22 Janssen Pharmaceuticals. Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
KR101432396B1 (en) 2009-06-18 2014-08-20 카딜라 핼쓰캐어 리미티드 Novel gpr 119 agonists
US8772302B2 (en) 2009-06-18 2014-07-08 Cadila Healthcare Limited GPR 119 agonists
WO2010146605A1 (en) * 2009-06-18 2010-12-23 Cadila Healthcare Limited Novel gpr 119 agonists
AU2010261341B2 (en) * 2009-06-18 2014-02-06 Cadila Healthcare Limited Novel GPR 119 agonists
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
JP2012533546A (en) * 2009-07-15 2012-12-27 イーライ リリー アンド カンパニー GPR119 agonist
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011025006A1 (en) 2009-08-31 2011-03-03 日本ケミファ株式会社 Gpr119 agonist
US20120157443A1 (en) * 2009-09-04 2012-06-21 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
US10577374B2 (en) 2009-09-04 2020-03-03 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
US9249146B2 (en) 2009-09-04 2016-02-02 Biogen Ma Inc. Bruton'S tyrosine kinase inhibitors
US8785440B2 (en) * 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
US9790229B2 (en) 2009-09-04 2017-10-17 Sunesis Pharmaceuticals, Inc. Bruton's tyrosine kinase inhibitors
US20230046457A1 (en) * 2009-09-04 2023-02-16 Viracta Therapeutics, Inc. Bruton's tyrosine kinase inhibitors
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
WO2011062885A1 (en) 2009-11-23 2011-05-26 Schering Corporation Fused bicyclic pyrimidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011127106A1 (en) 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103539791A (en) * 2010-09-22 2014-01-29 艾尼纳制药公司 Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101871011B1 (en) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103539791B (en) * 2010-09-22 2017-01-11 艾尼纳制药公司 Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN103221410A (en) * 2010-09-22 2013-07-24 艾尼纳制药公司 Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2011305525B2 (en) * 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN103221410B (en) * 2010-09-22 2017-09-15 艾尼纳制药公司 GPR119 receptor modulators and the treatment to relative obstacle
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
US10596120B2 (en) 2011-03-07 2020-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US20180185291A1 (en) 2011-03-07 2018-07-05 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US11564886B2 (en) 2011-03-07 2023-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US10618887B2 (en) 2012-06-08 2020-04-14 Sunesis Pharmaceuticals, Inc. Pyrimidinyl tyrosine kinase inhibitors
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US10584129B2 (en) 2013-06-04 2020-03-10 Janssen Pharmaceuticals Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US12048696B2 (en) 2014-01-21 2024-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11103506B2 (en) 2014-01-21 2021-08-31 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR20150126564A (en) 2014-05-02 2015-11-12 현대약품 주식회사 Novel cyclohexene derivatives, preparation method thereof and pharmaceutical composition for prevention or treatment of the metabolic diseases containing the same as an active ingredient
US9758527B2 (en) 2014-05-02 2017-09-12 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US10723699B2 (en) 2015-11-04 2020-07-28 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018236896A1 (en) 2017-06-19 2018-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash

Also Published As

Publication number Publication date
AU2004205642A1 (en) 2004-08-05
AU2004205642B2 (en) 2011-01-27
EA011009B1 (en) 2008-12-30
DE602004009295T2 (en) 2008-07-03
US20110082134A1 (en) 2011-04-07
AU2004205642C1 (en) 2012-01-12
DE602004009295D1 (en) 2007-11-15
CY1107085T1 (en) 2012-10-24
WO2004065380A8 (en) 2004-10-21
ES2295816T3 (en) 2008-04-16
NZ540612A (en) 2008-02-29
NO20053803D0 (en) 2005-08-11
US20130023527A1 (en) 2013-01-24
GEP20084540B (en) 2008-11-25
US20060217379A1 (en) 2006-09-28
MXPA05007485A (en) 2006-01-30
KR101078098B1 (en) 2011-10-28
PL377847A1 (en) 2006-02-20
BRPI0406761A (en) 2005-12-20
EP1599468A1 (en) 2005-11-30
DK1599468T3 (en) 2008-02-04
KR20050092748A (en) 2005-09-22
ECSP055916A (en) 2005-11-22
CO5640119A2 (en) 2006-05-31
EA200501132A1 (en) 2006-02-24
CN102558155A (en) 2012-07-11
MA27707A1 (en) 2006-01-02
CA2512899A1 (en) 2004-08-05
HRP20050696A2 (en) 2005-12-31
JP5566255B2 (en) 2014-08-06
IS7979A (en) 2005-08-12
IS2713B (en) 2011-01-15
KR20110010824A (en) 2011-02-07
SG182004A1 (en) 2012-07-30
EP1599468B1 (en) 2007-10-03
HRP20050696B1 (en) 2008-10-31
US8293751B2 (en) 2012-10-23
JP2006516572A (en) 2006-07-06
JP2011051998A (en) 2011-03-17
HK1076815A1 (en) 2006-01-27
AU2010257356A1 (en) 2011-01-20
RS20050532A (en) 2007-12-31
IL169081A (en) 2012-07-31
IS8859A (en) 2009-11-12
ATE374766T1 (en) 2007-10-15
PT1599468E (en) 2008-01-14
US8933083B2 (en) 2015-01-13
NO20053803L (en) 2005-10-12

Similar Documents

Publication Publication Date Title
US8933083B2 (en) 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2004215344B2 (en) Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
JP2006516572A5 (en)
EP1756084B1 (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP4777244B2 (en) Trisubstituted aryl and heteroaryl derivatives as metabolic modulators and the prevention and treatment of disorders associated therewith
ZA200505001B (en) 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP1927594A1 (en) 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0532

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004205642

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 169081

Country of ref document: IL

Ref document number: 540612

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 01150/KOLNP/2005

Country of ref document: IN

Ref document number: 1150/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005/05001

Country of ref document: ZA

Ref document number: 200505001

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2004205642

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200500929

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2512899

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006501019

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/007485

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057012965

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 377847

Country of ref document: PL

Ref document number: 20048022039

Country of ref document: CN

Ref document number: 1-2005-501308

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: P20050696A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 05078853

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2004702248

Country of ref document: EP

Ref document number: DZP2005000287

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 8939

Country of ref document: GE

Ref document number: 200501132

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020057012965

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004702248

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0406761

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2006217379

Country of ref document: US

Ref document number: 10541657

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10541657

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004702248

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2008-009861

Country of ref document: CR